

**International Society for Heart and Lung Transplantation  
29<sup>TH</sup> Annual Meeting and Scientific Sessions**

April 22-25, 2009

Final Program

April in Paris  
Palais des Congres de Paris

**International Society for Heart and Lung Transplantation  
BOARD OF DIRECTORS**

**PRESIDENT**

Mandeep R. Mehra, MD, Baltimore, MD

**PAST PRESIDENT**

Paul A. Corris, MB FRCP, Newcastle Upon Tyne, United Kingdom

**PRESIDENT-ELECT**

James K. Kirklin, MD, Birmingham, AL

**SECRETARY-TREASURER**

Heather J. Ross, MD, FRCPC, Toronto, ON, Canada

**DIRECTORS**

Duane Davis, MD, Durham, NC

Fabienne Dobbels, PhD, Leuven, Belgium

Roger W. Evans, PhD, Rochester, MN

Shaf Keshavjee, MD, FRCSC, FACS, Toronto, ON, Canada

Joren C. Madsen, MD, D.Phil, Boston, MA

Takeshi Nakatani, MD, PhD, Osaka, Japan

Randall C. Starling, MD, MPH, Cleveland, OH

Stuart C. Sweet, MD, PhD, St. Louis, MO

Jayan Parameshwar, FRCP, Cambridge, United Kingdom

Lori J. West, MD, D.Phil, Edmonton, AB, Canada

Andreas O. Zuckermann, MD, Vienna, Austria

**EX OFFICIO BOARD MEMBERS**

**JHLT EDITOR**

James K. Kirklin, MD, Birmingham AL

**TRANSPLANT REGISTRY MEDICAL DIRECTOR**

Marshall I. Hertz, MD, Minneapolis, MN

**STAFF**

Amanda W. Rowe

Executive Director

Phyllis Glenn

Director of Membership Services

Lisa A. Edwards

Director of Meetings

Lee Ann Mills

Director of Operations

Susie Newton

Administrative Assistant

14673 Midway Road, Suite 200

Addison, TX 75001

Phone: 972-490-9495

Fax: 972-490-9499

[www.ishlt.org](http://www.ishlt.org)

[ishlt@ishlt.org](mailto:ishlt@ishlt.org)

**International Society for Heart and Lung Transplantation  
29th Annual Meeting and Scientific Sessions**

**SCIENTIFIC PROGRAM COMMITTEE**

Randall C. Starling, MD, MPH, Cleveland, OH, **Program Chair**  
Mandeep R. Mehra, MD, Baltimore, MD, **President**  
Claus B. Andersen, MD, D.M.Sc, Copenhagen, Denmark  
Allen S. Anderson, MD, Chicago, IL  
Nicholas R. Banner, FRCP, Harefield, Middlesex, United Kingdom  
Mark L. Barr, MD, Los Angeles, CA  
Sharon A. Beer, RN, MSc, Birmingham, United Kingdom  
Raymond L. Benza, MD, Pittsburgh, PA  
Roberta C. Bogaev, MD, FACC, Houston, TX  
Maria G. Crespo-Leiro, MD, La Coruna, Spain  
Lara Danziger-Isakov, MD, MPH, Cleveland, OH  
Fabienne Dobbels, MSc, PhD, Leuven, Belgium  
Stephan M. Ensminger, MD, PhD, Erlangen, Germany  
Andrew J. Fisher, FRCP, PhD, Newcastle Upon Tyne, United Kingdom  
Kathleen L. Grady, PhD, APN, FAAN, Chicago, IL  
Cynthia J. Gries, MD, MSc, Seattle, WA  
Daphne T. Hsu, MD, Bronx, NY  
James K. Kirklin, MD, Birmingham, AL  
Kenneth B. Margulies, MD, Philadelphia, PA  
Edwin C. McGee, Jr., MD, Chicago, IL  
Tomislav Mihaljevic, MD, Cleveland, OH  
Martha L. Mooney, MD, Norfolk, VA  
Elaine F. Reed, PhD, Los Angeles, CA  
Hermann Reichenspurner, MD, PhD, Hamburg, Germany  
E. Rene Rodriguez, MD, Cleveland, OH  
Joseph G. Rogers, MD, Durham, NC  
Cumara C. Sivathasan, MBBS, FRCS, Singapore  
Redha R. Souilamas, MD, PhD, Paris, France  
Patricia A. Uber, Pharm.D, Baltimore, MD  
Lori J. West, MD, D.Phil, Edmonton, AB, Canada  
Andreas O. Zuckermann, MD, Vienna, Austria

**International Society for Heart and Lung Transplantation  
29th Annual Meeting and Scientific Sessions**

**ABSTRACT REVIEWERS**

Annalisa Angelini, Padova, Italy  
Selim Arcasoy, New York, NY  
Abbas Ardehali, Los Angeles, CA  
John Belperio, Los Angeles, CA  
Eliane Billaud, Paris, France  
Emma Birks, Harefield, Middlesex, United Kingdom  
Elizabeth Blume, Boston, MA  
Annette Boehler, Zurich, Switzerland  
Andrew Boyle, Mound, MN  
Gerard Boyle, Cleveland, OH  
Michael Burch, London, United Kingdom  
Margaret Burke, Harefield, Middlesex, United Kingdom  
Susan Chernenko, Toronto, ON, Canada  
Clifford Chin, Palo Alto, CA  
Jason Christie, Philadelphia, PA  
Bernice Coleman, Ladera Heights, CA  
Monica Colvin-Adams, Minneapolis, MN  
Paul Corris, Newcastle Upon Tyne, United Kingdom  
William Cotts, Chicago, IL  
John Dark, Newcastle Upon Tyne, United Kingdom  
Juan Delgado, Madrid, Spain  
Annette Devito Dabbs, Sewickley, PA  
Mary Amanda Dew, Pittsburgh, PA  
Roel De Weger, Utrecht, The Netherlands  
Robert Dowling, Louisville, KY  
Jeff Edelman, Seattle, WA  
Thomas Egan, Chapel Hill, NC  
Howard Eisen, Philadelphia, PA  
Aly El Banayosy, Bad Oeynhausen, Germany  
Arndt Fiane, Oslo, Norway  
Robert Frantz, Rochester, MN  
O. Howard Frazier, Houston, TX  
Edward Garrity, Chicago, IL  
James George, Birmingham, AL  
Allan Glanville, Sydney, Australia  
Lee Goldberg, Philadelphia, PA  
Gonzalo Gonzalez-Stawinski, Cleveland, OH  
Marc Halushka, Baltimore, MD  
Sharon Hunt, Palo Alto, CA  
Shahid Husain, Toronto, ON, Canada  
Mariel Jessup, Philadelphia, PA  
Ingo Kaczmarek, Munich, Germany  
Shaf Keshavjee, Toronto, ON, Canada  
Walter Klepetko, Vienna, Austria  
Robert Kormos, Pittsburgh, PA  
Christiane Kugler, Hannover, Germany  
Carlos Labarrere, Indianapolis, IN  
Chi Lai, Los Angeles, CA  
Dorothy Lanuza, Madison, WI  
Yuk Law, Seattle, WA  
Hans Lehmkuhl, Berlin, Germany  
Wayne Levy, Seattle, WA  
Joren Madsen, Boston, MA  
Sandra Martin, Leuven, Belgium  
Frauke Mattner, Hannover, Germany  
Kenneth McCurry, Pittsburgh, PA  
John F. McDyer, Baltimore, MD

Omar Minai, Cleveland, OH  
Thalachallour Mohanakumar, St. Louis, MO  
Stephanie Moore, Boston, MA  
Srinivas Murali, Pittsburgh, PA  
Catherine Murks, Chicago, IL  
Yoshifumi Naka, New York, NY  
Takeshi Nakatani, Osaka, Japan  
Kenneth Ng, Singapore  
Folke Nilsson, Goteborg, Sweden  
Robert Padera, Boston, MA  
Francesco Parisi, Rome, Italy  
Myung Park, Baltimore, MD  
Jignesh Patel, Pittsburgh, PA  
Michael Petty, Minneapolis, MN  
Richard N. Pierson, III, Baltimore, MD  
Jeffrey Platt, Ann Arbor, MI  
Luciano Potena, Bologna, Italy  
Doris Rassi, Cambridge, United Kingdom  
Kashif Raza, Allison Park, PA  
Robert Robbins, Stanford, CA  
Eulalia Roig Minguell, Barcelona, Spain  
Antonio Roman, Barcelona, Spain  
Marlene Rose, Harefield, Middlesex, United Kingdom  
Heather Ross, Toronto, ON, Canada  
Stuart Russell, Baltimore, MD  
Mark Slaughter, Oak Lawn, IL  
Nick Smedira, Cleveland, OH  
Joshua Sonett, New York, NY  
Marc Stern, Suresnes, France  
Nicole Suci-Foca, New York, NY  
Stuart Sweet, St. Louis, MO  
Jackie Szmuszkovicz, Los Angeles, CA  
Carmela Tan, Cleveland, OH  
Wilson Tang, Gates Mills, OH  
David Taylor, Cleveland, OH  
Doris Taylor, Minneapolis, MN  
George Tellides, New Haven, CT  
Jeff Teuteberg, Pittsburgh, PA  
Yoshi Toyoda, Pittsburgh, PA  
Steven Tsui, Cambridge, United Kingdom  
Dirk Van Raemdonck, Leuven, Belgium  
Vincent Valentine, Galveston, TX  
Shaïda Varnous, Paris, France  
Geert Verleden, Leuven, Belgium  
Erik Verschuuren, Groningen, The Netherlands  
Connie White-Williams, Birmingham, AL  
Trevor Williams, Melbourne, Australia  
Mohamed Yamani, Jacksonville, FL  
David Zaas, Durham, NC  
Adriana Zeevi, Pittsburgh, PA

## **SCIENTIFIC COUNCIL OPERATING BOARDS**

### **Heart Failure and Transplant Medicine**

Maria Rosa Costanzo, MD, Chair  
Maria G. Crespo-Leiro, MD, Vice-Chair  
Nicholas R. Banner, FRCP, Standards and Guidelines Workforce Leader  
Allen S. Anderson, MD, Education Workforce Leader  
Mariano Feccia, MD, Registries and Databases Workforce Leader  
David P. Nelson, MD, Communications Workforce Leader  
Robert C. Bourge, MD, Development Liaison

### **Mechanical Circulatory Support**

Emma Birks, MRCP PhD, Chair  
Francis D. Pagani, MD, PhD, Vice-Chair  
Stephanie A. Moore, MD, Standards and Guidelines Workforce Leader  
Roberta C. Bogaev, MD, FACC, Education Workforce Leader  
Jaap Lahpor, MD, PhD, Registries and Databases Workforce Leader  
Evgenij V. Potapov, MD, Communications Workforce Leader  
Mario C. Deng, MD, Development Liaison

### **Infectious Diseases**

Shahid Husain, MD, Chair  
Margaret M. Hannan, MD, Vice-Chair  
Kate Gould, FRCPath, Past-Chair  
Lara Danziger-Isakov, MD, MPH, Standards and Guidelines Workforce Leader  
Martha L. Mooney, MD, Education Workforce Leader  
Frauke Mattner, MD, Registries and Databases Workforce Leader  
Vincent G. Valentine, MD, Communications Workforce Leader  
Eric A. M. Verschuuren, MD, PhD, Development Liaison

### **Nursing and Social Sciences**

Annette J. Devito Dabbs, RN, PhD, Chair  
Connie White-Williams, MSN, Vice-Chair  
Catherine M. Murks, RN, APN, Past Chair  
Michael G. Petty, PhD(c), RN, CCNS, CNS, Standards and Guidelines Workforce Leader  
Sharon A. Beer, RN, MSn, Education Workforce Leader  
Fabienne Dobbels, PhD, Registries and Databases Workforce Leader  
Susan Chernenko, RN, MN, Communications Workforce Leader  
Bernice Coleman, PhD, RN, Grants and Awards Workforce Leader  
Kevin Carney, RN, CCTC, Membership Development Liaison

### **Pathology and Basic Science**

E. Rene Rodriguez, MD, Chair  
Carmela D. Tan, MD, Standards and Guidelines Workforce Leader  
E. Rene Rodriguez, MD, Education Workforce Leader  
Robert F. Padera, MD, PhD, Registries and Databases Workforce Leader  
James B. Atkinson, MD, PhD, Communications Workforce Leader

### **Pediatric Transplantation**

Michael Burch, MD, Chair  
Christian Benden, MD, Vice-Chair  
Stuart C. Sweet, MD, PhD, Past-Chair  
Okan Elidimir, MD, Standards and Guidelines Workforce Leader  
Daphne Hsu, MD, Education Workforce Leader  
Richard E. Chinnock, MD, Registries and Databases Workforce Leader  
Anne L. Dipchand, MD, Communications Workforce Leader

### **Pulmonary Arterial Hypertension**

Raymond L. Benza, MD, Chair  
Myung Park, MD, Vice-Chair  
John P. Scott, MD, Past-Chair

Evelyn Horn, MD, Standards and Guidelines Workforce Leader  
Omar A. Minai, MD, Education Workforce Leader  
Adaani Frost, MD, Registries and Databases Workforce Leader  
Deborah J. Levine, MD, Communications Workforce Leader  
Srinivas Murali, MD, Development Liaison

### **Pulmonary Transplantation**

Martin R. Zamora, MD, Chair  
Geert M. Verleden, MD, PhD, Vice Chair  
Lianne G. Singer, MD, FRCPC, Vice Chair-Elect/Secretary  
David Weill, MD, Standards and Guidelines Workforce Leader  
Andrew Fisher, FRCP, PhD, Education Workforce Leader  
Shaf Keshavjee, MD, Registries and Databases Workforce Leader  
Christine L. Lau, MD, Communications Workforce Leader  
Roger D. Yusen, MD, MPH, Quality of Life Workforce Leader

### **Junior Faculty and Trainee Council**

Cynthia J. Gries, MD, Chair  
Lorriana E. Leard, MD, Vice Chair  
Susan D. Moffatt-Bruce, MD, PhD, Standards and Guidelines Workforce Leader  
Daniel F. Dilling, MD, Education Workforce Leader  
Steven R. Hays, MD, Registries and Databases Workforce Leader  
David W. Markham, MD, Communications Workforce Leader  
Arezu, Z. Aliabadi, MD, Development Liaison

## **ISHLT COMMITTEES**

### **Thoracic Registry Steering**

Marshall I. Hertz, MD, Medical Director  
David O. Taylor, MD, FACC, Associate Medical Director, Heart  
Josef Stehlik, MD, MPH, Associate Medical Director, Heart  
Jason D. Christie, MD, Associate Medical Director, Lung  
Richard Kirk, MA, FRCP, FRCPC, Associate Medical Director, Pediatric Heart  
Paul Aurora, MRCP, PhD, Associate Medical Director, Pediatric Lung/Heart-Lung  
Fabienne Dobbels, PhD, Associate Medical Director, Outcomes  
Axel Rahmel, MD, Associate Medical Director, OEO Relations  
Leah Edwards, PhD, Associate Medical Director for Biostatistics  
Jaime Williamson, Associate Medical Director for Technology  
Kathryn A. Philibin, RN, TII Liaison  
Anna Kucheryavaya, Assistant Biostatistician

### **Grants and Awards**

Mark L. Barr, MD  
Duane Davis, MD  
John Dark, MB, FRCS  
Susan Stewart, FRCPath

### **Education**

Nicholas R. Banner, FRCP, Chair  
Keith McNeil, FRACP, Member at Large  
Andreas Oliver Zuckermann, MD, Member at Large  
Beatriz Diaz Molina, MD, Member at Large

### **JHLT Editorial Board**

James K. Kirklin, MD, Editor  
Mandeep Mehra, MD, Incoming Editor  
Peggy Holmes, Managing Editor  
Raymond L. Benza, MD, Associate Editors  
Robert C. Bourge, MD, Associate Editors  
Charles E. Canter, MD  
Richard E. Chinnock, MD

Maria Rosa Costanzo, MD

**Communications**

Maryl R. Johnson, MD, Chair

**Professional Standards and Guidelines**

Mariell Jessup, MD, Chair

Diego H. Delgado, MD, Member at Large

Maria G. Crespo-Leiro, MD, Member at Large

Daniela Pini, MD, Member at Large

**Registries and Databases**

Marshall I. Hertz, MD, Chair

Roger D. Yusen, MD, MPH, Outcomes Specialist

Maria G. Crespo-Leiro, MD, Outcomes Specialist



## ISHLT PAST PRESIDENTS

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD
2000-2001	Anne Keogh, MBBS, MD
2001-2002	James B. Young, MD
2002-2003	Stephan Schuler, MD
2003-2004	Jon Kobashigawa, MD
2004-2005	Alec Patterson, MD
2005-2006	Mark L. Barr, MD
2006-2007	Robert C. Robbins, MD
2007-2008	Paul A. Corris, MB FRCP

## **PAST PROGRAM CHAIRS**

1988 Los Angeles, CA  
John C. Baldwin, MD

1989 Munich, Germany  
Bruno Reichart, MD

1990 San Diego, CA  
D. Glenn Pennington, MD

1991 Paris, France  
John B. O'Connell, MD

1992 San Diego, CA  
Eric A. Rose, MD

1993 Boca Raton, FL  
Maria Rosa Costanzo, MD

1994 Venice, Italy  
John Wallwork, MBChB, FRCS

1995 San Francisco, CA  
Leslie W. Miller, MD

1996 New York, NY  
William A. Baumgartner, MD

1997 London, England  
Stephan Schueler, MD

1998 Chicago, IL  
James B. Young, MD

1999 San Francisco, CA  
Mark L. Barr, MD

2000 Osaka, Japan  
Jon Kobashigawa, MD

2001 Vancouver, Canada  
David O. Taylor, MD

2002 Washington, DC  
Robert C. Robbins, MD

2003 Vienna, Austria  
Bruce R. Rosengard, MD

2004 San Francisco, CA  
Mandeep Mehra, MD

2005 Philadelphia, PA  
Shaf Keshavjee, MD

2006 Madrid, Spain  
John Dark, MB, FRCS

2007 San Francisco, CA  
Duane Davis, MD

2008 Boston, MA  
Lori J. West, MD, DPhil

## **ISHLT AWARD RECIPIENTS**

### **Pioneers in Transplantation Lecture**

- 2000 Christian Barnard, MD  
Joel D. Cooper, MD  
Norman E. Shumway, MD
- 2008 Richard E. Lower, MD
- 2009 Christian E. A. Cabrol, MD

### **Lifetime Achievement Award**

- 2004 Sir Magdi Yacoub, MD
- 1999 Keith Reemtsma, MD
- 1996 Norman Shumway, MD

### **Lifetime Service Award**

- 1997 Jacques Losman
- 1996 Michael Kaye

### **Norman E. Shumway ISHLT Career Development Award**

- 2008 Glen Westall, MD, PhD (supported by Roche)
- 2006 Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)
- 2004 Allan M. Ramirez, MD (supported by Novartis Pharma)
- 2002 Anthony Azakie, MD (supported by Roche)
- 2000 Gordon D. Wu, MD (supported by Roche)

### **ISHLT Transplant Research Fellowship Grants**

- 2008 Jonathan Choy, PhD (supported by XDx)  
Satoshi Itoh, MD (supported by Transmedics)  
Tereza Martinu, MD (supported by Novartis)  
Deepti Saini, PhD (supported by Gilead)  
Atsushi Shiozaki, MD, PhD (supported by Astellas)  
Seiichiro Sugimoto, MD, PhD (supported by Roche)
- 2007 J. Raymond Fitzpatrick, III, MD (supported by Encysive)  
Howard J. Huang, MD (supported by Transmedics)  
Mylvaganam Jeyakanthan, MD (supported by XDx)  
Timothy M. Millington, MD (supported by Novartis)  
Satish N. Nadig, MD (supported by Roche)  
Takeshi Oyaizu, MD, PhD (supported by Actelion)  
Sonja Schrepfer, MD (supported by Astellas)
- 2006 Rachel L. Anderson, MBBS (supported by Roche)  
Zhaohui Li, PhD (supported by Transmedics)  
Heather E. Merry, MD (supported by Encysive)  
Edward N. Seung, PhD (supported by XDx)  
Matthew J. Weiss, MD (supported by Novartis)
- 2005 Ryan C. Fields, MD (supported by Chiron)  
Arne Neyrinck, MD (supported by Astellas)  
Ahmad Saad, MD (supported by Roche)
- 2004 Christian A. Gleissner, MD (supported by Astellas)  
Tsuyoshi Shoji, MD, PhD (supported by Actelion)  
Kendra N. Taylor, PhD (supported by Roche)  
Monica Zwierzchonieuska, MD (supported by XDx)
- 2003 Ewout J. van den Bos, MD (supported by Astellas)  
Felix Fernandez, MD (supported by Roche)
- 2002 Ruediger Hoebelt, MD (supported by Roche)
- 2001 Arnar Geirsson, MD (supported by Roche)  
Matteo Vatta, PhD (supported by Roche)
- 2000 Richard S. Lee, MD (supported by Novartis)  
Christopher H. Wigfield, FRCS (supported by Roche)
- 1999 George Juang, MD (supported by Novartis)  
Sivasai Krovvidi, PhD (supported by Roche)  
Satoshi Saito, MD (supported by Novartis)

- 1998 Donald Wong, PhD (supported by Roche)  
 Kelly S.A. Blair, MD (supported by Roche)  
 A.M. El Gamel, MD (supported by Roche)  
 Christine L. Lau, MD (supported by Wyeth-Ayerst)  
 Scott D. Ross, MD  
 Margaret L. Schwarze, MD (supported by Novartis)
- 1997 Jonathan Chen, MD (supported by Roche)  
 Alyssa M. Krasinskas, MD (supported by Astellas)  
 Owen T. Lawrence, MD (supported by Ortho-Biotech)  
 Anne K. Raisanen-Sokolowski, MD (supported by Roche)
- 1996 Tuija S. Ikonen, MD (supported by Roche)  
 Andrew F. Pierre, MD (supported by Ortho-Biotech)
- 1995 Frances L. Johnson, MD (supported by Ortho-Biotech)

#### **ISHLT Transplant Registry Junior Faculty Award**

- 2008 Cynthia Gries, MD, MSc  
 Scott Halpern, MD, PhD  
 Josef Stehlik, MD, MPH
- 2007 Beth D. Kaufman, MD

#### **ISHLT Nursing and Social Sciences Research Grant**

- 2008 Stacey M. Pollock-BarZiv, PhD
- 2007 Mi-Kyung Song, PhD
- 2006 Thierry Troosters, PhD
- 2005 Annemarie F. Kaan, MCN
- 2004 Deidre E. Logan, PhD
- 2003 Diane H. Leloudis, RN, MSN  
 Janet E. Madill, PhD
- 2002 Annette J. De Vito Dabbs, RN, MN, PhD
- 2001 Lynn Doering, RN, DNSc
- 2000 Nancy M. Albert, MSN, RN
- 1999 Jeanne Salyer, PhD
- 1998 Katherine St. Clair, RN, MSN
- 1997 Eileen Collins, RN, PhD

#### **Caves Award**

- 2008 Satish N. Nadig, MD
- 2007 Heather E. Merry, MD
- 2006 Gregor Warnecke, MD
- 2005 Sigrid Sandner, MD  
 Frank D'Ovidio, MD
- 2004 M.D. Peterson, MD
- 2003 Sigrid Sandner, MD
- 2002 Peter Blaha, MD
- 2001 Alexander S. Krupnick, MD
- 2000 Michael P. Fischbein, MD
- 1999 Joerg Koglin, MD
- 1998 Carla C. Baan, MD
- 1997 Simon D. Eiref, MD
- 1996 Moninder S. Bhabra, MD
- 1995 Elizabeth A. Davis, MD
- 1994 Jobst Winter, MD  
 Alain Chapelier, MD
- 1993 David Marshman, MD
- 1992 David P. Kapelanski, MD
- 1991 A. Jiminez, MD
- 1990 Andres J. Duncan, MD
- 1989 A.M. Wood, MD
- 1988 Charles D. Fraser, Jr., MD
- 1987 Wim Van Der Bij, MD
- 1986 Stuart J. Knechtle, MD
- 1985 Michael A. Breda, MD

1984 Hermann Reichensperner, MD  
1983 Robbin G. Cohen, MD

**Nursing Excellence Research Award**

2008 Annette DeVito Dabbs, RN, PhD  
2007 Christianne Kugler, PhD  
2006 Kathleen L. Grady, PhD, RN  
2005 Mary Amanda Dew, PhD

## **International Society for Heart and Lung Transplantation 29th Annual Meeting and Scientific Sessions**

### **ABOUT ISHLT**

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2700 members from over 45 countries, representing over 10 different disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, and transplant coordinators. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The mission of the Society is:

1. To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.
2. To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.
3. To hold scientific meetings featuring presentations and discussions relevant to these disciplines.
4. To sponsor a scientific journal for the publication of manuscripts related to these disciplines.
5. To establish and maintain an international registry for heart and lung transplantation.
6. To award research grants and establish endowments for the study of these disciplines.

### **ABOUT PARIS**

Dubbed the City of Light, Paris is the most popular tourist destination in the world. World class restaurants, world class museums, world class shopping, endless entertainment, fascinating history, beautiful and charming neighborhoods, easy to get around on foot or by metro – Paris has it all. By day or by night, you can explore the city as you please. Nothing we can say here can replace what has already been written and said about Paris. Enjoy April in Paris!

### **HIGHLIGHTS OF THE SCIENTIFIC PROGRAM**

#### **Plenary Session Highlights**

Several excellent Plenary Sessions have been organized, all of which are formatted to profile the best of the abstract submissions and invited lectures by experts on topics related to the abstracts. The plenary session themes include basic science and long term outcomes, mechanical support for the heart and lung, and important data from a variety of clinical trials. Of special note is the Pioneer Lecture that will be given by Christian Cabrol during the Opening Plenary Session. Dr. Cabrol performed the first heart transplant in Europe in 1968, performed the first heart lung transplant in Europe in 1982, and performed the first Jarvik total artificial heart implant in Europe in 1986. He was the President of ISHLT during the last ISHLT Annual Meeting in Paris in 1991.

#### **Lunch Symposia Highlights**

This year, ISHLT will again offer 3 lunch symposia. The first is oriented toward the treatment of nontraditional PH patients, the second will address coronary artery vasculopathy, and the third will address generics in transplantation. The CAV luncheon is designed as a complement to a CAV Diagnostic Grading Scale that ISHLT is developing. The generics in transplantation is designed as a complement to a white paper on the use of generics in transplantation that ISHLT is developing.

#### **Lung Transplant Highlights**

As a result of the enthusiasm and support of all members of the pulmonary council, Lung Transplantation will be very strongly represented in the program for the forthcoming meeting in Paris. There are 3 satellite symposia of specific relevance to pulmonary council members.

There is a symposium dedicated to furthering our understanding of immunomodulation strategies after lung transplantation, including both drug based and non-drug based approaches to immunosuppression. In addition the symposium will review evolving technologies for monitoring those on immunosuppression.

A second symposium will focus on maximizing donor and candidate management prior to lung transplant. This will provide a state of the art review of key donor related issues including the role of new approaches to increased donor lung supply and optimize donor lung management. This symposium will culminate in a debate on the relative value of high urgency listing for lung transplant which promises to be lively.

A third symposium is being held jointly with our colleagues from the Infectious Diseases council and will focus on the role of infection in the development and worsening of Bronchiolitis Obliterans Syndrome. The program will evaluate evidence

supporting the importance of non-alloimmune injury to the lung allograft due to infection and its consequences on graft function.

In addition to our 3 symposia, there will be an impressive 7 concurrent oral sessions during the meeting covering a wide range of clinical, translational and basic science studies in lung transplantation. These sessions represent the very best contemporary work being performed in the lung transplant community at present. Finally there are 2 mini-oral sessions and numerous posters specific to lung transplant to complete what promises to be an excellent and very exciting program for ISHLT Paris 2009.

### **Clinical Heart Transplantation Highlights**

There was a record number of abstracts submitted about clinical heart transplantation this year; the standard of the submissions was very high. We will be having 7 oral sessions covering clinical outcomes, immunosuppressive strategies including induction therapy, new perspectives in the diagnosis of cardiac rejection, the role of antibodies, long-term issues including CAV as well as specific clinical challenges. There will also be a whole mini-oral session devoted to heart transplantation. Among the pre-meeting satellite symposia, there will be a session devoted to the diagnosis and management of right ventricular failure both before and after transplantation and a session reviewing issues related to adult congenital heart disease and transplantation.

### **Infectious Disease Highlights**

The infectious disease content of the meeting is focused on presentations and discussions balanced between clinical and basic scientific work in transplantation.

How infection accelerates the pathway to rejection is explored using the BOS model and pseudomonas, respiratory viruses, and CMV, investigating the possibility of a common pathway. Advances in the understanding of CMV's role at the cellular and molecular level will be presented in several elegant studies along with several new diagnostic and therapeutic strategies to control infection in the transplant and VAD patient. Clinical studies will present data on varied CMV prophylaxis strategies, unique viral pathogenesis and fungal activity pre- and post transplantation as well as impact of different immunosuppression agents on clinical outcome. Donor infection issues will be discussed.

### **Junior Faculty Highlights**

The newly-formed Junior Faculty and Trainees Council (JFTC) would like to highlight some offerings at the ISHLT meeting for our younger members. To begin with, trainees should know that the ISHLT will be offering travel awards for between 10 and 25 attendees. Awardees must be residents or fellows in training, and applications will be available in early 2009. Our new council is hoping to grow, and an organizational meeting will be held in Paris of our group, where new workforce committee members will be selected, including a new chair-elect. The Junior Faculty Luncheon will be held once again: a forum for fellows to present their most challenging cases for comment by leaders in the field. We hope this will once again be fun for all involved. Some of the more interesting educational offerings will involve insight into how we might be practicing organ transplantation in the years to come with discussions of lung assist devices, engineered hearts, ex-vivo lung resuscitation, and calcineurin-inhibitor free immunosuppression. We look forward to all of this, as well as excellent reviews of immunosuppression, long-term survival, and donor management. Finally, don't miss the presentation of the Philip K. Caves Award where the society recognizes the best abstract presented by a trainee.

### **Nursing and Social Science Highlights**

The Nursing and Social Sciences Council will be very comprehensively and internationally represented at the ISHLT Meeting and Scientific Sessions in Paris, 2009. Our 2009 program has been designed, considering prior program evaluations from our council membership. Our exciting satellite symposium, "Hospital to Home: Life and Let Live" focuses on meeting the needs of our patients as they transition from hospital to home. Topics include discharge planning, caregiver burden, and management of VAD, heart transplant, and lung transplant patients in the community setting, as presented by our expert international clinicians.

Oral, mini oral, and general poster sessions will address the topics of quality of life, social support, patient compliance, and more in both pediatric and adult populations who receive mechanical circulatory support devices or are recipients of heart or lung transplantation. These presentations will highlight the best research submitted this year by researchers from around the globe.

Our sessions in Paris will provide you with the opportunity to consult with expert clinicians and researchers regarding your own clinical practice and research projects. We look forward to seeing you in Paris at this outstanding scientific meeting. Don't forget to join us at our Council meeting. Paris is the perfect place to meet your Council leadership, volunteer to join committees, and help us to plan for future council programs.

### **Pulmonary Hypertension Highlights**

Pulmonary Hypertension will be a major focus of the 2009 ISHLT Annual meeting in Paris. The PH council is excited that with the support of an exciting international faculty, we are looking forward to a stimulating program.

A half day satellite symposium on PAH covering several aspects of PAH is the most exciting feature of this year's meeting. The session, entitled State of the Art Management Issues in PH and RV Failure: A Comprehensive International



Perspective is comprised of three sub-sessions entitled Cardiovascular Consequence of PH: Focus on Preserving the Right Ventricle - Advanced Medical and Surgical Therapies, Universal Issues in Right Ventricular Failure and Pulmonary Hypertension: New Concepts in Pathophysiology, Imaging and Management, and Cardiovascular Consequence of PH: Focus on Non-Traditional PH Patients. This last sub-session is a luncheon symposium and includes a box lunch for all who register for it. There is no fee to register or to attend, but if you wish to receive a box lunch, you must register in advance. These sessions include invited lectures as well as Pro-Con debates.

A record number of excellent pulmonary hypertension abstracts were both submitted and accepted this year. These original works will be highlighted in three oral sessions addressing prognostication, lessons learned from registries and the bench, and genes and peptides. Additionally, there will be one mini-oral session and a number of posters.

Finally, one of the featured abstracts in the closing Plenary Session will feature data from the ARIES trial. These sessions represent a significant increased commitment by ISHLT to the pulmonary hypertension community and will offer an inspiring international perspective on the diagnosis, management and treatment of PH.

### **Pediatric Highlights**

There were a record number of submissions this year in the category of pediatric transplantation. Three oral scientific abstract sessions, a mini-oral session and a poster session will be devoted to pediatric transplantation. The themes of the oral and mini-oral poster sessions include recipient factors that determine outcomes of pediatric heart and lung transplantation, early and late rejection in pediatric heart and lung recipients, late outcomes following heart and lung transplantation, mechanical circulatory support and the importance of alloantibodies in pediatric heart transplantation. There will be several Satellite Symposia of particular interest to pediatric council members, including a session on "Heart Transplantation in the Adult with Congenital Heart Disease", a session entitled "Pediatric Transplantation- Looking beyond the graft" that covers topics such as nutrition, renal dysfunction, quality of life, adherence, cognition and transition of care in the pediatric transplant recipient and a session on issues in transplantation in the patient with genetic diseases. It should be a great meeting, look forward to seeing everyone in Paris!

### **Heart Failure Highlights**

The CHF council in conjunction with the Clinical Transplant and Pulmonary Hypertension Councils will sponsor a symposium entitled State of the Art Management Issues in PH and RV failure: A Comprehensive International Perspective which will review the current knowledge of right ventricular function and failure across the spectrum of pulmonary arterial hypertension, chronic heart failure, mechanical circulatory support and cardiac transplantation.

The Novel Alternative Therapies Session will focus upon emerging potential therapies for chronic heart failure and will feature an invited lecture on the potential role of gene therapy with SERCA 2A in advanced heart failure.

### **Pathology and Basic Science Highlights**

The pathology and basic science professionals within ISHLT will have several sessions of interest to them. Satellite sessions of interest include: Antibody Mediated Rejection and Accommodation in Heart Transplantation, Molecular Profiling in Heart and Lung transplantation. Concurrent sessions of interest include: the role of regulatory T-cells in allograft rejection, complement activation products as markers of antibody mediated rejection, the opening plenary session presentations on B-cell biology, basic mechanisms of BOS, novel therapeutics targeting rejection and injury, and regulation in experimental immunosuppression,

### **Mechanical Support Highlights**

Mechanical Circulatory Support will be well represented at the annual meeting. Sessions of note include the second sessions of the PH Symposium, Universal Issues in Right Ventricular Failure and Pulmonary Hypertension: New Concepts in Pathophysiology, Imaging and Management, which includes several lectures on RV failure, RVADS, and LVADS. There is also a satellite symposium entitled Prevention & Management of Adverse Events in VAD's and TAH. The Friday Plenary Session is devoted to discussions about mechanical support for hearts and lungs. There will be a lecture by Doris Taylor on Prospects for and Engineered Heart and a point counterpoint on Novalung and ECMO. Several featured abstracts will address improvements in quality of life after MCSD implant, major clinical outcomes in children bridged to heart transplant using MCS, main predictors for long-term weaning success. Eight concurrent oral sessions, a mini oral session, and numerous posters round out the MCS offerings at the meeting.

### **Phillip K. Caves Award Session**

The 8 finalists for the Philip K. Caves Award will present their original research work in a dedicated session. This prestigious Award is named for the pioneer of the technique of transvenous endomyocardial biopsy. The \$1000 prize is awarded to the best presentation by a resident/fellow/student who is first author of the abstract. Come and support the best and brightest residents, fellows and graduate students – the future of our society - as they present their research findings and are judged for the winner of this prestigious award.

### **President's Gala Reception**

The President's Gala Reception will be held at the **Hôtel de Ville**, which is French for City Hall. Work on the hall was begun in 1533 and completed in 1628. In 1871, a fire destroyed the building, leaving only the stone shell. The interior of the Hôtel de Ville was rebuilt within the stone shell that had survived the fire. While the rebuilt Hôtel de Ville is from the outside a copy of the 16th century building that stood before the fire, the new interior was based on an entirely new design, with ceremonial rooms lavishly decorated in the 1880s style. The decor featured murals by the leading painters of the day. It is a truly gorgeous building and an excellent setting for the President's Gala Reception. One ticket to the Gala Reception is included with each paid registration. **A cash bar will be available at the Gala. Please note that drink tickets must be purchased in advance at the ISHLT Registration Desk in the Palais des Congres. Note that transportation to the Gala is not provided by ISHLT. Excellent direct access is available via Metro (Line 1) from the Porte Maillot Station just outside the Palais des Congres, to the Hotel de Ville Station.**

## **International Society for Heart and Lung Transplantation 29th Annual Meeting and Scientific Sessions**

### **CONTINUING MEDICAL EDUCATION INFORMATION**

#### **Accreditation**

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 31 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

#### **Educational Objectives**

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

#### **Goals**

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease: and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

#### **Target Audience**

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

#### **Learning Objectives**

At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of:

1. Organ preservation, procurement, donor management and their implications for organ viability, donor selection, and recipient outcomes
2. Identification, prevention, and improvement of treatment for post-transplant infectious diseases and other complications to improve patient outcomes
3. Comparing and evaluating the advantages and disadvantages of various mechanical circulatory and respiratory support systems and their associated patient selection criteria
4. Describing the state-of-the-art in clinical heart and lung failure treatment and the criteria for and outcome implications of transplant versus non-transplant therapies
5. Evaluating issues of controversy in the selection of candidates for heart and lung transplantation, such as age, prior transplantation, and comorbidities
6. Comparing and evaluating the advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
7. Understanding the various methods of diagnosing, monitoring, and treating transplant rejection to improve patient outcomes
8. Describing how psychosocial and behavioral issues impact clinical post-transplant outcomes and quality of life for patients
9. Identifying current animal and other laboratory models relevant to the basic science of transplant immunobiology and discuss their application to the transplant setting
10. Understanding the immunobiology of organ selection and techniques utilized to detect and quantify HLA and non HLA antibody and the application of crossmatch results to select donors and subsequent post transplant management

The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of

**Gold Level Partner**  
**ASTELLAS PHARMA**  
**NOVARTIS**

**Silver Level Partner**  
**GILEAD**  
**ROCHE**  
**XDx**

**Friend of the Society**  
**QUALITY ASSURED SERVICES**

toward this

Twenty-Ninth Annual Meeting and Scientific Sessions

## **DISCLOSURE**

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Only those indicating such a relationship are listed in the table on the following pages. All others have indicated they have no such relationship to disclose. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Disclosure spreadsheet to come

**International Society for Heart and Lung Transplantation  
29th Annual Meeting and Scientific Sessions**

**SCHEDULE AT A GLANCE**

**TUESDAY, APRIL 21, 2009**

**8:00 AM – 1:00 PM**

ISHLT Board of Directors Meeting (Pissarro/Cezzane, Hotel Concorde LaFayette)

**8:00 AM – 8:00 PM**

Exhibit Booth Installation/Set-up (Hall Maillot)

**1:00 PM – 3:00 PM**

Registry Executive Committee Meeting (Salle de Sous-Commission J, Hotel Concorde LaFayette)

Communications Committee Meeting (Salle de Sous-Commission K, Hotel Concorde LaFayette)

**3:30 PM – 5:30 PM**

Education Committee Meeting (Salle de Sous-Commission I, Hotel Concorde LaFayette)

Registries and Databases Committee Meeting (Salle de Sous-Commission H, Hotel Concorde LaFayette)

**5:00 PM – 8:00 PM**

Registration Desk Open (Hall Maillot)

**5:00 PM – 8:00 PM**

Slide Ready Room Open (Room 202/203)

**WEDNESDAY, APRIL 22, 2009**

**7:00 AM – 7:00 PM**

Registration Desk Open (Hall Maillot)

**7:00 AM – 7:00 PM**

Slide Ready Room Open (Room 202/203)

**7:15 AM - 8:15 AM**

Corporate Partner Breakfast (Etoile/Longchamp, Hotel Concorde LaFayette)

**7:30 AM – 10:30 AM**

Exhibit Booth Set-up (Hall Maillot)

**7:30 AM – 10:30 AM**

Poster Mounting (Hall Maillot)

**7:30 AM – 8:00 PM**

Internet Café Open (Hall Maillot)

**8:30 AM – 10:30 AM**

**Satellite Symposia**

1: Prevention & Management of Adverse Events in Ventricular Assist Devices and Total Artificial Hearts (Main Theater)

2A: State of the Art Management Issues in PH and RV Failure: A Comprehensive International Perspective:

Cardiovascular Consequence of Pulmonary Hypertension: Focus on Preserving the Right Ventricle - Advanced Medical and Surgical Therapies (Blue Theater)

3: Heart Transplantation in Adults with Congenital Heart Disease (Salle Maillot)

4: Immunomodulation: Emerging Concepts in Therapy and Monitoring (Room 252AB)

5: Hospital to Home: "Live and Let Live" (Room 242AB)

6: Antibody Mediated Rejection and Accommodation in Heart Transplantation (Room 241)

**9:00 AM – 5:00 PM**

Press Office Open (Room 201)

**10:30 AM – 11:00 AM**

**Coffee Break/View Posters/Visit Exhibits** (Hall Maillot)

**10:30 AM – 8:00 PM**

**Exhibit and Poster Halls Open** (Hall Maillot)

**11:00 AM – 1:00 PM**

**Satellite Symposia**

7: Maximizing Donor and Candidate Management Prior to Lung Transplantation

2B: State of the Art Management Issues in PH and RV Failure: A Comprehensive International Perspective: Universal Issues in Right Ventricular Failure and Pulmonary Hypertension: New Concepts in Pathophysiology, Imaging and Management (Blue Theater)

9: Infection & BOS: The Chicken or the Egg (Salle Maillot)

10: Cardiac Transplantation for Unusual Diseases (Room 252AB)

11: Pediatric Transplantation – Looking Beyond the Graft (Room 242AB)

12: Molecular Profiling in Heart and Lung Transplant Rejection (Room 241)

**1:00 PM -1:30 PM**

**Box Lunch Pick-Up** (box lunches may be picked up in the Registration Area; advance purchase and ticket required; lunch seating is available in Salle Maillot and Blue Theater foyers; food and drink are not allowed in the Blue Theater; ticket required for box lunch only; symposium open to all meeting delegates.)

**1:30 PM – 2:45 PM**

**Lunchtime Symposium: *Cardiovascular Consequence of Pulmonary Hypertension: Focus on Non-Traditional Pulmonary Hypertension Patients*** (Blue Theater)

**1:15 PM – 2:45 PM**

**Past Presidents' Luncheon** (Room 243)

**3:00 PM – 5:00 PM**

**Opening Plenary Session** (Main Theatre)

**5:00 PM – 7:00 PM**

**Heart Failure Guidelines Workforce Meeting** (Room 243)

**5:00 PM – 5:30 PM**

**Coffee Break/View Posters/Visit Exhibits** (Hall Maillot)

**5:30 PM – 7:00 PM**

**Concurrent Sessions**

1: Priming the Pumps with Appropriate Patients (Main Theatre)

2: Measuring Clinical Outcomes after Lung Transplant (Blue Theatre)

3: Donor Management (Salle Maillot)

4: Outcomes of Pediatric Heart and Lung Transplant: Recipient Factors (252AB)

5: Allograft Rejection: Role of Regulatory T-Cells (242AB)

6: Complement Activation Products as Markers of Antibody Mediated Rejection (241)

**7:00 PM – 8:00 PM**

**General Posters/Wine Reception** (Hall Maillot)

**9:00 PM – 10:30 PM**

**Gala Reception** (City Hall/Hotel de Ville)

One ticket to the Gala Reception is included with each paid registration. A cash bar will be available at the Gala. Please note that drink tickets must be purchased in advance at the ISHLT Registration Desk in the Palais des Congres. Note that transportation to the Gala is not provided by ISHLT. Excellent direct access is available via Metro (Line 1) from the Porte Maillot Station, just outside the Palais des Congres, to the Hotel de Ville Station.

**THURSDAY, APRIL 23, 2009**

**7:30 AM – 6:30 PM**

Slide Ready Room Open (Room 202/203)

**7:30 AM – 7:00 PM**

Registration Desk Open (Hall Maillot)

**7:30 AM – 7:30 PM**

Internet Café Open (Hall Maillot)

**7:30 AM – 10:30 AM**

**Poster Mounting** (Hall Maillot)

**7:45 AM – 8:45 AM**

Scientific Council on Pathology and Basic Science Meeting (Room 241)

Scientific Council on Infectious Diseases Meeting (Room 243)

Scientific Council on Mechanical Circulatory Support Meeting (Salle Maillot)

Scientific Council on Pulmonary Hypertension Meeting (Room 242AB)

**9:00 AM – 5:00 PM**

**Press Office Open** (Room 201)

**9:00 AM – 11:00 AM**

**Plenary Session** (Main Theatre)

**11:00 AM – 11:30 AM**

**Coffee Break/View Posters/View Exhibits** (Hall Maillot)

**11:00 AM – 7:30 PM**

**Exhibit and Poster Halls Open** (Hall Maillot)

**11:30 AM – 1:00 PM**

**Concurrent Sessions**

7: Outcomes in Clinical Heart Transplantation (Main Theatre)

8: Approaches to Treating and Diagnosing BOS (Blue Theatre)

9: Stem Cell Therapy and Remodeling (Salle Maillot)

10: Pediatric Thoracic Transplantation: MCS and Rejection (252AB)

11: Organ Preservation (242 AB)

12: Quality of Life in Transplantation "Bonjour La Vie"? (241)

**1:00 PM -1:15 PM**

**Box Lunch Pick-Up** (box lunches may be picked up in the Registration Area; advance registration and ticket required; lunch seating is available in Salle Maillot and Blue Theater foyers; food and drink are not allowed in the Blue Theatre)

**1:15 PM – 2:45 PM**

**Lunch Symposium: *Die Another Day: New Perspectives on Cardiac Allograft Vasculopathy*** (Main Theater)

Supported by an Educational Grant from Novartis

(ticket required for box lunch only; symposium open to all meeting delegates)

**1:15 PM – 2:45 PM**

**JHLT Editorial Board Meeting** (Room 243) (Lunch Provided)

**1:15 PM – 2:45 PM**

**Mini-Oral Sessions 1-4**

**3:00 PM – 4:30 PM**

**Concurrent Sessions**

13: Role of Antibodies in Heart Transplantation (Main Theatre)

14: Medical Management of MCS Patients (Blue Theatre)

15: Prognosticating in Pulmonary Arterial Hypertension: Do We Have Enough Information? (Salle Maillot)

16: Primary Cardiac Allograft Failure: An Under-Reported But Frequently Fatal Problem (252 AB)

17: Immunologic Dance with Infection (242 AB)

18: Philip K. Caves Award Candidate Presentations (241)

**4:30 PM – 5:00 PM**

**Coffee Break/View Posters/Visit Exhibits** (Hall Maillot)



**5:00 PM – 7:30 PM**  
**CAV Guidelines Workforce Meeting** (Room 243)

**5:00 PM – 6:30 PM**  
**Concurrent Sessions**

- 19: Building Bridges to Transplant with Mechanical Support (Main Theatre)
- 20: Long Term Issues/Cardiac Allograft Vasculopathy (Blue Theatre)
- 21: Effects of Implementing an Allocation System in Lung Transplant (Salle Maillot)
- 22: Picking Your Poison: The Pitfalls of Immunosuppressive Therapy (252 AB)
- 23: Bronchiolitis Obliterans Syndrome: Basic Mechanisms (242 AB)
- 24: Risk Stratification and Management of Advanced Heart Failure (241)

**6:30 PM – 7:30 PM**  
**PAH Guidelines Workforce Meeting** (Room 273)

**6:30 PM – 7:30 PM**  
**General Posters/Wine Reception** (Hall Maillot)

**6:30 PM – 7:30 PM**  
**Junior Faculty and Trainee Council Meeting** (Room 241)

**FRIDAY, APRIL 24, 2009**

**7:30 AM – 10:30 AM**  
Poster Mounting (Hall Maillot)

**7:30 AM – 6:30 PM**  
Slide Ready Room Open (Room 202/203)

**7:30 AM – 7:00 PM**  
Registration Desk Open (Hall Maillot)

**7:30 AM – 7:30 PM**  
Internet Café Open (Hall Maillot)

**7:45 AM – 8:45 AM**  
Scientific Council on Pediatric Transplantation Meeting (Room 241)  
Scientific Council on Nursing and Social Science Meeting (Room 243)  
Scientific Council on Pulmonary Transplantation Meeting (Salle Maillot)  
Scientific Council on Heart Failure and Transplant Medicine Meeting (Room 242AB)

**9:00 AM – 5:00 PM**  
**Press Office Open** (Room 201)

**9:00 AM – 11:00 AM**  
**Plenary Session** (Main Theatre)

**11:00 AM – 11:30 AM**  
**Annual Business Meeting** (Main Theater)

**11:00 AM – 11:30 AM**  
**Coffee Break/View Posters/Visit Exhibits** (Hall Maillot)

**11:00 AM – 7:30 PM**  
**Exhibit and Poster Halls Open** (Hall Maillot)

**11:30 AM – 1:00 PM**  
**Concurrent Sessions**  
25: Optimizing Outcomes After Mechanical Circulatory Support (Main Theatre)  
26: Heart Transplantation: Clinical Challenges (Blue Theatre)  
27: Gastric Aspiration: Pathway to Allograft Injury (Salle Maillot)  
28: Steroid Free Immunosuppression: Myth or Reality (252 AB)

- 29: Novel Therapeutics Targeting Rejection and Injury (242 AB)  
30: Social Support - "The Good, the Bad, and the Lonely" (241)

**1:00 PM – 1:30 PM**

**Box Lunch Pick-Up** (box lunches may be picked up in the Registration Area; advance purchase and ticket required; lunch seating is available in Salle Maillot and Blue Theater foyers; food and drink are not allowed in the Blue Theater; ticket required for box lunch only; symposium open to all meeting delegates.)

**1:30 PM – 2:45 PM**

**Lunchtime Symposium: *Generics in Thoracic Transplantation: Boon or Bane?*** (Main Theater)

**1:15 PM – 2:45 PM**

**Fellows Luncheon** (Room 243) (pre-registration and ticket required)

**1:15 PM – 2:45 PM**

**Standards and Guidelines Committee Meeting** (Room 273) (bring your own box lunch)

**1:15 PM – 2:45 PM**

**Mini-Oral Sessions 5-8**

**3:00 PM – 4:30 PM**

**Concurrent Sessions**

- 31: New Perspectives in Cardiac Rejection (Main Theatre)  
32: Revelations about Rotary Pumps (Blue Theatre)  
33: Understanding Mechanism in the Development of BOS (Salle Maillot)  
34: Genes and Peptides: Can They Help Guide Pulmonary Hypertension Management? (252 AB)  
35: Pediatric Thoracic Transplantation: Late Outcomes (242 AB)  
36: Fitting It Together - CMV in the Underworld: Cellular & Molecular Mischief (241)

**4:30 PM – 5:00 PM**

**Coffee Break/View Posters/Visit Exhibits** (Exhibit Hall)

**5:00 PM – 6:30 PM**

**Concurrent Sessions**

- 37: Emergent Analyses of Novel Devices (Main Theatre)  
38: Donor Contributions to Lung Allograft Function (Blue Theatre)  
39: Induction Therapy, Clinical Outcomes (Salle Maillot)  
40: Experimental Immunosuppression: Is Regulation the Key? (252 AB)  
41: Good Heart + Bad Body = Good Outcomes? (242 AB)  
42: Optimizing the High Risk Heart Transplant Candidate (241)

**6:00 PM – 7:30 PM**

**2010 Program Committee Meeting** (Room 243)

**6:30 PM – 7:30 PM**

**PAH Guidelines Workforce Meeting** (Room 273)

**6:30 PM – 7:30 PM**

**General Posters/Wine and Cheese Reception** (Hall Maillot)

**7:30 PM – 11:59 PM**

**Exhibit Hall Tear Down**  
**Poster Tear Down**

**SATURDAY, APRIL 25, 2009**

**7:00 AM – NOON**

**Slide Ready Room Open** (Room 202/203)

**8:00 AM – 10:30 AM**

**Internet Café Open** (Hall Maillot)

**8:00 AM – 10:30 AM**

Registration Desk Open (Hall Maillot)

**8:15 AM – 10:15 AM**

**Plenary Session** (Main Theatre)

**10:15 AM – 10:30 AM**

**Coffee Break** (Hall Maillot)

**10:30 AM – NOON**

**Concurrent Sessions**

43: Mechanical Support and Myocardial Recovery (Main Theatre)

44: Immunosuppression for Heart Transplantation: New Strategies (Blue Theatre)

45: Primary Graft Dysfunction: Evaluating Mechanisms in the Lung (Salle Maillot)

46: Pulmonary Arterial Hypertension: Lessons from Registries and the Bench (252 AB)

47: Novel Technologies and Therapies in Heart Failure (242 AB)

48: Organ Allocation (241)

**NOON – 1:00 PM**

**Council Reports to the Membership and Board** (Room 242 AB)

**1:30 PM – 5:00 PM**

**ISHLT Board of Directors Meeting** (Sisley Room, Hotel Concorde LaFayette)

## SCIENTIFIC PROGRAM

All meetings and activities will take place at the Palais des Congres unless otherwise specified. All papers will be presented in English.

### WEDNESDAY, APRIL 22, 2009

**8:30 AM – 10:30 AM**

**SATELLITE SYMPOSIUM 1: *Prevention & Management of Adverse Events in Ventricular Assist Devices and Total Artificial Hearts*** (Main Theater)

Chairs: Matthias Loebe, MD, PhD and Roberta C. Bogaev, MD, FACC

**8:30 AM** *Prevention of Thromboembolic Events*, Patricia Massicotte, MD, Stollery Children's Hospital, Edmonton, Alberta, Canada

**8:55 AM** *Nutritional Rehabilitation Post-Ventricular Assist Device*, William Holman, MD, University of Alabama at Birmingham, AL

**9:20 AM** *Breaking My Mechanical Heart – MRSA*, Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

**9:45 AM** *Quality Standards for Device Durability*, Robert Kormos, MD, Presbyterian University Hospital, Pittsburgh, PA

**10:10 AM** *Discussion*

**8:30 AM – 10:30 AM**

**SATELLITE SYMPOSIUM 2: *State of the Art Management Issues in PH and RV Failure: A Comprehensive International Perspective*** (Blue Theater)

**A. *Cardiovascular Consequence of Pulmonary Hypertension: Focus on Preserving the Right Ventricle - Advanced Medical and Surgical Therapies*** (Blue Theater)

Chairs: Evelyn Horn, MD and Raymond L. Benza, MD

**8:30 AM** *Mechanism and Management of Right Ventricular Failure in Pulmonary Hypertension – Current Views*, Robert P. Frantz, MD, Mayo Clinic, Rochester, MN

**8:55 AM** *Going Beyond Monotherapy in Pulmonary Arterial Hypertension – Are Combination Therapies More Effective?* Olivier Sitbon, MD, Hopital Antoine Beclere, Paris, France

**9:20 AM** *Emerging New Therapies in Pulmonary Hypertension – What's On the Horizon*, Marc Humbert, MD, Hopital Antoine Beclere, Paris, France

**9:45 AM** *Report from WHO Conference: When Medical Therapy Fails in Advanced Pulmonary Hypertension – Surgical Options*, Anne Keogh, MBBS, MD, St. Vincent's Hospital, Sydney, Australia

**10:10 AM** *Panel Discussion*

**8:30 AM – 10:30 AM**

**SATELLITE SYMPOSIUM 3: *Heart Transplantation in Adults with Congenital Heart Disease*** (Salle Maillot)

Chairs: Elizabeth Blume, MD and Professor Magdi Yacoub, MD

**8:30 AM** *Indications and Timing: How to Evaluate, When to List*, Michael Burch, MD, Great Ormond Street Hospital for Sick Children, London, UK

**8:50 AM** *Pre-transplant Co-morbidities*, Daphne Hsu, MD, Montefiore Medical Center, Bronx, NY

**9:10 AM** *Use of Mechanical Circulatory Support in the Adult with Congenital Heart Disease*, Brigitte Stiller, MD, Department of Congenital Heart Defects, Deutsches Herzzentrum Berlin, Germany

**9:30 AM** *Surgical Approaches*, Ivan Rebeyka, MD, University of Alberta, Edmonton Canada

**9:50 AM** *Immediate Post-Transplant Considerations*, Clifford Chin, MD, Stanford University, Palo Alto, CA

**10:10 AM** *Long Term Outcomes: Late Morbidities, Re-Tx*, Jonathan Chen, MD, Columbia University, New York, NY

**8:30 AM – 10:30 AM**

**SATELLITE SYMPOSIUM 4: *Immunomodulation: Emerging Concepts in Therapy and Monitoring*** (Room 252AB)

Chairs: Jonathan B. Orens, MD and Hermann Reichenspurner, MD, PhD

**8:30 AM** *A Role for Induction Therapy in the 21<sup>st</sup> Century?* Edward R. Garrity, Jr., MD, University of Chicago Medical Center, Chicago, IL

**9:00 AM** *Clinical Trials, Is There a Place for CNI Free Protocols?* Hendrik Treede, MD, University Clinic Hamburg-Eppendorf, Hamburg, Germany

**9:30 AM** *Photophoresis*, David C. McGiffin, MD, University of Alabama at Birmingham, AL

**9:45 AM** *Total Lymphoid Irradiation*, Paul A. Corris, MB, FRCP, Newcastle University and CT Centre, Newcastle Upon Tyne, United Kingdom

**10:00 AM** *New Approaches to Monitoring the Extent of Immunosuppression*, Sangeeta M. Bhorade, MD, University of Chicago, IL

**8:30 AM – 10:30 AM**

**SATELLITE SYMPOSIUM 5: *Hospital to Home: “Live and Let Live”*** (Room 242AB)

Chairs: Sharon Beer, MSC, RN and Nancy Blumenthal, CRNP

**8:30 AM** *Discharge Planning and Supporting the Transplant Patient in the Community*

a) *Heart*, Kevin Carney, RN, CCTC, Hospital of the University of Pennsylvania, Philadelphia, PA

b) *Lung*, Christiane Kugler, PhD, Hannover Medical School, Hannover, Germany

**9:10 AM** *Home Management of MCS D Patients*, Dawn Christensen, MS, CRNP, Milton S. Hershey Medical Center, Hershey, PA

**9:30 AM** *Caregiver Burden and Support*, Jeanne Salyer, PhD, RN, Virginia Commonwealth University School of Nursing, Richmond, VA

**9:50 AM** *End of Life: Ethical and Practical Issues*

a) *Ethical Issues*, Jane MacIver, RN, MSn, Toronto General Hospital, Toronto, Ontario, Canada

b) *Practical Issues*, William M. Hallinan, RN, MS, University of Rochester Medical Center, Rochester, NY

**8:30 AM – 10:30 AM**

**SATELLITE SYMPOSIUM 6: *Antibody Mediated Rejection and Accommodation in Heart Transplantation*** (Room 241)

Chairs: Elizabeth Hammond MD, PhD and Patrick Bruneval, MD

**8:30 AM** *Complement and its Regulators in Heart Transplantation*, E. Rene Rodriguez, MD, Cleveland Clinic Foundation, Cleveland, OH

**9:00 AM** *Clinical Parameters that Define Cardiac AMR in Adults*, Abdallah Kfoury, MD, FACC, Intermountain Medical Center, Murray, UT

**9:30 AM** *Taking on the Antibodies in Pediatric Heart Transplantation*, Lori West, MD, D.Phil, University of Alberta, Alberta Diabetes Institute, Edmonton, Alberta, Canada

**10:00 AM** *Is Accommodation Relevant to Human Heart Transplantation?* Marilia Cascalho, MD, PhD, University of Michigan, Ann Arbor, MI

**10:30 AM – 11:00 AM**

Coffee Break/Visit Exhibits/View Posters (Exhibit Hall)

**10:30 AM – 8:00 PM**

Exhibit Hall Open

**11:00 AM – 1:00 PM**

**SATELLITE SYMPOSIUM 7: *Maximizing Donor and Candidate Management Prior to Lung Transplantation*** (Main Theater)

Chairs: John Dark, MB, FRCS and Gregory I. Snell, FRACP, MBB

**11:00 AM** *Infectious Concerns in the Potential Lung Brain Dead Donor*, Shahid Husain, MD, MS, University Health Network/University of Toronto, Ontario, Canada

**11:25 AM** *How Can the Opportunities for DCD Lung Donation Be Maximized?* Robert Love, MD, Loyola University Medical Center, Chicago, IL

**11:50 AM** *Ex-vivo Lung Resuscitation: The New Frontier in Donor Management*, Shaf Keshavjee, Toronto General Hospital, Toronto, Ontario, Canada

**12:15 PM** *Organ Care System for Lung*, Redha Souilamas, MD, PhD, European Georges Pompidou Hospital, Paris, France

**12:25 PM Debate:** *There is no Limit to the Severity of Lung Disease in Patients Considered for Lung Transplantation.*  
*Pro:* Stephan Fischer, MD, Medizinische Hochschule Hannover, Germany  
*Con:* Walter Klepetko, MD, University of Vienna, Austria

**12:55 PM** Discussion

**11:00 AM – 1:00 PM**

**SATELLITE SYMPOSIUM 2B. *Universal Issues in Right Ventricular Failure and Pulmonary Hypertension: New Concepts in Pathophysiology, Imaging and Management*** (Blue Theater)

Chairs: Myung H. Park, MD and Frank Pagani, MD, PhD

**11:00 AM** *Mechanisms of Right Ventricular Failure in Volume and Pressure Overload Syndromes*, Thomas G. DiSalvo, MD, Vanderbilt Heart Institute, Nashville, TN

**11:15 AM** *Imaging the Right Ventricle: What Are The Options?* Andrew Peacock, University of Glasgow, United Kingdom

**11:30 AM Debate:** *Pulmonary Hypertension and Chronic Left Heart Failure – Do Pulmonary Hypertension Drug Therapies Have A Place?*

*Pro:* Mardi Gomberg-Maitland, MD, MSc, University of Chicago, IL

*Con:* Robert Naeije, MD, Erasme University Hospital, Brussels, Belgium

**12:00 PM** *Predicting Right Ventricular Failure after Left Ventricular Assist Device: Risk Factors, Mechanisms, Surgical Planning*, David B. Dyke, MD, University of Michigan, Ann Arbor, MI

**12:15 PM** *Management of Right Ventricular Failure Post Heart Transplant and Ventricular Assist Device: Pharmacologic Options*, Allen S. Anderson, MD, University of Chicago Medical Center, Chicago, IL

**12:30 PM** *Management of Right Ventricular Failure Post Heart Transplant and Ventricular Assist Device: Device Options and Weaning*, Edwin C. McGee, Jr., MD, Northern Memorial Hospital, Chicago, IL

**12:45 PM** Panel Discussion

**11:00 AM – 1:00 PM**

**SATELLITE SYMPOSIUM 9: *Infection & BOS: The Chicken or the Egg*** (Salle Maillot)

Chairs: Annette Boehler, MD and Kate Gould, FRCPATH

**11:00 AM** *Pseudomonas Colonization and Infection*, Geert Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

**11:25 AM** *Respiratory Viral Infections*, Lara Danziger-Isakov, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH

**11:50 AM** *Cytomegalovirus*, John F. McDyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

**12:15 PM** *Tying It Together: Potential Common Mechanisms after Infectious Disease*, Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

**12:40 PM Panel Discussion**

**11:00 AM – 1:00 PM**

**SATELLITE SYMPOSIUM 10: *Cardiac Transplantation for Unusual Diseases*** (Room 252AB)

Chairs: J. David Vega, MD and Luis Alonso Pulpon, MD

**11:00 AM *Myocarditis***, Leslie Cooper, MD, Mayo Clinic, Rochester, MN

**11:20 AM *Amyloidosis***, Thomas J. Dengler, MD, Medizinische Universitaetsklinik III, Heidelberg, Germany

**11:40 AM *Metabolic and Skeletomuscular Diseases***, Steven A. Webber, MB, ChB, Children's Hospital of Pittsburgh, PA

**12:00 PM *HIV***, Mario C. Deng, MD, Columbia University Medical Center, New York, NY

**12:20 PM *Chagas Disease and Other Infections***, Fernando Bacal, MD, PhD, Instituto de Caracao, Sao Paulo, Brazil

**12:40 PM *The Best of the Rest***, Michel De Pauw, MD, University Hospital Ghent, Belgium

**11:00 AM – 1:00 PM**

**SATELLITE SYMPOSIUM 11: *Pediatric Transplantation – Looking Beyond the Graft*** (Room 242AB)

Chairs: George Mallory, Jr., MD and Yuk Law, MD

**11:00 AM *Bone Health and Nutrition – Do We Bother Enough?*** Beth D. Kaufman, MD, Children's Hospital of Philadelphia, PA

**11:20 AM *Chronic Kidney Disease – Do We Manage It Well?*** W. Robert Morrow, MD, Arkansas Children's Hospital, Little Rock, AR

**11:40 AM *Cognitive Function and Education – How Well Do They Do?*** Jo Wray, Royal Brompton and Harefield NHS Trust, London, UK

**12:00 PM *Quality of Life and Adherence – Do We Underestimate Their Importance?*** Samantha Anthony, MSW, PhDc, Hospital for Sick Children, Toronto, Ontario, Canada

**12:20 PM *Exercise and the Pediatric Heart or Lung Transplant Recipient – Is It a Good Thing?*** Elfriede Pahl Schuette, MD, Children's Memorial Hospital, Chicago, IL

**12:40 PM *Transition from Pediatric to Adult Care – How Do We Get It Right?*** Christian Benden, MD, University Hospital Zurich, Switzerland

**11:00 AM – 1:00 PM**

**SATELLITE SYMPOSIUM 12: *Molecular Profiling in Heart and Lung Transplant Rejection*** (Room 241)

Chairs: Ronald H. Kerman, PhD, and James George, PhD

**11:00 AM *Transcriptional Profiling as a Mechanistic Discovery Platform***, Kenneth B. Margulies, MD, University of Pennsylvania Health System, Philadelphia, PA

**11:20 AM *Bronchoalveolar Immunologic Profiling of CC Chemokines Predict BOS and Mortality***, John A. Belperio, MD, University of California at Los Angeles, CA

**11:40 AM *Multi Parameter Flow Antibody Detection of Donor Specific Antibodies***, Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

**12:00 PM *Humoral Immunity to Non-HLA Antigens in Antibody Mediated Rejection***, Marlene Rose, PhD, Harefield Hospital, Harefield, Middlesex, United Kingdom

**12:20 PM *Regulatory T Cells in Lung Tx***, Thalachallour Mohanakumar, PhD, Washington University School of Medicine, St. Louis, MO

**12:40 PM Panel Discussion**

**1:15 PM – 2:45 PM**

**PAST PRESIDENTS' LUNCHEON** (Room 243)

**1:00 PM – 1:30 PM**

**BOX LUNCH PICK-UP** (box lunches may be picked up in the Registration Area; advance purchase and ticket required; lunch seating is available in Salle Maillot and Blue Theater foyers; food and drink are not allowed in the Blue Theatre; ticket required for box lunch only; symposium open to all meeting delegates.)

**1:30 PM – 2:45 PM**

**LUNCHTIME SYMPOSIUM: Cardiovascular Consequence of Pulmonary Hypertension: Focus on Non-Traditional Pulmonary Hypertension Patients** (Blue Theater)

Chairs: Srinivas Murali, MD and Deborah Levine, MD

**1:30 PM** *Lessons from REVEAL Registry: Are We Already Treating the Non-Traditional Pulmonary Hypertension Patients?* Adaani Frost, MD, Baylor College of Medicine, Houston, TX

**1:40 PM** **Debate:** *Treating Pulmonary Hypertension in Parenchymal Lung Disease: Vasoactive Therapy Is Effective*

*Pro:* Keith McNeil, FRACP, The Prince Charles Hospital, Brisbane, Australia

*Con:* Reda Girgis, MB, BCh, Johns Hopkins University, Baltimore, MD

**2:00 PM** *Chronic Thromboembolic Pulmonary Hypertension – Are Medical and Surgical Therapies Complementary or Mutually Exclusive?* Stuart W. Jamieson, MB, FRCS, University of California San Diego Medical Center, San Diego, CA

**2:15 PM** *Panel Discussion*

**3:00 PM – 5:00 PM**

**OPENING PLENARY SESSION** (Main Theatre)

Chairs: Mandeep R. Mehra, MD and Randall C. Starling, MD, MPH, FACC

**3:00 PM** *Welcome*, Mandeep R. Mehra, MD, University of Maryland School of Medicine, Baltimore, MD

**3:05 PM** *Color Guard and French National Anthem*

**3:10 PM** *Welcome*, Bertrand Delanoe, Mayor of Paris, introduced by Redha R. Souilamas, MD, PhD, European Georges Pompidou Hospital, Paris, France

**3:15 PM** *Welcome*, Mrs. Roselyne Bachelot, French Minister of Health

**3:20 PM** *Program Committee Report*, Randall C. Starling, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH

**3:25 PM** *ISHLT International Thoracic Registry Report*, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN

**3:50 PM (1) Featured Abstract:** *Focusing on the Future: Development of a Predictive Model for Long-Term Survival*; C.J. Gries<sup>1</sup>, T.C. Rue<sup>2</sup>, P.J. Heagerty<sup>2</sup>, J. Edelman<sup>1</sup>, M.S. Mulligan<sup>3</sup>, C.H. Goss<sup>1</sup> <sup>1</sup>University of Washington School of Medicine, Seattle, WA; <sup>2</sup>University of Washington School of Medicine, Seattle, WA; <sup>3</sup>University of Washington School of Medicine, Seattle, WA

**4:05 PM (2) Featured Abstract:** *Outcomes Following Transplantation for Congenital Heart Disease in Adults*; R.R. Davies<sup>1</sup>, M.J. Russo<sup>1</sup>, J. Yang<sup>1</sup>, J.M. Quaegebeur<sup>1</sup>, R.S. Mosca<sup>1</sup>, J.M. Chen<sup>2</sup> <sup>1</sup>Children's Hospital of New York-Presbyterian, New York, NY; <sup>2</sup>Weill Medical College of Cornell University, New York, NY

**4:25 PM Pioneer Lecture:** Christian Cabrol, MD, La Pitie Hospital, Paris, France

**5:00 PM – 5:30 PM**

Coffee Break/Visit Exhibits/View Posters (Hall Maillot)

**5:00 PM – 7:00 PM**

**Heart Failure Guidelines Workforce Meeting** (Room 243)

**5:30 PM – 7:00 PM**

**CONCURRENT SESSION 1: Priming the Pumps with Appropriate Patients** (Main Theatre)

Chairs: Mark S. Slaughter, MD and Steven SL Tsui, MD, FRCS



**5:30 PM (3)** *Does VAD Therapy as a “Bridge to Candidacy” Apply to the Morbidly Obese?*; J.W. Haft<sup>1</sup>, M.A. Romano<sup>1</sup>, J.C. Matthews<sup>2</sup>, D.B. Dyke<sup>2</sup>, F.D. Pagani<sup>1</sup> <sup>1</sup>University of Michigan, Ann Arbor, MI; <sup>2</sup>University of Michigan, Ann Arbor, MI

**5:45 PM (4)** *HMGB1 — A Sentinel for Outcomes in VAD Patients?*; T.A. Snyder<sup>1</sup>, J. Hu<sup>2</sup>, E.N. Sorensen<sup>2</sup>, E.D. Feller<sup>2</sup>, S.L. Moainie<sup>2</sup>, R.N. Pierson<sup>2</sup>, R.S. Poston<sup>3</sup>, B.P. Griffith<sup>1</sup> <sup>1</sup>Integris Medical Center, Oklahoma City, OK; <sup>2</sup>University of Maryland Medical Center, Baltimore, MD; <sup>3</sup>Boston University, Boston, MA

**6:00 PM (5)** *Lack of Improvement in Prealbumin at Two Weeks Predicts a Poor Outcome after Mechanical Circulatory Support*; K.L. Lockard<sup>1</sup>, L. DeGore<sup>1</sup>, P. Schwarm<sup>1</sup>, S. Winowich<sup>1</sup>, G. O’Shea<sup>1</sup>, M. Siegenthaler<sup>1</sup>, M. Simon<sup>2</sup>, R.L. Kormos<sup>1</sup>, J.J. Teuteberg<sup>2</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>University of Pittsburgh, Pittsburgh, PA

**6:15 PM (6)** *Percutaneous LVAD Support Reverses Neurohormonal Dysregulation and Apoptosis but Increases Inflammation in Profound Refractory Cardiogenic Shock*; N.R. Shah<sup>1</sup>, M.C. Bieniarz<sup>1</sup>, S.S. Basra<sup>3</sup>, R.D. Paisley<sup>4</sup>, P. Loyalka<sup>2</sup>, D.L. Mann<sup>1</sup>, B. Kar<sup>1,2</sup> <sup>1</sup>Baylor College of Medicine, Houston, TX; <sup>2</sup>Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX; <sup>3</sup>University of Texas School of Public Health, Houston, TX; <sup>4</sup>University of Texas Health Science Center, Houston, TX

**6:30 PM (7)** *Risk of Infection after LVAD Placement for Long-Term Support by Body-Mass Index and Device Type*; S. Martin, L. Wellington, K. Stevenson, C. Sai-Sudhakar, M. Firstenberg, D. Blais, L. Louis, B. Sun The Ohio State University Medical Center, Columbus, OH

**6:45 PM (8)** *Using Risk Modeling To Identify Subjects for Studies of LVAD Destination Therapy in Less Ill Cohorts*; T.F. Dardas<sup>1</sup>, J.C. Matthews<sup>1</sup>, T.M. Koelling<sup>1</sup>, J.W. Haft<sup>1</sup>, W.C. Levy<sup>2</sup>, F.D. Pagani<sup>1</sup>, K.D. Aaronson<sup>1</sup> <sup>1</sup>University of Michigan, Ann Arbor, MI; <sup>2</sup>University of Washington, Seattle, WA

**5:30 PM – 7:00 PM**

**CONCURRENT SESSION 2: *Measuring Clinical Outcomes after Lung Transplant*** (Blue Theatre)

Chairs: Marc A. Stern, MD and Lianne G. Singer, FRCPC

**5:30 PM (9)** *Factors Indicative of Long Term Survival after Lung Transplantation: A Review of 890 10-Year Survivors*; E.S. Weiss<sup>1</sup>, J.G. Allen<sup>1</sup>, C.A. Merlo<sup>2</sup>, J.V. Conte<sup>1</sup>, A.S. Shah<sup>1</sup> <sup>1</sup>The Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>The Johns Hopkins University of School of Medicine, Baltimore, MD

**5:45 PM (10)** *Long-Term Outcomes after Alemtuzumab Induction in Lung Transplantation*; S. Shyu<sup>1</sup>, M.A. Dew<sup>2</sup>, A. De Vito Dabbs<sup>3</sup>, M. Crespo<sup>4</sup>, D.B. Zaldonis<sup>5</sup>, B.A. Johnson<sup>4</sup>, S.M. Studer<sup>6</sup>, Y. Toyoda<sup>5</sup>, C.A. Bermudez<sup>5</sup>, B.G. Hattler<sup>5</sup>, J.M. Pilewski<sup>4</sup>, K.R. McCurry<sup>5</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; <sup>3</sup>University of Pittsburgh School of Nursing, Pittsburgh, PA; <sup>4</sup>University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; <sup>5</sup>University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA; <sup>6</sup>Newark Beth Israel Medical Center, St. Barnabas Health Care System, Newark, NJ

**6:00 PM (11)** *HLA Mismatches Influence Lung Transplant Recipient Survival, Bronchiolitis Obliterans, and Rejection – Implications for Donor Lung Allocation*; M. Peltz<sup>1</sup>, L.B. Edwards<sup>2</sup>, M.E. Jessen<sup>1</sup>, D.M. Meyer<sup>1</sup> <sup>1</sup>University of Texas Southwestern Medical Center at Dallas, Dallas, TX; <sup>2</sup>United Network for Organ Sharing, Richmond, VA

**6:15 PM (12)** *ABO Minor Mismatch in Lung Transplantation – An Analysis of the UNOS Database*; D.G. Tang<sup>1</sup>, H.R. Mallidi<sup>1</sup>, D. Weill<sup>2</sup>, B.A. Reitz<sup>1</sup>, R.C. Robbins<sup>1</sup>, G.S. Dhillon<sup>2</sup> <sup>1</sup>Stanford University, Stanford, CA; <sup>2</sup>Stanford University, Stanford, CA

**6:30 PM (13)** *Early Indicators for Obstructive Airway Complications after Lung Transplantation*; T. Fuehner<sup>1</sup>, O. Wiesner<sup>1</sup>, C. DeWall<sup>1</sup>, A. Simon<sup>2</sup>, T. Welte<sup>1</sup>, J. Gottlieb<sup>1</sup> <sup>1</sup>Hannover Medical School, Hannover, Germany; <sup>2</sup>Hannover Medical School, Hannover, Germany

**6:45 PM (14)** *Anti-HLA Antibodies and Antibody-Directed Therapy after Lung Transplantation*; R.R. Hachem<sup>1</sup>, M.R. Morrell<sup>1</sup>, R.D. Yusen<sup>1</sup>, A.A. Aloush<sup>2</sup>, B.F. Meyers<sup>2</sup>, A. Patterson<sup>2</sup>, E.P. Trulock<sup>1</sup> <sup>1</sup>Washington University School of Medicine, St. Louis, MO; <sup>2</sup>Washington University School of Medicine, St. Louis, MO

**5:30 PM – 7:00 PM**

**CONCURRENT SESSION 3: *Donor Management*** (Salle Maillot)

Chairs: Joshua Sonett, MD and Redha R. Souilamas, MD, PhD

**5:30 PM (15) Increased Levels of Interleukin-1  $\alpha$  in Clinically Rejected Donor Lungs;** M. Cypel, H. Kaneda, M. Anraku, J. Yeung, M. DePerrot, A. Pierre, T.K. Waddell, M. Liu, S. Keshavjee University of Toronto, Toronto, ON, Canada

**5:45 PM (16) Trend or Treason: No Increase in Thromboembolic Events in LVAD Patients with Atrial Fibrillation Off Coumadin;** J.N. Baker<sup>1</sup>, S.C. Ennis<sup>1</sup>, K.M. Gonczarek<sup>2</sup>, L. Kleinkauf<sup>1</sup>, C.A. Ennis<sup>1</sup>, K.M. Lam<sup>2</sup>, S.A. Moore<sup>2</sup>, T.E. MacGillivray<sup>1</sup><sup>1</sup>Massachusetts General Hospital, Boston, MA; <sup>2</sup>Massachusetts General Hospital, Boston, MA

**6:00 PM (17) Early and Intermediate Outcomes after Lung Transplantation Using Lung Donation after Cardiac Death;** M. Cypel, M. Sato, E. Yildirim, F. Chen, W. Karolak, V. Leist, J. Yeung, C. Chaparro, M. Hutcheon, L.G. Singer, K. Yasufuku, M. DePerrot, T.K. Waddell, S. Keshavjee, A. Pierre University of Toronto, Toronto, ON, Canada

**6:15 PM (18) Pulmonary Edema in Organ Donors: Comparison of Chest Radiograph Scoring to Lung Weight as a Quantitative Index of Lung Water;** L.B. Ware<sup>1</sup>, A. Neyrinck<sup>2</sup>, H. O'Neal<sup>1</sup>, J.W. Lee<sup>2</sup>, B. Curtis<sup>1</sup>, C.S. Calfee<sup>2</sup>, M.A. Matthay<sup>2</sup><sup>1</sup>Vanderbilt University, Nashville, TN; <sup>2</sup>UCSF, San Francisco, CA

**6:30 PM (19) Serum Lactate Is a Highly Sensitive and Specific Predictor of Post Cardiac Transplant Outcomes Using the Organ Care System;** A. Hamed<sup>1</sup>, S. Tsui<sup>2</sup>, J. Huber<sup>3</sup>, R. Lin<sup>3</sup>, E.C. Poggio<sup>3</sup>, A. Ardehali<sup>4</sup><sup>1</sup>TransMedics, Andover, MA; <sup>2</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>3</sup>BioStatistical Consulting Inc., Burlington, MA; <sup>4</sup>UCLA Medical Center, Los Angeles, CA

**6:45 PM (20) The Resuscitated DCD Donor Heart Is Functionally Superior to the Brainstem Dead Donor Heart;** A. Ali<sup>1</sup>, G. Fajardo<sup>1</sup>, G. Budas<sup>1</sup>, S. Tsuda<sup>1</sup>, Z. Ali<sup>1</sup>, T. Quertermous<sup>1</sup>, D. Bernstein<sup>1</sup>, S. Tsui<sup>2</sup>, R. Robbins<sup>1</sup>, M. Fischbein<sup>1</sup>, S. Large<sup>2</sup>, E. Ashley<sup>1</sup><sup>1</sup>Stanford University Medical Center, Palo Alto, CA; <sup>2</sup>Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom

**5:30 PM – 7:00 PM**

**CONCURRENT SESSION 4: Outcomes of Pediatric Heart and Lung Transplant: Recipient Factors (252AB)**

Chairs: Gerard J. Boyle, MD and Cynthia S. Herrington, MD

**5:30 PM (21) BNP Levels Predict Outcome in Pediatric Heart Failure Patients: Post-Hoc Analysis of the Pediatric Carvedilol Trial;** S.R. Auerbach<sup>1</sup>, M.E. Richmond<sup>1</sup>, J.M. Lamour<sup>2</sup>, E.D. Blume<sup>3</sup>, L.J. Addonizio<sup>1</sup>, R.E. Shaddy<sup>4</sup>, L. Mahony<sup>5</sup>, E. Pahl<sup>6</sup>, D.T. Hsu<sup>2</sup><sup>1</sup>Columbia University, Morgan Stanley Children's Hosp of New York Presbyterian, New York, NY; <sup>2</sup>Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY; <sup>3</sup>Children's Hospital Boston, Boston, MA; <sup>4</sup>Children's Hospital of Philadelphia, Philadelphia, PA; <sup>5</sup>University of Texas Southwestern Medical Center, Dallas, TX; <sup>6</sup>Northwestern University's Feinberg School of Medicine, Children's Memorial Hospital, Chicago, IL

**5:45 PM (22) Impact of ABO-Incompatible Listing on Wait Times and Waitlist Mortality among Infants Listed for Heart Transplant in the US;** C.S.D. Almond<sup>1</sup>, K. Gauvreau<sup>1</sup>, G.E. Piercey<sup>1</sup>, D. Mah<sup>1</sup>, L.B. Smoot<sup>1</sup>, E.D. Blume<sup>1</sup>, F. Fynn-Thompson<sup>2</sup>, T.P. Singh<sup>1</sup><sup>1</sup>Children's Hospital Boston, Boston, MA; <sup>2</sup>Children's Hospital Boston, Boston, MA

**6:00 PM (23) Evaluation of Outcomes of Adolescent Lung Transplantation at Pediatric vs. Adult Centers;** J. Moore<sup>1</sup>, S.C. Sweet<sup>4</sup>, S.H. Covington<sup>2</sup>, J.C. Magee<sup>3</sup><sup>1</sup>SRTR, Arbor Research, Ann Arbor, MI; <sup>2</sup>United Network for Organ Sharing, Richmond, VA; <sup>3</sup>SRTR, University of Michigan, Ann Arbor, MI; <sup>4</sup>Washington University, St. Louis, MO

**6:15 PM (24) Outcomes Following Listing and Transplantation for Infants with Unoperated Non-Hypoplastic Left Ventricle Congenital Heart Disease: A Multi-Institutional Study;** K.J. Guleserian<sup>1</sup>, K.B. Schectman<sup>2</sup>, J. Zheng<sup>2</sup>, R.E. Edens<sup>3</sup>, J.P. Jacobs<sup>4</sup>, W.T. Mahle<sup>5</sup>, S.L. Emerson<sup>1</sup>, E.D. Blume<sup>6</sup>, C.E. Canter<sup>7</sup>, PHTS Investigators<sup>8</sup><sup>1</sup>Children's Medical Center, Dallas, TX; <sup>2</sup>Washington University School of Medicine, St. Louis, MO; <sup>3</sup>University of Iowa Children's Hospital, Iowa City, IA; <sup>4</sup>All Children's Hospital, St. Petersburg, FL; <sup>5</sup>Children's Healthcare of Atlanta, Atlanta, GA; <sup>6</sup>Children's Hospital Boston, Boston, MA; <sup>7</sup>St. Louis Children's Hospital, St. Louis, MO; <sup>8</sup>Pediatric Heart Transplant Study Group, Birmingham, AL

**6:30 PM (25) Perioperative Renal Failure in Pediatric Cardiac Transplant: Outcome and Risk Factors;** L. Tang, T.J. L'Ecuyer Children's Hospital of Michigan, Detroit, MI

**6:45 PM (26) Body Mass Index as Predictor of Pediatric Heart Transplant Outcome: An Analysis of the ISHLT Pediatric Heart Transplant Registry;** B.D. Kaufman<sup>1</sup>, S. Chuai<sup>2</sup>, F. Dobbels<sup>3</sup>, R.E. Shaddy<sup>1</sup><sup>1</sup>University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, PA; <sup>2</sup>University of Pennsylvania, School of Medicine, Philadelphia, PA; <sup>3</sup>University of Leuven, Leuven, Belgium

**5:30 PM – 7:00 PM**

**CONCURRENT SESSION 5: Allograft Rejection: Role of Regulatory T-Cells (242AB)**

Chairs: Howard J. Eisen, MD and Richard N. Pierson, III, MD

**5:30 PM (27)** *Targeting of the Histone Acetyltransferase, *Myst1*, Enhances *Foxp3*+ Regulatory T Cell Function and Prolongs Cardiac Allograft Survival*; P.J. Gruber<sup>1</sup>, L. Wang<sup>1</sup>, E.F. de Zoeten<sup>1</sup>, A. Granger<sup>1</sup>, D. Zhou<sup>2</sup>, W.W. Hancock<sup>1</sup>  
<sup>1</sup>Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA; <sup>2</sup>University of Pennsylvania School of Medicine, Philadelphia, PA

**5:45 PM (28)** *Donor-Specific Immune Regulation by CD8+ Graft Derived Lymphocytes during Rejection after Clinical Heart Transplantation*; E. Dijke<sup>1</sup>, K. Caliskan<sup>2</sup>, A.H.M.M. Balk<sup>2</sup>, W. Weimar<sup>1</sup>, C.C. Baan<sup>1</sup>  
<sup>1</sup>Erasmus MC, Rotterdam, Netherlands; <sup>2</sup>Erasmus MC, Rotterdam, Netherlands

**6:00 PM (29)** *Expansion of CD4+CD25+FoxP3+ Regulatory T Lymphocytes with Low-Dose Anti-Thymocyte Globulin Leads to Prolonged Survival of Cardiac Allografts but Not Tolerance*; T.M. Millington<sup>1</sup>, O. Boenisch<sup>2</sup>, S. Boskovic<sup>1</sup>, N. Najafian<sup>2</sup>, M.H. Sayegh<sup>2</sup>, J.C. Madsen<sup>1</sup>  
<sup>1</sup>Massachusetts General Hospital, Boston, MA; <sup>2</sup>Brigham and Women's Hospital, Boston, MA

**6:15 PM (30)** *CD4+CD25+ Regulatory T-Cells and Cardiac Allograft Vasculopathy*; W. Sherman<sup>1</sup>, S. Bastani<sup>1</sup>, R. Bhatia<sup>1</sup>, M.C. Fishbein<sup>2</sup>, A. Ardehali<sup>1</sup>  
<sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**6:30 PM (31)** *Innate Immune Activation by Hyaluronan Leads to Inflammation and Loss of Regulatory T Cells Resulting in Development of BOS Following Human Lung Transplantation*; S. Ramachandran<sup>1</sup>, K. Parekh<sup>2</sup>, A. Aloush<sup>1</sup>, E. Trulock<sup>2</sup>, A. Patterson<sup>1</sup>, T. Mohanakumar<sup>1,3</sup>  
<sup>1</sup>Washington University in St Louis, St. Louis, MO; <sup>2</sup>University of Iowa, Iowa; <sup>3</sup>Washington University in St Louis, St. Louis, MO; <sup>4</sup>Washington University in St Louis, St. Louis, MO

**6:45 PM (32)** *Regeneration of Naïve T-Lymphocytes from Heart-Thymus Grafts Occurs at a Low Level and Is Associated with Prolonged Survival but Not Tolerance*; T.M. Millington<sup>1</sup>, A. Tena<sup>2</sup>, S. Boskovic<sup>1</sup>, T. Kawai<sup>1</sup>, J. Wain<sup>1</sup>, J. Allan<sup>1</sup>, D.H. Sachs<sup>2</sup>, J.C. Madsen<sup>1</sup>  
<sup>1</sup>Massachusetts General Hospital, Boston, MA; <sup>2</sup>Massachusetts General Hospital, Boston, MA

**5:30 PM – 7:00 PM**

**CONCURRENT SESSION 6: Complement Activation Products as Markers of Antibody Mediated Rejection (241)**

Chairs: Carmela D. Tan, MD and Annalisa Angelini, MD

**5:30 PM (33)** *T-Cells Producing Both IFN-gamma and TGF-beta Induce Cardiac Allograft Vasculopathy*; J. van Kuik<sup>1</sup>, D.F. van Wichen<sup>1</sup>, E. Siera-de Koning<sup>1</sup>, N. de Jonge<sup>3</sup>, H.F.J. Dullens<sup>1</sup>, F.H.J. Gmelig-Meyling<sup>2</sup>, R.A. de Weger<sup>1</sup>  
<sup>1</sup>University Medical Center Utrecht, Utrecht, Netherlands; <sup>2</sup>University Medical Center Utrecht, Utrecht, Netherlands; <sup>3</sup>University Medical Center Utrecht, Utrecht, Netherlands

**5:45 PM (34)** *C4d Detection and Outcome in Long-Term Heart Transplant Recipients*; L. Potena<sup>1</sup>, T. Ionico<sup>1</sup>, O. Leone<sup>2</sup>, G. Magnani<sup>1</sup>, F. Grigioni<sup>1</sup>, F. Coccolo<sup>1</sup>, F. Fallani<sup>1</sup>, A. Russo<sup>1</sup>, A. Branzi<sup>1</sup>  
<sup>1</sup>University of Bologna, Bologna, Italy; <sup>2</sup>University of Bologna, Bologna, Italy

**6:00 PM (35)** *Combined Positive C4d and C3d Immunofluorescence in Human Heart Transplants: How Frequent Is the Coexpression Seen?*; B. Weynand<sup>1</sup>, A.B. Collins<sup>2</sup>, R.N. Smith<sup>2</sup>  
<sup>1</sup>Cliniques Universitaires St Luc, Brussels, Belgium; <sup>2</sup>Massachusetts General Hospital, Boston, MA

**6:15 PM (36)** *Pattern and Evolution of C4d Staining in Perioperative Ischemic Myocyte Injury Post Transplantation*; B.S. Fyfe, D.B. Iyer, J.M. Jaworski, M.D. Wood, G.T. Butchy, L.H. Arroyo  
UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ

**6:30 PM (37)** *The Role of C4d Immunostaining in the Evaluation of Microvascular Damage in Heart Transplantation*; M. Fedrigo<sup>1</sup>, F. Tona<sup>2</sup>, A. Gambino<sup>3</sup>, C. Castellani<sup>1</sup>, F. Poli<sup>4</sup>, E. Benazzi<sup>4</sup>, A. Vinci<sup>2</sup>, A.P. Caforio<sup>2</sup>, G. Feltrin<sup>3</sup>, G. Gerosa<sup>3</sup>, M. Valente<sup>1</sup>, G. Thiene<sup>1</sup>, A. Angelini<sup>1</sup>  
<sup>1</sup>University of Padua, Padua, Italy; <sup>2</sup>University of Padua, Padua, Italy; <sup>3</sup>University of Padua, Padua, Italy; <sup>4</sup>Policlinico S. Mattia IRCCS, Milan, Italy

**6:45 PM (38) WITHDRAWN**

**7:00 PM – 8:00 PM**

**GENERAL POSTERS/WINE RECEPTION (Hall Maillot)**

**(39)** *Tricuspid Valve Replacement Coincident with HeartMate LVAD Insertion*; R.M. Adamson<sup>1</sup>, W.P. Dembitsky<sup>1</sup>, J. Chammas<sup>1</sup>, S. Baradaran<sup>1</sup>, P. Hoagland<sup>2</sup>, B. Jaski<sup>2</sup>, M. Stahovich<sup>3</sup>, S. Chillcott<sup>3</sup>, K. Ortiz<sup>3</sup>, V. McCalmont<sup>3</sup>  
<sup>1</sup>Sharp Memorial Hospital, San Diego, CA; <sup>2</sup>Sharp Memorial Hospital, San Diego, CA; <sup>3</sup>Sharp Memorial Hospital, San Diego, CA

**(40) Usefulness of the INTERMACS Scale to Predict Outcomes Post-Mechanical Assist Device Implantation;** A.C. Alba<sup>1</sup>, V. Rao<sup>2</sup>, J. Ivanov<sup>2</sup>, H.J. Ross<sup>1</sup>, D.H. Delgado<sup>1</sup> <sup>1</sup>Toronto General Hospital, Toronto, ON, Canada; <sup>2</sup>Toronto General Hospital, Toronto, ON, Canada

**(41) Predictors of Acute Renal Dysfunction after Ventricular Assist Device Placement;** A.C. Alba<sup>1</sup>, V. Rao<sup>2</sup>, J. Ivanov<sup>2</sup>, H.J. Ross<sup>1</sup>, D.H. Delgado<sup>1</sup> <sup>1</sup>Toronto General Hospital, Toronto, ON, Canada; <sup>2</sup>Toronto General Hospital, Toronto, ON, Canada

**(42) Impact of Abdominal Complications on Outcomes Following Mechanical Circulatory Support Therapy;** J.K. Bhama<sup>1</sup>, P. Adusumulli<sup>1</sup>, M.P. Siegenthaler<sup>1</sup>, D. Zaldonis<sup>1</sup>, A. Bansal<sup>1</sup>, L. Garcia<sup>1</sup>, E. Gongora<sup>1</sup>, J.J. Teuteberg<sup>2</sup>, Y. Toyoda<sup>1</sup>, C.A. Bermudez<sup>1</sup>, G. Speziali<sup>1</sup>, K.R. McCurry<sup>1</sup>, R.L. Kormos<sup>1</sup> <sup>1</sup>University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA

**(43) Reversal of Severe Pulmonary Hypertension with a Continuous Flow Left Ventricular Assist Device in High Risk Candidates for Heart Transplantation;** S. Bhashyam, D. Dean, K. Jasti, G. Sokos, M. Akkineni, J. Rosenthal, D. Vido, S. Stutz, G. Magovern, S. Bailey, S. Murali The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA

#### **(44) WITHDRAWN**

**(45) Featured Poster: U.S. Experience with a Novel Centrifugal LVAD in Bridge to Transplant (BTT) Patients;** A. Boyle, R. John, N. Moazami, G. Ewald, C. Salerno, M. Walsh, J. Teuteberg, R. Kormos, A. Anyanwu, S. Pinney, S. Desai, N. Burton, J. Kirklin, S. Pamboukian, S. Park, M. Redfield, D.D. Ascheim, M. Parides, U. Rawiel, E. Moquete, L. Joyce, A. Gelijns, J. O'Connell, E. McGee, B. Sun, D. Feldman, M. Camacho, M. Zucker University of Minnesota, Minneapolis, MN; Barnes Jewish Hospital Washington University, St. Louis, MO; St Vincent Hospital and CorVascMDs, Indianapolis, IN; University of Pittsburgh Medical Center, Pittsburgh, PA; Mount Sinai Medical Center, New York, NY; Inova Heart and Vascular Institute, Fairfax, VA; University of Alabama at Birmingham, Birmingham, AL; Mayo Clinic, Rochester, MN; Mount Sinai School of Medicine, New York, NY; Northwestern University, Chicago, IL; Ohio State University, Columbus, OH, Newark Beth Israel Hospital, Newark, NJ

**(46) Right Ventricle Contractile Reserve as a Pre-Operative Tool for Assessing RV Failure after Continuous Flow LVAD Implantation;** G. Deswarte<sup>1,3</sup>, M. Kirsch<sup>2</sup>, J. C. Roussel<sup>1</sup>, P.F. Lesault<sup>3</sup>, E. Vermes<sup>2</sup>, D. Duveau<sup>1</sup>, P. Gueret<sup>3</sup>, J.L. Dubois Rande<sup>3</sup>, D. Loisanche<sup>2</sup>, L. Hittinger<sup>3</sup>, J. N. Trochu<sup>1</sup>, T. Damy<sup>3</sup> <sup>1</sup>University Hospital, Nantes, France; <sup>2</sup>Henri Mondor University Hospital, Créteil, France; <sup>3</sup>Henri Mondor University Hospital, Créteil, France

**(47) Featured Poster: Bridge-to-Transplant (BTT) Patients Supported with Non-Pulsatile Ventricular Assist Devices: All LVADs Are Not Created Equal;** L.A. Durham<sup>1</sup>, R.C. Daly<sup>1</sup>, C.C.G. McGregor<sup>1</sup>, B.A. Boilson<sup>2</sup>, J.A. Schirger<sup>2</sup>, B.S. Edwards<sup>2</sup>, S.S. Kushwaha<sup>2</sup>, A.L. Clavell<sup>2</sup>, S.J. Park<sup>1</sup> <sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Mayo Clinic, Rochester, MN

**(48) Featured Poster: Short and Long Term Survival of Patients Transferred to a Tertiary Care Center on Temporary Extracorporeal Circulatory Support;** J.W. Haft, F.D. Pagani University of Michigan, Ann Arbor, MI

**(49) Obesity – No Longer an Exclusion Criteria for LVAD Implantation;** F. Kamdar, K. Liao, F. Martinez, M. Colvin-Adams, A. Boyle, L. Joyce, R. John University of Minnesota, Minneapolis, MN

**(50) Metabolomic Profiling of the Terminal Failing Human Myocardium Pre and Post Mechanical Unloading by Ventricular Assist Devices;** S. Gezelbash<sup>1</sup>, K. Niehaus<sup>1</sup>, H. Neuweger<sup>1</sup>, P. Schwientek<sup>1</sup>, M. Morshuis<sup>2</sup>, S. Schulte-Eistrup<sup>2</sup>, R. Koerfer<sup>2</sup>, H. Milting<sup>2</sup> <sup>1</sup>Universitaet Bielefeld, Bielefeld, NRW, Germany; <sup>2</sup>Herz- und Diabeteszentrum NRW, Universitaetsklinikum der Ruhr Universitaet Bochum, Bad Oeynhausen, Germany

**(51) Successful Management of Pump Pocket Infections in Patients with Implanted Left Ventricular Assist Devices;** J.D. Pal<sup>1</sup>, B.D. Alexander<sup>2</sup>, A.J. Lodge<sup>1</sup>, L. Blue<sup>1</sup>, C.A. Milano<sup>1</sup> <sup>1</sup>Duke University, Durham, NC; <sup>2</sup>Duke University, Durham, NC

**(52) Featured Poster: Desensitization Therapy Is Associated with Improved Survival to Transplant in Sensitized Patients Bridged with a Left Ventricular Assist Device;** P.C. Patel<sup>1</sup>, K.P. Singh<sup>1</sup>, E.J. Seglem<sup>2</sup>, C.R. Ayers<sup>1</sup>, C.L. Fitzsimmons<sup>1</sup>, P.A. Kaiser<sup>1</sup>, J.M. DiMaio<sup>3</sup>, W.S. Ring<sup>3</sup>, C.W. Yancy<sup>2</sup>, P.P.A. Mammen<sup>1</sup>, M.H. Drazner<sup>1</sup>, D.M. Meyer<sup>3</sup>, D.W. Markham<sup>1</sup> <sup>1</sup>UT Southwestern Medical Center, Dallas, TX; <sup>2</sup>Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX; <sup>3</sup>UT Southwestern Medical Center, Dallas, TX

**(53) Right Heart Failure after HeartMate II Left Ventricular Assist Device Implantation;** S. Pauwaa<sup>1</sup>, R. Siemeck<sup>1</sup>, M.A. Sobieski<sup>1</sup>, C. Gallagher<sup>1</sup>, A.J. Tatoes<sup>1</sup>, M.S. Slaughter<sup>2</sup>, G. Bhat<sup>1</sup> <sup>1</sup>Advocate Christ Medical Center, Oak Lawn, IL; <sup>2</sup>University of Louisville, Louisville, KY

**(54) Featured Poster:** *Bleeding and Thromboembolic Complications with Pulsatile Versus Non-Pulsatile LVADs*; D.M. Pedrotty<sup>4</sup>, I. Welsby<sup>2</sup>, M.A. Daneshmand<sup>3</sup>, L. Blue<sup>1</sup>, A.J. Lodge<sup>1</sup>, A.F. Hernandez<sup>5</sup>, J.G. Rogers<sup>5</sup>, C.A. Milano<sup>1</sup> <sup>1</sup>Duke University Medical Center, Durham, NC; <sup>2</sup>Duke University Medical Center, Durham, NC; <sup>3</sup>Duke University Medical Center, Durham, NC; <sup>4</sup>Duke University, Durham, NC; <sup>5</sup>Duke University Medical Center, Durham, NC

**(55) Featured Poster:** *Clinical and Hemodynamic Findings with a System for Delivery of Aortic Flow Therapy in Patients with Acute Decompensated Heart Failure*; F. Raissi Shabari, R.M. Delgado, B. Kar, A. Civitello, P. Loyalka, B. Czerska, M. Klapholz, E. Haeusslein, S. Brown, M.A. Konstam Texas Heart Institute, Houston, TX; Henry Ford Hospital, Detroit, MI; UMDNJ, Newark, NJ; California Pacific Medical Center, San Francisco, CA; Integra, Brooklyn Park, MN; New England Medical Center, Tufts University, Boston, MA

**(56) Featured Poster:** *Gender and Pre-Operative CRP Influence Survival after LVAD Implantation*; J. Geens<sup>1</sup>, S. Tenson<sup>1</sup>, F. Rega<sup>1</sup>, W. Droogne<sup>2</sup>, J. Vancleemput<sup>2</sup>, J. Vanhaecke<sup>2</sup>, B. Meyns<sup>1</sup> <sup>1</sup>University Hospitals Leuven, Leuven, Belgium; <sup>2</sup>University Hospitals Leuven, Leuven, Belgium

**(57) Role of Implantable Cardioverter-Defibrillators in Patients with Left Ventricular Assist Devices**; D. Bonilla, M.S. Firstenberg, D. Blais, L.B. Louis, R. Weiss, J.D. Hummel, T. Yanssens, S. Wissman, B. Sun, C.B. Sai Sudhakar Ohio State University Medical Center, Columbus, OH

**(58) Brain Natriuretic Peptide Helps To Optimize Management of Patients Supported by Continuous Flow Left Ventricular Assist Devices**; B. Sareyyupoglu, B.A. Boilson, L.A. Durham, C.G.A. McGregor, R.C. Daly, M.M. Redfield, B.S. Edwards, R.P. Frantz, N.L. Pereira, S.J. Park Mayo Clinic, Rochester, MN; Mayo Clinic, Rochester, MN

**(59) Scheduled Implantation of VADs for Treatment of Terminal Heart Failure in Patients with Advanced Age: Single-Center Experience**; A. Stepanenko, E.W. Potapov, M. Dandel, B. Jurmann, H.B. Lehmkuhl, Y. Weng, T. Krabatsch, R. Hetzer Deutsches Herzzentrum Berlin, Berlin, Germany

**(60) Featured Poster:** *Increased Incidence of Gastrointestinal Bleeding Following Implantation of Heartmate II LVAD*; D.R. Stern, J. Kazam, S. Shariff, P. Edwards, N. McAllister, S. Maybaum, R. Bello, D. D'Alessandro, D. Goldstein Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY

**(61) Featured Poster:** *Changes in the Protein Profiles of the Human Failing Heart after Left Ventricular Assist Device (LVAD) Support*; P. van der Weide<sup>1</sup>, N. Bovenschen<sup>1</sup>, E. Siera-de Koning<sup>1</sup>, J. van Kuik<sup>1</sup>, M.E.I. Schipper<sup>1</sup>, N. de Jonge<sup>2</sup>, R.A. de Weger<sup>1</sup> <sup>1</sup>University Medical Center, Utrecht, Netherlands; <sup>2</sup>University Medical Center, Utrecht, Netherlands

**(62) C-Reactive Protein, Vascular Cell Adhesion Molecule and Neopterin Are Markers of Advanced Cardiac Allograft Vasculopathy Determined by Intravascular Ultrasound**; S. Arora, P. Aukrust, E. Gude, A. Andreassen, I. Grov, R. Skaardal, T. Ueland, O. Geiran, L. Gullestad Rikshospitalet Medical Center, Oslo, Norway

**(63) Cardiac Retransplantation: A Valid Option for All Patients?**; J.M. Barcelo, M. Gomez-Bueno, J. Segovia, R. Burgos, E. Castedo, S. Serrano, J. Ugarte, L. Alonso-Pulpon Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

**(64) Circulating Anti-Heart Autoantibodies Are Non-Invasive Markers of High Cellular Rejection Burden in Heart Transplantation**; A.L.P. Caforio<sup>1</sup>, A. Vinci<sup>1</sup>, A. Angelini<sup>2</sup>, F. Tona<sup>1</sup>, S. Bottaro<sup>3</sup>, G. Thiene<sup>2</sup>, G. Gerosa<sup>1</sup>, S. Iliceto<sup>1</sup> <sup>1</sup>University of Padova, Padova, Italy; <sup>2</sup>University of Padova, Padova, Italy; <sup>3</sup>University of Padova, Padova, Italy

**(65) Decreased Fungal Infections with Immunosuppression Modification in Cardiac Transplant Recipients**; A.B. Cochrane<sup>1</sup>, K.A. Lempicki<sup>1</sup>, K.J. Pursell<sup>2</sup>, A.S. Anderson<sup>2</sup>, S.E. Fedson<sup>2</sup> <sup>1</sup>University of Chicago, Chicago, IL; <sup>2</sup>University of Chicago, Chicago, IL

## **(66) WITHDRAWN**

**(67) CTLA-4, FasL and Granzyme B mRNA Expression in Sequential Biopsies from Heart Allografts Correlate with Episodes Allograft Rejection**; M. Ramsperger-Gleixner, R. Tandler, M. Kondruweit, M. Weyand, S.M. Ensminger University of Erlangen-Nuremberg, Erlangen, Germany

**(68) Historical Trends of Primary Graft Failure after Heart Transplantation**; M. Gomez-Bueno, J.M. Barcelo, J. Segovia, M. Cobo, J. Mirelis, E. Sufate, P. Garcia-Pavia, L. Alonso-Pulpon Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

**(69)** *Do MICA Antibodies Prior to Heart Transplantation Influence Development of Acute Rejection?*; S. Gupta, A. Medhat, A. Sabe, N. Ed, B. Eugene, G. Gonzalez-Stawinski Cleveland Clinic, Cleveland, OH

**(70)** *Rabbit Antithymocyte Globulin Dosing and Complications in Heart Transplant Induction and Rejection*; J. Lindsley, K. Pickworth, D. Blais, A.K. Hasan, D. Feldman Ohio State University, Columbus, OH

**(71)** *The Diachronic Observation of Coronary Flow Reserve by Echocardiography Would Be Useful in Optimizing the Timing of Routine Cardiac Biopsy and Coronary Angiogram in Heart Transplant Recipients*; S. Hashimoto<sup>1</sup>, T.S. Kato<sup>1</sup>, Y. Sumita<sup>1</sup>, N. Tanaka<sup>1</sup>, T. Sasaoka<sup>1</sup>, T. Sato<sup>1</sup>, K. Hashimura<sup>1</sup>, T. Nakatani<sup>2</sup> <sup>1</sup>National Cardiovascular Center, Osaka, Japan; <sup>2</sup>National Cardiovascular Center, Osaka, Japan

**(72)** *Changes in Lipid Profiles Associated with Everolimus- and MMF-Based Immunosuppression Are Clinically Comparable in De Novo Cardiac Transplant Recipients*; G. Magnani<sup>1</sup>, L. Almenar<sup>2</sup>, M. Vigano<sup>3</sup>, M. Maccherini<sup>4</sup>, L.A. Pulpon<sup>5</sup>, F. Musumeci<sup>6</sup>, G. Gerosa<sup>7</sup>, H. Lehmkühl<sup>8</sup>, U. Livi<sup>9</sup> <sup>1</sup>Istituto Malattie, Az.Osp. di Bologna Policl. S.Orsola - Malpighi, Bologna, Italy; <sup>2</sup>Hospital Universitario La Fe, Valencia, Spain; <sup>3</sup>IRCCS Università degli Studi di Pavia, Pavia, Italy; <sup>4</sup>AUO di Siena, Siena, Italy; <sup>5</sup>Hospital Universitario Clínica Puerta de Hierro, Madrid, Spain; <sup>6</sup>Ospedale S. Camillo-Forlanini - Azienda Ospedaliera, Rome, Italy; <sup>7</sup>Padova University Hospital, Padova, Italy; <sup>8</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>9</sup>Istituto di Chirurgia Cardiotoracica, Udine, Italy

**(73)** *Utility of Baseline Coronary Angiography in Prompting Intervention for Early Cardiac Allograft Vasculopathy*; J.N. Nativi, A.G. Kfoury, K. Brunisholz, B. Miller, M. Endo, P. Fisher, J. Connolly, S. Frampton, J. Doty, D. Renlund Intermountain Medical Center, Murray, UT

**(74)** *Endothelial Progenitor Cells Are Decreased in the Blood and in the Graft of Heart Transplant Patients with Microvasculopathy*; E. Osto<sup>1</sup>, F. Tona<sup>1</sup>, C. Castellani<sup>2</sup>, G. Fadini<sup>3</sup>, I. Baesso<sup>4</sup>, A. Gambino<sup>5</sup>, A. Vinci<sup>1</sup>, A. Avogaro<sup>3</sup>, A. Ramondo<sup>1</sup>, A.L.P. Caforio<sup>1</sup>, G. Gerosa<sup>5</sup>, G. Thiene<sup>2</sup>, A. Angelini<sup>2</sup>, S. Iliceto<sup>1</sup> <sup>1</sup>University of Padova, Padova, Italy; <sup>2</sup>University of Padova, Padova, Italy; <sup>3</sup>University of Padova, Padova, Italy; <sup>4</sup>University of Padova, Padova, Italy; <sup>5</sup>University of Padova, Padova, Italy

**(75)** *Short Term Outcomes Using CD3 Guided Low Dose Anti Thymocyte Globulin To Avoid Early Calcineurin Inhibition after Cardiac Transplantation*; K.A. Parks, K. Gonczarek, O. Onuma, G.V. Moukarbel, B.R. Rosengard, M.J. Semigran, W.D. Carlson Massachusetts General Hospital, Boston, MA

**(76)** *Obesity Confers Protection from Cardiac Allograft Vasculopathy?*; A. Ankrom<sup>1</sup>, J. Patel<sup>1</sup>, E. Shao<sup>1</sup>, S. Carr<sup>1</sup>, M. Kawano<sup>1</sup>, M. Kittleson<sup>1</sup>, K. Kiyosaki<sup>1</sup>, J. Moriguchi, A. Ardehali<sup>2</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**(77)** *Donor-Specific Antibodies Correlate with Rejection in Heart Transplant Patients*; N. Patel, B. Pavlovic-Surjancev, J. Sinacore, B. Susskind, N. Neuswanger, T. Dasari, A. Heroux Loyola University Medical Center, Maywood, IL

**(78)** *Magnetic Resonance Imaging Correlates with Transcript Gene Expression in Cardiac Allograft Biopsies*; I. Paterson, B. Sis, D. Kim, J. Ezekowitz, J. Burton, W. Tymchak, M. Mengel, T. Mueller, P. Halloran University of Alberta, Edmonton, AB, Canada

**(79)** *Implementation of Molecular Diagnostic Testing in the Early (2-6 Months) Post-Transplant Period*; T.M. Rowe<sup>1</sup>, A. Hicks<sup>2</sup>, H.J. Eisen<sup>3</sup>, J. Patel<sup>4</sup>, S.R. Hankins<sup>3</sup> <sup>1</sup>Hahnemann University Hospital, Philadelphia, PA; <sup>2</sup>Drexel University College of Medicine, Philadelphia, PA; <sup>3</sup>Drexel University College of Medicine, Philadelphia, PA; <sup>4</sup>Drexel University, Philadelphia, PA

**(80)** *Reduced Left Ventricular Torsion with Two-Dimensional Speckle Tracking Echocardiography Would Predict Acute Rejection in Heart Transplant Recipients*; T. Sato, T.S. Kato, S. Hashimoto, N. Oda, M. Yanase, H. Kanzaki, K. Hashimura, H. Ueda, K. Komamura, T. Shishido, M. Kitakaze, T. Nakatani National Cardiovascular Center, Suita, Osaka, Japan

**(81)** *Impact of Cold Ischemic Time on Post-Transplant Cardiac Outcomes and Rejection*; A.K. Singhal<sup>1</sup>, S.G. Drakos<sup>1,2</sup>, A.G. Kfoury<sup>2</sup>, J.R. Kotter<sup>2</sup>, B.D. Horne<sup>2</sup>, E.H. Hammond<sup>2</sup>, P.W. Fisher<sup>2</sup>, S. Clayson<sup>2</sup>, J. Stehlik<sup>1</sup>, M.R. Merida<sup>2</sup>, D.G. Renlund<sup>2</sup> <sup>1</sup>University of Utah, Salt Lake City, UT; <sup>2</sup>Intermountain HealthCare, Salt Lake City, UT

**(82)** *MRI Derived Measures of Left Ventricular Morphology Correlate with Clinical and Histopathological Heart Transplant Rejection*; M. Toma<sup>1</sup>, C. Butler<sup>1</sup>, G. Pearson<sup>1</sup>, R. Thompson<sup>2</sup>, I. Paterson<sup>1</sup> <sup>1</sup>University of Alberta, Edmonton, AB, Canada; <sup>2</sup>University of Alberta, Edmonton, AB, Canada

**(83) Brain Hippocampal Volumes Are Reduced in Patients with Heart Failure;** C.M. Abouzeid<sup>1</sup>, P.M. Macey<sup>2</sup>, R. Kumar<sup>3</sup>, M.A. Woo<sup>2</sup>, R.M. Harper<sup>3</sup> <sup>1</sup>University of California at Los Angeles, Los Angeles, CA; <sup>2</sup>University of California at Los Angeles, Los Angeles, CA; <sup>3</sup>University of California at Los Angeles, Los Angeles, CA

**(84) Featured Poster: Relationship between Skeletal Muscle Function, Peak Oxygen Consumption and Cardiac Output in Patients with Chronic Heart Failure;** D.N. Bartov<sup>1</sup>, S. Murthy<sup>1</sup>, G. Kamalakkannan<sup>1</sup>, Q. Smith<sup>1</sup>, J.J. Shin<sup>1</sup>, M. Galvao<sup>1</sup>, D. Burkhoﬀ<sup>2</sup>, S. Maybaum <sup>1</sup>Montefiore Medical Center, New York, NY; <sup>2</sup>Columbia University, New York, NY

**(85) Semi-Supervised Approach to Risk Evaluation in Stage-D Heart Failure Patients Referred for Heart Transplantation;** M. Cadeiras<sup>1</sup>, S.M. Yala<sup>2</sup>, G.D. Cadeiras<sup>3</sup>, K. Shahzad<sup>2</sup>, E.G. Tabak<sup>4</sup>, D.M. Mancini<sup>2</sup>, M.C. Deng<sup>2</sup> <sup>1</sup>University of Alabama, Birmingham, AL; <sup>2</sup>Columbia University, New York, NY; <sup>3</sup>Università di Bologna, Buenos Aires, Argentina; <sup>4</sup>New York University, New York, NY

**(86) Prognostic Assessment of Patients with Severe Idiopathic Dilated Cardiomyopathy Referred for Heart Transplantation;** M. Dandel, R. Jasaityte, H.B. Lehmkuhl, O. Grauhan, C. Knosalla, R. Hetzer Deutsches Herzzentrum Berlin, Berlin, Germany

**(87) The Relationship of Right and Left Ventricular Filling Pressures in Patients Undergoing Cardiac Transplantation: A 17-Year Multi-Institutional Analysis;** M.H. Drazner<sup>1</sup>, R.N. Brown<sup>2</sup>, P.A. Kaiser<sup>1</sup>, B. Cabuay<sup>6</sup>, N.P. Lewis<sup>5</sup>, M.J. Semigran<sup>3</sup>, G. Torre-Amione<sup>4</sup>, D.C. Naftel<sup>2</sup>, J.K. Kirklin<sup>2</sup> <sup>1</sup>University of Texas Southwestern Medical Center, Dallas, TX; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Massachusetts General Hospital, Boston, MA; <sup>4</sup>The Methodist Hospital, Houston, TX; <sup>5</sup>Virginia Commonwealth University, Richmond, VA; <sup>6</sup>University of Iowa, Iowa City, IA

**(88) Truncal Obesity Is a Risk Factor Cardiorenal Syndrome in Patients with Heart Failure;** N. Huda<sup>1</sup>, M.Z. Hoque<sup>1</sup>, K.S. Murthy<sup>1</sup>, H. Ra<sup>1</sup>, S. Mehta<sup>1</sup>, D.H. Karia<sup>1</sup> <sup>1</sup>Albert Einstein Medical Center, Philadelphia, PA; <sup>2</sup>Albert Einstein Medical Center, Philadelphia, PA; <sup>3</sup>Albert Einstein Medical Center, Philadelphia, PA; <sup>4</sup>Albert Einstein Medical Center, Philadelphia, PA

**(89) Blackout Period for Urgent Heart Transplantation during Mechanical Circulatory Support Set by Eurotransplant for Germany;** T. Komoda, H.B. Lehmkuhl, R. Hetzer Deutsches Herzzentrum Berlin, Berlin, Germany

**(90) Robotic Assisted Implantation of Left Ventricular Epicardial Pacing Leads for Cardiac Resynchronization Therapy;** K. Liao<sup>1</sup>, X. Li<sup>1</sup>, M. Colvin-Adams<sup>2</sup>, A. Boyle<sup>2</sup>, E. Missov<sup>2</sup>, M. Pritzker<sup>2</sup>, F. Lu<sup>2</sup>, S. Sakaguchi<sup>2</sup>, D. Benditt<sup>2</sup> <sup>1</sup>University of Minnesota, Minneapolis, MN; <sup>2</sup>University of Minnesota, Minneapolis, MN

**(91) T-Lymphocyte Cytolytic Therapy as Treatment of Fulminant Lymphocytic Myocarditis Is Associated with Rapid Improvement in Hemodynamic and Cardiac Rhythm Abnormalities;** V.N. Manins, N.M. Parle, L. Dembo, G. O'Driscoll Royal Perth Hospital, Perth, Western Australia, Australia; University of Notre Dame, Freemantle, Western Australia, Australia

**(92) Featured Poster: Mechanical Dyssynchrony Is Dynamic in Ambulatory Patients with Compensated Left Ventricular Dysfunction;** K.S. Murthy, N. Huda, M.Z. Hoque, D.H. Karia Albert Einstein Medical Center, Philadelphia, PA

**(93) Efficacy of Treatment with Pulsatile Pump as a Bridge to Transplantation in Patients with a Congestive Heart Failure – Polish Experiences with POLVAD;** J. Pacholewicz<sup>3</sup>, M. Zakliczynski<sup>3</sup>, A. Baranska-Kosakowska<sup>3</sup>, G. Religa<sup>1</sup>, P. Siondalski<sup>2</sup>, E. Kucewicz<sup>3</sup>, P. Nadziakiewicz<sup>3</sup>, M. Zembala<sup>3</sup> <sup>1</sup>Institute of Cardiology, Warsaw, Poland; <sup>2</sup>Medical University, Gdansk, Poland; <sup>3</sup>Silesian Center for Heart Disease, Medical University of Silesia, Zabrze, Poland

**(94) Arrhythmias and Implantable Cardioverter Defibrillators in Fabry Cardiomyopathy;** P.G. Robertson<sup>1</sup>, G.N. Kay<sup>1</sup>, D.G. Warnock<sup>2</sup>, L. Jackson<sup>2</sup>, J. Tallaj<sup>1</sup>, S. Pamboukian<sup>1</sup> <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL

**(95) Short Term Prognosis of Patients with Refractory Heart Failure and Atrial Fibrillation Qualified for Heart Transplantation – POLKARD HF;** M. Sobieszczanska-Malek<sup>1</sup>, T. Zielinski<sup>1</sup>, J. Korewicki<sup>1</sup> <sup>1</sup>National Institute of Cardiology, Warsaw, Poland; <sup>2</sup>National Institute of Cardiology, Warsaw, Poland; <sup>3</sup>National Institute of Cardiology, Warsaw, Poland

**(96) Previous Cardiovascular Disease or Diabetes Are Associated with a Very High Risk of Cardiovascular Disease after Lung Transplantation;** L. Plantier<sup>1</sup>, S. Neji<sup>1</sup>, G. Biondi<sup>1</sup>, G. Jebrak<sup>1</sup>, D. Himbert<sup>2</sup>, Y. Castier<sup>3</sup>, H. Mal<sup>1</sup>, G. Thabut<sup>1</sup>, M. Fournier<sup>1</sup> <sup>1</sup>Hôpital Bichat, Paris, France; <sup>2</sup>Hôpital Bichat, Paris, France; <sup>3</sup>Hôpital Bichat, Paris, France

**(97) Impact of Pre-Transplant Recipient Obesity on Outcomes after Lung Transplantation;** D. Hadjiliadis, N.P. Blumenthal, J. Mendez, K. Carney, D. Isaia, R. Lingaraju, J. Lee, R.M. Kotloff, J.D. Christie, V.N. Ahya, A. Pochettino University of Pennsylvania, Philadelphia, PA

**(98) Efficacy of Dobutamine Stress Echocardiography in Cardiac Evaluation for Lung Transplantation;** S.M. Lome<sup>1</sup>, F.F. Jeff<sup>1</sup>, F. Ling<sup>2</sup>, D.F. Dilling<sup>2</sup>, R.B. Love<sup>1</sup>, C.H. Wigfield<sup>3</sup>, J.P. Gagermeier<sup>3</sup>, C.G. Alex, R.S. Dieter, F. Leya<sup>1</sup> Loyola University Chicago, Maywood, IL; <sup>2</sup>Loyola University Chicago, Maywood, IL; <sup>3</sup>Loyola University Chicago, Maywood, IL

**(99) RAD in UIP: 3-Year Results of a Multicentre, Investigator Driven, Randomised Double Blind, Placebo Controlled Study of RAD in Surgical Lung Biopsy Proven UIP;** M.A. Malouf<sup>1</sup>, L. Singleton<sup>1</sup>, P. Hopkins<sup>2</sup>, G. Snell<sup>3</sup>, A.M. Southcott<sup>4</sup>, A.R. Glanville<sup>1</sup> <sup>1</sup>St.Vincent's Hospital, Sydney, NSW, Australia; <sup>2</sup>The Prince Charles Hospital, Brisbane, Queensland, Australia; <sup>3</sup>The Alfred Hospital, Melbourne, Victoria, Australia; <sup>4</sup>The Queen Elizabeth Hospital, Adelaide, South Australia, Australia

**(100) RAD in DPLD Associated CTD: 3-Year Results of a Pilot, Multicentre, Investigator Driven, Randomised Double Blind, Placebo Controlled Study of RAD in DPLD Associated CTD;** M.A. Malouf<sup>1</sup>, L. Singleton<sup>1</sup>, G. Snell<sup>2</sup>, P. Hopkins<sup>3</sup>, A.M. Southcott<sup>4</sup>, A.R. Glanville<sup>1</sup> <sup>1</sup>St.Vincent's Hospital, Sydney, NSW, Australia; <sup>2</sup>Alfred Hospital, Melbourne, Victoria, Australia; <sup>3</sup>The Prince Charles Hospital, Brisbane, Queensland, Australia; <sup>4</sup>The Queen Elizabeth Hospital, Adelaide, South Australia, Australia

**(101) Impact of Preexisting Coronary Artery Disease on Patients Undergoing Lung Transplantation;** A.A. Mangi<sup>1</sup>, G.B. Pettersson<sup>1</sup>, M.M. Budev<sup>2</sup>, K.M.G. Reyes<sup>1</sup>, J.J. Yun<sup>1</sup>, A.C. Mehta<sup>2</sup>, D.P. Mason<sup>1</sup>, S.C. Murthy<sup>1</sup> <sup>1</sup>Cleveland Clinic, Cleveland, OH; <sup>2</sup>Cleveland Clinic, Cleveland, OH

**(102) Functional Class IV Heart Failure Patients Treated with Cardiac Resynchronization Therapy;** M.A. Castel, L. Mont, F. Perez-Villa, J. Tolosana, M. Sitges, E. Roig Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain

**(103) Outcomes after Aortic Valve Replacement in Patients with Severe Aortic Regurgitation and Significantly Reduced Left Ventricular Ejection Fraction;** M.A. Castel, A. Garcia, A. Sionis, M. Cordero, F. Perez-Villa, M. Josa, E. Roig Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinic, Barcelona, Spain

**(104) Featured Poster: Plasmapheresis: Quality of Life and Clinical Improvements in Chronic Heart Failure;** N.A. Khalil, C.M. Orrego, C. Assad-Kottner, C. Leveque, K.A. Youker, G. Torre-Amione The Methodist Hospital, Houston, TX

**(105) Featured Poster: Efficacy of the Generation-2 Acorn Cardiac Support Device in Dogs with Chronic Heart Failure;** H.N. Sabbah Henry Ford Hospital, Detroit, MI

**(106) Low Strength Electric Field Network-Mediated Ex Vivo IL-4 and IL-10 Combined Gene Therapy Induced Rabbit Cardiac Allograft Tolerance;** L. Sen<sup>1,2</sup>, G. Cui<sup>1,2</sup>, H. Laks<sup>1</sup>, C. Chen<sup>1</sup> <sup>1</sup>David Geffen School of Medicine in UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine in UCLA, Los Angeles, CA

**(107) Preliminary Outcomes after Lung Transplantation from Donors with Cardiac Death;** J.M. Ahmed<sup>1</sup>, M. Yap<sup>2</sup>, A. Hamilton<sup>2</sup>, M. Harkess<sup>2</sup>, P.M. Spratt<sup>2</sup>, P. Jansz<sup>2</sup>, A. Farnsworth<sup>2</sup>, G. Emily<sup>2</sup>, P. Macdonald<sup>2</sup>, A.R. Glanville<sup>2</sup> <sup>1</sup>Freeman Hospital, Newcastle upon Tyne, Northumbria, United Kingdom; <sup>2</sup>St Vincent's Hospital, Sydney, NSW, Australia

**(108) NHBD Meet the Standard of HBD Regarding Early Outcome after LTx;** S. De Vleeschauwer, D. Van Raemdonck, B. Vanaudenaerde, R. Vos, G. Verleden Katholieke Universiteit Leuven, Leuven, Belgium

**(109) Heart-Lung Transplantation: A Single Center Experience with 152 Cases;** E. Fadel, O. Mercier, S. Mussot, D. Fabre, J. Cerrina, F. LeRoy Ladurie, P. Darteville Hopital Marie Lannelongue, Le Plessis Robinson, France

**(110) Size-Reduced Lung Transplantation: Correlation of Donor Predicted Postoperative FEV1 with Recipient Best FEV1;** I. Ilhan<sup>1</sup>, P. Kestenholz<sup>1</sup>, D. Schneiter<sup>1</sup>, S. Hillinger<sup>1</sup>, I. Opitz<sup>1</sup>, S. Irani<sup>2</sup>, A. Boehler<sup>2</sup>, W. Weder<sup>1</sup> <sup>1</sup>University Hospital, Zurich, Switzerland; <sup>2</sup>University Hospital, Zurich, Switzerland

**(111) Pulmonary Fibrosis and Functional Restriction: A Different Type of BO(S);** P. Jaksch<sup>1</sup>, C. Mueller-mang<sup>2</sup>, B. Zwegtick<sup>1</sup>, A. Hoda<sup>1</sup>, M. Keplinger<sup>1</sup>, A. Scheed<sup>1</sup>, G. Lang<sup>1</sup>, W. Klepetko<sup>1</sup> <sup>1</sup>University Hospital Vienna, Vienna, Austria; <sup>2</sup>University Hospital Vienna, Vienna, Austria

**(112) Does the BODE Index Predict Survival in Patients with COPD Referred for Lung Transplantation?;** A.K. McDiarmid, A.G. DeSoyza, G. Parry, J.J. Lordan, A.J. Fisher, P.A. Corris Newcastle University and Freeman Hospital, Newcastle upon Tyne, Tyne Wear, United Kingdom



**(113) Assessment of Anti-CMV Specific Reactivity on BAL Cells by Enzyme Linked Immunospot Assay (ELISPOT);** M. Agnesi<sup>1</sup>, V. Conio<sup>1</sup>, P. Draghi<sup>1</sup>, C. Lastoria<sup>1</sup>, D. Lilleri<sup>2</sup>, V. Rognoni<sup>2</sup>, N. Solari<sup>1</sup>, A.M. Fietta<sup>1</sup>, F. Meloni<sup>1</sup> <sup>1</sup>University of Pavia Foundation IRCCS San Matteo, Pavia, Italy; <sup>2</sup>Foundation IRCCS San Matteo, Pavia, Italy

**(114) Early Epithelial Remodeling and Bronchiolitis Obliterans Post Lung Transplantation;** M. Nataatmadja<sup>1</sup>, M. Passmore<sup>1</sup>, A. Corley<sup>2</sup>, E. Venz<sup>2</sup>, P. Hopkins<sup>2</sup>, F. Kermeen<sup>2</sup>, J. Fraser<sup>2</sup>, B. Thomson<sup>1</sup>, G. Hart<sup>2</sup>, D. Chambers<sup>2</sup>, T. Daniels<sup>2</sup> <sup>1</sup>University of Queensland, Brisbane, Queensland, Australia; <sup>2</sup>Prince Charles Hospital, Brisbane, Queensland, Australia

**(115) A High Diploid DEFA1A3 Copy Number Predispose to Lung Transplant Rejection;** H. Nuytten<sup>1</sup>, H. Cuppens<sup>1</sup>, G. Verleden<sup>2</sup>, L.J. Dupont<sup>2</sup> <sup>1</sup>Campus Gasthuisberg ON, Leuven, Belgium; <sup>2</sup>University Hospital Gasthuisberg, Leuven, Belgium

**(116) Lung Transplantation with Direct Bronchial Arterial Revascularization (BAR): Feasible and Effective – Time To Revisit?;** G.B. Pettersson<sup>1</sup>, J.J. Yun<sup>1</sup>, J. Nocero<sup>2</sup>, D.P. Mason<sup>1</sup>, S.C. Murthy<sup>1</sup>, S. Kapadia<sup>3</sup>, A.A. Mangi<sup>1</sup>, A.C. Mehta<sup>2</sup>, M.M. Budev<sup>2</sup> <sup>1</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>2</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>3</sup>Cleveland Clinic Foundation, Cleveland, OH

**(117) Aspiration in the Immediate Post Lung Transplantation Period;** A.G.N. Robertson<sup>1</sup>, S.M. Griffin<sup>1</sup>, C. Ward<sup>2</sup>, J.P. Pearson<sup>4</sup>, A.J. Bredenoord<sup>5</sup>, J.H. Dark<sup>2,3</sup>, A.J. Fisher<sup>2</sup>, J. Lordan<sup>2</sup>, P.A. Corris<sup>2</sup> <sup>1</sup>Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Newcastle University, Newcastle upon Tyne, United Kingdom; <sup>3</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom; <sup>4</sup>Newcastle University, Newcastle upon Tyne, United Kingdom; <sup>5</sup>Sint Antonius Hospital, Nieuwegein, Netherlands

**(118) Impact of Spirometry on Survival after Lung Transplantation;** J.W. Su, D.P. Mason, J. Rajeswaran, L. Li, S.C. Murthy, G.B. Petterson, E.H. Blackstone Cleveland Clinic, Cleveland, OH

**(119) Risk of Bronchiolitis Obliterans in Lung Transplant Recipients Who Require ECMO for Primary Graft Failure;** M.D. Taylor<sup>1</sup>, J. Um<sup>2</sup>, B.D. Kozower<sup>1</sup>, D.R. Jones<sup>1</sup>, G. Ailawadi<sup>1</sup>, M. Scavuzzo<sup>3</sup>, T. Guthrie<sup>3</sup>, B.F. Meyers<sup>3</sup>, R.D. Davis<sup>2</sup>, G.A. Patterson<sup>3</sup>, C.L. Lau<sup>1</sup> <sup>1</sup>University of Virginia, Charlottesville, VA; <sup>2</sup>Duke University, Durham, NC; <sup>3</sup>Washington University, St. Louis, MO

**(120) Determinants of Time To Peak FEV<sub>1</sub> after Lung Transplantation;** V.G. Valentine<sup>1</sup>, A. Raza<sup>2</sup>, S.P. Nishi<sup>1</sup>, M.R. Gupta<sup>1</sup>, L. Seoane<sup>2</sup>, G.A. Lombard<sup>1</sup>, G.S. Dhillon<sup>3</sup> <sup>1</sup>University of Texas Medical Branch, Galveston, TX; <sup>2</sup>Ochsner Medical Center, New Orleans, LA; <sup>3</sup>Stanford University Hospital, Stanford, CA

**(121) C-Reactive Protein in Broncho-Alveolar Lavage Is Associated with Airway Inflammation after Lung Transplantation;** R. Vos, B.M. Vanaudenaerde, S.I. De Vleeschauwer, L.J. Dupont, D. Van Raemdonck, G.M. Verleden Katholieke Universiteit and University Hospital Leuven, Leuven, Belgium

**(122) The Relationship between Positive HLA Antibodies, Acute Rejection Episodes and Lung Function Decline Following Lung Transplantation;** C.I. Whale, A. Higton, N. Fernandez, S. Lawrence, C. Jary, E. Gabbay, M. Musk Royal Perth Hospital, Perth, WA, Australia

**(123) Featured Poster: REVEAL Registry: Prevalence, Demographics and Outcomes in Patients with Pulmonary Arterial Hypertension (PAH) Characterized by Higher Left Sided Pressures;** A. Frost<sup>1</sup>, D. Miller<sup>2</sup>, H. Farber<sup>3</sup>, M.D. McGoan<sup>4</sup>, R. Barst<sup>5</sup>, C.G. Elliott<sup>6</sup> <sup>1</sup>Baylor College of Medicine, Houston, TX; <sup>2</sup>ICON Clinical Research, Lifecycle Science Group, San Francisco, CA; <sup>3</sup>Boston University School of Medicine, Boston, MA; <sup>4</sup>Mayo Clinic, Rochester, MN; <sup>5</sup>Columbia University College of Physicians Surgeons, New York, NY; <sup>6</sup>Intermountain Medical Center, University of Utah, Salt Lake, UT

**(124) Featured Poster: Severe Pulmonary Hypertension in IPF: Characteristics and Implications;** O.A. Minaj, J. Santacruz, M.M. Budev, K. McCarthy, L. Thuita, J. Alster Cleveland Clinic, Cleveland, OH

**(125) Impact of Pulmonary Hypertension on Early Hemodynamics, Morbidity and Mortality after Orthotopic Heart Transplantation;** H. Bedanova, M. Orban, E.D. Petrikovits, J. Ondrasek, P. Nemeč, J. Cerny Center of Cardiovascular and Transplant Surgery, Brno, Czech Republic

**(126) Exercise Pulmonary Hypertension-Systemic Sclerosis: Four Distinct Entities;** R. Saggari<sup>1</sup>, D. Khanna<sup>2</sup>, S. Shapiro<sup>1</sup>, D.E. Furst<sup>2</sup>, D.J. Ross<sup>1</sup>, J.A. Belperio<sup>1</sup>, D.A. Zisman<sup>1</sup>, P.J. Clements<sup>2</sup>, N. Chauhan, J.P. Lynch<sup>1</sup>, S. Weigt<sup>1</sup>, R. Saggari<sup>1</sup> <sup>1</sup>David Geffen School of Medicine, UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine, UCLA, Los Angeles, CA

**(127) Characterization of Patients with Drugs and Toxins Associated Pulmonary Arterial Hypertension: A Clinical and Outcomes Perspective;** S. Snook<sup>1</sup>, K. Kudelko<sup>1</sup>, E. Spiekerkoetter<sup>1</sup>, E. Fuh<sup>2</sup>, F. Haddad<sup>3</sup>, R.T. Zamanian<sup>1</sup> <sup>1</sup>Division of Pulmonary Critical Care Medicine, Stanford, CA; <sup>2</sup>Internal Medicine, Stanford, CA; <sup>3</sup>Cardiovascular Medicine, Stanford, CA

**(128) Decreased Expression of Thrombospondin-1 in Failing Hearts Could Favour Ventricular Remodeling;** M. Battle, F. Perez-Villa, A. Lazaro, E. Garcia-Pras, I. Vallejos, A. Arias, A. Sionis, A. Castel, E. Roig Thorax Institute - IDIBAPS - Hospital Clínic, Barcelona, Spain; Thorax Institute - IDIBAPS - Hospital Clínic, Barcelona, Spain; Thorax Institute - IDIBAPS - Hospital Clínic, Barcelona, Spain; Thorax Institute - IDIBAPS - Hospital Clínic, Barcelona, Spain; Hospital Clínic, Barcelona, Spain; Hospital Clínic, Barcelona, Spain; Hospital Clínic, Barcelona, Spain; Hospital Clínic, Barcelona, Spain; Hospital Clínic, Barcelona, Spain; Hospital Clínic, Barcelona, Spain

**(129) Treatment of Endothelial Cells with ATG Prevents Transendothelial Migration of Leukocytes;** A. Beiras-Fernandez, I. Hartmann, I. Kaczmarek, G. Eissner, B. Reichart LM-University, Munich, Germany

**(130) Featured Poster: Versican Expression Induces Tissue Remodeling;** J.M. Carthy, S. Boroomand, M. Rahmani, D. Knight, B.M. McManus The University of British Columbia/The James Hogg iCAPTURE Centre, Vancouver, BC, Canada

**(131) The Association between Killer Immunoglobulin-Like Receptors (KIR) Genotype Profile and Primary CMV Infection in CMV D+/R- Heart and Lung Transplant Recipients;** S. Hemachandra<sup>1</sup>, M. Askar<sup>2</sup>, A. Zhang<sup>2</sup>, D. Thomas<sup>2</sup>, D. Pidwell<sup>2</sup>, N.K. Shrestha<sup>1</sup>, D. van Duin<sup>1</sup>, R.K. Avery<sup>1</sup> <sup>1</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>2</sup>Cleveland Clinic Foundation, Cleveland, OH

**(132) The Role of Mast Cells in Acute and Chronic Cardiac Allograft Rejection;** S. Itoh<sup>1</sup>, S. Nakae<sup>2</sup>, J. Velotta<sup>1</sup>, H. Kosuge<sup>1</sup>, S. Schrepter<sup>1</sup>, A. Connolly<sup>3</sup>, M. Tsai<sup>3</sup>, H. Adachi<sup>4</sup>, S.J. Galli<sup>3</sup>, R.C. Robbins<sup>1</sup>, M.P. Fischbein<sup>1</sup> <sup>1</sup>Stanford University School of Medicine, Stanford; <sup>2</sup>University of Tokyo, Tokyo, Japan; <sup>3</sup>Stanford University School of Medicine, Stanford; <sup>4</sup>Saitama Medical Center, Jichi Medical School, Saitama, Japan

**(133) Stromal Cell-Derived Factor-1(SDF-1): A Novel Cardiac Rejection Biomarker;** A. Khanna, J. Xu, M.R. Mehra University of Maryland School of Medicine, Baltimore, MD

**(134) Does the Direct Myocardial Application of Electrical Microcurrent Heal Heart Failure by Downregulation of the Pro-Inflammatory Cytokines?;** J. Mueller<sup>1</sup>, B. Kapeller<sup>2</sup>, H. Heinze<sup>1</sup>, M. Hofmann<sup>2</sup>, J. Holfeld<sup>2</sup>, U.M. Losert<sup>2</sup>, K. Macfelda<sup>2</sup> <sup>1</sup>Berlin Heart, Berlin, Germany; <sup>2</sup>Medizinische Universität Wien, Wien, Austria

### **(135) WITHDRAWN**

**(136) Blockage of the Discoidin Domain Receptor 1 Expression by Small Interference RNA Attenuates the Rejection of an Allogeneic Tracheal Graft;** Y. Niu, H. Fan, G. Liu, H. Cao, Q. Shi, Z. Liu Shanghai East Hospital Affiliated to Tongji University, Shanghai, China

**(137) OX40 Triggering Breaks Costimulation Blockade-Mediated Lung Allograft Acceptance;** M. Okazaki<sup>1</sup>, W. Li<sup>1</sup>, J. Lai<sup>1</sup>, S. Sugimoto<sup>1</sup>, C.G. Kornfeld<sup>1</sup>, F.H. Kreisel<sup>2</sup>, X. Lin<sup>1</sup>, G.A. Patterson<sup>1</sup>, A.S. Krupnick<sup>1</sup>, A.E. Gelman<sup>1</sup>, D. Kreisel<sup>1</sup> <sup>1</sup>Washington University in St. Louis, St. Louis, MO; <sup>2</sup>Washington University in St. Louis, St. Louis, MO

**(138) T-Cadherin Expression in Cardiac Allograft Vasculopathy after Human Heart Transplantation;** A. Roussoulières<sup>1,2</sup>, S. Collot-Teixeira<sup>3</sup>, K. Morser<sup>3</sup>, L. Chalabreysse<sup>4</sup>, C. McDermott-Roe<sup>3</sup>, C. Cerutti<sup>2</sup>, A. Guzman<sup>5</sup>, J.-B. Michel<sup>5</sup>, P. Boissonnat<sup>1</sup>, L. Sebbag<sup>1</sup>, F. Thivolet-Bejui<sup>4</sup>, G. Bricca<sup>2</sup>, J. McGregor<sup>3,6</sup> <sup>1</sup>Hôpital Cardiologique Louis Pradel, Lyon, France; <sup>2</sup>INSERM/Université Claude Bernard, Lyon, France; <sup>3</sup>King's College, London, United Kingdom; <sup>4</sup>Hôpital Cardiologique Louis Pradel, Lyon, France; <sup>5</sup>INSERM, Paris, France; <sup>6</sup>INSERM/Hôpital Lariboisière, Paris, France

**(139) MyD88 Dependent Signaling Pathway Is Involved with Lung Ischemia-Reperfusion Injury;** A. Shimamoto, Y. Yajima, S. Shomura, M. Takao, H. Shimpo Mie University Graduate School of Medicine, Tsu, Mie, Japan

**(140) Early In Vivo Events Leading to Operational Tolerance in Neonatal Mice;** R.A. Bascom<sup>1</sup>, K. Tao<sup>1</sup>, L.J. West<sup>1,2,3</sup> <sup>1</sup>University of Alberta, Edmonton, Canada; <sup>2</sup>University of Alberta, Edmonton, Canada; <sup>3</sup>University of Alberta, Edmonton, Canada

### **9:00 PM – 10:30 PM**

Gala Reception (City Hall/Hotel de Ville)

**One ticket to the Gala Reception is included with each paid registration. A cash bar will be available at the Gala. Please note that drink tickets must be purchased in advance at the ISHLT Registration Desk in the Palais des**

Congres. Note that transportation to the Gala is not provided by ISHLT. Excellent direct access is available via Metro (Line 1) from the Porte Maillot Station, just outside the Palais des Congres, to the Hotel de Ville Station.

THURSDAY, APRIL 23, 2009

7:45 AM – 8:45 AM

**SCIENTIFIC COUNCIL MEETINGS**

Scientific Council on Pathology and Basic Science Meeting (Room 241)

Scientific Council on Infectious Diseases Meeting (Room 243)

Scientific Council on Mechanical Circulatory Support Meeting (Salle Maillot)

Scientific Council on Pulmonary Hypertension Meeting (Room 242AB)

9:00 AM – 11:00 AM

**PLENARY SESSION** (Main Theatre)

Chairs: Paul A. Corris, MB, FRCP and John O'Connell, MD

**9:00 AM (141) Featured Abstract:** Can C4d Staining Alone Predict Acute Antibody-Mediated Rejection in Heart Transplants?; C.D. Tan<sup>1</sup>, G.G. Sokos<sup>2</sup>, D.J. Pidwell<sup>3</sup>, G. Gonzalez-Stawinski<sup>4</sup>, D.O. Taylor<sup>2</sup>, R.C. Starling<sup>2</sup>, E.R. Rodriguez<sup>1</sup> <sup>1</sup>Cleveland Clinic, Cleveland, OH; <sup>2</sup>Cleveland Clinic, Cleveland, OH; <sup>3</sup>Cleveland Clinic, Cleveland, OH; <sup>4</sup>Cleveland Clinic, Cleveland, OH

**9:15 AM (142) Featured Abstract:** *The Role of Alloantibody in the Development of Cardiac Allograft Vasculopathy*; A.J. Gareau<sup>1</sup>, B. Nashan<sup>1</sup>, T.D.G. Lee<sup>1,2,3</sup> <sup>1</sup>Dalhousie University, Halifax, NS, Canada; <sup>2</sup>Dalhousie University, Halifax, NS, Canada; <sup>3</sup>Dalhousie University, Halifax, NS, Canada

**9:30 AM Invited Lecture:** *The Emerging Role of B Cells in Chronic Allograft Rejection*, Mohamed H. Sayegh, MD, Brigham & Women's Hospital, Boston, MA

**10:00 AM (143) Featured Abstract:** *Lung Resident Mesenchymal Stem Cells in Bronchoalveolar Lavage – A Novel Marker of Immune-Mediated Injury in Human Lung Transplant Recipients*; V.N. Lama, L. Badri, L. Liu, K. Chan, D.J. Pinsky, F.J. Martinez, S. Murray University of Michigan, Ann Arbor

**10:15 AM (144) Featured Abstract:** *The CCR7 Ligand CCL21 Recruits a CCR7+ Treg Population to the Lung Allograft That Prevents Development of Bronchiolitis Obliterans Syndrome*; A. Gregson<sup>1</sup>, S. Weigt<sup>2</sup>, R. Elashoff<sup>3</sup>, O. Yang<sup>1</sup>, J. Belperio<sup>2</sup> <sup>1</sup>UCLA, Los Angeles, CA; <sup>2</sup>UCLA, Los Angeles, CA; <sup>3</sup>UCLA, Los Angeles, CA

**10:30 AM Invited Lecture:** *Mechanisms of Graft Destruction by Antibodies*, Elaine F. Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA

11:00 AM – 11:30 AM

Coffee Break/View Posters/View Exhibits (Hall Maillot)

11:00 AM – 7:30 PM

Exhibit Hall Open (Hall Maillot)

11:30 AM – 1:00 PM

**CONCURRENT SESSION 7: Outcomes in Clinical Heart Transplantation** (Main Theatre)

Chairs: Nicholas R. Banner, FRCP and Edwin C. McGee, Jr., MD

**11:30 AM (145) Quantitative Donor Risk Index Predicts Mortality in Orthotopic Heart Transplantation**; E.S. Weiss<sup>1</sup>, J.G. Allen<sup>1</sup>, S.D. Russell<sup>2</sup>, W.A. Baumgartner<sup>1</sup>, J.V. Conte<sup>1</sup>, A.S. Shah<sup>1</sup> <sup>1</sup>The Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>The Johns Hopkins University School of Medicine, Baltimore, MD

11:45 AM (146) *Cancelled*

**12:00 PM (147) Outcomes of Heart Transplantation for Peripartum Cardiomyopathy: Analysis of the United Network for Organ Sharing (UNOS) Database**; K.D. Rasmuson<sup>1,2</sup>, D.G. Renlund<sup>1,3</sup>, B.D. Horne<sup>1</sup>, K.D. Brunisholz<sup>1</sup>, S.A. Brush<sup>1</sup>, P.W. Fisher<sup>1</sup>, M.M. Endo<sup>1</sup>, B.C. Miller<sup>1</sup>, J.J. Connolly<sup>1</sup>, J. Stehlik<sup>4</sup>, A.G. Kfoury<sup>1</sup> <sup>1</sup>Intermountain Medical Center, Salt Lake City, UT; <sup>2</sup>College of Nursing, Salt Lake City, UT; <sup>3</sup>University of Utah, Salt Lake City, UT; <sup>4</sup>George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT

**12:15 PM (148) Serum SMARCAL1 Concentrations in Donors Predict Primary Graft Dysfunction in Cardiac Transplantation;** S. Aharinejad<sup>1,2</sup>, O. Andrukhova<sup>2</sup>, M. Gmeiner<sup>1,2</sup>, A. Zuckermann<sup>1</sup>, D. Zimpfer<sup>1</sup>, A. Thomas<sup>2</sup>, M. Grimm<sup>1</sup>  
<sup>1</sup>Medical University of Vienna, Vienna, Austria; <sup>2</sup>Medical University of Vienna, Vienna, Austria

**12:30 PM (149) Quantitation of the Effect of Donor-Associated Characteristics on Post-Transplant Survival. ISHLT Registry Analysis;** J. Stehlik<sup>1</sup>, G. Stoddard<sup>1</sup>, L.B. Edwards<sup>2,4</sup>, D.O. Taylor<sup>2,4</sup> <sup>1</sup>University of Utah/VA SLC HCS, Salt Lake City, UT; <sup>2</sup>United Network for Organ Sharing, Richmond, VA; <sup>3</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>4</sup>International Society for Heart and Lung Transplantation, Addison, TX

**12:45 PM (150) Short- and Long-Term Survival of Combined Heart-Kidney Transplants Performed in the United States;** S. Lee<sup>1</sup>, J. Connett<sup>2</sup>, M. Colvin-Adams<sup>1</sup> <sup>1</sup>University of Minnesota, Minneapolis, MN; <sup>2</sup>University of Minnesota, Minneapolis, MN

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 8: Approaches to Treating and Diagnosing BOS** (Blue Theatre)

Chairs: Erik AM Verschuuren, MD, PhD and Allan R. Glanville, FRACP

**11:30 AM (151) Severity of Lymphocytic Bronchiolitis after Lung Transplantation: Implications of the New ISHLT Grading System;** A.R. Glanville<sup>1</sup>, C.L. Aboyou<sup>1</sup>, K. Hanning<sup>1</sup>, A. Havryk<sup>1</sup>, M. Plit<sup>1</sup>, S. Rainer<sup>2</sup>, M.A. Malouf<sup>1</sup> <sup>1</sup>St.Vincent's Hospital, Sydney, NSW, Australia; <sup>2</sup>St.Vincent's Hospital, Sydney, NSW, Australia

**11:45 AM (152) Bronchiolitis Obliterans Syndrome: Do Uncultured Bacterial Species Play a Role?;** T.W.V. Daniels<sup>1</sup>, G.B. Rogers<sup>2</sup>, B. Banarjee<sup>3</sup>, J.F. Fraser<sup>4</sup>, P.M.A. Hopkins<sup>1</sup>, F.D. Kermeen<sup>1</sup>, M. Musk<sup>3</sup>, A. Corley<sup>4</sup>, K.D. Bruce<sup>2</sup>, D.C. Chambers<sup>1</sup>  
<sup>1</sup>Prince Charles Hospital, Brisbane, Queensland, Australia; <sup>2</sup>Kings College London, London, United Kingdom; <sup>3</sup>Royal Perth Hospital, Perth, Western Australia, Australia; <sup>4</sup>Prince Charles Hospital, Brisbane, Queensland, Australia

**12:00 PM (153) Randomized, Double-Blind, Placebo-Controlled Trial of Azithromycin in Lung Transplantation: First Interim Results;** R. Vos, B.M. Vanaudenaerde, S.I. Si De Vleeschauwer, A. Schoonis, D.E. Van Raemdonck, L.J. Dupont, G.M. Verleden Katholieke Universiteit Leuven and University Hospital Gasthuisberg, Leuven, Belgium

**12:15 PM (154) Long Term Follow-Up in the AIRSAC Trial, a Multicenter Randomized Clinical Trial in Lung Transplant Recipients;** S.M. Bhorade<sup>1</sup>, V. Ahya<sup>2</sup>, R. Kotloff<sup>2</sup>, M. Baz<sup>3</sup>, V. Valentine<sup>4</sup>, S. Arcasoy<sup>5</sup>, R. Love<sup>6</sup>, A. deOliveira<sup>7</sup>, R. Bag<sup>8</sup>, H. Seethamraju<sup>9</sup>, C. Alex<sup>6</sup>, W.T. Vigneswaran<sup>1</sup>, J. Charbeneau<sup>1</sup>, J. Krishnan<sup>1</sup>, R. Durazo<sup>6</sup>, E.R. Garrity<sup>1</sup> <sup>1</sup>University of Chicago Medical Center, Chicago, IL; <sup>2</sup>University of Pennsylvania Medical Center, Philadelphia, PA; <sup>3</sup>University of Florida Medical Center, Gainesville, FL; <sup>4</sup>University of Texas Galveston, Galveston, TX; <sup>5</sup>Columbia University Medical Center, New York, NY; <sup>6</sup>Loyola University Medical Center, Maywood, IL; <sup>7</sup>University of Wisconsin Medical Center, Madison, WI; <sup>8</sup>University of Oklahoma, Oklahoma City, OK; <sup>9</sup>Baylor Medical Center, Houston, TX

**12:30 PM (155) Clinical and Immunological Evaluation of Azithromycin in Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation;** N. Solari<sup>1</sup>, M. Morosini<sup>1</sup>, A. Cascina<sup>1</sup>, T. Oggionni<sup>1</sup>, A.M. D'Armini<sup>2</sup>, A.M. Fietta<sup>1</sup>, F. Meloni<sup>1</sup>  
<sup>1</sup>University of Pavia Foundation IRCCS San Matteo Pavia, Pavia, Italy; <sup>2</sup>University of Pavia Foundation IRCCS San Matteo Pavia, Pavia, Italy

**12:45 PM (156) The Efficacy of Photopheresis in Lung Transplantation;** M.R. Morrell, E.P. Trulock, R.R. Hachem  
Washington University/Barnes-Jewish Hospital, St. Louis, MO

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 9: Stem Cell Therapy and Remodeling** (Salle Maillot)

Chairs: Steve Xydas, MD and Guillermo Torre-Amione, MD, PhD

**11:30 AM (157) Early Benefits of Intracoronary CD34+ Stem Cell Transplantation in Patients with Dilated Cardiomyopathy Are Sustained over Time;** B. Vrtovc<sup>1</sup>, G. Pogljajen<sup>1</sup>, M. Sebestjen<sup>1</sup>, R. Okrajsek<sup>1</sup>, M. Bunc<sup>1</sup>, P. Cernelc<sup>2</sup>, M. Sever<sup>2</sup>, D. Domanovic<sup>3</sup>, G. Torre-Amione<sup>4</sup> <sup>1</sup>Ljubljana University Medical Center, Ljubljana, Slovenia; <sup>2</sup>Ljubljana University Medical Center, Ljubljana, Slovenia; <sup>3</sup>National Blood Transfusion Center, Ljubljana, Slovenia; <sup>4</sup>Methodist DeBakey Heart Center, Houston, TX

**11:45 AM (158) Heart Transplantation with Adjuvant Autologous Cardiac Progenitor Cell Therapy;** D.A. D'Alessandro<sup>1</sup>, R. Bello<sup>1</sup>, D. Stern<sup>1</sup>, J. Kajstura<sup>2</sup>, C. Bearzi<sup>2</sup>, D. Goldstein<sup>1</sup>, M. Zembala<sup>1</sup>, M. Rota<sup>2</sup>, A. Leri<sup>2</sup>, P. Anversa<sup>2</sup>, R.E. Michler<sup>1</sup>  
<sup>1</sup>Montefiore-Einstein Heart Center, New York, NY; <sup>2</sup>Harvard Medical School, Boston, MA

**12:00 PM (159) Right Ventricular Cell Transplantation Attenuates Impaired LV-Contractility, Modulates Gene Expression Profile and Angiogenesis in Non-Ischemic Cardiomyopathy;** J. Garbade<sup>1</sup>, M. Arsalan<sup>1</sup>, H. Aupperle<sup>2</sup>, H.B. Bittner<sup>1</sup>, T.

Walther<sup>1</sup>, S. Dhein<sup>1</sup>, F.-W. Mohr<sup>1</sup> <sup>1</sup>Heart Center, University of Leipzig, Leipzig, Germany; <sup>2</sup>Faculty of Veterinary Medicine, University of Leipzig, Leipzig, Germany

**12:15 PM (160) Human Cord Blood Derived Stem Cells Improve Left Ventricular Function and High Energy Phosphates in a Porcine Model of Myocardial Infarction;** B.A. Bruckner<sup>1</sup>, A. Ghodsizad<sup>1</sup>, B. Fahy<sup>1</sup>, M. Karck<sup>2</sup>, G. Kogler<sup>3</sup>, H.M. Kline<sup>4</sup>, A. Haverich<sup>5</sup>, R. Schulz<sup>6</sup>, M. Loebe<sup>1</sup>, M. Reardon<sup>1</sup>, I. Gregoric<sup>1</sup>, A. Ruhparwar<sup>2</sup> <sup>1</sup>Methodist DeBakey Heart Center, Houston; <sup>2</sup>University of Heidelberg, Heidelberg, Germany; <sup>3</sup>University of Duesseldorf, Dusseldorf, Germany; <sup>4</sup>University of Duesseldorf, Dusseldorf, Germany; <sup>5</sup>Medical School of Hannover, Hannover, Germany; <sup>6</sup>University of Essen Medical School, Essen, Germany

**12:30 PM (161) Stem Cells Homing, Ventricular Remodeling and Plasma Brain Natriuretic Peptide in Heart Failure;** C. Castellani<sup>1</sup>, B. Ravara<sup>2</sup>, V. Gobbo<sup>2</sup>, M. Piccoli<sup>3</sup>, C. Franzin<sup>4</sup>, M. Pozzobon<sup>3</sup>, R. Vettor<sup>4</sup>, G. Thiene<sup>1</sup>, L. Dalla Libera<sup>2</sup>, G. Vescovo<sup>5</sup>, A. Angelini<sup>1</sup> <sup>1</sup>University of Padua, Padua, Italy; <sup>2</sup>University of Padua, Padua, Italy; <sup>3</sup>University of Padua, Padua, Italy; <sup>4</sup>University of Padua, Padua, Italy; <sup>5</sup>Vicenza Hospital, Vicenza, Italy

**12:45 PM (162) Self Renewal Gene Networks in Bronchioalveolar Stem Cells (BASCs);** J. Dong, S. Sutor, D.A. Wigle  
Mayo Clinic, Rochester, MN

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 10: Pediatric Thoracic Transplantation: MCS and Rejection (252AB)**

Chairs: Paul Aurora, MRCP, PhD and Daphne T. Hsu, MD

**11:30 AM (163) Safety and Efficacy of Extra-Corporeal Membrane Oxygenation for Bridge-to-Heart Transplantation in Children: Analysis of Data from the Extra-Corporeal Life Support (ELSO) Registry;** C.S.D. Almond<sup>1</sup>, T.P. Singh<sup>1</sup>, K. Gauvreau<sup>1</sup>, R. Bartlett<sup>2</sup>, P. Rykus<sup>2</sup>, F. Fynn-Thompson<sup>3</sup>, R.R. Thiagarajan<sup>1</sup> <sup>1</sup>Children's Hospital Boston, Boston, MA; <sup>2</sup>University of Michigan, Ann Arbor, MI; <sup>3</sup>Children's Hospital Boston, Boston, MA

**11:45 AM (164) Mechanical Bridging to Heart Transplantation in Children <10 kg;** A. Karimova<sup>1</sup>, C. VanDoorn<sup>2</sup>, K. Brown<sup>1</sup>, M. Burch<sup>3</sup>, A. Goldman<sup>1</sup>, A. Hoskote<sup>1</sup> <sup>1</sup>Great Ormond Street Hospital for Children, London, United Kingdom; <sup>2</sup>Great Ormond Street Hospital for Children, London, United Kingdom; <sup>3</sup>Great Ormond Street Hospital for Children, London, United Kingdom

**12:00 PM (165) A Single Episode of Minimal Acute Rejection after Lung Transplantation – Does It Matter in Children?;** C. Benden<sup>1</sup>, A. Faro<sup>2</sup>, S. Worley<sup>3</sup>, S. Arrigain<sup>3</sup>, P. Aurora<sup>4</sup>, M. Ballmann<sup>5</sup>, D. Boyer<sup>6</sup>, C. Conrad<sup>7</sup>, I. Eichler<sup>8</sup>, O. Elidemir<sup>9</sup>, S. Goldfarb<sup>10</sup>, G.B. Mallory<sup>9</sup>, P.J. Mogayzel<sup>11</sup>, D. Parakininkas<sup>12</sup>, M. Solomon<sup>13</sup>, G. Visner<sup>6</sup>, S.C. Sweet<sup>2</sup>, L.A. Danziger-Isakov<sup>3</sup> <sup>1</sup>University Hospital Zurich, Zurich, Switzerland; <sup>2</sup>Washington University School of Medicine, Washington, MO; <sup>3</sup>Cleveland Clinic, Cleveland, OH; <sup>4</sup>Institute of Child Health, London, United Kingdom; <sup>5</sup>Hannover Medical School, Hannover, Germany; <sup>6</sup>Harvard Medical School, Boston, MA; <sup>7</sup>Stanford University, Palo Alto, CA; <sup>8</sup>Medical University Vienna, Vienna, Austria; <sup>9</sup>Baylor College of Medicine, Houston, TX; <sup>10</sup>Children's Hospital of Philadelphia, Philadelphia, PA; <sup>11</sup>The Johns Hopkins Medical Institutions, Baltimore, MD; <sup>12</sup>Medical College of Wisconsin, Milwaukee, WI; <sup>13</sup>Hospital for Sick Children, Toronto, ON, Canada

**12:15 PM (166) Renin Angiotensin Aldosterone (RAAS) Gene Polymorphisms Mediate Cardiac Allograft Dysfunction through Cytokine Upregulation in Pediatric Patients;** C. Manlhiot<sup>1</sup>, S.R. Auerbach<sup>2</sup>, B.W. McCrindle<sup>1</sup>, A.I. Dipchand<sup>1</sup>, C. Kinnear<sup>1</sup>, J.M. Chen<sup>2</sup>, D. Gruber<sup>2</sup>, L.J. Addonizio<sup>2</sup>, W.K. Chung<sup>2</sup>, S. Mital<sup>1</sup> <sup>1</sup>The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; <sup>2</sup>Morgan Stanley Children's Hospital of New-York Presbyterian, Columbia University, New York, NY

**12:30 PM (167) The Presence of Cardiac Allograft Vasculopathy in Infant and Pediatric Heart Transplant Recipients: A 10-Year Intravascular Ultrasound Study;** M.A. Kuhn<sup>1</sup>, R.E. Chinnock<sup>2</sup>, D.D. Deming<sup>2</sup>, A.J. Razzouk<sup>3</sup>, L.L. Bailey<sup>3</sup> <sup>1</sup>Loma Linda University Medical Center and Children's Hospital, Loma Linda, CA; <sup>2</sup>Loma Linda University Medical Center and Children's Hospital, Loma Linda, CA; <sup>3</sup>Loma Linda University Medical Center and Children's Hospital, Loma Linda, CA

**12:45 PM (168) Decline in Rejection in the First Year after Pediatric Cardiac Transplantation: A Multi-Institutional Study;** J.G. Gossett<sup>1</sup>, C.E. Canter<sup>2</sup>, J. Zheng<sup>3</sup>, K.B. Schechtman<sup>3</sup>, E.D. Blume<sup>4</sup>, S. Rodgers<sup>1</sup>, J. Scheel<sup>5</sup>, J. Fricker<sup>6</sup>, P.F. Kantor<sup>7</sup>, E. Pahl<sup>1</sup> <sup>1</sup>Children's Memorial Hospital, Chicago, IL; <sup>2</sup>Washington University School of Medicine, Saint Louis, MO; <sup>3</sup>Washington University School of Medicine, Saint Louis, MO; <sup>4</sup>Children's Hospital Boston, Boston, MA; <sup>5</sup>Johns Hopkins Hospital, Baltimore, MD; <sup>6</sup>University of Florida, Gainesville, FL; <sup>7</sup>Hospital for Sick Children, Toronto, ON, Canada

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 11: Organ Preservation (242 AB)**

Chairs: Paul Mohacsi, MD and Kenneth R. McCurry, MD

**11:30 AM (169) Carbon Monoxide Inhalation Reduces Pulmonary Ischemia Reperfusion Injury in Miniature Swine;** H. Sahara<sup>1</sup>, M. Okumi<sup>1</sup>, M. Oku<sup>1</sup>, K. Setoyama<sup>1</sup>, A. Shimizu<sup>2</sup>, K. Yamada<sup>1</sup> <sup>1</sup>Frontier Science Research Center, Kagoshima University, Kagoshima, Japan; <sup>2</sup>Nippon Medical School, Tokyo, Japan

**11:45 AM (170) Ex Vivo Adenoviral Mediated IL-10 Gene Therapy (AdhIL-10) Improves Lung Function with a Reduced Vector Associated Inflammatory Response;** J.C. Yeung, D. Wagnetz, M. Cypel, M. Rubacha, J. Chung, D. Hwang, T.K. Waddell, M. Liu, S. Keshavjee University of Toronto, Toronto, ON, Canada

**12:00 PM (171) The Influence of Oxygen Concentration and Inflation Pressure during Ischemia on Lung Ischemia Reperfusion Injury;** N.P. van der Kaaij<sup>1</sup>, J. Kluin<sup>2</sup>, R.A. Lachmann<sup>3</sup>, M.A. den Bakker<sup>4</sup>, J.J. Haitisma<sup>3</sup>, B.N. Lambrecht<sup>5</sup>, R.W.F. de Bruin<sup>6</sup>, B. Lachmann<sup>3</sup>, A.J.J.C. Bogers<sup>1</sup> <sup>1</sup>Erasmus MC, Rotterdam, Netherlands; <sup>2</sup>UMC Utrecht, Utrecht, Netherlands; <sup>3</sup>Erasmus MC, Rotterdam, Netherlands; <sup>4</sup>Erasmus MC, Rotterdam, Netherlands; <sup>5</sup>Erasmus MC, Rotterdam, Netherlands; <sup>6</sup>Erasmus MC, Rotterdam, Netherlands

**12:15 PM (172) Recipient Hypertonic Saline Infusion Prevents Cardiac Allograft Dysfunction;** D. Ramzy, L.C. Tumiaty, M. Badiwala, E. Tepperman, R. Sheshgiri, V. Rao Toronto General Hospital, Toronto, ON, Canada

**12:30 PM (173) Normothermic Human Ex Vivo Lung Perfusion (EVLP) for Improved Assessment of Extended Criteria Donor Lungs for Transplantation;** M. Cypel, J. Yeung, M. Liu, F. Chen, W. Karolak, K. Yasufuku, M. DePerrot, A. Pierre, T. Waddell, C.-W. Chow, M. Hutcheon, C. Chaparro, L.G. Singer, S. Keshavjee University of Toronto, Toronto, ON, Canada

**12:45 PM (174) Maintenance of Human Heart Oxidative Metabolism after 12 Hour Perfusion Preservation;** M. Cobert, M. Peltz, L. West, M.E. Jessen University of Texas Southwestern Medical Center at Dallas, Dallas, TX

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 12: Quality of Life in Transplantation "Bonjour La Vie"?** (241)

Chairs: Susan M. Chernenko, MN and Sandra Martin, RN, MSN

**11:30 AM (175) Post-Lung Transplant Health-Related Quality of Life: Perception and Reality;** L.G. Singer<sup>1,2</sup>, N. Chowdhury<sup>2</sup>, C. Chaparro<sup>1,2</sup>, M.A. Hutcheon<sup>1,2</sup> <sup>1</sup>University of Toronto, Toronto, ON, Canada; <sup>2</sup>University Health Network, Toronto, ON, Canada

**11:45 AM (176) Health-Related Quality of Life in Long-Term Survivors after Heart and Lung Transplantation: A Comparative Cohort Study;** C. Kugler<sup>1</sup>, U. Tegtbur<sup>2</sup>, J. Gottlieb<sup>3</sup>, C. Bara<sup>1</sup>, D. Malehsa<sup>1</sup>, T. Fuehner<sup>3</sup>, M. Strueber<sup>1</sup>, A. Haverich<sup>1</sup>, A. Simon<sup>1</sup> <sup>1</sup>Hannover Medical School, Hannover, Germany; <sup>2</sup>Hannover Medical School, Hannover, Germany; <sup>3</sup>Institute of Sports medicine, Hannover Medical School, Hannover, Hannover, Germany

**12:00 PM (177) LVAD Therapy: Impact of Family Caregivers' Stress, Coping, Social Support on Perceived Burden Quality of Life (QOL);** M. Petty<sup>1</sup>, K. Savik<sup>2</sup> <sup>1</sup>University of Minnesota Med. Center, Fairview, Minneapolis, MN; <sup>2</sup>University of Minnesota, Minneapolis, MN

**12:15 PM (178) The Relationship of Social Support and Quality of Life 5 to 10 Years after Heart Transplantation;** C. White-Williams<sup>1</sup>, K.L. Grady<sup>2</sup>, E.C. Wang<sup>2</sup>, D.C. Naftel<sup>3</sup>, B. Rybarczyk<sup>4</sup>, J.B. Young<sup>5</sup>, D. Pelegrin<sup>5</sup>, S. Myers<sup>3</sup>, J. Kirklin<sup>3</sup>, J. Czerr<sup>5</sup>, J. Kobashigawa<sup>6</sup>, J. Chait<sup>6</sup>, A. Heroux<sup>7</sup>, R. Higgins<sup>8</sup> <sup>1</sup>University of Alabama, Birmingham, AL; <sup>2</sup>Northwestern Memorial Hospital, Chicago, IL; <sup>3</sup>University of Alabama, Birmingham, AL; <sup>4</sup>Virginia Commonwealth University, Richmond, VA; <sup>5</sup>The Cleveland Clinic, Cleveland, OH; <sup>6</sup>UCLA Medical Center, Los Angeles, CA; <sup>7</sup>Loyola University Medical Center, Chicago, IL; <sup>8</sup>Rush University Medical Center, Chicago, IL

**12:30 PM (179) Impact of Donor-Transmitted Coronary Atherosclerosis on Quality of Life and Quality-Adjusted Life Years after Heart Transplantation;** O. Grauhan<sup>1</sup>, H. Chang<sup>2</sup>, W. Albert<sup>1</sup>, N. Hiemann<sup>1</sup>, R. Meyer<sup>1</sup>, H. Lehmkühl<sup>1</sup>, M. Dandel<sup>1</sup>, C. Knosalla<sup>1</sup>, M. Hubler<sup>1</sup>, M. Pasic<sup>1</sup>, R. Hetzer<sup>1</sup> <sup>1</sup>German Heart Institute Berlin, Berlin, Germany; <sup>2</sup>Taipeh Veterans General Hospital, Taipei, Taiwan

**12:45 PM (180) What They Say Versus What We See: 'Hidden' Distress and Impaired Quality of Life in Heart Transplant Recipients;** S. Abbey<sup>1</sup>, E. De Luca<sup>1</sup>, O. Mauthner<sup>1</sup>, P. Mc Keever<sup>2</sup>, M. Shildrick<sup>3</sup>, J. Poole<sup>4</sup>, H.J. Ross<sup>1</sup> <sup>1</sup>University Health Network, Toronto, Canada; <sup>2</sup>University of Toronto, Toronto, Canada; <sup>3</sup>Queen's University Belfast, Belfast, Ireland; <sup>4</sup>Ryerson University, Toronto, Canada

**1:00 PM -1:15 PM**

**BOX LUNCH PICK-UP** (box lunches may be picked up in the Registration Area; advance registration and ticket required; lunch seating is available in Salle Maillot and Blue Theater foyers; food and drink are not allowed in the Blue Theatre)

**1:15 PM – 2:45 PM**

**LUNCH SYMPOSIUM: *Die Another Day: New Perspectives on Cardiac Allograft Vasculopathy*** (Main Theater)

Supported by an Educational Grant from Novartis

(ticket required for box lunch only; symposium open to all meeting delegates)

Chairs: Joren Madsen, MD, D.Phil and Hannah Valentine, MD

**1:15 PM *Progenitor Cells: First Settlers of Cardiac Allograft Vasculopathy***, Christian Weber, Institute for Molecular Cardiovascular Research IMCAR, Aachen, Germany

**1:30 PM *Platelets as Underestimated Effectors***, Stephan M. Ensminger, MD, PhD, University of Erlangen-Nurnberg, Erlangen, Germany

**1:45 PM Debate: *mTOR Inhibitors Should Be the Standard of Care in Preventing and Treating Cardiac Allograft Vasculopathy***

*Pro:* Hans B. Lehmkuhl, MD, Deutsches Herzzentrum Berlin, Germany

*Con:* Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT

**1:15 PM – 2:45 PM**

**JHLT EDITORIAL BOARD MEETING** (Room 243) (lunch provided)

**1:15 PM – 2:45 PM**

**MINI-ORAL SESSION 1** (Blue Theatre)

Chairs: Stephen R. Large, MB, MA, MSF and Maria Rosa Costanzo, MD

**1:15 PM (181) *Early Neurological Adverse Events (NAE) after Pulsatile VAD Implantation in 455 Patients: Incidence, Severity and Outcome***; R.L. Kormos<sup>1</sup>, J.K. Kirklin<sup>2</sup>, D.C. Naftel<sup>2</sup>, J.B. Young<sup>3</sup>, M. Acker<sup>4</sup>, M. Jessup<sup>4</sup>, V. Jeevanandam<sup>5</sup>, T.L. Baldwin<sup>6</sup>, M. Camacho<sup>7</sup>, D.D. Ascheim<sup>8</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>University of Alabama, Birmingham, AL; <sup>3</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>4</sup>University of Pennsylvania, Philadelphia, PA; <sup>5</sup>University of Chicago, Chicago, IL; <sup>6</sup>National Heart, Lung and Blood Institute, Bethesda, MD; <sup>7</sup>Newark Beth Israel Medical Center, Newark, NJ; <sup>8</sup>Columbia University, New York, NY

**1:20 PM (182) *The Effects of Left Ventricular Assist Device (LVAD) Unloading on Cardiac Sympathetic Innervation***; R.S. George<sup>1</sup>, M.H. Yacoub<sup>3</sup>, A. Cheetham<sup>2</sup>, R. Manlapig<sup>2</sup>, A. Khaghani<sup>1</sup>, A. Kelion<sup>2</sup>, E.J. Birks<sup>1</sup> <sup>1</sup>Royal Brompton and Harefield NHS Trust, Uxbridge, Middlesex, United Kingdom; <sup>2</sup>Royal Brompton and Harefield NHS Trust, Uxbridge, Middlesex, United Kingdom; <sup>3</sup>Imperial College, Uxbridge, Middlesex, United Kingdom

**1:25 PM (183) *Limited Surgical Approaches for LVAD Explant Following Myocardial Recovery Are Associated with Low Morbidity and Improved Outcome***; S. Haj-Yahia<sup>1,2</sup>, R. George<sup>2</sup>, S. Waligorski<sup>1</sup>, G. Dreyfus<sup>1</sup>, M. Amrani<sup>1,2</sup>, M. Yacoub<sup>2</sup>, A. Khaghani<sup>1,2</sup> <sup>1</sup>Royal Brompton Harefield Hospital, London, United Kingdom; <sup>2</sup>Imperial College London, London, United Kingdom

**1:30 PM (691) *Myocardial Hypertrophy at Implantation Correlates with Duration of Left Ventricular Assist Device Support***; A.M. Segura, O.H. Frazier, L.M. Buja Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX

**1:35 PM (185) WITHDRAWN**

**1:40 PM (186) *Differential Sensitization Incidence between HeartMate I and HeartMate II Left Ventricular Assist Devices***; J.R. Kotter, S.G. Drakos, A.G. Kfoury, D.D. Eckels, P.W. Fisher, B.B. Reid, D.A. Bull, E.M. Gilbert, J. Stehlik, M.R. Merida III, D.G. Renlund U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT

**1:45 PM (187) *Predicting Factors for Inotropic Dependency after Left Ventricular Assist Device Implantation***; I. Nakajima<sup>1</sup>, T.S. Kato<sup>2</sup>, N. Oda<sup>2</sup>, M. Yanase<sup>2</sup>, K. Komamura<sup>2</sup>, T. Nakatani<sup>2</sup> <sup>1</sup>National Cardiovascular Center, Suita, Osaka, Japan; <sup>2</sup>National Cardiovascular Center, Suita, Osaka, Japan

**1:50 PM (188) *Off Pump Placement of Implantable LVADs Results in Significant Reductions of Transfusion Requirements and Re-Exploration for Hemorrhage***; L.B. Louis<sup>1</sup>, C.B. Sai-Sudhakar<sup>1</sup>, P.A. Vesco<sup>1</sup>, M.S. Firstenberg<sup>1</sup>, A.K. Hasan<sup>2</sup>, B.C. Sun<sup>1</sup> <sup>1</sup>The Ohio State University, Columbus, OH; <sup>2</sup>The Ohio State University, Columbus, OH

**1:55 PM (189) *Right Ventricle Dysfunction Persists after 3 Months of LVAD Support on Current Therapies***; M. Palardy, N. Lakdawala, M. Kato, P.M. Campbell, M.M. Givertz, C.W. May, G.S. Couper, P.S. Shekar, G.C. Stewart, W.A. Alhabeeb, C.M. Smith, L.M. Griffin, G.H. Mudge, L.W. Stevenson Brigham and Women's Hospital, Boston, MA

**2:00 PM (190)** *Minimally Invasive Approach to the Management of Pleural and Pericardial Complications in the Ventricular Assist Device (VAD) Patient*; S. Gilbert, A. Kilic, K. Yaeger, Y. Toyoda, C. Bermudez, M. Siegenthaler, R.L. Kormos University of Pittsburgh Medical Center, Pittsburgh, PA

**2:05 PM (191)** *Occurrence of Ventricular Arrhythmias in Patients with a Continuous Flow Left Ventricular Assist Device (Heartmate II)*; M. Andersen, R. Videbaek, S. Boesgaard, K. Sander, P.B. Hansen, F. Gustafsson Rigshospitalet, Copenhagen, Denmark

**2:10 PM (192)** *Predictors of Improvement in Right Ventricular Function after Placement of a Left Ventricular Assist Device*; B.A. Boilson<sup>1</sup>, J.A. Schirger, I. Penev<sup>2</sup>, S.S. Kushwaha<sup>1</sup>, C.G.A. McGregor<sup>2</sup>, R.C. Daly<sup>2</sup>, L.C. Durham<sup>2</sup>, B.S. Edwards<sup>1</sup>, M. M. Redfield<sup>1</sup>, S.J. Park<sup>2</sup> <sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Mayo Clinic, Rochester, MN

**2:15 PM (193)** *Long-Term Support with a Bi-Ventricular Assist Device – A Single Center Experience*; P. Sfirakis<sup>1</sup>, A. Gkouziouta<sup>2</sup>, L. Tsourelis<sup>1</sup>, D. Zarkalis<sup>1</sup>, E. Leontiadis<sup>3</sup>, L. Louca<sup>1</sup>, G. Stavridis<sup>1</sup>, P.A. Alivizatos<sup>1</sup> <sup>1</sup>Onassis Cardiac Surgery Center, Athens, Greece; <sup>2</sup>Onassis Cardiac Surgery Center, Athens, Greece; <sup>3</sup>Onassis Cardiac Surgery Center, Athens, Greece

**2:20 PM (194)** *Effect of Continuous Flow Left Ventricular Assist Devices on Left Ventricular Size and Severity of Mitral Regurgitation*; S.A. Mandras, S. Joseph, I.M. Saeed, T.J. Guthrie, S.V. Arnold, I.-W. Wang, N. Moazami, G.A. Ewald Washington University in Saint Louis, Saint Louis, MO

**2:25 PM (195)** *Improved Outcomes after Ventricular Assist Device Implantation in Patients Older Than 60 Years of Age*; T. Kohmoto<sup>1</sup>, S. Osaki<sup>1</sup>, M.R. Johnson<sup>2</sup>, M.A. Murray<sup>1</sup>, A.K. Proebstle<sup>1</sup>, L. Lozonschi<sup>1</sup>, N.M. Edwards<sup>1</sup> <sup>1</sup>University of Wisconsin School of Medicine and Public Health, Madison, WI; <sup>2</sup>University of Wisconsin School of Medicine and Public Health, Madison, WI

**2:30 PM (196)** *Single Center Experience with 104 Total Artificial Heart Implant Patients*; O. Amabile, Jr., J. Copland, R. Smith, P. Nolan, G. Sethi, C. Smith, R. Bose, P. Tsau, D. Covington, M. McCarthy University of Arizona, Tucson, AZ

**1:15 PM – 2:45 PM**

**MINI-ORAL SESSION 2 (252 AB)**

Chairs: Trevor J. Williams, MD and Marie M. Budev, DO, MPH

**1:15 PM (197)** *27-Year Experience with Combined Heart-Lung Transplantation at Stanford University*; T. Deuse<sup>1</sup>, R. Sista<sup>2</sup>, F. Haddad<sup>3</sup>, D. Weill<sup>2</sup>, G. Dhillon<sup>2</sup>, D. Tang<sup>1</sup>, H. Mallidi<sup>1</sup>, S. Hunt<sup>3</sup>, P. Oyer<sup>1</sup>, R.C. Robbins<sup>1</sup>, B.A. Reitz<sup>1</sup> <sup>1</sup>Stanford University, Stanford, CA; <sup>2</sup>Stanford University, Stanford, CA; <sup>3</sup>Stanford University, Stanford, CA

**1:20 PM (198)** *Donor Outcome after Living-Donor Lobar Lung Donation: 93 Donor Lobectomies in a Single-Center Experience*; Y. Sano<sup>1</sup>, T. Oto<sup>1</sup>, M. Yamane<sup>1</sup>, S. Toyooka<sup>1</sup>, M. Okazaki<sup>1</sup>, M. Okazaki<sup>1</sup>, S. Kasahara<sup>2</sup>, S. Sano<sup>2</sup> <sup>1</sup>Okayama University Hospital, Okayama, Japan; <sup>2</sup>Okayama University Hospital, Okayama, Japan

**1:25 PM (199)** *Survival Benefit of Contemporary Lung Transplantation in Patients with IPF*; S. Bastani<sup>1</sup>, W. Sherman<sup>1</sup>, R. Mahidhara<sup>1</sup>, D. Ross<sup>2</sup>, R. Sagar<sup>2</sup>, J. Lynch<sup>2</sup>, D. Zisman<sup>2</sup>, J. Belperio<sup>2</sup>, A. Ardehali<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**1:30 PM (200)** *Clinical Experience with the Use of Virtual Crossmatch in Adult Lung Transplantation*; C. Bermudez, A. Gironita, F. Avila, A. Zeevi, M. Crespo, J. Pilewski, G. Speziali, B. Johnson, D. Zaldonis, Y. Toyoda University of Pittsburgh Medical Center, Pittsburgh, PA

**1:35 PM (201)** *The Outcome of Conventional Lung Volume Reduction Surgery Significantly Exceeds That of Lung Transplantation for Emphysema*; H.E. Seale<sup>1</sup>, J. Walsh<sup>1</sup>, M.N. Windsor<sup>2</sup>, S.C. Bell<sup>2</sup>, P.M.A. Hopkins<sup>1</sup> <sup>1</sup>The Prince Charles Hospital, Brisbane, Qld, Australia; <sup>2</sup>The Prince Charles Hospital, Brisbane, Qld, Australia

**1:40 PM (202)** *Lung Transplantation (LT) from Non-Heart Beating Donors (NHBD)s: The Harefield Experience*; S. Haj-Yahia<sup>1,2</sup>, T. Bahrami<sup>1</sup>, A. Khaghani<sup>1,2</sup>, M. Amrani<sup>1,2</sup>, N. Crouchen<sup>1</sup>, B. Soleimani<sup>1</sup>, M. Carby<sup>1</sup>, M. Petrou<sup>1</sup> <sup>1</sup>Royal Brompton Harefield Hospital, London, United Kingdom; <sup>2</sup>Imperial College London, London, United Kingdom

**1:45 PM (203)** *Combined Lung Liver Transplantation in Cystic Fibrosis Population: A French Experience Update*; R. Souilamas<sup>1</sup>, O. Scatton<sup>2</sup>, P. Sogni<sup>2</sup>, Y. Calmus<sup>2</sup>, R. Kanaan<sup>3</sup>, R. Guillemin<sup>1</sup>, V. Boussaud<sup>1</sup>, P. Chevalier<sup>1</sup>, C. Amrein<sup>1</sup>, O. Soubrane<sup>2</sup> <sup>1</sup>European Georges Pompidou Hospital, Paris, France; <sup>2</sup>Cochin Hospital, Paris, France; <sup>3</sup>Cochin Hospital, Paris, France



**1:50 PM (204) WITHDRAWN**

**1:55 PM (205)** *Clinical Evolution of a Mechanical Bridge to Pulmonary Transplantation*; C. Hoopes University of California San Francisco, San Francisco, CA

**2:00 PM (206)** *A Retrospective Analysis of Long-Term Azithromycin Therapy for Bronchiolitis Obliterans Syndrome after Lung Transplantation*; B.M. Vanaudenaerde, R. Vos, A. Ottevaere, S.I. De Vleeschauwer, K. De Vusser, D.E. Van Raemdonck, L.J. Dupont, G.M. Verleden Katholieke Universiteit Leuven, Leuven, Belgium

**2:05 PM (207)** *Comparison of Outcomes from Smoking and Non-Smoking Donors – 13-Year Experience*; M. Berman<sup>1</sup>, K. Goldsmith<sup>2</sup>, K. Dhital<sup>1</sup>, S.S. Tsui<sup>1</sup>, J.S. Parmar<sup>1</sup> <sup>1</sup>Papworth Hospital, Papworth Everard, Cambridge, United Kingdom; <sup>2</sup>Papworth Hospital, Papworth Everard, Cambridge, United Kingdom

**2:10 PM (208)** *Mucosal Integrin Expressing CD8 Lymphocytes Infiltrate Small Airways during Episodes of Acute Lung Allograft Rejection – Link between Rejection and BOS?*; D.C. Chambers<sup>1</sup>, P.M.A. Hopkins<sup>1</sup>, F. Kermeen<sup>1</sup>, J. Ahern<sup>2</sup>, G. Hodge<sup>2</sup>, P. Reynolds<sup>2</sup>, M. Holmes<sup>3</sup>, S. Hodge<sup>2</sup> <sup>1</sup>The Prince Charles Hospital, Brisbane, Queensland, Australia; <sup>2</sup>Hanson Institute, Adelaide, South Australia, Australia; <sup>3</sup>Royal Adelaide Hospital, Adelaide, South Australia, Australia

**2:15 PM (209)** *Sirolimus Is Associated with an Increase Risk of Venous Thromboembolism in Lung Transplantation*; P.J. McShane<sup>1</sup>, S.M. Bhorade<sup>1</sup>, M. Baz<sup>2</sup>, V. Valentine<sup>3</sup>, S. Arcasoy<sup>4</sup>, R. Love<sup>5</sup>, H. Seethamraju<sup>6</sup>, E. Garrity<sup>1</sup>, C. Alex<sup>5</sup>, R. Bag<sup>7</sup>, A. deOliveira<sup>8</sup>, W. Vigneswaran<sup>1</sup>, J. Charbeneau<sup>1</sup>, J. Krishnan<sup>1</sup>, R. Durazo<sup>5</sup>, V. Ahya<sup>9</sup> <sup>1</sup>University of Chicago Medical Center, Chicago, IL; <sup>2</sup>University of Florida, Gainesville, FL; <sup>3</sup>University of Texas Medical Center, Galveston, TX; <sup>4</sup>Columbia University Medical Center, New York, NY; <sup>5</sup>Loyola University Medical Center, Maywood, IL; <sup>6</sup>Baylor University Medical Center, Houston, TX; <sup>7</sup>University of Oklahoma Medical Center, Oklahoma City, OK; <sup>8</sup>University of Wisconsin Medical Center, Madison, WI; <sup>9</sup>University of Pennsylvania Medical Center, Philadelphia, PA

**2:20 PM (210)** *Bacterial Isolation from Respiratory Specimens and the Risk of Bronchiolitis Obliterans Syndrome*; M.R. Morrell, E.P. Trulock, R.R. Hachem Washington University/Barnes-Jewish Hospital, St. Louis, MO

**2:25 PM (211)** *Survival of Lung Transplant Recipients with Concomitant Myocardial Revascularization*; D.G. Rabkin<sup>1</sup>, S. Bastani<sup>1</sup>, R.S. Mahidhara<sup>1</sup>, D.J. Ross<sup>2</sup>, R. Saggar<sup>2</sup>, J.P. Lynch<sup>2</sup>, C.T. Hunter<sup>1</sup>, M.A. Hamilton<sup>2</sup>, A. Ardehali<sup>1</sup> <sup>1</sup>UCLA Medical Center, Los Angeles, CA; <sup>2</sup>UCLA Medical Center, Los Angeles, CA

**1:15 PM – 2:45 PM**

**MINI-ORAL SESSION 3 (242 AB)**

Chairs: Fabienne Dobbels, MSc, PhD and Savitri E. Fedson, MD

**1:15 PM (212)** *Evaluation of Six Prognostic Models in 80 Heart Failure Patients with a Fatal Heart Failure Admission*; A.L. Nutter<sup>1</sup>, T. Tanawuttiwat<sup>2</sup>, M.A. Silver<sup>2</sup> <sup>1</sup>University of Iowa, Iowa City, IA; <sup>2</sup>Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL

**1:20 PM (213)** *Hospice Indicated for Inotrope-Dependent Heart Failure Patients Unable To Receive Transplantation or Ventricular Assist Device*; E.C. Chu, E.Z. Gorodeski, J.R. Reese, J.M. Fink, R.C. Starling Cleveland Clinic, Cleveland, OH

**1:25 PM (214)** *Clinical Efficacy of Intermittent Outpatient Ultrafiltration in Refractory Heart Failure: A Novel Approach to Heart Failure Management*; R.L. Scott, D.E. Steidley, R.S. Gopalan, M.J. Marchi, A.M. Wenzel, J.M. Spadafore, S.G. Shatillo Mayo Clinic Arizona, Phoenix, AZ

**1:30 PM (215)** *Elevated Unprocessed Brain Natriuretic Peptide (proBNP) and an Increased Ratio of proBNP/BNP Are Associated with Early Heart Failure Progression in African-Americans: Results from an A-HeFT Substudy*; J.E. Rame<sup>1</sup>, A. Wu<sup>4</sup>, D. McGlothlin<sup>1</sup>, A. Jafari Mehr<sup>1</sup>, J.O. Hernandez<sup>1</sup>, C. Hoopes<sup>3</sup>, K. Chatterjee<sup>1</sup>, T. De Marco<sup>1</sup>, D.L. Dries<sup>2</sup> <sup>1</sup>University of California San Francisco, San Francisco, CA; <sup>2</sup>University of Pennsylvania, Philadelphia, PA; <sup>3</sup>University of California San Francisco, San Francisco, CA; <sup>4</sup>University of California San Francisco, San Francisco, CA

**1:35 PM (216)** *Risk Stratification for Dilated Cardiomyopathy; the Decisive Role of Cardiovascular MRI Delayed Hyperenhancement (DHE)*; J.V. Venero, S. Murali, M. Doyle, V.K. Rathi, S.B. Grant, J.A. Yamrozik, R.B. Williams, D.A. Vido, G. Rayarao, R.W. Biederman Allegheny General Hospital, Pittsburgh, PA

**1:40 PM (217)** *Cardiac Fibrosis Correlates with the Degree of Reverse Remodeling after Restrictive Mitral Annuloplasty in Patients with Idiopathic Dilated Cardiomyopathy*; S. Saito<sup>1</sup>, G. Matsumiya<sup>1</sup>, T. Sakaguchi<sup>1</sup>, T. Fujita<sup>1</sup>, T. Yamauchi<sup>1</sup>, K.

Takeda<sup>1</sup>, T. Kurata<sup>1</sup>, H. Ichikawa<sup>1</sup>, K. Taniguchi<sup>2</sup>, T. Masai<sup>3</sup>, Y. Sawa<sup>1</sup> <sup>1</sup>Osaka University Graduate School of Medicine, Suita, Osaka, Japan; <sup>2</sup>Osaka Rosai Hospital, Sakai, Osaka, Japan; <sup>3</sup>Sakurabashi Watanabe Hospital, Osaka, Japan

**1:45 PM (218)** *It There Still a Role for Undersized Mitral Annuloplasty for Mitral Regurgitation in End-Stage Dilated Cardiomyopathy: Single Centre Long Term Follow-Up*; G. Bruschi, T. Colombo, S. Trunfio, E. Ribera, C. Russo, F. Turazza, F. Oliva, M. Frigerio, L. Martinelli Niguarda Ca' Granda Hospital, Milan, Italy

**1:50 PM (219)** *Quality of Life in Patients Surviving Greater Than One Year after Left Ventricular Assist Device Placement*; J.G. Allen<sup>1</sup>, E.S. Weiss<sup>1</sup>, J.M. Schaffer<sup>1</sup>, N.D. Patel<sup>1</sup>, S.D. Russell<sup>1</sup>, A.S. Shah<sup>1</sup>, J.V. Conte<sup>1</sup> <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD

**1:55 PM (220)** *Improvement in Survival with Implantation of Levitronix CentriMag Biventricular Circulatory Support in Patients with Acute ST-Elevation Myocardial Infarction (STEMI) and Refractory Cardiogenic Shock*; J.A. Morgan, T.M. Naseem, F.H. Cheema, M.J. Russo, R.R. Davies, T.B. Scripps, A. Mignatti, K. Lietz, Y. Naka, U.P. Jorde Columbia Presbyterian Medical Center, New York, NY

**2:00 PM (221)** *Prediction of Post VAD Implant ICU Outcome by Easy Accessible Clinical Parameter*; S. Klotz, C. Riehl, A. Hoffmeier, J. Sindermann, H.H. Scheld University Hospital Muenster, Muenster, Germany

**2:05 PM (222)** *Prospective Study on Development of Quality of Life and Exercise Tolerance after Implantation of Left Ventricular Assist Devices*; C. Kugler<sup>1</sup>, D. Malehsa<sup>1</sup>, U. Tegtbur<sup>2</sup>, C. Bara<sup>1</sup>, E. Guetzlaff<sup>2</sup>, A. Simon<sup>1</sup>, A. Meyer<sup>1</sup>, A. Haverich<sup>1</sup>, M. Strueber<sup>1</sup> <sup>1</sup>Hannover Medical School, Hannover, Germany; <sup>2</sup>Institute of Sportsmedicine, Hannover Medical School, Hannover, Hannover, Germany

**2:10 PM (223)** *Brain Gray Matter Loss in Heart Failure Is Gender-Dependent*; M.A. Woo<sup>1</sup>, R. Kumar<sup>2</sup>, P.M. Macey<sup>2</sup>, G.C. Fonarow<sup>3</sup>, M.A. Hamilton<sup>3</sup>, R.M. Harper<sup>2</sup> <sup>1</sup>University of California at Los Angeles, Los Angeles, CA; <sup>2</sup>University of California at Los Angeles, Los Angeles, CA; <sup>3</sup>University of California at Los Angeles, Los Angeles, CA

**2:15 PM (224)** *High-Risk Sexual Activity and Complications of Adolescent Cardiothoracic Transplant Recipients*; M. Carson, D. Guadiz, C. Buckley, M.S. Woo Children's Hospital Los Angeles, Los Angeles, CA

**2:20 PM (225)** *The Impact of Non-Compliance (NC) on Survival after Heart Transplantation (HT): A Multi-Institutional Study*; C. White-Williams<sup>1</sup>, M. Collier<sup>2</sup>, M. Flattery<sup>3</sup>, K. Law<sup>4</sup>, C. Laxson<sup>5</sup>, A. Schlemm<sup>6</sup>, K. St. Clair<sup>7</sup>, R.N. Brown<sup>8</sup>, J.K. Kirklin<sup>8</sup> <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>Sentara Norfolk General Hospital, Norfolk, VA; <sup>3</sup>Medical College of Virginia, Richmond, VA; <sup>4</sup>Medical University of South Carolina, Charleston, SC; <sup>5</sup>University of Iowa Hospitals and Clinics, Iowa City, IA; <sup>6</sup>Aurora St. Luke's Medical Center, Milwaukee, WI; <sup>7</sup>Mid America Heart Institute of St. Luke's Hospital, Kansas City, MO; <sup>8</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>9</sup>University of Alabama at Birmingham, Birmingham, AL

**2:25 PM (226)** *Hemodynamic Features Which Distinguish Diastolic Dysfunction (DD) from Pulmonary Arterial Hypertension (PAH)*; P.J. Engel<sup>1</sup>, R.P. Baughman<sup>2</sup>, L. Taylor<sup>1</sup> <sup>1</sup>The Christ Hospital, Ohio Heart Vascular Center, Cincinnati, OH; <sup>2</sup>Univ Cincinnati, Cincinnati, OH

**1:15 PM – 2:45 PM**

#### **MINI-ORAL SESSION 4 (241)**

Chairs: Mardi Gomberg-Maitland, MD, MSc and Tomislav Mihaljevic, MD

**1:15 PM (227)** *The Demethylating Agent 5-aza-2'Deoxycytidine (Decitabine) Reverses SOD2 Methylation and Restores H<sub>2</sub>O<sub>2</sub> Production in the Pulmonary Arterial Smooth Muscle Cells of Fawn-Hooded Rats with Pulmonary Hypertension*; H.J. Zhang, G.H. Kim, P.T. Toth, G. Marsboon, D. Urboniene, E.C. Svensson, J. Rehman, S.L. Archer The University of Chicago, Chicago, IL

**1:20 PM (228)** *REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Idiopathic Pulmonary Arterial Hypertension*; R.J. Barst<sup>1</sup>, D. Ivy<sup>2</sup>, D.B. Badesch<sup>3</sup>, R.L. Benza<sup>4</sup>, C.G. Elliott<sup>5</sup>, H.W. Farber<sup>6</sup>, A.E. Frost<sup>7</sup>, A. Krichman<sup>8</sup>, T.G. Liou<sup>9</sup>, G.E. Raskob<sup>10</sup>, P. Wason<sup>11</sup>, K. Feldkircher<sup>11</sup>, A.J. Foreman<sup>12</sup>, M.D. McGoon<sup>13</sup> <sup>1</sup>Columbia University College of Physicians Surgeons, New York, NY; <sup>2</sup>University of Colorado Denver School of Medicine, The Children's Hospital, Aurora, CO; <sup>3</sup>University of Colorado Health Sciences Center, Aurora, CO; <sup>4</sup>Allegheny General Hospital, Pittsburgh, PA; <sup>5</sup>Intermountain Medical Center, Murray, UT; <sup>6</sup>Boston University School of Medicine, Boston, MA; <sup>7</sup>Baylor College of Medicine, Houston, TX; <sup>8</sup>Duke University Medical Center, Durham, NC; <sup>9</sup>University of Utah, Salt Lake City, UT; <sup>10</sup>University of Oklahoma Health Sciences Center, Oklahoma City, OK; <sup>11</sup>Actelion Pharmaceuticals US, Inc., South San Francisco, CA; <sup>12</sup>ICON Clinical Research, San Francisco, CA; <sup>13</sup>Mayo Clinic, Rochester, MN

**1:25 PM (229) Clinical Benefits of Pharmacological Therapy in Exercise Induced Pulmonary Arterial Hypertension;** M.H. Park, G.V. Ramani, W.J. Kop, P.A. Uber, M.R. Mehra University of Maryland, Baltimore, MD

**1:30 PM (230) Pulmonary Hemodynamics in Patients with Obstructive Sleep Apnea Syndrome: Results in Patients Undergoing Right Heart Catheterization;** O.A. Minai, B. Ricaurte, R. Kaw, J.K. Stoller Cleveland Clinic, Cleveland, OH

**1:35 PM (231) Twenty Years Experience of Heart Lung Transplantation for Pulmonary Vascular Disease;** L.A. Tanner<sup>2</sup>, N.J. Green<sup>2</sup>, G. Parry<sup>2</sup>, A. Hasan<sup>2</sup>, J.H. Dark<sup>1,2</sup>, P.A. Corris<sup>1,2,1</sup> Newcastle University, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom

**1:40 PM (232) Treatment of Pulmonary Hypertension Secondary to Left Heart Insufficiency with a Dual Endothelin Receptor Antagonist (Bosentan®) in Patients Awaiting Heart Transplantation;** U. Schulz, G. Tenderich, S. Schulte-Eistrup, R. Koerfer Heart and Diabetes Center NRW, Bad Oeynhausen, NRW, Germany

**1:45 PM (233) Prevalence and Risk Factors of Non-Adherence after Lung Transplantation;** O.H. Bosma<sup>1</sup>, K.M. Vermeulen<sup>2</sup>, E.A. Verschuuren<sup>1</sup>, M.E. Erasmus<sup>3</sup>, W. Van der Bij<sup>1</sup> <sup>1</sup>University Medical Centre Groningen, Groningen, Netherlands; <sup>2</sup>University Medical Centre Groningen, Groningen, Netherlands; <sup>3</sup>University Medical Centre Groningen, Groningen, Netherlands

**1:50 PM (234) Smoking Status in Patients after Lung Transplantation;** V. Schaevers, A. Schoonis, C. Jans, C. Rosseel, M. Meelberghs, B. Vanaudenaerde, D. Van Raemdonck, L. Dupont, G. Verleden University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium

**1:55 PM (235) Increased Resource Utilization and Financial Costs of Lung Transplantation after Implementation of the Lung Allocation Score;** D.W. Zaas, S. Hawig, K. Ferrell, S.M. Palmer, R.D. Davis Duke University Medical Center, Durham, NC

**2:00 PM (236) Removing Interleukin-8 by Adsorbent Membrane Does Not Improve Lung Function during Prolonged Ex-Vivo Lung Perfusion;** T. Kakishita, T. Oto, S. Otani, S. Yamamoto, O. Yoshida, N. Waki, S. Hori, M. Okazaki, M. Yamane, S. Toyooka, Y. Sano Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

**2:05 PM (237) A Novel Method of Ex Vivo Lung Preservation Assessment Using the Organ Care System (OCS);** A. Abdelazim<sup>1</sup>, R. Havener<sup>1</sup>, R. Fishman<sup>1</sup>, I. Abdel Fattah<sup>2</sup> <sup>1</sup>TransMedics, Andover; <sup>2</sup>Cairo University, Cairo, Egypt

**2:10 PM (238) Donor Lungs from Donation after Cardiac Death Have a Decreased Inflammatory Cytokine Profile Compared to Lungs from Brain Dead Donors;** C.-H. Kang, M. Cypel, M. Sato, J. Yeung, M. de Perrot, T.K. Waddell, A. Pierre, M. Liu, S. Keshavjee Toronto General Hospital, Toronto, ON, Canada

**2:15 PM (239) A Recombinant Human Neuregulin-1 Peptide Added to Celsior Solution Further Improves Preservation of the Transplanted Rat Heart after Prolonged Hypothermic Storage;** A. Jabbour<sup>1</sup>, L. Gao<sup>1</sup>, J. Kwan<sup>1</sup>, A. Watson<sup>1</sup>, X. Liu<sup>1</sup>, M.D. Zhou<sup>1</sup>, R.M. Graham<sup>1</sup>, M. Hicks<sup>1</sup>, P.S. Macdonald<sup>1</sup> <sup>1</sup>St Vincent's Hospital and Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; <sup>2</sup>Zensun (Shanghai) Sci Tech Co., Ltd, Shanghai, China

**2:20 PM (240) Brain Death Induces Early Coronary but Not Pulmonary Artery Endothelial Dysfunction;** A. Mommerot, B. Marcheix, M. Carrier, L.P. Perrault Montreal Heart Institute, Montreal, QC, Canada

**2:25 PM (241) The Organ Care System (OCS) Enables Ex-Vivo Assessment of Donor Heart Coronary Perfusion Using Contrast Echocardiography;** A.H. Hassanein<sup>1</sup>, A. Elbatanony<sup>2</sup>, A. Abdelaziem<sup>2</sup>, S.D. Solomon<sup>1</sup> <sup>1</sup>Brigham Women's Hospital, Boston, MA; <sup>2</sup>TransMedics, Andover, MA

**2:30 PM (242) Functional, Metabolic, and Morphological Aspects of Continuous, Normothermic Heart Preservation: Effects of Different Preparation and Perfusion Techniques;** J. Garbade<sup>1</sup>, C. Krautz<sup>1</sup>, H. Aupperle<sup>2</sup>, C. Ullmann<sup>1</sup>, H.B. Bittner<sup>1</sup>, S. Dhein<sup>1</sup>, J.F. Gummert<sup>3</sup>, F.-W. Mohr<sup>1</sup> <sup>1</sup>Heart Center, University of Leipzig, Leipzig, Germany; <sup>2</sup>Faculty of Veterinary Medicine, University of Leipzig, Leipzig, Germany; <sup>3</sup>Friedrich-Schiller University Jena, Jena, Germany

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 13: Role of Antibodies in Heart Transplantation** (Main Theatre)

Chairs: Daniel J. Cook, PhD and Marlene Rose, PhD

**3:00 PM (243) Impact of Virtual Crossmatch on Outcomes in Heart Transplantation;** W.G. Cotts<sup>1</sup>, A.R. Tambur<sup>2</sup>, L. Klein<sup>1</sup>, K. Grady<sup>1</sup>, B. Lapin<sup>3</sup>, H. Subacius<sup>3</sup>, G. Ferguson<sup>4</sup>, E. Schupbach<sup>4</sup>, D. Ramon<sup>2</sup>, S. Zeigler<sup>4</sup>, P. Kansal<sup>1</sup>, J.B. O'Connell<sup>1</sup>, M.

Montpetit<sup>1</sup>, E.C. McGee<sup>4</sup> <sup>1</sup>Northwestern University, Chicago, IL; <sup>2</sup>Northwestern University, Chicago, IL; <sup>3</sup>Northwestern University, Chicago, IL; <sup>4</sup>Northwestern University, Chicago, IL

**3:15 PM (244)** *The Outcome of Treatment of 100% PRAs in Heart Failure Patients Awaiting Heart Transplantation*; K. Kiyosaki<sup>1</sup>, J. Kobashigawa<sup>1</sup>, E. Reed<sup>2</sup>, J. Moriguchi<sup>1</sup>, M. Kawano<sup>1</sup>, A. Ankrom<sup>1</sup>, J. Patel<sup>1</sup>, M. Kittleson<sup>1</sup>, E. Shao<sup>1</sup>, A. Ardehali<sup>3</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>3</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**3:30 PM (245)** *HLA Alloantibodies Are Associated with Increased Inflammatory Transcript Expression in Cardiac Allograft Biopsies, and Related to Decreased Graft Function*; B. Sis, D. Kim, M. Mengel, P. Campbell, T. Mueller, K. Famulski, J. Burton, W. Tymchak, J. Ezekowitz, I. Paterson, P. Halloran University of Alberta, Edmonton, AB, Canada

**3:45 PM (246)** *Outcome of Retrospective Positive Donor Specific Crossmatch after Heart Transplantation: Are They Doomed?*; M. Kawano<sup>1</sup>, J. Kobashigawa<sup>1</sup>, K. Kiyosaki<sup>1</sup>, A. Ankrom<sup>1</sup>, J. Patel<sup>1</sup>, M. Kittleson<sup>1</sup>, E. Reed<sup>2</sup>, A. Ardehali<sup>3</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>3</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**4:00 PM (247)** *Transplantation of Donor Specific Antibody Positive, Crossmatch Negative (AHG/FCXM) Cardiac Allograft Recipients*; R. Bogaev<sup>1</sup>, J. George<sup>1</sup>, O.H. Frazier<sup>1</sup>, W.B. Etheridge<sup>1</sup>, F. Raissi<sup>1</sup>, L. Jacob<sup>1</sup>, B. Kar<sup>1</sup>, R. Delgado<sup>1</sup>, P. Loyalka<sup>1</sup>, I. Gregoric<sup>1</sup>, R.H. Kerman<sup>2</sup> <sup>1</sup>The Texas Heart Institute, Houston, TX; <sup>2</sup>The University of Texas Medical School, Houston, TX

**4:15 PM (248)** *HLA-Specific Antibody Strength and HLA Haplotype Frequency as Predictors for Responsiveness to Desensitization Protocols and Transplantability Rate in Heart Transplant Candidates*; A.L. Girnita, C. Bermudez, J.J. Teuteberg, R. Kormos, G. Speziali, Y. Toyoda, T. Sabatine, K. Shoemaker, D. McNamara, L. Jelinek, J. Lomago, A. Zeevi University of Pittsburgh Medical Center, Pittsburgh, PA

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 14: Medical Management of MCS Patients** (Blue Theatre)

Chairs: Andrew J. Boyle, MD and Robert D. Dowling, MD

**3:00 PM (249)** *Postoperative Heparin Is Not Required in Transitioning Patients with HeartMate II LVAD to Long Term Warfarin Therapy*; M.S. Slaughter<sup>1</sup>, Y. Naka<sup>2</sup>, R. John<sup>3</sup>, A.J. Boyle<sup>4</sup>, J.V. Conte<sup>5</sup>, S.D. Russell<sup>5</sup>, K.D. Aaronson<sup>6</sup>, D.J. Farrar<sup>7</sup>, F.D. Paggani<sup>6</sup> <sup>1</sup>University of Louisville, Louisville, KY; <sup>2</sup>Columbia University, New York City, NY; <sup>3</sup>University of Minnesota, Minneapolis, MN; <sup>4</sup>UCSF Heart and Vascular Center, San Francisco, CA; <sup>5</sup>Johns Hopkins University, Baltimore, MD; <sup>6</sup>University of Michigan, Ann Arbor, MI; <sup>7</sup>Thoratec Corporation, Pleasanton, CA

**3:15 PM (250)** *Pre-VAD Implant Risk Factors Influence the Onset of Adverse Events (AEs) while on a VAD*; R.L. Kormos<sup>1</sup>, J.J. Teuteberg<sup>1</sup>, M.P. Siegenthaler<sup>2</sup>, S.A. Marc<sup>2</sup>, J.J. Kay<sup>1</sup>, E. Genovese<sup>1</sup>, C. Bermudez<sup>1</sup>, Y. Toyoda<sup>1</sup>, K.L. Lockard<sup>1</sup>, S. Winowich<sup>1</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>University of Pittsburgh, Pittsburgh, PA

**3:30 PM (251)** *Seven-Fold Stroke Reduction in Ventricular-Assist Device (VAD) Patients with Titrated Antiplatelet Therapy*; E.N. Sorensen<sup>1</sup>, T.A. Snyder<sup>2</sup>, M.J. Lindsay<sup>1</sup>, S.L. Moainie<sup>1</sup>, E.D. Feller<sup>1</sup>, B.P. Griffith<sup>1</sup> <sup>1</sup>University of Maryland Medical Center, Baltimore, MD; <sup>2</sup>Integrus Baptist Medical Center, Oklahoma City, OK

**3:45 PM (252)** *Increasing Pump-Speed of a Continuous Flow Left Ventricular Assist Device during Exercise Is Safe and Elevates Cardiac Output in Patients with End-Stage Heart Failure: A Double-Blind, Randomized Trial*; A.S. Jensen<sup>3</sup>, P. Brassard<sup>1</sup>, N. Nordsborg<sup>1</sup>, F. Gustafsson<sup>3</sup>, J.E. Moeller<sup>3</sup>, C. Hassager<sup>3</sup>, S. Boesgaard<sup>3</sup>, P.B. Hansen<sup>1</sup>, K. Sander<sup>2</sup>, P.S. Olsen<sup>2</sup>, N.H. Secher<sup>1</sup>, P.L. Madsen<sup>3</sup> <sup>1</sup>Rigshospitalet, Copenhagen, Denmark; <sup>2</sup>Rigshospitalet, Copenhagen, Denmark; <sup>3</sup>Rigshospitalet, Copenhagen, Denmark

**4:00 PM (253)** *Bleeding Exceeds Thromboembolism in Outpatients with Heartmate II Left Ventricular Assist Device: A Single Center Experience*; S.M. Joseph, I.-W. Wang, T. Guthrie, S. Arnold, N. Moazami, G.A. Ewald Washington University School of Medicine, Saint Louis, MO

**4:15 PM (254)** *Early Infections after MCSD Implant in 455 Patients: Incidence, Location and Outcome*; W.L. Holman<sup>1</sup>, J.K. Kirklin<sup>1</sup>, D.C. Naftel<sup>1</sup>, R.L. Kormos<sup>2</sup>, P. Desvign-Nickens<sup>3</sup>, M. Camacho<sup>4</sup>, D. Ascheim<sup>5</sup> <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>University of Pittsburgh, Pittsburgh, PA; <sup>3</sup>National Heart Lung and Blood Institute, Bethesda, MD; <sup>4</sup>Newark Beth Israel Medical Center, Newark, NJ; <sup>5</sup>Columbia University, New York, NY

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 15: Prognosticating in Pulmonary Arterial Hypertension: Do We Have Enough Information?** (Salle Maillot)

Chairs: Robert D. Levy, MD, FRCP (C) and Robert P. Frantz, MD

**3:00 PM (255) Determinants of Early Post-Operative Mortality among Patients with Idiopathic Pulmonary Arterial Hypertension;** C.A. Merlo, R.E. Girgis Johns Hopkins University School of Medicine, Baltimore, MD

**3:15 PM (256) REVEAL Registry: Implications of Functional Class and Hemodynamics on Outcome in Patients with PAH;** H.W. Farber<sup>1</sup>, M.D. McGoon<sup>2</sup>, R.L. Benza<sup>3</sup>, P. Wason<sup>4</sup>, D.P. Miller<sup>5</sup>, D.B. Badesch<sup>6</sup> <sup>1</sup>Boston University School of Medicine, Boston, MA; <sup>2</sup>Mayo Clinic, Rochester, MN; <sup>3</sup>Allegheny General Hospital, Pittsburgh, PA; <sup>4</sup>Actelion Pharmaceuticals US, Inc., South San Francisco, CA; <sup>5</sup>ICON Clinical Research, San Francisco, CA; <sup>6</sup>University of Colorado Health Sciences Center, Aurora, CO

**3:30 PM (257) The COMPASS-3 Study: Utilizing Hemodynamics and Non-Invasive Measures (c-MRI) To Evaluate Baseline Severity in Pulmonary Arterial Hypertension (PAH);** H. Gupta<sup>3</sup>, F. Soto<sup>1</sup>, M. Park<sup>4</sup>, S. Murali<sup>2</sup>, F. Torres<sup>5</sup>, R. Benza<sup>2</sup> <sup>1</sup>Medical College of Wisconsin, Milwaukee, WI; <sup>2</sup>Allegheny General Hospital, Pittsburgh, PA; <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>4</sup>University of Maryland, Baltimore, MD; <sup>5</sup>Southwest Pulmonary Associates, Dallas

**3:45 PM (258) Predictors of Clinical Worsening in Patients with PAH Treated with Bosentan;** D.C. Vizza, R. Badagliacca, R. Poscia, E. Crescenzi, C. Gambardella, A. Nona, F. Fedele University of Rome La Sapienza, Rome, Italy

**4:00 PM (259) Right Ventricle Systolic Function in Severe Pulmonary Hypertension: Echocardiographic Study with Longitudinal 2D-Strain;** L. Unzué Vallejo, C. Jimenez, R. Tello de Meneses, A. Gonzalez, M. Riva, P. Escribano, C. Saenz de la Calzada Hospital 12 de Octubre, Madrid, Spain

**4:15 PM (260) A Novel Method for Non-Invasive Estimation of Pulmonary Vascular Resistance in Patients with Pulmonary Arterial Hypertension;** F. Haddad<sup>2</sup>, R. Zamanian<sup>4</sup>, A.S. Beraud<sup>2</sup>, T. Peterson<sup>3</sup>, I. Schnittger<sup>2</sup>, P. Yang<sup>2</sup>, D. Rosenthal<sup>1</sup> <sup>1</sup>Pediatric Cardiology, Stanford; <sup>2</sup>Cardiovascular Medicine, Stanford; <sup>3</sup>Internal Medicine, Stanford; <sup>4</sup>Pulmonary Critical Care Medicine, Stanford

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 16: Primary Cardiac Allograft Failure: An Under-Reported But Frequently Fatal Problem** (252 AB)

Chairs: G. Michael Felker, MD and Angela Rajek, MD

**3:00 PM (261) A Novel Primary Graft Failure Risk Score in Heart Transplantation;** J. Segovia, J.M. Barcelo, M. Gomez-Bueno, M. Cobo, P. Garcia-Pavia, J. Mirelis, E. Sufrate, L. Alonso-Pulpon Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

**3:15 PM (262) Primary Graft Failure Following Heart Transplantation: Risk Factors and Outcomes;** M.J. Russo<sup>1</sup>, K.N. Hong<sup>1</sup>, R.R. Davies<sup>1</sup>, A. Iribarne<sup>1</sup>, S. Xydas<sup>1</sup>, M. Argenziano<sup>1</sup>, M. Williams<sup>1</sup>, A.S. Stewart<sup>1</sup>, J.S. Morgan<sup>1</sup>, D.M. Mancini<sup>2</sup>, Y. Naka<sup>1</sup> <sup>1</sup>Columbia University Medical Center, New York, NY; <sup>2</sup>Columbia University Medical Center, New York, NY

**3:30 PM (263) WITHDRAWN**

**3:45 PM (264) Impact of Different Pulmonary Hypertension Parameters on Severe Right Ventricular Failure and Early Death after Heart Transplantation;** J.M. Barcelo, J. Segovia, M. Gomez-Bueno, M. Cobo, P. Garcoa-Pavia, J. Mirellis, E. Sufrate, L. Alonso-Pulpon Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

**4:00 PM (265) Primary Graft Failure in Heart Transplantation: The Need of a Working Definition;** J. Segovia, J.M. Barcelo, M. Gomez-Bueno, C. Garcia-Montero, C. Tellez, M. Cobo, L. Alonso-Pulpon Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

**4:15 PM (266) Right Ventricular Dysfunction Immediately Post Transplant – A Marker for Poor Outcome?;** E. Shao<sup>1</sup>, M. Kawano<sup>1</sup>, N. Moradzadeh<sup>1</sup>, A. Ankrom<sup>1</sup>, K. Kiyosaki<sup>1</sup>, J. Patel<sup>1</sup>, M. Kittleson<sup>1</sup>, J. Moriguchi<sup>1</sup>, A. Ardehali<sup>2</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 17: Immunologic Dance with Infection** (242 AB)

Chairs: Kashif Raza, MD and Bernard M. Kubak, MD, PhD

**3:00 PM (267) High Rates of False-Positive Hepatitis C Antibody Tests Can Occur after Left Ventricular Assist Device Implantation;** A.V. Srivastava<sup>1</sup>, B. Czerska<sup>2</sup>, C. Williams<sup>2</sup>, I. Alesh<sup>2</sup>, L. Krese<sup>2</sup>, M.A. Huang<sup>2</sup>, C. Drost<sup>2</sup>, C. Smith<sup>2</sup>, H. Nemeh<sup>2</sup>, C. Tita<sup>2</sup>, R. Brewer<sup>2</sup>, D. Lanfear<sup>2</sup> <sup>1</sup>Yale University, School of Medicine, New Haven, CT; <sup>2</sup>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI

**3:15 PM (268) Parainfluenza Viral Infection after Lung Transplantation: Not Just Another CARV;** M. Benzimra, C.-L. Liew, K. Hanning, A. Havryk, M. Plit, M.A. Malouf, A.R. Glanville St Vincent's Hospital, Sydney, NSW, Australia

**3:30 PM (269) Antimicrobial Activity of Novel S-(benzyl) Isothiourea Derivatives Against Multiply Resistant Pseudomonas aeruginosa and Burkholderia cepacia Complex from Patients with Cystic Fibrosis Undergoing Lung Transplant Assessment;** A. Nicholson<sup>1</sup>, J.D. Perry<sup>1</sup>, A.L. James<sup>2</sup>, S.P. Stanforth<sup>2</sup>, A. De Soyza<sup>3</sup>, K. Gould<sup>1</sup> <sup>1</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Northumbria University, Newcastle upon Tyne, United Kingdom; <sup>3</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom

**3:45 PM (270) Preceding Respiratory Viral Infection Is a Strong Risk Factor for Fungal Infection in Lung Transplant Recipients;** P.M.A. Hopkins, F.D. Kermeen, B. Tsang, T.W.V. Daniels, H. Seale, C. Bec, D.C. Chambers The Prince Charles Hospital, Brisbane, Queensland, Australia

**4:00 PM (271) The Clinical Impact of Non-Aspergillus Mold Colonization in Lung Transplant Recipients (LuTx);** F. Mattner<sup>1</sup>, C. Fegbeutel<sup>2</sup>, H. Weissbrodt<sup>3</sup>, A. Simon<sup>2</sup> <sup>1</sup>Universität zu Lübeck, Lübeck, Germany; <sup>2</sup>Medizinische Hochschule Hannover, Hannover, Germany; <sup>3</sup>Medizinische Hochschule Hannover, Hannover, Germany

**4:15 PM (272) Intragam Use for Severe Refractory Paramyxoviral Infection in Lung Transplant Recipients;** P.M.A. Hopkins, F.D. Kermeen, B. Tsang, T.W.V. Daniels, J. Walsh, T.M. Leisfield, D.C. Chambers The Prince Charles Hospital, Brisbane, Queensland, Australia

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 18: Philip K. Caves Award Candidate Presentations (241)**

Chairs: John Dark, MB, FRCS and Jon Kobashigawa, MD

**3:00 PM (273) The Panel-Reactive Antibody Paradox: PRA Class II Predicts Rejection within 1 Year but PRA Class I Predicts Graft Survival;** C.A. Silverstein, A.J. Naftilan, T.G. DiSalvo, M.A. Wigger, D.B. Sawyer, H. Ooi Vanderbilt Medical Center, Nashville, TN

**3:15 PM (274) Deletion of Inhibitory  $\square$  Kinase  $\square$  from Myeloid Cells Prevents Induction of Mouse Lung Allograft Acceptance;** H. Huang<sup>1</sup>, S. Sugimoto<sup>2</sup>, G.A. Patterson<sup>2</sup>, S.A. Krupnick<sup>2</sup>, D. Kreisel<sup>2</sup>, A.E. Gelman<sup>2</sup> <sup>1</sup>Washington University School of Medicine, Saint Louis, MO; <sup>2</sup>Washington University School of Medicine, Saint Louis, MO

**3:30 PM (275) Heart Transplantation Using Donor Hearts from Infants with Sudden Infant Death Syndrome;** J.N. Avari<sup>1</sup>, C.E. Canter<sup>2</sup>, T.P. Singh<sup>1</sup>, K. Gauvreau<sup>1</sup>, G.E. Piercey<sup>1</sup>, C.I. Berul<sup>1</sup>, E.D. Blume<sup>1</sup>, L.B. Smoot<sup>1</sup>, F. Fynn-Thompson<sup>3</sup>, C.S. Almond<sup>1</sup> <sup>1</sup>Children's Hospital, Boston, MA; <sup>2</sup>Washington University School of Medicine, Saint Louis, MO; <sup>3</sup>Children's Hospital, Boston, MA

**3:45 PM (276) Investigations into the Pathogenesis of Cytomegalovirus-Induced Transplant-Arteriosclerosis Using a Humanized Mouse Model;** S. Abele<sup>1</sup>, M. Leis<sup>2</sup>, M. Wollin<sup>2</sup>, S. Mahmoudian<sup>2</sup>, M. Weyand<sup>1</sup>, T. Stamminger<sup>2</sup>, S.M. Ensminger<sup>1</sup> <sup>1</sup>University of Erlangen-Nuremberg, Erlangen, Germany; <sup>2</sup>University of Erlangen-Nuremberg, Erlangen, Germany

**4:00 PM (277) The Role of Indoleamine 2,3-Dioxygenase (IDO) on Maintenance of Immunological Tolerance to Cardiac Allografts;** I. Schmitt-Knosalla<sup>1</sup>, S. Broesel<sup>1</sup>, D. Lange<sup>1</sup>, A. Andersson<sup>1</sup>, U. Hoepken<sup>2</sup>, M. Dandel<sup>3</sup>, H.B. Lehmkuhl<sup>3</sup>, H.-D. Volk<sup>1</sup>, M. Bader<sup>2</sup>, R. Hetzer<sup>3</sup>, C. Knosalla<sup>3</sup> <sup>1</sup>Institute of Medical Immunology, Charité-University Medicine Berlin, Berlin, Germany; <sup>2</sup>Max-Delbrück-Center of Molecular Medicine, Berlin, Germany; <sup>3</sup>Deutsches Herzzentrum Berlin, Berlin, Germany

**4:15 PM (278) Pro-Inflammatory Cytokines IL-1 $\square$  and TNF $\square$ , but Not IL-8, Cause Aberrant Lung Epithelial Wound Repair Via TGF- $\square$ 1 Driven Epithelial to Mesenchymal Transition (EMT);** L.A. Borthwick, E.I. McIlroy, M.J. Brodlie, C. Ward, J.L. Lordan, J.A. Kirby, P.A. Corris, A.J. Fisher Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

**4:30 PM – 5:00 PM**

Coffee Break/View Posters/Visit Exhibits (Hall Maillot)

**5:00 PM – 7:30 PM**

**CAV Guidelines Workforce Meeting** (Room 243)

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 19: *Building Bridges to Transplant with Mechanical Support*** (Main Theatre)

Chairs: Benjamin C. Sun, MD and Johannes Mueller, MD

**5:00 PM (279) *Axial vs. Pulsatile Flow in Reversing Pulmonary Hypertension in Heart Failure Patients Supported by Left Ventricular Assist Devices***; L. Jacob<sup>1</sup>, R. Delgado<sup>1</sup>, M. Reardon<sup>2</sup>, M. Loebe<sup>2</sup>, I. Gregoric<sup>1</sup>, G. Torre-Amione<sup>2</sup>, R. Bogaev<sup>1</sup>, O.H. Frazier<sup>1</sup>, B.A. Bruckner<sup>2</sup> <sup>1</sup>Texas Heart Institute, Houston, TX; <sup>2</sup>Methodist DeBakey Heart Center, Houston, TX

**5:15 PM (280) *Higher Center Volume with Bridge-to-Transplant Recipients Predicts Superior Post-Transplant Outcomes in Bridged and Non-Bridged Recipients***; M.J. Russo<sup>1</sup>, K.N. Hong<sup>1</sup>, R.R. Davies<sup>1</sup>, A. Iribarne<sup>1</sup>, M. Argenziano<sup>1</sup>, M. Williams<sup>1</sup>, A.S. Stewart<sup>1</sup>, K. Lietz<sup>2</sup>, P.U. Jorde<sup>2</sup>, Y. Naka<sup>1</sup> <sup>1</sup>Columbia University Medical Center, New York, NY; <sup>2</sup>Columbia University Medical Center, New York, NY

**5:30 PM (281) *Ventricular Assist Devices as Successful Bridge to Cardiac Re-Transplantation in Late Graft Failure: The Columbia-Presbyterian Experience***; B. Ramlawi<sup>1</sup>, U. Jorde<sup>2</sup>, M.G. Flores<sup>1</sup>, M. Flannery<sup>1</sup>, R. Te-Frey<sup>1</sup>, J.S. Murphy<sup>1</sup>, D. Mancini<sup>2</sup>, Y. Naka<sup>1</sup> <sup>1</sup>Columbia University Medical Center/NY-Presbyterian Medical Center, New York, NY; <sup>2</sup>Columbia University Medical Center/NY-Presbyterian Medical Center, New York, NY

**5:45 PM (282) *A Single-Institutional 4-Year Experience Comparing HM II and HM I XVE as a Bridge to Transplant***; J.A. Morgan, T.M. Naseem, F.H. Cheema, T.B. Scripps, M.J. Russo, R.R. Davies, K. Lietz, Y. Naka Columbia Presbyterian Medical Center, New York, NY

**6:00 PM (283) *Post Transplant Survival Following Support with a Continuous Flow Left Ventricular Assist Device***; R. John<sup>1</sup>, F.D. Pagani<sup>2</sup>, Y. Naka<sup>3</sup>, S.D. Russell<sup>4</sup>, A.J. Boyle<sup>1</sup>, C.T. Klodell<sup>5</sup>, J.G. Rogers<sup>6</sup>, D.J. Farrar<sup>7</sup>, O.H. Frazier<sup>8</sup> <sup>1</sup>University of Minnesota, Minneapolis, MN; <sup>2</sup>University of Michigan, Ann Arbor; <sup>3</sup>Columbia University, New York; <sup>4</sup>John Hopkins Hospital, Baltimore; <sup>5</sup>University of Florida, Gainesville; <sup>6</sup>Duke University, Durham; <sup>7</sup>Thoratec Corporation, Pleasanton; <sup>8</sup>Texas Heart Institute, Houston

**6:15 PM (284) *Pre-Implant Risk for VAD's and VAD AE's Influences the Onset of Adverse Events (AE's) Following Cardiac Transplantation (CTX) and Ultimate Survival***; S. Rayappa, J.J. Teuteberg, M.P. Siegenthaler, J. Kay, E. Genovese, M. Simon, M.A. Dew, J.J. Bhama, K.L. Lockard, R.L. Kormos University of Pittsburgh, Pittsburgh, PA

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 20: *Long Term Issues / Cardiac Allograft Vasculopathy*** (Blue Theatre)

Chairs: Beatriz Diaz Molina, MD and Nader Moazami, MD

**5:00 PM (285) *Prognostic Impact of Non-HLA Antibodies Targeting Vascular Receptors for the Development of Microvasculopathy in Biopsy after Heart Transplantation***; N.E. Hiemann<sup>1</sup>, C. Renner<sup>1</sup>, R. Meyer<sup>1</sup>, E. Wellnhofer<sup>2</sup>, C. Schoenemann<sup>3</sup>, H. Heidecke<sup>4</sup>, R. Hetzer<sup>1</sup>, D. Dragun<sup>5</sup> <sup>1</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>3</sup>Institute of Transfusion Medicine, Humboldt University Berlin Charité, Berlin, Germany; <sup>4</sup>Celltrend GmbH, Berlin, Germany; <sup>5</sup>Humboldt University Berlin Charité, Berlin, Germany

**5:15 PM (286) *Coronary Flow Velocity Reserve by Contrast-Enhanced Transthoracic Echocardiography Predicts Maximal Epicardial Intimal Thickening in Cardiac Allograft Vasculopathy***; F. Tona<sup>1</sup>, E. Osto<sup>1</sup>, G. Tarantini<sup>1</sup>, M. Napodano<sup>1</sup>, A. Gambino<sup>2</sup>, A. Vinci<sup>1</sup>, A. Vecchiati<sup>1</sup>, A. Ramondo<sup>1</sup>, G. Gerosa<sup>2</sup>, A.L.P. Caforio<sup>1</sup>, S. Illiceto<sup>1</sup> <sup>1</sup>University of Padova, Padova, Italy; <sup>2</sup>University of Padova, Padova, Italy

**5:30 PM (287) *Inflammatory Burden of Cardiac Allograft Coronary Atherosclerotic Plaque Is Associated with Recurrent Acute Cellular Rejections and Predicts a Higher Risk of Vasculopathy Progression***; E. Raichlin<sup>1</sup>, J.-H. Bae<sup>2</sup>, S.S. Kushwaha<sup>3</sup>, R.J. Lennon<sup>4</sup>, A. Prasad<sup>5</sup>, C.S. Rihal<sup>6</sup>, A. Lerman<sup>7</sup> <sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Mayo Clinic, Rochester, MN; <sup>3</sup>Mayo Clinic, Rochester, MN; <sup>4</sup>Mayo Clinic, Rochester, MN; <sup>5</sup>Mayo Clinic, Rochester, MN; <sup>6</sup>Mayo Clinic, Rochester, MN; <sup>7</sup>Mayo Clinic, Rochester, MN

**5:45 PM (288) *20-Year Survivors of Heart Transplantation at Stanford University***; T. Deuse<sup>1</sup>, F. Haddad<sup>2</sup>, M. Pham<sup>2</sup>, S. Hunt<sup>2</sup>, H. Valantine<sup>2</sup>, P. Oyer<sup>1</sup>, R.C. Robbins<sup>1</sup>, B.A. Reitz<sup>1</sup> <sup>1</sup>Stanford University School of Medicine, Stanford, CA; <sup>2</sup>Stanford University School of Medicine, Stanford, CA

**6:00 PM (289) *Extremes of Body Mass Index Do Not Affect Short- and Long-Term Survival Outcomes Following Cardiac Transplantation***; S. Lee<sup>1</sup>, J. Connett<sup>2</sup>, M. Colvin-Adams<sup>1</sup> <sup>1</sup>University of Minnesota, Minneapolis, MN; <sup>2</sup>University of Minnesota, Minneapolis, MN

**6:15 PM (290) *Atrial Fibrillation and Atrial Flutter in Heart Transplant Patients: Incidence, Risk Factors and Clinical Outcomes***; T.W. Dasari, B. Pavlovic-Surjancev, N. Patel, A.A. Williams, P. Ezidinma, A. Rupani, J.L. Sinacore, A.L. Heroux Loyola University Medical Center, Maywood, IL

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 21: *Effects of Implementing an Allocation System in Lung Transplant*** (Salle Maillot)

Chairs: David Weill, MD, and Christopher H. Wigfield, MD, FRCS

**5:00 PM Invited Lecture: *Airway Complications Following Lung Transplantation: Technical and/or Ischemic Issues?***, Redha R. Souilamas, MD, PhD, European Georges Pompidou Hospital, Paris, France

**5:15 PM (293) *Including Bilirubin in Lung Allocation Score Improves Prediction***; S. Murray<sup>1</sup>, J. Moore<sup>2</sup>, T.H. Shearon<sup>1</sup>, D.B. Dyke<sup>1</sup> <sup>1</sup>SRTR, University of Michigan, Ann Arbor, MI; <sup>2</sup>SRTR, Arbor Research, Ann Arbor, MI

**5:30 PM (294) *Six-Minute Walk Test as an Indicator of Lung Transplant Survival at 1 Year***; A.M. Lotshaw<sup>1</sup>, M. Thompson<sup>2</sup>, D.M. Meyer<sup>1</sup>, D.L. Nichols<sup>2</sup> <sup>1</sup>Baylor University Medical Center, Dallas, TX; <sup>2</sup>Texas Woman's University, Denton, TX

**5:45 PM (295) *Waiting Times and Mortality for IPF Patients Listed for Bilateral or Single Lung Transplantation***; O.A. Shlobin<sup>1</sup>, E. Edwards<sup>2</sup>, S.D. Nathan<sup>1</sup> <sup>1</sup>Inova Fairfax Hospital, Falls Church, VA; <sup>2</sup>UNOS, Richmond, VA

**6:00 PM (296) *The Effect of Center Volume on Early Post Lung Transplantation Survival among Patients with Cystic Fibrosis***; C.A. Merlo<sup>1</sup>, E.S. Weiss<sup>2</sup>, A.S. Shah<sup>2</sup> <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD

**6:15 PM (292) *Elevated Lung Allocation Score Is Associated with Decreased Survival and Increased Complications after Lung Transplantation***; M.J. Russo<sup>1</sup>, A. Iribarne<sup>1</sup>, R.R. Davies<sup>1</sup>, K.N. Hong<sup>1</sup>, S. Xydas<sup>1</sup>, A.C. Gelijs<sup>1</sup>, M.D. Bacchetta<sup>1</sup>, F. D'Ovidio<sup>1</sup>, S. Arcasoy<sup>2</sup>, J.R. Sonett<sup>1</sup> <sup>1</sup>Columbia University Medical Center, New York, NY; <sup>2</sup>Columbia University Medical Center, New York, NY

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 22: *Picking Your Poison: The Pitfalls of Immunosuppressive Therapy*** (252 AB)

Chairs: Shaida Varnous, MD and Mazen Hanna, MD

**5:00 PM Invited Lecture: *Strategies to Reduce Immunosuppression-Related Complications***, Sudhir S. Kushwaha, Mayo Clinic College of Medicine, Rochester, MN

**5:15 PM (297) *Incidences of Incisional Complications after De Novo Cardiac Transplantation in AZA-, MMF- or Everolimus-Based Regimens: A Cross-Study Analysis on 1008 Patients***; A. Zuckermann, J. Kobashigawa, J.M. Arizon, S.-S. Wang, M. Vigano, H. Lehmkuhl, H. Ross, G. Dong, H. Eisen Univ.-Klinik für Chirurgie, Vienna, Austria; The David Geffen School of Medicine at UCLA, Los Angeles; Hospital Universitario Reina Sofía, Córdoba, Spain; National Taiwan University Hospital, Taipei, Taiwan; Policlinico S. Matteo, IRCCS Università degli Studi di Pavia, Pavia, Italy; Deutsches Herzzentrum Berlin, Berlin, Germany; University Health Network, Toronto, Canada; Novartis Pharmaceuticals Corporation, East Hanover; Drexel University College of Medicine, Philadelphia

**5:30 PM (298) *Usefulness of mTOR Inhibitors for Treatment of Heart Transplant Patients with Non-Cutaneous Non-Lymphomatous Tumours: Data from the Spanish Post-Heart-Transplant Tumour Registry***; M.G. Crespo-Leiro<sup>1</sup>, L.A. Alonso-Pulpon<sup>2</sup>, V. Brosa<sup>3</sup>, J. Fernandez-Yanez<sup>4</sup>, L. Almenar-Bonet<sup>5</sup>, F. Fernandez-Vilchez<sup>6</sup>, J.F. Delgado<sup>7</sup>, N. Manito<sup>8</sup>, B. Diaz-Molina<sup>9</sup>, G. Rabago<sup>10</sup>, J.M. Arizon<sup>11</sup>, N. Romero<sup>12</sup>, E. Roig<sup>13</sup>, T. Blasco<sup>14</sup>, D. Pascual<sup>15</sup>, J. Muniz<sup>16</sup> <sup>1</sup>Hospital Juan Canalejo, La Coruña, Spain; <sup>2</sup>Hospital Puerta de Hierro, Madrid, Spain; <sup>3</sup>Hospital Sta Creu i San Pau, Barcelona, Spain; <sup>4</sup>Hospital Gregorio Marañon, Madrid, Spain; <sup>5</sup>Hospital La Fe, Valencia, Spain; <sup>6</sup>Hospital Valdecilla, Santander, Spain; <sup>7</sup>Hospital 12 de Octubre, Madrid, Spain; <sup>8</sup>Hospital Bellvitche, Barcelona, Spain; <sup>9</sup>Hospital Central Asturias, Oviedo, Spain; <sup>10</sup>Clinica Navarra, Pamplona, Spain; <sup>11</sup>H. Reina Sofia, Cordoba, Spain, <sup>12</sup>H. Virgen del Rocio, Sevilla, Spain; <sup>13</sup>H.Clinic, Barcelona, Spain; <sup>14</sup>H. Miguel Servet, Zaragoza, Spain; <sup>15</sup>H. Virgen Arrixaca, Murcia, Spain; <sup>16</sup>Instituto Ciencias Salud, La Coruña, Spain

**5:45 PM (299) *Comparability of Pattern of Occurrence of Pericardial Effusions between Everolimus- and MMF-Based Regimen in De Novo Cardiac Transplant Recipients***; H. Lehmkuhl<sup>1</sup>, H. Ross<sup>2</sup>, J. Arizon<sup>3</sup>, S. S. Wang<sup>4</sup>, U. Livi<sup>5</sup>, T. Dengler<sup>6</sup>, C. Pellegrini<sup>7</sup>, A. Zuckermann<sup>8</sup>, G. Dong<sup>9</sup>, S. Korom<sup>10</sup>, C. Bara<sup>11</sup> <sup>1</sup>Deutsches Herzzentrum Berlin, Berlin,



Germany; <sup>2</sup>University Health Network, Toronto, Canada; <sup>3</sup>Hospital Universitario Reina Sofía, Córdoba, Spain; <sup>4</sup>National Taiwan University Hospital, Taipei, Taiwan; <sup>5</sup>Istituto di Chirurgia Cardiotoracica, Udine, Italy; <sup>6</sup>SLK-Klinikum am Plattenwald, Bad Friedrichshall, Germany; <sup>7</sup>Policlinico S. Matteo, Pavia, Italy; <sup>8</sup>Univ.-Klinik für Chirurgie, Vienna, Austria; <sup>9</sup>Novartis Pharmaceuticals Corporation, East Hanover; <sup>10</sup>Novartis Pharma AG, Basel, Switzerland; <sup>11</sup>Hannover Medical School, Hannover, Germany,

**6:00 PM (300) A Low Incidence of CMV Infections in De Novo Cardiac Transplant Recipients in the Presence of Everolimus-Based Immunosuppressive Regimens;** J. Kobashigawa<sup>1</sup>, H.J. Eisen<sup>2</sup>, H.A. Valantine-von Kaeppler<sup>3</sup>, T. Dengler<sup>4</sup>, L. Potena<sup>5</sup>, S.-S. Wang<sup>6</sup>, H. Ross<sup>7</sup>, J. Delgado<sup>8</sup>, R.C. Starling<sup>9</sup>, C. Bara<sup>10</sup> <sup>1</sup>Univ. Cardiovascular Medical Group, Los Angeles, CA; <sup>2</sup>Drexel University College of Medicine and Hahnemann University Hospital, Philadelphia, PA; <sup>3</sup>Falk Cardiovascular Research Center, Stanford; <sup>4</sup>SLK-Klinikum am Plattenwald, Bad Friedrichshall, Germany; <sup>5</sup>Istituto di Malattie dell'apparato Cardiovascolare, Bologna, Italy; <sup>6</sup>National Taiwan University Hospital, Taipei, Taiwan; <sup>7</sup>University Health Network, Toronto, Canada; <sup>8</sup>Hospital Universitario 12 de Octubre, Madrid, Spain; <sup>9</sup>Cleveland Clinic Foundation, Cleveland; <sup>10</sup>Hannover Medical School, Hannover, Germany

**6:15 PM (301) Post Transplant Renal Dysfunction Is Rarely a Result of Direct Calcineurin Inhibitor Toxicity: A Clinicopathologic Study;** S. Pinney, R. Balakrishnan, A. Lala, N. Ajith, A. Anyanwu, G. Deboccardo Mount Sinai Medical Center, New York, NY

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 23: Bronchiolitis Obliterans Syndrome: Basic Mechanisms (242 AB)**

Chairs: Thalachallour Mohanakumar, PhD and Roelof A. De Weger, PhD

**5:00 PM (302) Alloimmunity Induced Remodeling of Airway Epithelium Exposes Cryptic Self Antigens (K $\alpha$ 1 Tubulin CollagenV), Leading to Autoimmunity and Chronic Rejection Following Human Lung Transplantation;** D. Saini<sup>1</sup>, S. Ramachandran<sup>1</sup>, M. Liu<sup>1</sup>, G. Simon<sup>1</sup>, N. Steward<sup>1</sup>, A. Aloush<sup>1</sup>, R. Hachem<sup>2</sup>, E. Trulock<sup>2</sup>, A. Patterson<sup>1</sup>, T. Mohanakumar<sup>1,3</sup> <sup>1</sup>Washington University in St Louis, St. Louis, MO; <sup>2</sup>Washington University in St Louis, St. Louis, MO; <sup>3</sup>Washington University in St Louis, St. Louis, MO

**5:15 PM (303) Tolerance Induction to Collagen Type V (Col V) Prevents Fibrosis in the Bleomycin (Blm) Lung Injury Model;** R.K. Braun, C.H. Wigfield, A. Martin, P. Sethupathi, R.B. Love Loyola University Medical Center, Maywood, IL

**5:30 PM (304) Th17 Lymphocyte Proportion Increased in Animal Model of Bronchiolitis Obliterans after Lung Transplantation;** T. Nakagiri<sup>1</sup>, M. Inoue<sup>1</sup>, E. Morii<sup>2</sup>, M. Minami<sup>1</sup>, N. Sawabata<sup>1</sup>, T. Utsumi<sup>1</sup>, Y. Kadota<sup>1</sup>, N. Shigemura<sup>1</sup>, K. Ideguchi<sup>1</sup>, T. Tokunaga<sup>1</sup>, T. Oda<sup>1</sup>, M. Okumura<sup>1</sup> <sup>1</sup>Osaka University Graduate School of Medicine, Suita, Osaka, Japan; <sup>2</sup>Osaka University Graduate School of Medicine, Suita, Osaka, Japan

**5:45 PM (305) Increased Levels of T-Cell Granzyme b in Bronchiolitis Obliterans Syndrome (BOS) Are Not Adequately Suppressed by Current Immunosuppressive Regimens;** S. Hodge<sup>1</sup>, G. Hodge<sup>1</sup>, J. Ahern<sup>1</sup>, J. Nairn<sup>1</sup>, C.-L. Liew<sup>1,2</sup>, P.N. Reynolds<sup>1</sup>, P. Hopkins<sup>3</sup>, D. Chambers<sup>3</sup>, M. Holmes<sup>1,2</sup> <sup>1</sup>Royal Adelaide Hospital and Hanson Institute, Adelaide, Australia; <sup>2</sup>Royal Adelaide Hospital, Adelaide, Australia; <sup>3</sup>The Prince Charles Hospital, Brisbane, Australia

**6:00 PM (306) Respiratory Viral Infections through TLR7 Signaling Lead to Loss of Tregs and Contribute to Development of Chronic Rejection (BOS) Following Lung Transplantation;** S. Ramachandran<sup>1</sup>, D. Saini<sup>1</sup>, M. Walter<sup>2</sup>, A. Patterson<sup>1</sup>, E. Trulock<sup>1</sup>, T. Mohanakumar<sup>1,3</sup> <sup>1</sup>Washington University in St Louis, St. Louis, MO; <sup>2</sup>Washington University in St Louis, St. Louis, MO; <sup>3</sup>Washington University in St Louis, St. Louis, MO

**6:15 PM (307) A Polymorphism in the Hepatocyte Growth Factor (HGF) Gene Is Associated with Bronchiolitis Obliterans Syndrome (BOS)-Free Survival after Lung Transplantation;** D.C. Chambers<sup>1</sup>, M. Musk<sup>2</sup>, S. Wong<sup>3</sup>, S. Temple<sup>3</sup>, T.M. Liesfield<sup>1</sup>, F. Kermeen<sup>1</sup>, P.M.A. Hopkins<sup>1</sup> <sup>1</sup>The Prince Charles Hospital, Brisbane, Qld, Australia; <sup>2</sup>Royal Perth Hospital, Perth, Western Australia, Australia; <sup>3</sup>Murdoch University, Perth, Western Australia, Australia

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 24: Risk Stratification and Management of Advanced Heart Failure (241)**

Chairs: Bart Meyns, MD and Keith D. Aaronson, MD

**5:00 PM (308) Serum Albumin Concentration as Predictor of Mortality in Patients with End Stage Heart Failure Treated Medically and with Mechanical Circulatory Support – Analysis of the UNOS/OPTN Data and the DT Thoratec Registry – Years 1999-2007;** K. Lietz, M. Farr, Y. Naka, D. Mancini Columbia-University Medical Center, New York, NY

**5:15 PM (309) Long-Term Results of Immunoglobulin Absorption Treatment in Patients with End-Stage Idiopathic Dilated Cardiomyopathy Referred for Heart Transplantation;** M. Dandel<sup>1</sup>, G. Wallukat<sup>2</sup>, A. Englert<sup>1</sup>, H.B. Lehmkühl<sup>1</sup>, R. Hetzer<sup>1</sup>  
<sup>1</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Max Delbrück Centrum für Molekulare Medizin, Berlin, Germany

**5:30 PM (310) Validation of the Model for End Stage Liver Disease in Predicting LVAD Mortality;** J.C. Matthews<sup>1</sup>, T.F. Dardas<sup>1</sup>, J.W. Haft<sup>2</sup>, F.D. Pagani<sup>2</sup>, K.D. Aaronson<sup>1</sup>  
<sup>1</sup>University of Michigan Health Systems, Ann Arbor, MI; <sup>2</sup>University of Michigan Health Systems, Ann Arbor, MI

**5:45 PM (311) Defibrillation Threshold Testing Should Not Be Abandoned in Patients Receiving an Implantable Cardioverter Defibrillator for Primary Prevention;** T. Tanawuttiwat<sup>1</sup>, A. Bhan<sup>2</sup>, T. Harindhanavudhi<sup>1</sup>, M. Duggal<sup>2</sup>, M. Silver<sup>3</sup>  
<sup>1</sup>Advocate Christ Medical Center/University of Illinois at Chicago, Oak Lawn, IL; <sup>2</sup>Advocate Christ Medical Center/University of Illinois at Chicago, Oak Lawn, IL; <sup>3</sup>Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL

**6:00 PM (312) First North American Experience with Microaxial Percutaneous LVAD for Severe Cardiogenic Shock;** A. Cheung<sup>1</sup>, J. Higgins<sup>1</sup>, A. Kaan<sup>2</sup>, J. Kealy<sup>2</sup>, R. Moss<sup>2</sup>, J. Bashir<sup>1</sup>, A. Ignaszewski<sup>2</sup>  
<sup>1</sup>St. Paul's Hospital, Vancouver, BC, Canada; <sup>2</sup>St. Paul's Hospital, Vancouver, BC, Canada

**6:15 PM (313) Outcomes of Medical Therapy and Mechanical Circulatory Support as Bridge to Transplantation in UNOS Status 1 Heart Transplant Candidates – Analysis of the U.S. UNOS/OPTN Data, Years 1999-2007;** K. Lietz<sup>1</sup>, M. Slaughter<sup>2</sup>, M.C. Deng<sup>1</sup>, Y. Naka<sup>1</sup>, D. Mancini<sup>1</sup>  
<sup>1</sup>Columbia-University Medical Center, New York, NY; <sup>2</sup>University of Louisville, Louisville, KY

**6:30 PM – 7:30 PM  
PAH Guidelines Workforce Meeting (Room 273)**

**6:30 PM – 7:30 PM  
GENERAL POSTERS/WINE AND CHEESE RECEPTION (Hall Maillot)**

**(314) Featured Poster: High Risk Groups in the Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) Trial: Evaluation of Allograft Rejection and Survival;** D.A. Baran<sup>1</sup>, A. Pillai<sup>1</sup>, A. Patil<sup>1</sup>, M. Camacho<sup>1</sup>, C. Carr<sup>1</sup>, J. Prevost-Fernandez<sup>1</sup>, A. Martin<sup>1</sup>, S. Pardi<sup>1</sup>, V. Hou<sup>1</sup>, M. Binetti<sup>1</sup>, J. Ebuenga<sup>1</sup>, M.G. SanAugustin<sup>1</sup>, L. McBride<sup>1</sup>, A.L. Gass<sup>2</sup>, D. Blicharz<sup>1</sup>, H. Castillo<sup>1</sup>, M.J. Zucker<sup>1</sup>  
<sup>1</sup>Newark Beth Israel Medical Center, Newark, NJ; <sup>2</sup>Westchester County Medical Center, Westchester, NY

**(315) Renal Dysfunction Post Heart Transplantation – Mycophenolate Mofetil Plus Prednisolone Is Adequate Immunosuppression in Long-Term Survivors;** A. Barker<sup>1</sup>, C. Hyde<sup>1</sup>, C. Lewis<sup>1</sup>, M. Guilfoyle<sup>2</sup>, D. Jenkins<sup>1</sup>, S. Large<sup>1</sup>, J. Dunning<sup>1</sup>, S. Tsui<sup>1</sup>, J. Parameshwar<sup>1</sup>  
<sup>1</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>2</sup>Addenbrookes Hospital, Cambridge, United Kingdom

**(316) WITHDRAWN**

**(317) Does Ciclosporine C2 Levels Determine Outcome in De Novo Heart and Lung Transplant Patients: Results from the NOCTURNE Nordic Multi Centre Study;** F. Nilsson, S. Simonsen, J. Sipponen, H. Eiskjaer, L. Mared, S. Bergan, H. Fagertun, D. Solbu, M. Iversen  
Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

**(318) WITHDRAWN**

**(319) Proton Pump Inhibitor Co-Medication Reduces Mycophenolate Acid Drug Exposure in Heart Transplant Recipients;** S. Kofler<sup>1,2</sup>, A.K. Bigdeli<sup>2</sup>, M. Vogeser<sup>3</sup>, B.M. Meiser<sup>2</sup>, B. Reichart<sup>2</sup>, I. Kaczmarek<sup>2</sup>  
<sup>1</sup>University Hospital Grosshadern, Munich, Germany; <sup>2</sup>University Hospital Grosshadern, Munich, Germany; <sup>3</sup>University Hospital Grosshadern, Munich, Germany

**(320) Clinical Use of Tacrolimus Once-Daily Regimen in Patients with Heart Transplant. A Single Center Initial Experience;** J.L.R. Lambert<sup>1</sup>, B. Diaz Molina<sup>1</sup>, M.J. Bernardo<sup>1</sup>, M. Martin<sup>1</sup>, L. Tricas<sup>2</sup>, D. Martin Cid<sup>1</sup>  
<sup>1</sup>Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; <sup>2</sup>Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

**(321) Everolimus Prevents Allograft Microvasculopathy after Heart Transplantation;** E. Osto<sup>1</sup>, F. Tona<sup>1</sup>, C. Castellani<sup>2</sup>, A. Gambino<sup>3</sup>, G. Tarantini<sup>1</sup>, A. Vinci<sup>1</sup>, M. Napodano<sup>1</sup>, A. Ramondo<sup>1</sup>, A.L.P. Caforio<sup>1</sup>, G. Thiene<sup>2</sup>, G. Gerosa<sup>3</sup>, A. Angelini<sup>2</sup>, S. Iliceto<sup>1</sup>  
<sup>1</sup>University of Padova, Padova, Italy; <sup>2</sup>University of Padova, Padova, Italy; <sup>3</sup>University of Padova, Padova, Italy

- (322) Spare Me the Renal Sparing Protocol – Poor Long Term Outcomes;** S. Sohrabian<sup>1</sup>, M. Kawano<sup>1</sup>, K. Kiyosaki<sup>1</sup>, A. Ankrom<sup>1</sup>, J. Patel<sup>1</sup>, J. Moriguchi<sup>1</sup>, M. Kittleson<sup>1</sup>, A. Ardehali<sup>2</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA
- (323) Influence of Sirolimus on Survival in Heart Transplant Recipients;** M. Zakliczynski, D. Konecka-Mrowka, J. Nozynski, S. Zeglen, A. Mrowka, R. Przybylski, M. Zembala Silesian Center for Heart Disease, Zabrze, Poland
- (324) Role of IFN- $\gamma$  and CTL Mediators in CD8+ T Cell Driven Allograft Vasculopathy;** M.H. Hart- Matyas<sup>1</sup>, S. Nejat<sup>1</sup>, B.M. Ross<sup>2</sup>, G.M. Hirsch<sup>2</sup>, T.D.G. Lee<sup>1,2,3</sup> <sup>1</sup>Dalhousie University, Halifax, NS, Canada; <sup>2</sup>Dalhousie University, Halifax, NS, Canada; <sup>3</sup>Dalhousie University, Halifax, NS, Canada
- (325) Novel Agent To Ablate CD8+ Cardiac Allograft Vasculopathy;** J.L. Jordan<sup>1</sup>, B.M. Ross<sup>2</sup>, G.M. Hirsch<sup>2</sup>, T.D.G. Lee<sup>3</sup> <sup>1</sup>Dalhousie University, Halifax, NS, Canada; <sup>2</sup>Dalhousie University, Halifax, NS, Canada; <sup>3</sup>Dalhousie University, Halifax, NS, Canada
- (326) Featured Poster: Regulatory T Cells Are Associated with Favorable Outcomes Following ExtraCorporeal Photopheresis;** S. Kankirawatana<sup>1</sup>, S. Huang<sup>2</sup>, P. Atkinson<sup>1</sup>, J.K. Kirklin<sup>3</sup>, J.F. George<sup>3</sup> <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL
- (327) Differential Effects of Cyclosporine, Sirolimus and Tacrolimus on Intra-graft mRNA Expression of Pro-Inflammatory and Cytotoxic Molecular Pathways;** A. Khanna, J. Xu, M.R. Mehra University of Maryland, Baltimore, MD
- (328) Sirolimus Associated Nephropathy in Cardiac Transplantation: Histological and Molecular Pathways;** A. Khanna, J. Xu, M.R. Mehra University of Maryland, Baltimore, MD
- (329) Simvastatin Treatment Attenuates Obliterative Airway Disease Development in Rat Tracheal Allograft Model;** J.O. Ropponen<sup>1,2</sup>, J.M. Tikkanen<sup>1</sup>, M. Hollmen<sup>1</sup>, R. Krebs<sup>1</sup>, M.A. Keranen<sup>1</sup>, K.B. Lemstrom<sup>1,2</sup> <sup>1</sup>University of Helsinki, Helsinki, Finland; <sup>2</sup>University of Helsinki, Helsinki, Finland
- (330) Effects of the JAK3-Inhibitor R348 on Different Cell Types Involved in Obliterative Airway Disease;** J.B. Velotta<sup>1</sup>, T. Deuse<sup>1</sup>, C. Peter<sup>2</sup>, E. Masuda<sup>3</sup>, V. Taylor<sup>3</sup>, G. Park<sup>3</sup>, D. Carroll<sup>3</sup>, R.C. Robbins<sup>1</sup>, S. Schrepfer<sup>1,2</sup> Rigel Inc, South San Francisco, CA
- (331) Oral Administration of Nitrite or Nitrate, Abundant in the Mediterranean Diet, Attenuates Cardiac Allograft Rejection in Rats;** J. Zhan<sup>1,2</sup>, A. Nakao<sup>1</sup>, R. Sugimoto<sup>1</sup>, Y. Wang<sup>1</sup>, Z. Wang<sup>1</sup>, K.R. McCurry<sup>1</sup> <sup>1</sup>Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Tianjin Children's Hospital, Tianjin, China
- (332) Molecular Remodeling on Beta-Blocker Therapy in the Failing Human Heart;** A. Brieke<sup>1</sup>, S.F. Shakar<sup>1</sup>, R. Zolty<sup>2</sup>, W. Minobe<sup>1</sup>, M. Bristow<sup>1</sup>, B.D. Lowes<sup>1</sup> <sup>1</sup>University of Colorado Denver, Aurora, CO; <sup>2</sup>Albert Einstein College of Medicine, Bronx, NY
- (333) The Effects of Antioxidants (N-Acetylcystein and Epigallocatechin-3-Gallate) in Ischemia-Reperfusion Injury of Rat Lungs;** S.J. Haam, D.Y. Lee, H.C. Paik Yongdong Severance Hospital, Seoul, Republic of Korea
- (334) Featured Poster: Identification of Genome-Wide Single Nucleotide Polymorphisms in Peripartum Cardiomyopathy;** B.D. Horne<sup>1,2</sup>, A.G. Kfoury<sup>1</sup>, K.D. Rasmusson<sup>1,3</sup>, K.D. Brunisholz<sup>1</sup>, A.N. Zeigler<sup>1</sup>, J.J. Connolly<sup>1</sup>, T.F. Porter<sup>4,6</sup>, P.W. Fisher<sup>1</sup>, J.B. Muhlestein<sup>1,5</sup>, J.F. Carlquist<sup>1,5</sup>, H.T. May<sup>1</sup>, J.L. Anderson<sup>1,5</sup>, D.G. Renlund<sup>1,5</sup> <sup>1</sup>Intermountain Medical Center, Salt Lake City, UT; <sup>2</sup>University of Utah, Salt Lake City, UT; <sup>3</sup>University of Utah, Salt Lake City, UT; <sup>4</sup>Intermountain Medical Center, Salt Lake City, UT; <sup>5</sup>University of Utah, Salt Lake City, UT; <sup>6</sup>University of Utah, Salt Lake City, UT
- (335) Mechanical Unloading Induces Differential Changes in Cardiac MicroRNA Expression;** R. Ramani, A. Nakao, D. McNamara, B. Lemster, R. Kormos, C. McTiernan University of Pittsburgh Medical Center, Pittsburgh, PA
- (336) Hypoxia and Reperfusion: Role of Protein Kinase B and NADPH Oxidase;** D. Ramzy, L.C. Tumiati, E. Tepperman, R. Sheshgiri, V. Rao Toronto General Hospital, Toronto, ON, Canada
- (337) Endothelin-1 and Nitric Oxide in Hypoxia and Reperfusion: The Role of Akt;** D. Ramzy, L.C. Tumiati, E. Tepperman, R. Sheshgiri, V. Rao Toronto General Hospital, Toronto, ON, Canada
- (338) The Role of Intrapulmonary De Novo Lymphoid Tissue in Obliterative Bronchiolitis after Lung Transplantation;** M. Sato<sup>1</sup>, S. Hirayama<sup>1</sup>, D.M. Hwang<sup>1,2</sup>, H. Lara-Guera<sup>1</sup>, D. Wagnetz<sup>1</sup>, T.K. Waddell<sup>1</sup>, M. Liu<sup>1</sup>, S. Keshavjee<sup>1</sup> <sup>1</sup>University

Health Network, University of Toronto, Toronto, ON, Canada; <sup>2</sup>University Health Network, University of Toronto, Toronto, ON, Canada

**(339) Whole Transcriptome Analysis of Changes in Immune Function Early after Mechanical Circulatory Support Device Implantation in End Stage Heart Failure Patients;** K. Shahzad<sup>1</sup>, A. Sinha<sup>2</sup>, F. Latif<sup>1</sup>, M. Cadeiras<sup>1</sup>, M. Vonbayern<sup>1</sup>, S. Oz<sup>1</sup>, Y. Naka<sup>1</sup>, M.C. Deng<sup>1</sup> <sup>1</sup>Columbia University Medical Center, New York, NY; <sup>2</sup>Columbia University, New York, NY

**(340) Coronary Atherosclerosis in Explanted Hearts with Presumed Idiopathic Dilated Cardiomyopathy;** J.M. Barcelo, C. Salas, J. Segovia, M. Gomez-Bueno, P. Garcia-Pavia, M. Cobo, J. Mirelis, L. Alonso-Pulpon Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

**(341) Proteomic Biomarkers of Chronic Heart Allograft Rejection;** G.V. Cohen Freue<sup>1</sup>, D. Lin<sup>2</sup>, C. Imai<sup>3</sup>, A. Ignaszewski<sup>3</sup>, J. Mancini<sup>3</sup>, Z. Hollander<sup>4</sup>, A. Bergman<sup>5</sup>, M. Sasaki<sup>5</sup>, J. Wilson-McManus<sup>2</sup>, R. Balshaw<sup>1</sup>, R.T. Ng<sup>6</sup>, C. Borchers<sup>7</sup>, P. Keown<sup>3</sup>, B. McManus<sup>2</sup>, R. McMaster<sup>5</sup> <sup>1</sup>University of British Columbia, Vancouver, BC, Canada; <sup>2</sup>University of British Columbia, Vancouver, BC, Canada; <sup>3</sup>University of British Columbia, Vancouver, BC, Canada; <sup>4</sup>The James Hogg iCAPTURE Centre for Cardiovascular Pulmonary Research, Vancouver, Canada; <sup>5</sup>University of British Columbia, Vancouver, Canada; <sup>6</sup>University of British Columbia, Vancouver, Canada; <sup>7</sup>University of Victoria Proteomics Centre, Victoria, Canada

**(342) Featured Poster: Determining the Etiology of Quilty Lesions: A Repeat Heart Transplantation Study;** C. Ellis<sup>1</sup>, D.J. Carter<sup>2</sup>, W.M. Baldwin III<sup>3</sup>, M.K. Halushka<sup>1</sup> <sup>1</sup>Johns Hopkins Medical Institutions, Baltimore, MD; <sup>2</sup>Johns Hopkins Medical Institutions, Baltimore, MD; <sup>3</sup>Cleveland Clinic Foundation, Cleveland, OH

**(343) Featured Poster: The Role of Pre-Existing Donor Vascular Disease on Allograft Vasculopathy;** A.M. Zaki<sup>1</sup>, T.D.G. Lee<sup>1,2,3</sup>, G.M. Hirsch<sup>3</sup>, B.M. Ross<sup>3</sup> <sup>1</sup>Dalhousie University, Halifax, NS, Canada; <sup>2</sup>Dalhousie University, Halifax, NS, Canada; <sup>3</sup>Dalhousie University, Halifax, NS, Canada

**(344) Risk Factors for Early Death on the French Cardiac Waiting List;** C. Cantrelle, F. Pessione, D. Tixier, E. Herquelot, Transplant Teams, B. Loty Agence de la Biomedecine, Saint Denis La Plaine, France

**(345) Does Hormonal Resuscitation Increase Recovery of Thoracic Organs? A Single OPO Experience;** D.S. Nath<sup>1</sup>, M.H. Liu<sup>1</sup>, J. Coleman<sup>2</sup>, J. Wagner<sup>2</sup>, N. Moazami<sup>1</sup>, G.A. Ewald<sup>3</sup> <sup>1</sup>Washington University School of Medicine, Saint Louis, MO; <sup>2</sup>Mid-America Transplant Services, Saint Louis, MO; <sup>3</sup>Washington University School of Medicine, Saint Louis, MO

**(346) Featured Poster: The Impact of Donor-Recipient Gender Matching on Survival and Rejection after Cardiac Transplantation;** R.A. Bello, D.A. D'Alessandro, S. Maybaum, D.J. Goldstein Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY

**(347) The Effect of Tri-Iodothyronine (T3) on Thyroid Hormone Responsive Cardiac Genes in the Brain Stem Dead Cardiac Donor;** S.R. James<sup>1</sup>, A.M. Ranasinghe<sup>1,2</sup>, R. Venkateswaran<sup>2</sup>, C.J. McCabe<sup>1</sup>, J.A. Franklyn<sup>1</sup>, R.S. Bonser<sup>2</sup> <sup>1</sup>University of Birmingham, Birmingham, United Kingdom; <sup>2</sup>UHB NHS FT, Birmingham, United Kingdom

**(348) Featured Poster: Beta-Adrenergic Receptor Polymorphisms Are Associated with Cardiac Graft Function in Potential Organ Donors;** K.K. Khush<sup>1</sup>, L. Pawlikowska<sup>2</sup>, R. Menza<sup>3</sup>, V. Hayden<sup>4</sup>, W. Babcock<sup>4</sup>, A. Sapru<sup>2</sup>, M.A. Matthay<sup>2</sup>, M. Landeck<sup>4</sup>, W. Young<sup>2</sup>, C. Hoopes<sup>2</sup>, L.A. Baxter-Lowe<sup>2</sup>, J.G. Zaroff<sup>5</sup> <sup>1</sup>Stanford University, Palo Alto; <sup>2</sup>University of California, San Francisco; <sup>3</sup>Victoria University, Wellington, New Zealand; <sup>4</sup>California Transplant Donor Network, Oakland; <sup>5</sup>Kaiser Permanente, San Francisco

**(349) Lung Transplantation from None Heart Beating Donor (NHBD) Maastricht Classification Category IV: Brain-Death and Circulatory Arrest;** S. Lehmann, C. Topf, S. Dhein, F.W. Mohr, H.B. Bittner Heart Center of the University of Leipzig, Leipzig, Germany

**(350) The Lung Allocation Score (LAS) Evaluation from Transplant Coordinators' Perspective;** E. Mahoney<sup>2</sup>, J. Johnson<sup>2</sup>, C.H. Wigfield<sup>1,2</sup>, C. Alex<sup>2</sup>, R.B. Love<sup>1,2</sup> <sup>1</sup>Loyola University, Maywood, IL; <sup>2</sup>Loyola University, Maywood, IL

**(351) Immune Activation and Cardiac Allograft Survival: Effects of Donor and Recipient Tobacco Smoke Exposure;** M.R. Mehra, J. Xu, C. Baquet, A. Khanna University of Maryland, Baltimore, MD

**(352) Pathology Influences Device Development: The TransMedics Organ Care System for Heart;** R.F. Padera<sup>1</sup>, P. Lezberg<sup>2</sup>, E. Hansen<sup>2</sup>, D. Sousa<sup>2</sup>, G.L. Winters<sup>1</sup> <sup>1</sup>Brigham and Women's Hospital, Boston, MA; <sup>2</sup>TransMedics, Inc., Andover, MA

**(353) *The Role of Brain Stem Death and Ischemia Reperfusion Injury in the Alteration of the Endothelin and RAS Pathways Pre and Post Lung Transplantation***; M. Passmore<sup>1</sup>, M. Nataatmadja<sup>1</sup>, F. Russell<sup>2</sup>, A. Corley<sup>3</sup>, E. Venz<sup>3</sup>, P. Hopkins<sup>3</sup>, F. Kermeen<sup>3</sup>, J. Fraser<sup>1</sup>, B. Thomson<sup>1</sup>, G. Hart<sup>2</sup>, D. Chambers<sup>2</sup>, T. Daniels<sup>2</sup> <sup>1</sup>University of Queensland, Brisbane, Australia; <sup>2</sup>University of the Sunshine Coast, Maroochydore, Australia; <sup>3</sup>Prince Charles Hospital, Brisbane, Australia

**(354) *FP15 a Novel Peroxynitrite Decomposition Catalyst Protects Against Myocardial and Endothelial Reperfusion Injury after Orthotopic Heart Transplantation***; G. Szabo, N. Stumpf, T. Radovits, M. Karck University of Heidelberg, Heidelberg, Germany

**(355) *Featured Poster: Pre-Treatment of Rat Cardiac Allograft Donors with Simvastatin Prevents Early Ischemia-Reperfusion-Induced Vascular Permeability and Later Development of Chronic Rejection***; R. Tuuminen, A.I. Nykanen, R. Krebs, K.B. Lemstrom University of Helsinki, Helsinki, Finland

**(356) *Donor Brain Death Causes Acute Allograft Rejection in an Established Model of Cardiac Tolerance***; G.R. Veillette, A.J. Meltzer, K.M. Kim, T. Millington, A. Aoyama, M. Cochrane, S. Houser, D.H. Sachs, J.S. Allan, J.C. Madsen, B.R. Rosengard Massachusetts General Hospital, Boston, MA

**(357) *Erythropoietin Improves Functional Recovery of the Rat Heart after Prolonged Cold Storage in Celsior Solution***; A.J. Watson<sup>1,2</sup>, L. Gao<sup>1</sup>, J. Tsun<sup>1</sup>, J.C. Kwan<sup>1</sup>, A. Jabbour<sup>1,2</sup>, P.S. Macdonald<sup>1,2</sup>, M. Hicks<sup>1,3</sup> <sup>1</sup>Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; <sup>2</sup>St Vincent's Hospital, Sydney, NSW, Australia; <sup>3</sup>St Vincent's Hospital, Sydney, NSW, Australia

**(358) *Donor Cause of Brain Death Has No Impact on Outcome after Lung Transplantation***; S. Wauters<sup>1</sup>, D. Van Raemdonck<sup>1,2</sup>, C. Meers<sup>1</sup>, A. Neyrinck<sup>1</sup>, F. Rega<sup>1</sup>, C. Van de Wauwer<sup>1</sup>, D. Vanhees<sup>4</sup>, G. Verleden<sup>3</sup>, L. Dupont<sup>3</sup>, W. Coosemans<sup>2</sup>, H. Decaluwe<sup>2</sup>, P. De Leyn<sup>2</sup>, P. Nafteux<sup>2</sup>, T. Lerut<sup>2</sup> <sup>1</sup>Catholic University Leuven, Leuven, Belgium; <sup>2</sup>University Hospital Gasthuisberg, Leuven, Belgium; <sup>3</sup>University Hospital Gasthuisberg, Leuven, Belgium; <sup>4</sup>University Hospital Gasthuisberg, Leuven, Belgium

**(359) *Cadaveric Lobar Lung Transplantation: Long Term Follow Up of a Case Series***; D.T. Keating<sup>1</sup>, G.P. Westall<sup>1</sup>, S.F. Marasco<sup>2</sup>, J. Negri<sup>2</sup>, J.H. Burton<sup>1</sup>, M.R. Buckland<sup>3</sup>, T.J. Williams<sup>1</sup>, G.I. Snell<sup>1</sup> <sup>1</sup>Alfred Hospital, Melbourne, Victoria, Australia; <sup>2</sup>Alfred Hospital, Melbourne, Victoria, Australia; <sup>3</sup>Alfred Hospital, Melbourne, Victoria, Australia

**(360) *How the Cause of Death Affects the Quality of DCD Donor Lung? – An Experimental Study***; T. Yamada, F. Chen, J. Zhang, T. Okamoto, T. Fujinaga, H. Morikawa, I. Matsumoto, N. Satoda, A. Takahashi, T. Shoji, H. Sakai, T. Bando, H. Date Kyoto University, Kyoto-City, Japan

**(361) *Does Morbid Obesity Adversely Effect Outcomes Following Cardiac Transplantation?***; K.B. Allen, A.M. Borkon, G.L. Zorn, A. Kao, A. Magalski, R.S. Stuart, E. Daon, A.F. Pak, N. Long, K. St. Clair Mid America Heart Institute, Kansas City, MO

**(362) *Biatrial Implantation with Modified Cabrol Technique Provides Similar Outcomes Compared to Bicaval Anastomosis***; A.M. Borkon, A. Kao, S. Stuart, E. Daon, G. Zorn, A. Pak, K. Allen Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO

**(363) *Complement Fragment 9 Immunohistochemistry as Marker of Peri-Transplant Injury in Heart Transplantation***; V. Dronavalli<sup>1</sup>, E. Clarke<sup>2</sup>, R. Bonser<sup>1</sup>, M. Mukadam<sup>1</sup>, S. Beer<sup>1</sup>, I. Wilson<sup>1</sup>, J. Mascaro<sup>1</sup>, R. Thompson<sup>1</sup>, J. Townsend<sup>1</sup>, D. Neil<sup>3</sup> <sup>1</sup>University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, United Kingdom; <sup>2</sup>University of Birmingham, Birmingham, United Kingdom; <sup>3</sup>University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, United Kingdom

**(364) *ECMO as Support of Primary Graft Dysfunction (PGD) in Cardiac Transplantation***; M. Groemmer<sup>1</sup>, S. Mahr<sup>1</sup>, A.Z. Aliabadi<sup>1</sup>, M. Grimm<sup>1</sup>, A.O. Zuckermann<sup>1</sup>, G. Wieselthaler<sup>1</sup>, E. Wolner<sup>1</sup>, A.M. Rajek<sup>2</sup>, K. Herbert<sup>2</sup>, S. Barbara<sup>2</sup>, S. Taghavi<sup>1</sup> <sup>1</sup>General Hospital Vienna, Vienna, Austria; <sup>2</sup>General Hospital Vienna, Vienna, Austria

**(365) *Recipients and Donors Selection in Heart Transplantation: How Much Risk Is Too High?***; G. Guzzi<sup>1</sup>, G. Aresu<sup>1</sup>, M. Maiani<sup>1</sup>, T. Bisceglia<sup>1</sup>, V. Tursi<sup>1</sup>, E. Spagna<sup>1</sup>, L. Vetrugno<sup>2</sup>, U. Livi<sup>1</sup> <sup>1</sup>University-General Hospital, Udine, Italy; <sup>2</sup>University-General Hospital, Udine, Italy

**(366) *Outcomes of Cardiac Transplantation for Adult Congenital Heart Disease***; C. Irving, R. Kirk, A. Hasan, G. Parry Freeman Hospital, Newcastle upon Tyne, United Kingdom

- (367) Clinical and Hemodynamic Effects of Early Renin Angiotensin Aldosterone System Blockade in Cardiac Transplant Recipients;** S. Karabsheh<sup>1</sup>, M. Jain<sup>2</sup>, N. Sergerson<sup>1</sup>, E. Gilbert<sup>1</sup>, J. Stehlik<sup>1</sup>, F. Bader<sup>1</sup> <sup>1</sup>University of Utah, Salt Lake City, UT; <sup>2</sup>Norwalk Hospital, Norwalk
- (368) Sympathetic Reinnervation Assessed by Iodine-123 Metaiodobenzylguanidine Imaging Are Not Consistent with the Response of Left Ventricular Function to Adrenergic Stimulation in Heart Transplant Recipients;** T.S. Kato<sup>1</sup>, T. Sasaoka<sup>1</sup>, M. Yanase<sup>1</sup>, T. Nakatani<sup>2</sup>, K. Hahimura<sup>1</sup>, Y. Ishida<sup>1</sup> <sup>1</sup>National Cardiovascular Center, Osaka, Japan; <sup>2</sup>National Cardiovascular Center, Osaka, Japan
- (369) Thoracic Transplantation and Pregnancy: A French Experience in the Nantes Hospital;** M. Michel, S. Pattier, A. Haloun, J. Esbelin, M. Treilhaud, J.C. Roussel, P. Despins, J.N. Trochu CHU-Hôpital Laennec, Nantes, France; CHU-Hôpital Laennec, Nantes, France; CHU-Hôpital Laennec, Nantes, France; CHU-Hôtel Dieu, Nantes, France; CHU-Hôpital Laennec, Nantes, France; CHU-Hôpital Laennec, Nantes, France; CHU-Hôpital Laennec, Nantes, France; CHU-Hôpital Laennec, Nantes, France
- (370) Heart Transplantation with Non-Identical Compatible ABO Blood-Groups: Impact on Early Rejection and Long-Term Survival;** J. Nilsson<sup>1</sup>, J. Sjogren<sup>1</sup>, F. Ljungdahl Waller<sup>1</sup>, E. Senneby<sup>1</sup>, B. Ekmehag<sup>2</sup>, B. Koul<sup>1</sup> <sup>1</sup>Institution for Clinical Science, Lund, Sweden; <sup>2</sup>Institution for Clinical Science, Lund, Sweden
- (371) Mycophenolic Trough Levels and Adverse Effects in Heart Transplant Population;** L.S.L. Ting<sup>1</sup>, J. Haymond<sup>1</sup>, N. Partovi<sup>1</sup>, C. Imai<sup>2</sup>, A.P. Ignaszewski<sup>2,3</sup>, M.H.H. Ensom<sup>1</sup> <sup>1</sup>University of British Columbia, Vancouver, BC, Canada; <sup>2</sup>St. Paul's Hospital, Vancouver, BC, Canada; <sup>3</sup>University of British Columbia, Vancouver, BC, Canada
- (372) Heart Transplantation in Adults with Congenital Heart Disease;** E. Ribera, G. Bruschi, P. Austoni, G. Vignati, A. Corato, S. Marianeschi, R. Paino, M. Firgerio, L. Martinelli, F. Santoro Niguarda Ca' Granda Hospital, Milan, Italy
- (373) Cardiac Ischemia Postoperative Adverse Events after Adult Heart Transplantation;** C.A. Rogers, R.S. Bonser, N.R. Banner The Royal College of Surgeons of England, London, United Kingdom
- (374) Retrospective Review of Japanese Heart Transplant Recipients Transplanted in Japan and Transplanted at UCLA in the U.S.;** T. Sasaoka<sup>1</sup>, T. Nakatani<sup>1</sup>, N. Oda<sup>1</sup>, M. Yanase<sup>1</sup>, J.A. Kobashigawa<sup>2</sup>, J. Patel<sup>2</sup>, M. Isobe<sup>3</sup>, T.S. Kato<sup>1</sup> <sup>1</sup>National Cardiovascular Center, Osaka, Japan; <sup>2</sup>The David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>3</sup>Tokyo Medical and Dental University, Tokyo, Japan
- (375) Featured Poster: Dual Right Atrial Pacing Improves Paced Heart Rate Response in Orthotopic Heart Transplant Patients;** M.A. Thompson, H. Patel Ochsner Clinic, New Orleans, LA
- (376) Featured Poster: Risk Factors for Early Transplant Mortality, Predictive Modeling, and Their Relation to Institutional Outcomes in the Modern Era;** A.B. Van Bakel<sup>1</sup>, R.N. Brown<sup>2</sup>, M. Hess<sup>3</sup>, A. Heroux<sup>4</sup>, L.A. Nikolaidis<sup>5</sup>, M.T. Oliveri<sup>6</sup>, K. Law<sup>1</sup>, D.C. Naftel<sup>2</sup> <sup>1</sup>Medical University of South Carolina, Charleston, SC; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Medical College of Virginia, Richmond, VA; <sup>4</sup>Loyola University Medical Center, Chicago, IL; <sup>5</sup>Temple University Hospital, Philadelphia, PA; <sup>6</sup>Abbott Northwestern Hosp/Minneapolis Heart Inst, Minneapolis, MN
- (377) Featured Poster: Indoleamine 2,3-Dioxygenase in Lung Allograft Tolerance;** F. Bini<sup>1</sup>, S. Giuliano<sup>2</sup>, P. Draghi<sup>1</sup>, M. Pappalettera<sup>3</sup>, A.M. Bardoni<sup>2</sup>, R. Salvini<sup>2</sup>, A.M. Fietta<sup>1</sup>, F. Meloni<sup>1</sup> <sup>1</sup>University of Pavia Foundation IRCCS San Matteo, Pavia, Pavia, Italy; <sup>2</sup>University of Pavia, Pavia, Italy; <sup>3</sup>University of Milan IRCCS POMARE Foundation, Milano, Italy
- (378) Featured Poster: Validation of Diagnostic Classifier for Acute Lung Rejection Based on Bronchoalveolar Lavage Cell Gene Expression;** J.R. Patil<sup>1</sup>, M.I. Hertz<sup>1</sup>, A. Hofer<sup>1</sup>, H. Guo<sup>2</sup>, T. Berryman<sup>1</sup> <sup>1</sup>University of Minnesota, Minneapolis, MN; <sup>2</sup>University of Minnesota, Minneapolis, MN
- (379) Does Drug-Eluting Stents Reduce In-Stent Re-Stenosis in Cardiac Allograft Vasculopathy? A Single Center Experience;** P. Colombo, G. Bruschi, A. Sacco, P.L. Silva, F. Turazza, M. Frigerio, L. Martinelli, S. Klugmann Niguarda Ca' Granda Hospital, Milan, Italy
- (380) Featured Poster: Pre-Transplant Anti-Pneumococcal Antibodies Add to the Prognostic Value for Infection of IgG Levels in a Cohort of Heart Transplant Recipients;** J. Carbone<sup>1</sup>, E. Sarmiento<sup>1</sup>, J. Rodriguez-Molina<sup>1</sup>, N. Lanio<sup>1</sup>, J. Fernandez-Yanez<sup>2</sup>, P. Munoz<sup>3</sup>, A. Gallego<sup>1</sup>, C. Rodriguez<sup>4</sup>, E. Fernandez-Cruz<sup>1</sup> <sup>1</sup>Gregorio Marañon Hospital, Madrid, Spain; <sup>2</sup>Gregorio Marañon Hospital, Madrid, Spain; <sup>3</sup>Gregorio Marañon Hospital, Madrid, Spain; <sup>4</sup>Gregorio Marañon Hospital, Madrid, Spain

**(381) Featured Poster:** *Immunosuppression after Post-Heart-Transplant Neoplasia with MMF and mTOR Inhibitors and Withdrawal of Calcineurin Inhibitors. Is It Safe Enough for Rejection Control?*; M.G. Crespo-Leiro, M.J. Paniagua-Martin, J.P. Abugattas, S. Antolin-Novoa, M.R. Garcia-Campelo, M. Gomez-Gutierrez, Z. Grille, C. Naya, J.A. Rodriguez, N. Vazquez-Gonzalez, J.J. Cuenca, A. Castro-Beiras Complejo Hospitalario Universitario Juan Canalejo, La Coruña, Spain

**(382) Predictive Factors of Early Graft Failure after Cardiac Transplantation;** C. D'Alessandro<sup>1</sup>, J.L. Golmard<sup>2</sup>, S. Varnous<sup>1</sup>, A. Ouattara<sup>3</sup>, S. Aubert<sup>1</sup>, A. Combes<sup>4</sup>, A. Pavie<sup>1</sup>, P. Leprince<sup>1</sup> <sup>1</sup>La Pitie-Salpetriere Hospital, Paris, France; <sup>2</sup>La Pitie-Salpetriere Hospital, Paris, France; <sup>3</sup>La Pitie-Salpetriere Hospital, Paris, France; <sup>4</sup>La Pitie-Salpetriere Hospital, Paris, France

**(383) Serum Cystatin C as an Easy To Obtain Biomarker for the Onset of Late Renal Impairment in Heart Transplantation;** D. Duller<sup>1</sup>, D. Kniepeiss<sup>1</sup>, G. Wirnsberger<sup>2</sup>, A. Wasler<sup>1</sup>, K.H. Tscheliessnigg<sup>1</sup> <sup>1</sup>Medical University Graz, Graz, Austria/Styria, Austria; <sup>2</sup>Medical University Graz, Graz, Austria/Styria, Austria

**(384) Transplant Coronary Artery Disease: Long-Term Results of Interventional Revascularization;** T. Dziodzio<sup>1</sup>, A. Juraszek<sup>1</sup>, S. Roedler<sup>1</sup>, A. Zuckermann<sup>1</sup>, M. Czerny<sup>1</sup>, M. Grimm<sup>1</sup>, D. Glogar<sup>2</sup> <sup>1</sup>General Hospital, Vienna, Austria; <sup>2</sup>General Hospital, Vienna, Austria

**(385) Advanced Cardiac Allograft Vasculopathy Results in a Unique Cardiac Remodeling Pattern;** F. Khan, S. Hecker, J.N. Nativi, M.P. Revelo, E.M.E. Hammond, A.G. Kfoury, S. Drakos, E.M. Gilbert, D.G. Renlund, F. Bader, P.W. Fisher, J. Stehlik UTAH Cardiac Transplant Program, Salt Lake City

**(386) Early Permanent Pacemaker after Heart Transplantation Is a Surrogate Marker for Poor Outcome: Possible Immune Mechanisms;** B.J. Kim<sup>1</sup>, K.K. Kiyosaki<sup>1</sup>, E. Shao<sup>1</sup>, J.K. Patel<sup>1</sup>, M. Kittleson<sup>1</sup>, M.A. Kawano<sup>1</sup>, A. Ankrom<sup>1</sup>, J. Moriguchi<sup>1</sup>, A. Ardehali<sup>2</sup>, J.A. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**(387) Development of Metabolic Syndrome during the First Year after Heart Transplantation Is Associated with Transplant Vasculopathy;** R.U. Shah, N.P. Johnson, M.C. Montpetit, E. Schupbach, K.L. Grady, J.B. O'Connell, E.C. McGee, W.G. Cotts, L. Klein Northwestern University Feinberg School of Medicine, Chicago, IL

**(388) Disappointing Outcomes of Drug Eluting Stent (DES) Implantation To Treat Cardiac Allograft Vasculopathy;** R.J. Margey<sup>1</sup>, N.G. Mahon<sup>1</sup>, D. Sugrue<sup>1</sup>, A. Wood<sup>2</sup> <sup>1</sup>Mater Misericordiae University Hospital, Dublin, Ireland; <sup>2</sup>Mater Misericordiae University Hospital, Dublin, Ireland

### **(389) WITHDRAWN**

**(390) When Is Too Old, Too Old for Redo Heart Transplantation?;** J. Patel<sup>1</sup>, M.A. Kawano<sup>1</sup>, K.K. Kiyosaki<sup>1</sup>, A. Ankrom<sup>1</sup>, M. Kittleson<sup>1</sup>, J. Moriguchi<sup>1</sup>, A. Ardehali<sup>2</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**(391) Adiponectin Time Course, Metabolic Profile and Cardiac Allograft Vasculopathy after Heart Transplantation;** C. Quarta, L. Potena, L. Tomasi, F. Grigioni, G. Magnani, P. Ortolani, F. Coccolo, F. Fallani, A. Branzi University of Bologna, Bologna, Italy

**(392) Cardiac Allograft Coronary Endothelial Dysfunction Is Characterized by Epicardial Vasoconstriction and Decrease in Endogenous Nitric Oxide Levels;** E. Raichlin<sup>1</sup>, S.S. Kushwaha<sup>2</sup>, R.J. Lennon<sup>3</sup>, R.P. Frantz<sup>4</sup>, B.S. Edwards<sup>5</sup>, A. Prasad<sup>6</sup>, C.S. Rihal<sup>7</sup>, A. Lerman<sup>8</sup> <sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Mayo Clinic, Rochester, MN; <sup>3</sup>Mayo Clinic, Rochester, MN; <sup>4</sup>Mayo Clinic, Rochester, MN; <sup>5</sup>Mayo Clinic, Rochester, MN; <sup>6</sup>Mayo Clinic, Rochester, MN; <sup>7</sup>Mayo Clinic, Rochester, MN; <sup>8</sup>Mayo Clinic, Rochester, MN

**(393) Association of NT-Pro Brain Natriuretic Peptide Levels and Echocardiographic Variables in Long-term Heart Transplant Recipients;** J. Renoldner<sup>1</sup>, R. Berger<sup>1</sup>, S. Roedler<sup>2</sup>, A. Aliabadi<sup>2</sup>, A. Zuckermann<sup>2</sup>, B. Stanek<sup>1</sup> <sup>1</sup>Medical University of Vienna, Vienna, Austria; <sup>2</sup>Medical University of Vienna, Vienna, Austria

**(394) Dynamics of Pleural Effusions in the Presence of Everolimus-Based Immunosuppression in De Novo Cardiac Transplant Recipients;** H. Ross<sup>1</sup>, H. Lehmkuhl, S. S. Wang, M. Vigano, A. Zuckermann, S. Varnous, M. Frigerio, G. Laufer, L. Potena, A. Keogh, U. Livi <sup>1</sup>University Health Network, Toronto, ON, Canada; <sup>2</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>3</sup>National Taiwan University Hospital, Taipei, Taiwan; <sup>4</sup>Policlinico S. Matteo, IRCCS Università degli Studi di Pavia, Pavia, Italy; <sup>5</sup>Univ.-Klinik für Chirurgie, Vienna, Austria; <sup>6</sup>Hôpital La Pitié Salpêtrière, Paris, France; <sup>7</sup>Ospedale Niguarda Ca'Granda, Milan, Italy; <sup>8</sup>Univ.-Klinik für Chirurgie, Innsbruck, Austria; <sup>9</sup>Istituto di Malattie

dell'apparato Cardiovascolare, Bologna, Italy; <sup>10</sup>St Vincent's Hospital, Sydney, Australia; <sup>11</sup>Az. Ospedaliero-Universitaria S. Maria della Misericordia di Udine, Udine, Italy

**(395) Relationship between Peripheral Blood Mononuclear Cell Gene Expression and QTc-Interval after Heart Transplantation in the Absence of Moderate or Severe Acute Cellular Rejection;** K. Shahzad<sup>1</sup>, M. Cadeiras<sup>1</sup>, M.M. John<sup>1</sup>, F. Latif<sup>1</sup>, A. Sinha<sup>2</sup>, S. Memon<sup>1</sup>, S. Restaino<sup>1</sup>, C.C. Marboe<sup>1</sup>, M.C. Deng<sup>1</sup> <sup>1</sup>Columbia University Medical Center, New York, NY; <sup>2</sup>Columbia University, New York, NY

**(396) Late Rapidly Progressive Cardiac Allograft Vasculopathy Is Associated with Poor Outcome;** E. Shao<sup>1</sup>, M. Kawano<sup>1</sup>, K. Kiyosaki<sup>1</sup>, J. Patel<sup>1</sup>, M. Kittleson<sup>1</sup>, J. Moriguchi<sup>1</sup>, A. Ardehali<sup>2</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**(397) REVEAL Registry: Pediatric IPAH Versus Pediatric Pulmonary Vascular Disease Associated with Congenital Heart Disease;** R.J. Barst<sup>1</sup>, D. Ivy<sup>2</sup>, D.B. Badesch<sup>3</sup>, R.L. Benza<sup>4</sup>, C.G. Elliott<sup>5</sup>, H.W. Farber<sup>6</sup>, A.E. Frost<sup>7</sup>, A. Krichman<sup>8</sup>, T.G. Liou<sup>9</sup>, G.E. Raskob<sup>10</sup>, P. Wason<sup>11</sup>, K. Feldkircher<sup>11</sup>, A.J. Foreman<sup>12</sup>, M.D. McGoon<sup>13</sup> <sup>1</sup>Columbia University College of Physicians Surgeons, New York, NY; <sup>2</sup>University of Colorado Denver School of Medicine, The Children's Hospital, Aurora, CO; <sup>3</sup>University of Colorado Health Sciences Center, Aurora, CO; <sup>4</sup>Allegheny General Hospital, Pittsburgh, PA; <sup>5</sup>Intermountain Medical Center, Murray, UT; <sup>6</sup>Boston University School of Medicine, Boston, MA; <sup>7</sup>Baylor College of Medicine, Houston, TX; <sup>8</sup>Duke University Medical Center, Durham, NC; <sup>9</sup>University of Utah, Salt Lake City, UT; <sup>10</sup>University of Oklahoma Health Sciences Center, Oklahoma City, OK; <sup>11</sup>Actelion Pharmaceuticals US, Inc., South San Francisco, CA; <sup>12</sup>ICON Clinical Research, San Francisco, CA; <sup>13</sup>Mayo Clinic, Rochester, MN

**(398) Plasma Matrix Metalloproteinase Levels and Disease Severity in Pulmonary Arterial Hypertension;** K. Jasti, S. Bhashyam, C. Melegari, D. Vido, L. Machen, R. Benza, S. Murali Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA

**(399) Endothelin-1 (ET-1) across the Lung Circulation in Patients with Pulmonary Arterial Hypertension and Influence of Epoprostenol Infusion;** N. Selimovic<sup>1</sup>, C. H. Bergh<sup>1</sup>, B. Andersson<sup>1</sup>, E. Sakiniene<sup>2</sup>, H. Carlsten<sup>2</sup>, B. Rundqvist<sup>1</sup> <sup>1</sup>Sahlgrenska University Hospital, Gothenburg, Sweden; <sup>2</sup>Sahlgrenska University Hospital, Gothenburg, Sweden

**(400) Reverse Remodulation of the RV in Patients with PAH Treated with Ambrisentan;** S. Blalock<sup>2</sup>, F. Torres<sup>1</sup>, K. Chin<sup>1</sup>, R. Peshock<sup>1</sup>, S. Matulevicius<sup>1</sup> <sup>1</sup>UT Southwestern Medical Center, Dallas, TX; <sup>2</sup>UT Southwestern Medical Center, Dallas, TX

**(401) Outcome of Patients with Primary Pulmonary Hypertension after Lung Transplantation;** B. Zweytick<sup>1</sup>, P. Jaksch<sup>1</sup>, M. Keplinger<sup>1</sup>, K. Czebe<sup>2</sup>, W. Klepetko<sup>1</sup> <sup>1</sup>General Hospital Vienna, Vienna, Austria; <sup>2</sup>Pulmology, Budapest, Hungary

**(402) Scaffold Manufacturing for Heart Valve Tissue Engineering;** Y.L. Elgudin<sup>1</sup>, M.E. Smith<sup>3</sup>, B. Cmolik<sup>1</sup>, D. Golovaty<sup>4</sup>, N.J. Greco<sup>2</sup>, M. Laughlin<sup>2</sup>, G.E. Wnek<sup>3</sup> <sup>1</sup>Cleveland VA Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH; <sup>2</sup>University Hospitals of Cleveland Case Medical Center, Cleveland, OH; <sup>3</sup>Case Western Reserve University, Cleveland, OH; <sup>4</sup>University of Akron, Akron, OH

**(403) Immunosuppressive or Immunogenic? Culture Medium Strongly Influences the In Vitro Immunomodulatory Properties of Mesenchymal Stem Cells (MSC);** A. Poncelet<sup>1</sup>, P. Gianello<sup>1</sup>, J. Vercruyse<sup>1</sup>, C. Lecuivre<sup>1,2</sup>, Y. Nizet<sup>1,2</sup> <sup>1</sup>Université Catholique de Louvain, Brussels, Belgium; <sup>2</sup>Université Catholique de Louvain, Brussels, Belgium

**(404) Immune Modulatory Properties of Mesenchymal Stem Cells Are Independent of Their Derived-Tissue of Origin and Are Maintained across Xenogeneic Barriers;** A. Poncelet<sup>1</sup>, D. Dufrane<sup>1</sup>, C. Lecuivre<sup>1,2</sup>, Y. Nizet<sup>1,2</sup>, P. Gianello<sup>1</sup> <sup>1</sup>Université Catholique de Louvain, Brussels, Belgium; <sup>2</sup>Université Catholique de Louvain, Brussels, Belgium

**(405) Cytokine Enhancement with HGF or VEGF in the Infarct Border Zone Is Key to Attenuating the Negative Remodeling after Myocardial Infarction;** S. Schrepfer<sup>1</sup>, T. Deuse<sup>1</sup>, C. Peter<sup>2</sup>, B. Stein<sup>1</sup>, H. Reichenspurner<sup>3</sup>, W.H. Zimmermann<sup>4</sup>, T. Eschenhagen<sup>4</sup>, M.P. Pelletier<sup>1</sup>, R.C. Robbins<sup>1</sup> <sup>1</sup>Stanford University School of Medicine, Stanford, CA; <sup>2</sup>Stanford University School of Medicine, Stanford, CA; <sup>3</sup>University Heart Center, Hamburg, Germany

**(406) Novel Nuclear Proteins in Mouse Lung Alveolar Development;** S.K. Murari, J. Dong, S. Sutor, T. Kislinger, D.A. Wigle Mayo Clinic, Rochester, MN

**6:30 PM – 7:30 PM**

**Junior Faculty and Trainee Council Meeting (Room 241)**

**FRIDAY, APRIL 24, 2009**



**7:45 AM – 8:45 AM**

**SCIENTIFIC COUNCIL MEETINGS**

Scientific Council on Pediatric Transplantation Meeting (Room 241)  
Scientific Council on Nursing and Social Science Meeting (Room 243)  
Scientific Council on Pulmonary Transplantation Meeting (Room 252)  
Scientific Council on Heart Failure and Transplant Medicine Meeting (Room 242AB)

**9:00 AM – 11:00 AM**

**PLENARY SESSION** (Main Theatre)

Chairs: Stephan Schueler, MD, PhD and Robert L. Kormos, MD

**9:00 AM Invited Lecture:** *Cardiac Repair: Progress and Pitfalls*, Loren J. Field, MD, Indiana University, Indianapolis, IN

**9:30 AM (407) Featured Abstract:** *Clinical Durability and Low Incidence of Pump Replacement of a Continuous-Flow Left Ventricular Assist Device*; N. Moazami<sup>1</sup>, G.A. Ewald<sup>1</sup>, F.D. Pagani<sup>2</sup>, R. John<sup>3</sup>, T.E. MacGillivray<sup>4</sup>, L. Chen<sup>5</sup>, W.P. Dembitsky<sup>6</sup>, D.J. Farrar<sup>7</sup>, O.H. Frazier<sup>8</sup> <sup>1</sup>Washington University School of Medicine, St. Louis, MO; <sup>2</sup>University of Michigan, Ann Arbor, MI; <sup>3</sup>University of Minnesota, Minneapolis, MN; <sup>4</sup>Massachusetts General Hospital, Boston, MA; <sup>5</sup>University of Rochester, Rochester, NY; <sup>6</sup>Sharp Memorial Hospital, San Diego, CA; <sup>7</sup>Thoratec Corporation, Pleasanton, CA; <sup>8</sup>Texas Heart Institute, Houston, TX

**9:45 AM (408) Featured Abstract:** *Important Improvements in Quality of Life after MCS Implant: First Results from INTERMACS*; K.L. Grady<sup>1</sup>, K.L. Ullisney<sup>2</sup>, J.K. Kirklin<sup>3</sup>, D.C. Naftel<sup>3</sup>, A.C. Gelijns<sup>4</sup>, J.B. Young<sup>5</sup>, T. Martin<sup>6</sup>, K. Chisholm<sup>7</sup>, A. Moskowitz<sup>1</sup> <sup>1</sup>Bluhm Cardiovascular Institute Northwestern University Medical Center, Chicago, IL; <sup>2</sup>National Heart Lung and Blood Institute, Bethesda, MD; <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>4</sup>Columbia University Medical Center, New York, NY; <sup>5</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>6</sup>Newark Beth Israel Hospital, Newark, NJ; <sup>7</sup>University of Arizona Medical Center, Tucson, AZ; <sup>8</sup>Columbia University, New York, NY

**10:00 AM (409) Featured Abstract:** *Use of INTERMACS Criteria To Assess Major Clinical Outcomes in Children Bridged to Heart Transplant Using Mechanical Circulatory Support*; M.L. Stein<sup>1</sup>, R. Robbins<sup>1</sup>, A. Sabati<sup>1</sup>, O. Reinhartz<sup>1</sup>, C. Chin<sup>1</sup>, E. Liu<sup>2</sup>, D. Bernstein<sup>1</sup>, S. Roth<sup>1</sup>, G. Wright<sup>1</sup>, B. Reitz<sup>1</sup>, D.N. Rosenthal<sup>1</sup> <sup>1</sup>Stanford University, Stanford, CA; <sup>2</sup>Lucile Packard Children's Hospital, Stanford, CA

**10:15 AM (410) Featured Abstract:** *Cardiac Stability for More Than 5 Years after Ventricular Assist Device Removal: Main Predictors for Long-Term Weaning Success*; M. Dandel, Y. Weng, H. Siniawski, M. Pasic, H.B. Lehmkuhl, E. Potapov, T. Krabatsch, T. Drews, C. Knosalla, R. Hetzer Deutsches Herzzentrum Berlin, Berlin, Germany

**10:30 AM Invited Lecture:** *Novalung/ECMO Point Counterpoint*, Martin Strueber, MD, Hannover Medical School, Hannover, Germany and David P. Mason, MD, Cleveland Clinic Foundation, Cleveland, OH

**11:00 AM – 11:30 AM**

**ANNUAL BUSINESS MEETING** (Main Theater)

**11:00 AM – 11:30 AM**

Coffee Break/View Posters/Visit Exhibits (Hall Maillot)

**11:00 AM – 7:30 PM**

Exhibit Hall Open (Hall Maillot)

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 25: Optimizing Outcomes After Mechanical Circulatory Support** (Main Theatre)

Chairs: Leslie W. Miller, MD and Emma Birks, MRCP

**11:30 AM (411) Poor Outcomes Resulting from Ventricular Assist Devices Implanted in Hospitals without Dedicated VAD Programs**; A.C. Anyanwu, S. Pinney, K. Ashley, K. Hammond, D.H. Adams Mount Sinai Medical Center, New York, NY

**11:45 AM (412) Twenty-Five Patients with Aortic Valve Closure Associated with HeartMate LVAD Insertion**; R.M. Adamson<sup>1</sup>, W.P. Dembitsky<sup>1</sup>, S. Baradaran<sup>1</sup>, J. Chammas<sup>1</sup>, B. Jaski<sup>2</sup>, P. Hoagland<sup>2</sup>, S. Chillcott<sup>3</sup>, M. Stahovich<sup>3</sup>, V. McCalmont<sup>3</sup>, K. Ortiz<sup>3</sup> <sup>1</sup>Sharp Memorial Hospital, San Diego, CA; <sup>2</sup>Sharp Memorial Hospital, San Diego, CA; <sup>3</sup>Sharp Memorial Hospital, San Diego, CA

**12:00 PM (413)** *Outcomes of Patients over 70 Receiving Left Ventricular Assist Devices*; M. Stahovich, S. Chillcott, R. Adamson, S. Baradaran, J. Chammus, B. Jaski, P. Hoagland, W. Dembitsky Sharp Memorial Hospital, San Diego, CA

**12:15 PM (414)** *Improved Survival with Simultaneous RVAD Placement in LVAD Recipients at High Risk for RV Failure*; J.E. Patrick, L.W. Miller, S.W. Boyce Washington Hospital Center/Georgetown University Hospital, Washington, DC

**12:30 PM (415)** *Improvement in Two Year Survival for Ventricular Assist Device Patients after Implementation of an Intensive Surveillance Protocol*; S.V. Pamboukian<sup>1</sup>, M.C. Smallfield<sup>1</sup>, R.N. Brown<sup>2</sup>, W.L. Holman<sup>2</sup>, J.A. Tallaj<sup>1</sup>, M. Blood<sup>1</sup>, J. Sharpton<sup>1</sup>, B.K. Rayburn<sup>1</sup>, R.C. Bourge<sup>1</sup>, T. Nielsen<sup>1</sup>, J.K. Kirklin<sup>2</sup><sup>1</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL

**12:45 PM (416)** *Adverse Event (AE) Rates in Patients Receiving Pulsatile VAD's: Incidence and Composition Change Dramatically 3 Months after Implant*; R.L. Kormos<sup>1</sup>, J.J. Teuteberg<sup>1</sup>, J.K. Kirklin<sup>2</sup>, D.C. Naftel<sup>2</sup>, L.W. Stevenson<sup>3</sup>, C.A. Milano<sup>4</sup>, M.A. Miller<sup>5</sup>, F.D. Pagani<sup>6</sup>, J.G. Rogers<sup>4</sup>, K.D. Aaronson<sup>6</sup><sup>1</sup>University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>University of Alabama, Birmingham, Birmingham, AL; <sup>3</sup>Brigham and Women's Medical Center, Boston, MA; <sup>4</sup>Duke University Medical Center, Durham, NC; <sup>5</sup>National Heart, Lung and Blood Institute, Bethesda, MD; <sup>6</sup>University of Michigan Medical Center, Ann Arbor, MI

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 26: Heart Transplantation: Clinical Challenges** (Blue Theatre)

Chairs: William G. Cotts, MD and Nicholas G. Smedira, MD

**11:30 AM (417)** *Combined Organ Transplantation for Familial Amyloidosis*; C.G.A. McGregor<sup>1</sup>, B.S. Edwards<sup>2</sup>, R.C. Daly<sup>1</sup>, J.K. Heimbach<sup>1</sup>, J.A. Dearani<sup>1</sup>, T.M. Sundt<sup>1</sup>, H.M. Burkhart<sup>1</sup>, R.M. Suri<sup>1</sup>, S.J. Park<sup>1</sup>, S.S. Kushwaha<sup>2</sup>, R.P. Frantz<sup>2</sup>, A.L. Clavell<sup>2</sup>, N. Pereira<sup>2</sup>, R.J. Rodeheffer<sup>2</sup><sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Mayo Clinic, Rochester, MN

**11:45 AM (418)** *Should We Retransplant in Early Graft Failure?*; N. Vistarini, C. Pellegrini, M. Aiello, G. Silvaggio, C. Monterosso, B. Cattadori, A.M. D'Armini, M. Viganò Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

**12:00 PM (419)** *Heart Transplantation in HIV Positive Patients*; N. Uriel, U.P. Jorde, V. Cotarlan, P.C. Colombo, M. Farr, S.W. Restino, M.C. Deng, D.M. Mancini Columbia University Medical Center, New York, NY

**12:15 PM (420)** *Low Peak Oxygen Consumption by Cardiopulmonary Stress Testing after Heart Transplantation Predicts Poor Outcome*; K. Lo<sup>1</sup>, K. Kiyosaki<sup>1</sup>, J. Kobashigawa<sup>1</sup>, M. Kawano<sup>1</sup>, A. Ankrom<sup>1</sup>, M. Kittleson<sup>1</sup>, E. Shao<sup>1</sup>, J. Moriguchi<sup>1</sup>, J. Patel<sup>1</sup>, A. Ardehali<sup>2</sup><sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**12:30 PM (421)** *Combined Heart and Liver Transplantation: A Single Center Experience*; E. Raichlin, R.C. Daly, C.B. Rosen, R.P. Frantz, S.S. Kushwaha, A.L. Clavell, R.J. Rodeheffer, N.L. Pereira, W.K. Kremers, B.S. Edwards Mayo Clinic, Rochester, MN

**12:45 PM (422)** *Clinical Outcome of Orthotopic Heart Transplantation for End-Stage Heart Disease Due to Mediastinal Radiation Therapy*; N. Uriel, A. Vainrib, V. Cotarlan, U.P. Jorde, Y. Naka, D.M. Mancini, P.C. Colombo Columbia University Medical Center, New York, NY

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 27: Gastric Aspiration: Pathway to Allograft Injury** (Salle Maillot)

Chairs: Duane Davis, MD and Martin P. Iversen, MD, PhD

**11:30 AM (423)** *Effect of Gastric Juice from Patients "on" Acid Suppressive Therapy (PPI) on Human Bronchial Epithelial Cells*; V. Mertens<sup>1</sup>, K. Blondeau<sup>1</sup>, A. Pauwels<sup>1</sup>, R. Vos<sup>2</sup>, B. Vanaudenaerde<sup>2</sup>, D.E. Van Raemdonck<sup>2,3</sup>, G.M. Verleden<sup>2,3</sup>, D. Sifrim<sup>1</sup>, L.J. Dupont<sup>2,3</sup><sup>1</sup>University Hospital Gasthuisberg, Leuven, Belgium; <sup>2</sup>University Hospital Gasthuisberg, Leuven, Belgium; <sup>3</sup>University Hospital Gasthuisberg, Leuven, Belgium

**11:45 AM (424)** *Temporal Patterns of Lung Pepsin Levels in Allografts Suggest Aspiration Is an Ongoing Injury, Which Can Occur Early Following Lung Transplantation*; R. Stovold<sup>2</sup>, I. Forrest<sup>1</sup>, D. Murphy<sup>1</sup>, G. Johnston<sup>1</sup>, J. Lordan<sup>1</sup>, A. Fisher<sup>1</sup>, J. Dark<sup>1</sup>, P. Corris<sup>1</sup>, J. Pearson<sup>2</sup>, C. Ward<sup>1</sup><sup>1</sup>University of Newcastle, Newcastle upon Tyne, United Kingdom; <sup>2</sup>University of Newcastle, Newcastle upon Tyne, United Kingdom

**12:00 PM (425)** *Gastroesophageal Reflux Disease Increases the Rate of Acute Rejection in Lung Transplant Allografts*; N.S. Shah<sup>1</sup>, K.V. Leeper<sup>1</sup>, K.A. Easley<sup>3</sup>, J. Qian<sup>3</sup>, S.D. Force<sup>4</sup>, A.A. Gal<sup>5</sup>, A.M. Ramirez<sup>1,2</sup>, D.C. Neujahr<sup>1,2</sup>, E.C. Lawrence<sup>1,2</sup>, A. Pelaez<sup>1,2</sup><sup>1</sup>Emory University School of Medicine, Atlanta, GA; <sup>2</sup>Emory University School of Medicine,

Atlanta, GA; <sup>3</sup>Rollins School of Public Health, Atlanta, GA; <sup>4</sup>Emory University School of Medicine, Atlanta, GA; <sup>5</sup>Emory University School of Medicine, Atlanta, GA

**12:15 PM (426) Exhaled Breath Condensate Pepsin Correlates with BAL Pepsin: A Potential Marker of GERD Post Lung Transplantation?**; A. Krishnan<sup>1</sup>, D.H. Yates<sup>1</sup>, S. Chow<sup>2</sup>, M.A. Malouf<sup>1</sup>, M.L. Pliit<sup>1</sup>, A.R. Glanville<sup>1</sup> <sup>1</sup>St.Vincent's Hospital, Sydney, New South Wales, Australia; <sup>2</sup>University of New South Wales, Sydney, NSW, Australia

**12:30 PM (427) Aspiration of Gastric Components in Lung Transplant Recipients: Do Bile Acids Account for the Inflammatory Reaction?**; V. Mertens<sup>1</sup>, K. Blondeau<sup>1</sup>, A. Pauwels<sup>1</sup>, R. Vos<sup>2</sup>, B. Vanaudenaerde<sup>2</sup>, D.E. Van Raemdonck<sup>2,3</sup>, G.M. Verleden<sup>2,3</sup>, D. Sifrim<sup>1</sup>, L.J. Dupont<sup>2,3</sup> <sup>1</sup>University Hospital Gasthuisberg, Leuven, Belgium; <sup>2</sup>University Hospital Gasthuisberg, Leuven, Belgium; <sup>3</sup>University Hospital Gasthuisberg, Leuven, Belgium

**12:45 PM (428) Preoperative Gastroesophageal Reflux Impacts Early Outcomes after Lung Transplantation**; S.C. Murthy<sup>1</sup>, E.R. Nowicki<sup>1</sup>, D.P. Mason<sup>1</sup>, M.M. Budev<sup>2</sup>, A.I. Nunez<sup>1</sup>, L. Thuita<sup>3</sup>, J.T. Chapman<sup>2</sup>, G.B. Pettersson<sup>1</sup>, E.H. Blackstone<sup>1,3</sup> <sup>1</sup>Cleveland Clinic, Cleveland, OH; <sup>2</sup>Cleveland Clinic, Cleveland, OH; <sup>3</sup>Cleveland Clinic, Cleveland, OH

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 28: Steroid Free Immunosuppression: Myth or Reality (252 AB)**

Chairs: David O. Taylor, MD and Maria G. Crespo-Leiro, MD

**11:30 AM Invited Lecture: Steroid Free Immunosuppression: Scientific Rationale**, Lori J. West, MD, D.Phil, Edmonton, Canada

**11:45 AM (429) Alemtuzumab Induction Facilitates Steroid-Free Immunosuppression in Human Cardiac Transplantation – One Year Outcomes**; J.J. Teuteberg<sup>1</sup>, M. Shullo<sup>2</sup>, R. Zomak<sup>3</sup>, J. Bhamra<sup>3</sup>, Y. Toyoda<sup>3</sup>, C. Bermudez<sup>3</sup>, D. McNamara<sup>1</sup>, R.L. Kormos<sup>3</sup>, K. McCurry<sup>3</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>University of Pittsburgh, Pittsburgh, PA; <sup>3</sup>University of Pittsburgh, Pittsburgh, PA

**12:00 PM (430) Alemtuzumab Induction Therapy in Lung Transplantation: Early Outcomes**; K. van Loenhout<sup>1</sup>, S. Groves<sup>2</sup>, S. Moainie<sup>3</sup>, M. Galazka<sup>2</sup>, B. Sherman<sup>3</sup>, S. O'Keefe<sup>3</sup>, C. Wade<sup>3</sup>, E. Britt<sup>2</sup>, S. Lesser<sup>2</sup>, N. Todd<sup>2</sup>, P. van Hal<sup>1</sup>, B. Griffith<sup>3</sup>, A. Iacono<sup>2</sup> <sup>1</sup>Erasmus University, Rotterdam, Netherlands; <sup>2</sup>University of Maryland School of Medicine, Baltimore, MD; <sup>3</sup>University of Maryland School of Medicine, Baltimore, MD

**12:15 PM (431) A Prospective Trial of Steroid Discontinuation in Stable Heart Transplant Patients as Guided by Serum Cortisol Measurement**; D.A. Baran, A. Pillai, A. Patil, S. Pardi, C. Rosenfeld, M. Camacho, M.J. Zucker Newark Beth Israel Medical Center, Newark, NJ

**12:30 PM (432) Peripheral Blood Transcriptomic Signature-Based Corticosteroid Minimization: A Single Center 24-Month Experience**; R.L. Scott, D.L. Kasper, F.A. Arabia, D.E. Steidley, H.D. Tazelaar, C.S. Bachtel, L.A. Lanza, R.S. Gopalan, P.A. DeValeria, D.E. Jaroszewski Mayo Clinic Arizona, Phoenix, AZ

**12:45 PM (433) Does Molecular Diagnostic Testing Offer an Insight in the Differential Effects of Cyclosporine and Tacrolimus on Immune Activation?**; J. Patel<sup>1</sup>, T.M. Rowe<sup>2</sup>, A. Hicks<sup>3</sup>, S.R. Hankins<sup>4</sup>, H.J. Eisen<sup>4</sup> <sup>1</sup>Drexel University, Philadelphia, PA; <sup>2</sup>Hahnemann University Hospital, Philadelphia, PA; <sup>3</sup>Drexel University College of Medicine, Philadelphia, PA; <sup>4</sup>Drexel University College of Medicine, Philadelphia, PA

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 29: Novel Therapeutics Targeting Rejection and Injury (242 AB)**

Chairs: John F. McDyer, MD and James F. George, PhD

**11:30 AM (434) Identifying PKC Epsilon as a Target Molecule To Control Intimal Hyperplasia**; S. Schrepfer<sup>1</sup>, T. Deuse<sup>1</sup>, E. Churchill<sup>2</sup>, T. Koyanagi<sup>2</sup>, R.C. Robbins<sup>1</sup>, D. Mochly-Rosen<sup>2</sup> <sup>1</sup>Stanford University School of Medicine, Stanford, CA; <sup>2</sup>Stanford University School of Medicine, Stanford, CA

**11:45 AM (435) CXCR3 and CCR5 in Acute and Chronic Rejection**; W. Sherman<sup>1</sup>, S. Bastani<sup>1</sup>, G.T. Schnickel<sup>1</sup>, G.R. Hsieh<sup>1</sup>, R. Bhatia<sup>1</sup>, M.C. Fishbein<sup>2</sup>, A. Ardehali<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**12:00 PM (436) Combined Ex Vivo IL-4 and IL-10 Gene Therapy Reduces Chronic Rejection in Cardiac Allografts**; G. Cui<sup>1,2</sup>, H. Furukawa<sup>1</sup>, J. Xu<sup>2</sup>, H. Laks<sup>1</sup>, L. Sen<sup>1,2</sup> <sup>1</sup>David Geffen School of Medicine in UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine in UCLA, Los Angeles, CA

**12:15 PM (437)** *Development of Cyclin Kinase Inhibitor as a Potent Immunosuppressive Drug*; A.K. Khanna OncoDetect Inc., Clarksville, MD

**12:30 PM (438)** *LPS Preconditioning Confers Ischemic Tolerance in the Lung through a MyD88-Independent Pathway*; J.C. Keech, E. Fitzsullivan, P.S. Wolf, H.E. Merry, M.S. Mulligan University of Washington, Seattle, WA

**12:45 PM (439)** *Vasoactive Intestinal Peptide and CD26/Dipeptidyl-Peptidase IV: Influence on Ischemia/Reperfusion-Injury in a Mouse Model of Orthotopic Pulmonary Transplantation*; W. Jungraithmayr<sup>1</sup>, I. De Meester<sup>2</sup>, I. Inci<sup>1</sup>, M. Bain<sup>1</sup>, S. Hillinger<sup>1</sup>, K. Augustyns<sup>2</sup>, S. Arni<sup>1</sup>, S. Scharpe<sup>2</sup>, W. Weder<sup>1</sup>, S. Korom<sup>1</sup><sup>1</sup>University Hospital Zurich, Zurich, Switzerland; <sup>2</sup>University of Antwerp, Antwerp, Belgium

**11:30 AM – 1:00 PM**

**CONCURRENT SESSION 30: Social Support - "The Good, the Bad, and the Lonely"** (241)

Chairs: Annette J. DeVito Dabbs, RN, PhD and Michael Petty, PhD(c), RN, CCNS,CNS

**11:30 AM (440)** *Emotional Experiences of Caregivers of Patients Discharged on Ventricular Assist Device (EECVAD)*; A.F. Kaan, Q. R. Young, S. Cockell, M.H. Mackay St Paul's Hospital, Vancouver, BC, Canada

**11:45 AM (441)** *Return to Work, Education and Social Activities after Lung Transplantation*; D. Delva, A. Schoonis, D. Van Raemdonck, L. Dupont, G. Verleden University Hospitals Leuven, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium

**12:00 PM (442)** *Social Support and Optimism Impact Depression and Caregiver Burden among Organ Transplant Candidates and Their Caregivers*; S. Holtzman<sup>1,2,3</sup>, S.E. Abbey<sup>2,3</sup>, L.G. Singer<sup>2</sup>, H.J. Ross<sup>2</sup>, D.E. Stewart<sup>1,3</sup><sup>1</sup> University Health Network, University of Toronto, Toronto, ON, Canada; <sup>2</sup>University Health Network, University of Toronto, Toronto, ON, Canada; <sup>3</sup>University of Toronto, Toronto, ON, Canada

**12:15 PM (443)** *Social Isolation and Depression as Predictors of 12 Month Outcomes in the Waiting for a New Heart Study*; G. Weidner<sup>1</sup>, H. Spaderna<sup>1</sup>, D. Zahn<sup>1</sup>, J.M.A. Smits<sup>2</sup><sup>1</sup>Johannes Gutenberg University, Mainz, Germany; <sup>2</sup>Eurotransplant International Foundation, Leiden, Netherlands

**12:30 PM (444)** *Does High Risk Status Identified by Pre-Transplant Social Worker and Psychiatric Evaluation Predict Outcome after Heart Transplant?*; E. Moreno<sup>1</sup>, A. Vallecá<sup>1</sup>, J. Patel<sup>1</sup>, M. Kawano<sup>1</sup>, D. Lockhart<sup>1</sup>, S. Montgomery<sup>1</sup>, C. Burch<sup>1</sup>, L. Rangel<sup>1</sup>, T. Kao<sup>1</sup>, K. Kiyosaki<sup>1</sup>, S. Wong<sup>1</sup>, A. Ankrom<sup>1</sup>, L. Ventura<sup>1</sup>, M. Kittleson<sup>1</sup>, J. Moriguchi<sup>1</sup>, E. Shao<sup>1</sup>, A. Ardehali<sup>2</sup>, J.A. Kobashigawa<sup>1</sup><sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**12:45 PM (445)** *The Validation of the STOP-D in Heart Transplant: A One-Minute Screening Tool That Provides Severity Scores for Depression, Anxiety, Stress and Social Support*; Q.-R. Young, A. Kaan, A. Ignaszewski St. Paul's Hospital, Vancouver, BC, Canada

**1:00 PM – 1:30 PM**

**BOX LUNCH PICK-UP** (box lunches may be picked up in the Registration Area; advance purchase and ticket required; lunch seating is available in Salle Maillot and Blue Theater foyers; food and drink are not allowed in the Main Theatre or the Blue Theatre; ticket required for box lunch only; symposium open to all meeting delegates)

**1:30 PM – 2:45 PM**

**MID-DAY SYMPOSIUM: Generics in Thoracic Transplantation: Boon or Bane?** (Main Theater)

Chairs: Keith McNeil, FRACP and Fernando Bacal, MD, PhD

**1:30 PM** Why Worry About Generics? *Patricia A. Uber, Pharm.D, University of Maryland, Baltimore, MD*

**1:45 PM** Perspective from the Americas, *Heather Ross, MD, MHSc, FRCP(c), Toronto General Hospital, Toronto, Ontario, Canada*

**2:00 PM** Perspective from Eurasia, *Andreas O. Zuckermann, MD, University of Vienna, Austria*

**2:15 PM** Does the Pediatric Population Represent a Unique Challenge? *Stuart Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO*

**2:30 PM** Panel Discussion, *Paul Corris, MB, FRCP, Katherine Hoercher, RN, Heather Ross, MD, MHSc, FRCP(c), Stuart Sweet, MD, PhD, Andreas O. Zuckermann, MD, Patricia A. Uber, Pharm.D, and Fernando Bacal, MD, PhD*

**1:15 PM – 2:45 PM**

**FELLOWS LUNCHEON** (Room 243) (pre-registration and ticket required)

**1:15 PM – 2:45 PM**

**Standards and Guidelines Committee Meeting** (Room 273) (bring your own box lunch)

**1:15 PM – 2:45 PM**

**MINI-ORAL SESSION 5** (Blue Theatre)

Chairs: Claus B. Andersen, MD, D.M.Sc and Nancy L. Reinsmoen, PhD, D Abhi

**1:15 PM (446)** *Dynamic Regulation of Micro RNAs in Ischemic Cardiac Remodeling and Heart Failure*; R. Ali, R.W. Kim, G. Tellides, A. Geirsson Yale University School of Medicine, New Haven, CT

**1:20 PM (447)** *Egfl7 Suppresses ICAM-1 Expression in Response to H/R Injury and Tacrolimus*; M.V. Badiwala, R. Zener, L.C. Tumiaty, J.L. Prodger, R. Sheshgiri, V. Rao Toronto General Hospital, Toronto, ON, Canada

**1:25 PM (448)** *Nanotechnology-Based Src Protein Tyrosine Kinase Inhibition To Prevent Lung Reperfusion Injury*; I. Oyaizu, S. Y. Fung, A. Shiozaki, B. Han, S. Keshavjee, M. Liu University Health Network, University of Toronto, Toronto, ON, Canada

**1:30 PM (449)** *Cellular Immunity Is Enhanced in a Non-human Primate Lung Transplantation Model, as Compared to an Analogous Kidney Transplantation Model*; A. Aoyama, C.Y. Ng, T.M. Millington, S. Boskovic, S. Ito, J.C. Wain, S.L. Houser, J.C. Madsen, D.H. Sachs, T. Kawai, J.S. Allan Massachusetts General Hospital and Harvard Medical School, Boston, MA

**1:35 PM (450)** *Increased Endothelial Permeability after Anti-HLA I Administration*; M. Bieri<sup>1</sup>, M. Oroszlan<sup>1</sup>, N. Ligeti<sup>1</sup>, J. Bieri<sup>2</sup>, P. Mohacsi<sup>1</sup> <sup>1</sup>Swiss Cardiovascular Center, University of Bern, Bern, Switzerland; <sup>2</sup>Lindehof Hospital, Bern, Switzerland

**1:40 PM (451)** *A Revisit to the Pathogenesis of Allograft Fibrosis: Intra-graft Fibroblasts Derive from Heterogeneous Progenitors*; G. Wu, Y. He, H. Wang, A.S. Klein Cedars-Sinai Medical Center, Los Angeles, CA

**1:45 PM (452)** *Brain Stem Death Induced Pulmonary Hypertension and Bronchiole Damage in an Ovine Model*; J. Fraser<sup>1</sup>, M. Nataatmadja<sup>2</sup>, M. Passmore<sup>2</sup>, K. Dunster<sup>1</sup>, F. Kermeen<sup>1</sup> <sup>1</sup>Prince Charles Hospital, Brisbane, Queensland, Australia; <sup>2</sup>University of Queensland, Brisbane, Queensland, Australia

**1:50 PM (453)** *Fresh and Cryopreserved Vascular Allografts Suppress Methicillin-Resistant Staphylococcus aureus Proliferation Via Indoleamine 2,3-Dioxygenase (IDO) Expression*; E.E. Karimov<sup>1</sup>, N. Motomura<sup>1</sup>, K. Sakuta<sup>2</sup>, K. Kakimi<sup>2</sup>, K. Narui<sup>3</sup>, N. Noguchi<sup>3</sup>, S. Takamoto<sup>1</sup> <sup>1</sup>Graduate School of Medicine of the University of Tokyo, Tokyo, Japan; <sup>2</sup>Graduate School of Medicine of the University of Tokyo, Tokyo, Japan; <sup>3</sup>Tokyo University of Pharmacy and Life Science, Tokyo, Japan

**1:55 PM (454)** *Targeting Lymphatic Vessel CCL21 Production by VEGFR-3 Inhibition Prevents Cardiac Allograft Rejection and Arteriosclerosis*; A.I. Nykanen<sup>1</sup>, H. Sandelin<sup>1</sup>, R. Krebs<sup>1</sup>, M.A.I. Keranen<sup>1</sup>, R. Tuuminen<sup>1</sup>, T. Karpanen<sup>2</sup>, Y. Wu<sup>3</sup>, B. Pytowski<sup>3</sup>, P.K. Koskinen<sup>1</sup>, S. Yla-Herttuala<sup>4</sup>, K. Alitalo<sup>2</sup>, K.B. Lemstrom<sup>1</sup> <sup>1</sup>University of Helsinki, Helsinki, Finland; <sup>2</sup>University of Helsinki, Helsinki, Finland; <sup>3</sup>ImClone, New York, NY; <sup>4</sup>University of Kuopio, Kuopio, Finland

**2:00 PM (455)** *Surgical Repair of Gastroesophageal Reflux in Lung Transplant Recipients Is Associated with Decreased Armed Effector T Cells and Increased Exhausted T Cells within the Allograft*; D.C. Neujahr<sup>1</sup>, A. Pelaez<sup>1</sup>, A. Ramirez<sup>1</sup>, S.D. Force<sup>2</sup>, E.C. Lawrence<sup>1</sup>, A.C. Cardona<sup>1</sup>, A.D. Kirk<sup>2</sup>, C.P. Larsen<sup>2</sup> <sup>1</sup>Emory University, Atlanta, GA; <sup>2</sup>Emory University, Atlanta, GA

**2:05 PM (456)** *Preclinical Orthotopic Cardiac Xenotransplantation*; C.G.A. McGregor<sup>1</sup>, G.W. Byrne<sup>1</sup>, M. Vlasin<sup>1</sup>, R.C. Walker<sup>2</sup>, H.D. Tazelaar<sup>1</sup>, W.R. Davies<sup>1</sup>, K. Chandrasekaran<sup>2</sup>, E.A. Oehler<sup>2</sup>, B.A. Boilson<sup>2</sup>, B.S. Wiseman<sup>1</sup>, J.S. Logan<sup>1</sup> <sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Mayo Clinic, Rochester, MN

**2:10 PM (457)** *Regulation of the RNA Inhibition Component Dicer in Lung Transplant Rejection*; M. Keplinger<sup>1</sup>, P. Jaksch<sup>1</sup>, B. Zweytick<sup>1</sup>, B. Ghanim<sup>1</sup>, W. Klepetko<sup>1</sup>, G. Dekan<sup>2</sup>, A. Soleiman<sup>2</sup> <sup>1</sup>General Hospital of Vienna, Vienna, Austria; <sup>2</sup>General Hospital of Vienna, Vienna, Austria

**2:15 PM (458) Nodular Inflammatory Infiltrates with B-Lymphocytes: Incidence in Heart Allograft Biopsies;** D.M. Lam-Himlin, C. Sailey, A.P. Burke University of Maryland Medical Center, Baltimore, MD

**2:20 PM (459) Altered Micro-RNA Expression in the Heart after LVAD Support;** H.F.J. Dullens<sup>1</sup>, J. van Kuik<sup>1</sup>, M.E.I. Schipper<sup>1</sup>, N. de Jonge<sup>2</sup>, R.A. de Weger<sup>1</sup> <sup>1</sup>University Medical Center Utrecht, Utrecht, Netherlands; <sup>2</sup>University Medical Center Utrecht, Utrecht, Netherlands

**2:25 PM (460) Aortic Xeno-Transplantation for Tracheal Replacement: Mechanistical Analysis of Tissue Metaplasia;** S.P. Salzberg, M.Y. Emmert, K. von Harbou, J. Fallon, D.H. Adams Mount Sinai Medical Center, New York

**2:30 PM (461) Intragraft Authentication of Peripheral Transcriptomic Molecular Biomarkers for Cardiac Allograft Rejection;** M.R. Mehra, J. Xu, P.A. Uber, C. Baquet, A. Khanna University of Maryland School of Medicine, Baltimore, MD

**1:15 PM – 2:45 PM**

**MINI-ORAL SESSION 6 (252 AB)**

Chairs: Mazen A. Hanna, MD and Bruno M. Meiser, MD

**1:15 PM (462) Long-Term Effects of Sildenafil on Pulmonary Pressures and Right Heart Function in Heart Transplant Recipients;** J.E. Wilcox, W.G. Cotts, S. Zeigler, P. Kansal, J.B. O'Connell, K.L. Grady, G. Ferguson, E.C. McGee, L. Klein Northwestern University Feinberg School of Medicine, Chicago, IL

**1:20 PM (463) Addressing the Myth of Elevated Bilirubin as a Contraindication to Heart Transplantation;** J. Patel<sup>1</sup>, M. Kawano<sup>1</sup>, K. Kiyosaki<sup>1</sup>, E. Shao<sup>1</sup>, A. Ankrom<sup>1</sup>, M. Kittleson<sup>1</sup>, J. Moriguchi<sup>1</sup>, A. Ardehali<sup>2</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**1:25 PM (464) The AlloMap Test Fails To Distinguish between Quilty Lesions and Acute Allograft Rejection in Heart Transplant Patients;** R.M. Kabad<sup>1</sup>, B. Ebert<sup>1</sup>, C. Flannagan<sup>1</sup>, J.L. Farber<sup>2</sup>, P.J. Mather<sup>1</sup> <sup>1</sup>Thomas Jefferson University Hospital, Philadelphia, PA; <sup>2</sup>Thomas Jefferson University Hospital, Philadelphia, PA

**1:30 PM (465) Cellular Changes Associated with Increased Left Ventricular Mass Following Cardiac Transplantation;** D.V. Miller<sup>1</sup>, R.J. Rodeheffer<sup>2</sup>, S.S. Kushwaha<sup>2</sup>, R.P. Frantz<sup>2</sup>, A.L. Clavell<sup>2</sup>, N.L. Pereira<sup>2</sup> <sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Mayo Clinic, Rochester, MN

**1:35 PM (466) Long-Term Effects of the Selective I<sub>f</sub> Channel Antagonist Ivabradine in Stable Patients after Heart Transplantation;** A.O. Doesch<sup>1</sup>, K. Ammon<sup>1</sup>, M. Konstandin<sup>1</sup>, S. Celik<sup>1</sup>, L. Frankenstein<sup>1</sup>, B. Sebastian<sup>1</sup>, F.-U. Sack<sup>2</sup>, H.A. Katus<sup>1</sup>, T.J. Dengler<sup>1</sup> <sup>1</sup>University of Heidelberg, Heidelberg, Germany; <sup>2</sup>University of Heidelberg, Heidelberg, Germany

**1:40 PM (467) Microvasculopathy Precedes Epicardial Coronary Stenosis in Heart Transplant Patients with Cardiac Allograft Vasculopathy;** F. Tona<sup>1</sup>, E. Osto<sup>1</sup>, G. Tarantini<sup>1</sup>, M. Napodano<sup>1</sup>, A. Gambino<sup>2</sup>, A. Vinci<sup>1</sup>, A. Ramondo<sup>1</sup>, G. Gerosa<sup>2</sup>, A.L.P. Caforio<sup>1</sup>, S. Iliceto<sup>1</sup> <sup>1</sup>University of Padova, Padova, Italy; <sup>2</sup>University of Padova, Padova, Italy

**1:45 PM (468) Microvascular Dysfunction and Suboptimal Glycemic Control Predicts Poor Outcome Following Heart Transplantation;** P. Khazanie<sup>1</sup>, F. Haddad<sup>2</sup>, A.M. Simos<sup>3</sup>, D.M. Weisshaar<sup>4</sup>, S.V. Desai<sup>2</sup>, M. Pham<sup>2</sup>, T.L. McLaughlin<sup>5</sup>, M.G. Shah<sup>2</sup>, S.A. Hunt<sup>2</sup>, H.A. Valentine<sup>2</sup>, W. Fearon<sup>2</sup> <sup>1</sup>Stanford University, Stanford, CA; <sup>2</sup>Stanford University, Stanford, CA; <sup>3</sup>Stanford University, Stanford, CA; <sup>4</sup>Kaiser Permanente- Santa Clara, Santa Clara, CA; <sup>5</sup>Stanford University, Stanford, CA

**1:50 PM (469) Increased Incidence of Acute Graft Rejection on CNI-Free Immunosuppression after Heart Transplantation;** S. Celik<sup>1</sup>, T.J. Dengler<sup>1</sup>, A.O. Doesch<sup>1</sup>, M.H. Konstandin<sup>1</sup>, A.V. Kristen<sup>1</sup>, F.-U. Sack<sup>2</sup>, P. Schnabel<sup>3</sup>, H.A. Katus<sup>1</sup> <sup>1</sup>Med III, Heidelberg, Ba-Wü, Germany; <sup>2</sup>Cardiac Surgery, Heidelberg, Ba-Wü, Germany; <sup>3</sup>Pathology, Heidelberg, Ba-Wü, Germany

**1:55 PM (470) Patient-Specific Longitudinal Patterns of AlloMap Test Scores – Path towards Personalized Medicine?;** M.C. Deng<sup>1</sup>, B. Halpern<sup>2</sup>, H. Wolters<sup>2</sup>, M. Cadeiras<sup>1</sup>, A. Hicks<sup>3</sup>, T. Rowe<sup>3</sup>, K. Shahzad<sup>1</sup>, T. Klingler<sup>2</sup>, H.J. Eisen<sup>3</sup> <sup>1</sup>Columbia University Medical Center, New York, NY; <sup>2</sup>XDx, South San Francisco, CA; <sup>3</sup>Drexel University College of Medicine, Philadelphia, PA

**2:00 PM (471) Outcome of Heart Transplantation with Preoperative Prophylactic Approach for Sensitized Recipients with Donor Specific Antibodies;** S. Saheb<sup>1</sup>, S. Varnous<sup>2</sup>, C. Suberbielle Boissel<sup>3</sup>, R. Makri<sup>4</sup>, C.E. Luyt<sup>5</sup>, N. Azar<sup>1</sup>, F. Fernandez<sup>2</sup>, E. Vaissier<sup>4</sup>, A. Pavie<sup>2</sup>, P. Leprince<sup>2</sup> <sup>1</sup>UPMC, APHP, Pitié Salpêtrière, Paris, France; <sup>2</sup>UPMC, APHP, Pitié

Salpêtrière, Paris, France; <sup>3</sup>St Louis Hospital, Paris, France; <sup>4</sup>UPMC, APHP, Pitié Salpêtrière, Paris, France; <sup>5</sup>UPMC, APHP, Pitié Salpêtrière, Paris, France

**2:05 PM (472) *The Problem of Rejection in Redo Heart Transplant Recipients***; E. Shao<sup>1</sup>, M. Kawano<sup>1</sup>, J. Patel<sup>1</sup>, M. Kittleson<sup>1</sup>, A. Ankrom<sup>1</sup>, K. Kiyosaki<sup>1</sup>, J. Moriguchi, A. Ardehali<sup>2</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**2:10 PM (473) *Inter-Observer Variability in the Interpretation of Cardiac Biopsies Remains a Challenge: Results of the Cardiac Allograft Rejection Gene Expression Observational (CARGO) II Study***; M.G. Crespo-Leiro<sup>1</sup>, U. Schulz<sup>2</sup>, J. Vanhaecke<sup>3</sup>, A. Zuckermann<sup>4</sup>, C. Bara<sup>5</sup>, P. Mohacsi<sup>6</sup>, R.C. Bogaev<sup>7</sup>, A. Boyle<sup>8</sup>, H. Ross<sup>9</sup>, J. Parameshwar<sup>10</sup>, M. Zakliczynski<sup>11</sup>, R. Fiocchi<sup>12</sup>, J. Stypmann<sup>13</sup>, D. Hoefler<sup>14</sup>, H. Lehmkühl<sup>15</sup>, M.C. Deng<sup>16</sup>, P. Leprince<sup>17</sup>, G. Berry<sup>18</sup>, C.C. Marboe<sup>19</sup>, S. Stewart<sup>20</sup>, H.D. Tazelaar<sup>21</sup>, M. Brown<sup>22</sup> <sup>1</sup>Complejo Hospitalario Universitario Juan Canalejo, La Coruña, Spain; <sup>2</sup>Heart and Diabetes Center North Rhine-Westphalia, Ruhr University of Bochum, Bad Oeynhausen, Germany; <sup>3</sup>University Hospital of Leuven, Leuven, Belgium; <sup>4</sup>Medical University of Vienna, Vienna, Austria; <sup>5</sup>Hannover Medical School, Hannover, Germany; <sup>6</sup>University Hospital Bern, Bern, Switzerland; <sup>7</sup>Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX; <sup>8</sup>University of Minnesota, Minneapolis, MN; <sup>9</sup>Toronto General Hospital, Toronto, Canada; <sup>10</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>11</sup>Silesian Center for Heart Disease, Zabrze, Poland; <sup>12</sup>Ospedali Riuniti di Bergamo, Bergamo, Italy; <sup>13</sup>Hospital of the University of Münster, Münster, Germany; <sup>14</sup>Innsbruck Medical University, Innsbruck, Austria; <sup>15</sup>Deutsches Herzzentrum, Berlin, Germany; <sup>16</sup>Columbia University College of Physicians Surgeons, New York, NY; <sup>17</sup>Groupe Hospitalier Pitié-Salpêtrière, Paris, France; <sup>18</sup>Stanford University Medical Center, Stanford, CA; <sup>19</sup>College of Physicians Surgeons of Columbia University, New York, NY; <sup>20</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>21</sup>Mayo Clinic, Scottsdale, AZ; <sup>22</sup>XDx, Inc., Brisbane, CA

**2:15 PM (474) *Combinatorial Diagnostic Biomarkers of Acute Cardiac Allograft Rejection***; Z. Hollander<sup>1</sup>, G. Cohen Freue<sup>2</sup>, D. Lin<sup>3</sup>, A. Ignaszewski<sup>4</sup>, C. Imai<sup>4</sup>, A. Kaan<sup>4</sup>, J. Wilson-McManus<sup>3</sup>, R. Balshaw<sup>2</sup>, R.T. Ng<sup>5</sup>, R.W. McMaster<sup>6</sup>, P. Keown<sup>4</sup>, B.M. McManus<sup>3</sup> <sup>1</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>2</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>3</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>4</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>5</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>6</sup>The University of British Columbia, Vancouver, BC, Canada

**2:20 PM (475) *Allomap and ImmuKnow – Can They Partner for Post Cardiac Transplant Management?***; M. Mathur<sup>2</sup>, C.P. Flanagan<sup>1</sup>, E.A. Barbara<sup>1</sup>, P.J. Mather<sup>1</sup> <sup>1</sup>Thomas Jefferson University Hospital, Philadelphia, PA; <sup>2</sup>Jefferson Medical College, Philadelphia, PA

**2:25 PM (476) *Virtual Cross-Matching in Heart Transplantation: Large Scale Simulation of Survival after Heart Transplantation Using Artificial Neural Networks***; J. Nilsson<sup>1</sup>, M. Ohlsson<sup>2</sup>, P. Hoglund<sup>3</sup>, B. Ekmehag<sup>4</sup>, B. Koul<sup>1</sup> <sup>1</sup>Institution for Clinical Science, Lund, Sweden; <sup>2</sup>Institution for Theoretical Physics, Lund, Sweden; <sup>3</sup>Institution for Clinical Science, Lund, Sweden; <sup>4</sup>Institution for Clinical Science, Lund, Sweden

**2:30 PM (477) *Whole Blood Genomic Predictive Biomarkers of Acute Cardiac Allograft Rejection***; Z. Hollander<sup>1</sup>, D. Lin<sup>2</sup>, G. Cohen Freue<sup>3</sup>, R. Balshaw<sup>3</sup>, R.T. Ng<sup>4</sup>, J. Wilson-McManus<sup>2</sup>, A. Mui<sup>5</sup>, R.W. McMaster<sup>6</sup>, P. Keown<sup>7</sup>, B.M. McManus<sup>2</sup> <sup>1</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>2</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>3</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>4</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>5</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>6</sup>The University of British Columbia, Vancouver, BC, Canada; <sup>7</sup>The University of British Columbia, Vancouver, BC, Canada

**1:15 PM – 2:45 PM**

**MINI-ORAL SESSION 7 (242 AB)**

Chairs: Arnt E. Fiene, MD and Charles E. Canter, MD

**1:15 PM (478) *Impact of Panel-Reactive Antibodies on Long-Term Outcome in Pediatric Heart Transplant Patients: An Analysis of the United Network of Organ Sharing Database***; J.W. Rossano<sup>1</sup>, D.L. Morales<sup>2</sup>, S.W. Denfield<sup>1</sup>, F. Zafar<sup>2</sup>, J.L. Jefferies<sup>1</sup>, J.J. Kim<sup>1</sup>, J.S. Heinle<sup>2</sup>, J.A. Towbin<sup>1</sup>, W.J. Dreyer<sup>1</sup> <sup>1</sup>Texas Children's Hospital/Baylor College of Medicine, Houston, TX; <sup>2</sup>Baylor College of Medicine, Houston, TX

**1:20 PM (479) *Association between Donor-Specific HLA Antibodies and Adverse Outcome Following Pediatric Cardiac Transplantation***; C. Irving, A. Hasan, V. Carter, A. Gennery, G. Parry, R. Kirk Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom

**1:25 PM (480) *Is HLA Sensitization after Pediatric Thoracic Transplantation Age-Dependent?***; S. Urschel<sup>1</sup>, S.R. Meyer<sup>2</sup>, I. Larson<sup>1</sup>, K. Derkatz<sup>1</sup>, K. Tinckam<sup>3</sup>, J. Nuebel<sup>4</sup>, J. Birnbaum<sup>4</sup>, P.M. Campbell<sup>5</sup>, L.J. West<sup>1</sup> <sup>1</sup>University of Alberta, Edmonton,

AB, Canada; <sup>2</sup>University of Alberta, Edmonton, AB, Canada; <sup>3</sup>University of Toronto, Toronto, ON, Canada; <sup>4</sup>Ludwig Maximilians University, Munich, Germany; <sup>5</sup>University of Alberta, Edmonton, AB, Canada

**1:30 PM (481)** *Heart Transplantation Survival in Infants with Congenital Heart Disease with and without Prior Surgery (ws/wos): A Multi-Institutional Study*; G.J. Boyle<sup>1</sup>, K.J. Guleserian<sup>2</sup>, J. Zheng<sup>3</sup>, K. Schechtman<sup>3</sup>, M.D. Everitt<sup>4</sup>, C.M. Nasman<sup>1</sup>, C.E. Canter<sup>5</sup> <sup>1</sup>Children's Hospital, Cleveland Clinic, Cleveland, OH; <sup>2</sup>UT Southwestern Medical Center Children's Medical Center, Dallas, TX; <sup>3</sup>Washington University, St. Louis, MO; <sup>4</sup>University of Utah, Salt Lake City, UT; <sup>5</sup>Washington University, St. Louis, MO

**1:35 PM (482)** *Era Effect on Early and Conditional Survival Adjusted for Baseline Risk Factors in Pediatric Heart Transplant Recipients*; T.P. Singh<sup>1</sup>, L.B. Edwards<sup>2</sup>, M.M. Boucek<sup>3</sup> <sup>1</sup>Children's Hospital Boston, Boston, MA; <sup>2</sup>ISHLT Registry, Richmond, VA; <sup>3</sup>Joe DiMaggio Children's Hospital, Hollywood, FL

**1:40 PM (483)** *Everolimus in Pediatric Heart Transplantation: Report on Efficacy, Pharmacokinetics and Safety in Infants below the Age of 1 Year*; H. Lehmkuhl, S. Schubert, M. Dandel, C. Knosalla, M. Hubler, O. Grauhan, R. Hetzer Deutsches Herzzentrum Berlin, Berlin, Germany

**1:45 PM (484)** *Use of Everolimus in Pediatric Patients after Heart Transplantation: A Single Center Experience*; F.I. Calo Carducci<sup>1</sup>, G. Grutter<sup>2</sup>, P. D'Argenio<sup>1</sup>, F. Parisi<sup>2</sup> <sup>1</sup>Pediatric Hospital "Bambino Gesù", Rome, Italy; <sup>2</sup>Pediatric Hospital "Bambino Gesù", Rome, Italy

**1:50 PM (485)** *Association of Socioeconomic Status with Graft Failure in Pediatric Heart Transplant Recipients: Analysis from Pediatric Heart Transplant Study*; T.P. Singh<sup>1</sup>, D.C. Naftel<sup>2</sup>, L. Addonizio<sup>3</sup>, W. Mahle<sup>4</sup>, M.T. Foushee<sup>2</sup>, S. Zangwill<sup>5</sup>, E.D. Blume<sup>1</sup>, J.K. Kirklin<sup>2</sup>, R. Chinnock<sup>6</sup> <sup>1</sup>Children's Hospital Boston, Boston, MA; <sup>2</sup>University of Alabama, Birmingham, AL; <sup>3</sup>Columbia University, New York, NY; <sup>4</sup>Emory University, Atlanta, GA; <sup>5</sup>Children's Hospital Wisconsin, Milwaukee, WI; <sup>6</sup>Loma Linda University Medical Center, Loma Linda, CA

**1:55 PM (486)** *Cystic Fibrosis Is an Independent Risk Factor for the Development of Bronchiolitis Obliterans Syndrome in Pediatric Lung Transplant Recipients*; N.P. Varghese<sup>1</sup>, M.G. Schecter<sup>1</sup>, J.S. Heinle<sup>2</sup>, D.L. Morales<sup>2</sup>, E. O'Brian Smith<sup>1</sup>, G.B. Mallory<sup>1</sup>, O. Elidemir<sup>1</sup> <sup>1</sup>Baylor College of Medicine, Houston, TX; <sup>2</sup>Baylor College of Medicine, Houston, TX

**2:00 PM (487)** *Waitlist Mortality among Children under 12 Years of Age Listed for Lung Transplantation in the United States*; F. Fynn-Thompson, G. Visner, K. Gauvreau, G.E. Piercey, D. Boyer, C. Lillehei, T.P. Singh, C.S. Almond Children's Hospital Boston, Boston

**2:05 PM (488)** *Exercise Stress Tests in Children with Heart Failure: Peak Oxygen Consumption and Endurance Correlate with Adverse Cardiac Events*; E. Pahl<sup>1</sup>, J. Devries<sup>1</sup>, K. Ward<sup>1</sup>, E. Trapp<sup>1</sup>, K. Lazewski<sup>1</sup>, C. Sullivan<sup>2</sup> <sup>1</sup>Children's Memorial Hospital, Chicago, IL; <sup>2</sup>Children's Memorial Research Center, Chicago, IL

**2:10 PM (489)** *Maintenance Immunosuppression with Mycophenolate Mofetil: Long-Term Efficacy and Safety after Heart Transplantation*; M. Dandel, H.B. Lehmkuhl, R. Jasaityte, C. Knosalla, R. Hetzer Deutsches Herzzentrum Berlin, Berlin, Germany

**2:15 PM (490)** *Prolonged Immunosuppression with Anti-CD25 Monoclonal Antibodies in Long-Term Heart Transplant Patients*; M. Cantarovich, N. Giannetti, J.-P. Routy, R. Cecere, J. Barkun McGill University Health Center, Montreal, QC, Canada

**2:20 PM (491)** *Sirolimus Based Immunosuppression Improves Coronary Endothelial and Vasomotor Function Compared to Calcineurin-Inhibitors in Stable Cardiac Transplant Recipients*; E. Raichlin<sup>1</sup>, A. Prasad<sup>2</sup>, W.K. Kremers<sup>3</sup>, B.S. Edwards<sup>4</sup>, R.S. Charanjit<sup>5</sup>, A. Lerman<sup>6</sup>, S.S. Kushwaha<sup>7</sup> <sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Mayo Clinic, Rochester, MN; <sup>3</sup>Mayo Clinic, Rochester, MN; <sup>4</sup>Mayo Clinic, Rochester, MN; <sup>5</sup>Mayo Clinic, Rochester, MN; <sup>6</sup>Mayo Clinic, Rochester, MN; <sup>7</sup>Mayo Clinic, Rochester, MN

**2:25 PM (492)** *New Tools for Tacrolimus (Tac) Dose Optimization in Lung Transplant Recipients during the First Post-Transplant Year: Preliminary Results of STIMMUGREP Study*; C. Monchaud<sup>1,2</sup>, M. Estenne<sup>3</sup>, M. Reynaud-Gaubert<sup>4</sup>, C. Pison<sup>5</sup>, M. Stern<sup>6</sup>, R. Kessler<sup>7</sup>, C. Dromer<sup>8</sup>, R. Guillemain<sup>9</sup>, A. Rousseau<sup>1</sup>, P. Marquet<sup>1,2</sup> <sup>1</sup>Univ Limoges, Limoges, France; <sup>2</sup>CHU Limoges, Limoges, France; <sup>3</sup>Erasmus University Hospital, Université Libre de Bruxelles, Brussels, Belgium; <sup>4</sup>Hôpital Ste Marguerite, Marseille, France; <sup>5</sup>CHU Grenoble, Univ Grenoble, Grenoble, France; <sup>6</sup>Hôpital Foch, Suresnes, France; <sup>7</sup>Hôpitaux Universitaires de Strasbourg, Strasbourg, France; <sup>8</sup>Hôpital du Haut-Lévêque, CHU Bordeaux, Pessac, France; <sup>9</sup>Hôpital European Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France



**2:30 PM (493) Ex-Vivo Repair of Donor Pig-Lungs Damaged by Aspiration;** S. Wipper, L. Janna, A. Dupree, C. Pahrman, H. Reichenspurner, F.M. Wagner University Heart Center Hamburg, Hamburg, Germany

**1:15 PM – 2:45 PM**

**MINI-ORAL SESSION 8 (241)**

Chairs: Marie M. Budev, DO, MPH and David S. Feldman, MD

**1:15 PM (494) Changing Trends in Infectious Complications among Heart Transplant Recipients;** F. Haddad<sup>1</sup>, T. Deuse<sup>2</sup>, F. Rosso<sup>3</sup>, M. Pham<sup>1</sup>, P. Khazanie<sup>4</sup>, H. Luikart<sup>1</sup>, H.A. Valantine<sup>1</sup>, S.A. Hunt<sup>1</sup>, T. Vu<sup>1</sup>, P.E. Oyer<sup>2</sup>, R.C. Robbins<sup>2</sup>, J.G. Montoya<sup>3</sup> <sup>1</sup>Stanford University, Stanford, CA; <sup>2</sup>Stanford University, Stanford, CA; <sup>3</sup>Stanford University, Stanford, CA; <sup>4</sup>Stanford University, Stanford, CA

**1:20 PM (495) You Are What You Eat or the Fatter the Better? Obesity as Risk Factor in Cardiac Transplant Recipients;** S.L. Mahr, D. Dunkler, M. Groemmer, A. Aliabadi, D. Zimpfer, M. Grimm, E. Wolner, A.O. Zuckermann Medical University of Vienna, Vienna, Austria

**1:25 PM (496) Perfusion MRI Lacks Sensitivity in the Detection of Cardiac Allograft Vasculopathy;** S. Petros<sup>1</sup>, R. Wilson<sup>1</sup>, G. Raveendran<sup>1</sup>, M. Pritzker<sup>1</sup>, J. Connett<sup>2</sup>, M. Colvin-Adams<sup>1</sup> <sup>1</sup>University of Minnesota, Minneapolis, MN; <sup>2</sup>University of Minnesota, Minneapolis, MN

**1:30 PM (497) Incidence and Underlying Cause of Anemia in Cardiac Transplant Recipients Treated with Sirolimus;** A. Almasood, F. Gustafsson, D. Barth, D. Delgado, S. Kozusko, H. Ross Toronto General Hospital, Toronto, ON, Canada

**1:35 PM (498) Prognostic Value of the Sequential Organ Failure Assessment Score (SOFA) for Early Postoperative Monitoring of Heart Transplanted Patients;** N. Qedra, K. Yilmaz, T. Gromann, H. Lehmkuhl, C. Knosalla, R. Hetzer German Heart Institute Berlin (DHZB), Berlin, Germany

**1:40 PM (499) Acute Rejection and Survival Following Late Replacement of CNIs with an mTOR Inhibitor Plus MMF after Heart Transplantation;** M.G. Crespo-Leiro, M.J. Paniagua-Martin, R. Franco-Gutierrez, J.P. Abugattas, C. Naya-Leira, Z. Grille, J.A. Rodriguez, I. Outeda, N. Vazquez-Gonzalez, A. Juffe-Stein, A. Castro-Beiras Complejo Hospitalario Universitario Juan Canalejo, La Coruña, Spain

**1:45 PM (500) Influence of Reinnervation after Heart Transplantation on Coronary Allograft Vasculopathy and Cardiovascular Death;** J. Segovia, J.M. Barcelo, M. Gomez-Bueno, J.C. Gallego-Page, M. Cobo, J. Mirelis, P. Garcia-Pavia, L. Alonso-Pulpon Hospital Universitario Puerta de Hierro, Madrid, Spain

**1:50 PM (501) CMV Infection in the New Millennium;** A.Z. Aliabadi<sup>1</sup>, C. Bauer<sup>2</sup>, H. Kerschner<sup>2</sup>, D. Dunkler<sup>1</sup>, M. Groemmer<sup>1</sup>, S.L. Mahr<sup>1</sup>, D. Zimpfer<sup>1</sup>, M. Grimm<sup>1</sup>, E. Wolner<sup>1</sup>, T. Popow-Kraupp<sup>2</sup>, A.O. Zuckermann<sup>1</sup> <sup>1</sup>Medical University of Vienna, Vienna, Austria; <sup>2</sup>Medical University of Vienna, Vienna, Austria

**1:55 PM (502) CMVIG Decreases the Risk of Cytomegalovirus Infection but Not Disease after Pediatric Lung Transplantation;** L. Danziger-Isakov<sup>1</sup>, M.G. Michaels<sup>2</sup>, K. Ranganathan<sup>1</sup>, S. Worley<sup>1</sup>, S. Arrigain<sup>1</sup>, P. Aurora<sup>3</sup>, M. Ballman<sup>4</sup>, D. Boyer<sup>5</sup>, C. Conrad<sup>6</sup>, I. Eichler<sup>7</sup>, O. Elidemir<sup>8</sup>, S. Goldfarb<sup>9</sup>, G.B. Mallory, Jr.<sup>8</sup>, P.J. Mogayzel, Jr.<sup>10</sup>, D. Parakininkas<sup>11</sup>, M. Solomon<sup>12</sup>, G. Visner<sup>5</sup>, S. Sweet<sup>13</sup>, A. Faro<sup>13</sup> <sup>1</sup>Cleveland Clinic, Cleveland; <sup>2</sup>University of Pittsburgh, Pittsburgh; <sup>3</sup>Great Ormond Street Hospital, London, United Kingdom; <sup>4</sup>Hannover Medical School, Hannover, Germany; <sup>5</sup>Harvard University, Boston; <sup>6</sup>Stanford University, Palo Alto; <sup>7</sup>Medical University Vienna, Vienna, Austria; <sup>8</sup>Baylor College of Medicine, Houston; <sup>9</sup>Children's Hospital of Philadelphia, Philadelphia; <sup>10</sup>The Johns Hopkins Medical Institutions, Baltimore; <sup>11</sup>Medical College of Wisconsin, Milwaukee; <sup>12</sup>Hospital for Sick Children, Toronto, Canada; <sup>13</sup>Washington University School of Medicine, St. Louis

**2:00 PM (503) A Prophylaxis-Free Strategy for the Management of CMV Infection after Thoracic Organ Transplantation (TOTx);** P. Vitulo<sup>1</sup>, A. Bertani<sup>2</sup>, S. Soresi<sup>1</sup>, C. Mina<sup>3</sup>, F. Clemenza<sup>3</sup>, C. Falletta<sup>3</sup>, B.G. Gridelli<sup>4</sup> <sup>1</sup>ISMETT-UPMC, Palermo, Italy; <sup>2</sup>ISMETT-UPMC, Palermo, Italy; <sup>3</sup>ISMETT-UPMC, Palermo, Italy; <sup>4</sup>ISMETT-UPMC, Palermo, Italy

**2:05 PM (504) The Efficacy of Shorter Duration CMV Prophylaxis after Heart Transplantation;** J. Patel<sup>1</sup>, B. Kubak<sup>2</sup>, M. Kawano<sup>1</sup>, A. Ankrom<sup>1</sup>, M. Yajnik<sup>1</sup>, K. Kiyosaki<sup>1</sup>, M. Kittleson<sup>1</sup>, J. Moriguchi<sup>1</sup>, A. Ardehali<sup>3</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>3</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**2:10 PM (505) CMV Infection after Heart Transplantation (HT) Occurs in the Setting of Prolonged Valganciclovir (VGC) Prophylaxis (Proph);** V. Stosor<sup>1,4</sup>, M. Angarone<sup>1</sup>, K. Scarsi<sup>1</sup>, T. Zembower<sup>1</sup>, M. Ison<sup>1,4</sup>, E. McGee<sup>3</sup>, K. Grady<sup>3</sup>, W. Cotts<sup>2</sup> <sup>1</sup>Northwestern University Feinberg School of Medicine, Chicago, IL; <sup>2</sup>Northwestern University Feinberg School of

Medicine, Chicago, IL; <sup>3</sup>Northwestern University Feinberg School of Medicine, Chicago, IL; <sup>4</sup>Northwestern University Feinberg School of Medicine, Chicago, IL

**2:15 PM (506) ADAMTS 13 Activity in Patients with Suspected Thrombotic Microangiopathy (TMA) after Lung Transplantation;** A.C. Metivier<sup>1</sup>, G. Biondi<sup>1</sup>, A. Veyradier<sup>2</sup>, A. Geoffroy<sup>3</sup>, S. Lasocki<sup>3</sup>, E. Azoulay<sup>4</sup>, G. Dauriat<sup>1</sup>, O. Brugiere<sup>1</sup>, M. Fournier<sup>1</sup>, H. Mal<sup>1</sup> <sup>1</sup>Hopital Bichat, Paris, France; <sup>2</sup>Hopital Bécélère, Paris, France; <sup>3</sup>Hopital Bichat, Paris, France; <sup>4</sup>Hopital Saint Louis, Paris, France

**2:20 PM (507) Voriconazole Use Increases the Incidence of Skin Cancer in Lung Transplant Recipients;** A.A. Feist<sup>1</sup>, S.L. Osborne<sup>2</sup>, P.A. Thistlethwaite<sup>3</sup>, M. Madani<sup>3</sup>, S. Reed<sup>2</sup>, G. Yung<sup>4</sup>, A. Kemp<sup>1</sup>, S. W. Jamieson<sup>1</sup>, <sup>1</sup>University of California Medical Center, San Diego; <sup>2</sup>University of California Medical Center, San Diego; <sup>3</sup>University of California Medical Center, San Diego; <sup>4</sup>University of California Medical Center, San Diego

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 31: New Perspectives in Cardiac Rejection** (Main Theatre)

Chairs: Mario C. Deng, MD and Jayan Parameshwar, FRCP

**3:00 PM (508) Utility of Routine Immunofluorescence Staining for C4d in Cardiac Transplant Recipients;** S. Gupta, J.D. Mitchell, B. Lavingia, W.S. Ring, P.A. Kaiser, P.C. Patel, D.W. Markham, P.P. Mammen, J.M. Dimairo, M.H. Drazner UT Southwestern Medical Center, Dallas, TX

**3:15 PM (509) Myocardial Expression of Calreticulin Predicts Ca<sup>2+</sup>-Dependent Cardiac Allograft Apoptosis in Rejection;** S. Aharinejad<sup>1,2</sup>, O. Andrukhova<sup>2</sup>, M. Gmeiner<sup>1,2</sup>, A. Thomas<sup>2</sup>, A. Aliabadi<sup>1</sup>, A. Zuckermann<sup>1</sup>, M. Grimm<sup>1</sup> <sup>1</sup>Medical University of Vienna, Vienna, Austria; <sup>2</sup>Medical University of Vienna, Vienna, Austria

**3:30 PM (510) AlloMap Molecular Expression Test Has Reduced Discriminatory Value Greater Than Two Years after Cardiac Transplantation;** B. Ristow, R. Shaw, D. Miniaci, S. Milechman, E. Lo, E. Haeusslein California Pacific Medical Center, San Francisco, CA

**3:45 PM (511) The Benefit of Immune Monitoring (Cylex): A Review of 864 Immune Monitoring Assays in Heart Transplantation;** K. Kiyosaki<sup>1</sup>, J. Kobashigawa<sup>1</sup>, J. Patel<sup>1</sup>, J. Patel<sup>1</sup>, A. Ankrom<sup>1</sup>, M. Kittleson<sup>1</sup>, M. Kawano<sup>1</sup>, J. Moriguchi<sup>1</sup>, E. Shao<sup>1</sup>, A. Ardehalil<sup>2</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**4:00 PM (512) Cardiac Magnetic Resonance Imaging in the Diagnosis of Cardiac Allograft Rejection;** A.J. Taylor<sup>1</sup>, G. Vaddadi<sup>1</sup>, L. Iles<sup>1</sup>, H. Pfluger<sup>1</sup>, M. Butler<sup>2</sup>, P. Bergin<sup>2</sup>, A. Leet<sup>2</sup>, M. Richardson<sup>2</sup>, D.M. Kaye<sup>1</sup> <sup>1</sup>Alfred Hospital and Baker IDI Heart and Diabetes Research Institute, Melbourne, Australia; <sup>2</sup>Alfred Hospital, Melbourne, Australia

**4:15 PM (513) Hemodialysis Is Associated with Increased AlloMap Molecular Expression Score in Cardiac Transplant Recipients;** B. Ristow, R. Shaw, D. Miniaci, S. Milechman, E. Lo, E. Haeusslein California Pacific Medical Center, San Francisco, CA

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 32: Revelations about Rotary Pumps** (Blue Theatre)

Chairs: Aly El Banayosy, MD and O. Howard Frazier, MD

**3:00 PM (514) Echocardiographic Evaluation of Flow across HeartMate II Axial Flow LVADs at Varying Low Speeds;** R.S. George<sup>1</sup>, N.K. Sabharwal<sup>2</sup>, C. Webb<sup>2</sup>, M. Hedger<sup>1</sup>, M.H. Yacoub<sup>3</sup>, G. Dreyfus<sup>1</sup>, A. Khaghani<sup>1</sup>, E.J. Birks<sup>1</sup> <sup>1</sup>Royal Brompton and Harefield NHS Trust, Uxbridge, Middlesex, United Kingdom; <sup>2</sup>Royal Brompton and Harefield NHS Trust, Uxbridge, Middlesex, United Kingdom; <sup>3</sup>Imperial College, Uxbridge, Middlesex, United Kingdom

**3:15 PM (515) WITHDRAWN**

**3:30 PM (516) LVAD-Related Infections and Readmission Diagnoses Are Decreased in the Era of the Rotary Pump;** A. Aziz<sup>1</sup>, J.J. Sava<sup>1</sup>, T.J. Guthrie<sup>1</sup>, S. Schena<sup>1</sup>, A.M. Lee<sup>1</sup>, G.A. Ewald<sup>2</sup>, I.-W. Wang<sup>1</sup>, N. Moazami<sup>1</sup> <sup>1</sup>Washington University School of Medicine, Saint Louis, MO; <sup>2</sup>Washington University School of Medicine, Saint Louis, MO

**3:45 PM (517) Severely Impaired Von Willebrand Factor-Dependent Platelet Aggregation in Patients with Continuous-Flow Left Ventricular Assist Device (HeartMate II);** J. Klovaite<sup>1</sup>, F. Gustafsson<sup>2</sup>, K. Sander<sup>2</sup>, S.-A. Mortensen<sup>2</sup>, L.-B. Nielsen<sup>1</sup> <sup>1</sup>Rigshospitalet, Copenhagen, Denmark; <sup>2</sup>Rigshospitalet, Copenhagen, Denmark

**4:00 PM (518)** *Incidence of Thromboembolic Cerebral Events after Implantation of the Thoratec HeartMate II Left Ventricular Assist Device*; T. Krabatsch, E. Potapov, A. Stepanenko, T. Drews, A. Unbehaun, M. Dandel, H.B. Lehmkuhl, R. Hetzer German Heart Institute Berlin, Berlin, Germany

**4:15 PM (519)** *Initial Hospitalization Dominates the Mid-Term Costs for Rotary Left Ventricular Assist Devices*; A.M. Lee<sup>1</sup>, A. Aziz<sup>1</sup>, A.K. Leahy<sup>2</sup>, G. Ridolfi<sup>3</sup>, I.-W. Wang<sup>1</sup>, G.A. Ewald<sup>4</sup>, N. Moazami<sup>1</sup> <sup>1</sup>Washington University, Saint Louis, MO; <sup>2</sup>Barnes-Jewish Hospital, Saint Louis, MO; <sup>3</sup>Barnes-Jewish Hospital, Saint Louis, MO; <sup>4</sup>Washington University, Saint Louis, MO

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 33: *Understanding Mechanism in the Development of BOS*** (Salle Maillot)

Chairs: Amy L. Pope-Harman, MD, MHS and Kenneth R. McCurry, MD

**3:00 PM (520)** *Bronchoalveolar Lavage Neutrophilia and MMP-9 at 3 Months Post Lung Transplantation May Predict the Development of BOS*; I. Forrest, C. Ward, D. Murphy, V. Ryan, G. Johnson, J. Lordan, A. Fisher, T. Cawston, P. Corris Newcastle University and Freeman Hospital, Newcastle upon Tyne, United Kingdom

**3:15 PM (521)** *Epithelial Mesenchymal Transition (EMT) in Bronchiolitis Obliterans Syndrome (BOS) Is Not Restricted to Small Airways*; D.C. Chambers<sup>1</sup>, B. Banerjee<sup>5</sup>, G. Hodge<sup>2</sup>, P. Hopkins<sup>1</sup>, A. Kicic<sup>5</sup>, M. Musk<sup>4</sup>, S. Stick<sup>5</sup>, P. Reynolds<sup>2</sup>, M. Holmes<sup>3</sup>, S. Hodge<sup>2</sup> <sup>1</sup>The Prince Charles Hospital, Brisbane, Queensland, Australia; <sup>2</sup>Hanson Institute, Adelaide, South Australia, Australia; <sup>3</sup>Royal Adelaide Hospital, Adelaide, South Australia, Australia; <sup>4</sup>Royal Perth Hospital, Perth, Western Australia, Australia; <sup>5</sup>Telethon Institute for Child Health Research, Perth, Western Australia, Australia

**3:30 PM (522)** *The Mouse Intrapulmonary Tracheal Transplant Model of Obliterative Bronchiolitis: A Novel Tool To Investigate Lymphoid Neogenesis in the Lung after Transplantation*; D. Wagnetz, M. Sato, S. Hirayama, J. Yeung, M. Liu, T. Waddell, S. Keshavjee Toronto General Research Institute, University Health Network, Toronto, ON, Canada

**3:45 PM (523)** *Cells of Epithelial Lineage Are Detectable in Peripheral Blood and Are Increased in Lung Transplantation*; L.A. May<sup>1</sup>, A. Kicic<sup>2</sup>, K. Heel<sup>3</sup>, B. Banerjee<sup>1</sup>, M. Musk<sup>1</sup>, P.M.A. Hopkins<sup>4</sup>, D.C. Chambers<sup>4</sup> <sup>1</sup>Royal Perth Hospital, Perth, WA, Australia; <sup>2</sup>Telethon Institute for Child Health Research, University of Western Australia, Perth, WA, Australia; <sup>3</sup>University of Western Australia, Perth, WA, Australia; <sup>4</sup>The Prince Charles Hospital, Brisbane, Qld, Australia

**4:00 PM (524)** *Bronchoalveolar Lavage (BAL) Fluid Fox P3+ T Cells Are Decreased in Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome (BOS)*; S.M. Bhorade, H. Chen, M. Alegre University of Chicago Medical Center, Chicago, IL

**4:15 PM (525)** *Role of Vascular Endothelial Growth Factor Receptors 1 and 2 in Experimental Obliterative Airway Disease*; R. Krebs<sup>1</sup>, J.M. Tikkanen<sup>1</sup>, M. Hollmen<sup>1</sup>, Y. Wu<sup>2</sup>, D.J. Hicklin<sup>2</sup>, P.K. Koskinen<sup>1</sup>, K.B. Lemstrom<sup>1</sup> <sup>1</sup>University of Helsinki, Helsinki, Finland; <sup>2</sup>ImClone Systems Incorporated, New York

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 34: *Genes and Peptides: Can They Help Guide Pulmonary Hypertension Management?*** (252 AB)

Chairs: Stephen Archer, MD and Jean-Luc Vachiery, MD

**3:00 PM (526)** *ENOS Polymorphisms and 6MWD Interactions in PAH Patients on Endothelin Antagonists*; R.L. Benza<sup>1</sup>, P. William<sup>2</sup>, A. Torbicki<sup>3</sup>, D. Langleben<sup>4</sup>, P. Tomas<sup>5</sup>, S. Murali<sup>1</sup>, C. Coffey<sup>2</sup>, H. Grenett<sup>2</sup> <sup>1</sup>Allegheny General Hospital, Pittsburgh, PA; <sup>2</sup>University of Alabama, Birmingham, AL; <sup>3</sup>Instytut Gruzlicy, Warsaw, Poland; <sup>4</sup>Jewish General Hospital, Montreal, Canada; <sup>5</sup>Instituto Nacional de Cardiologia, Mexico City, Mexico

**3:15 PM (527)** *Agonistic Autoantibodies against Alpha-1 Adrenergic and Endothelin-1 Receptors in Sera of Patients with Pulmonary Arterial Hypertension: Potential Involvement in the Pathogenesis of the Disease*; M. Dandel<sup>1</sup>, G. Wallukat<sup>2</sup>, A. Englert<sup>1</sup>, H.B. Lehmkuhl<sup>1</sup>, R. Hetzer<sup>1</sup> <sup>1</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Max Delbrück Centrum für Molekulare Medizin, Berlin, Germany

**3:30 PM (528)** *Endothelin-1 and BNP Plasma Levels Predict Survival in Patients with Pulmonary Arterial Hypertension*; R.P. Frantz<sup>1</sup>, I.M. Robbins<sup>2</sup>, M.D. McGoon<sup>1</sup>, C.J. Severson<sup>1</sup>, L.A. Durst<sup>1</sup>, K.V. Ballman<sup>3</sup>, D.E. Grill<sup>3</sup>, K.R. Bailey<sup>3</sup>, J.C. Burnett<sup>4</sup> <sup>1</sup>College of Medicine Mayo Clinic, Rochester, MN; <sup>2</sup>Vanderbilt University School of Medicine, Nashville, TN; <sup>3</sup>College of Medicine, Mayo Clinic, Rochester, MN; <sup>4</sup>College of Medicine, Rochester, MN

**3:45 PM (529) Simultaneous Measurement of Serum N-Terminal Brain Natriuretic Peptide and Troponin T in Risk Assessment of Patients with Precapillary Pulmonary Hypertension;** A.K. Andreassen<sup>1</sup>, S. Arora<sup>1</sup>, E. Gude<sup>1</sup>, O.G. Solberg<sup>1</sup>, R. Wergeland<sup>2</sup> <sup>1</sup>Rikshospitalet University Hospital, Oslo, Norway; <sup>2</sup>Rikshospitalet University Hospital, Oslo, Norway

**4:00 PM (530) Endothelin-1 (ET-1) Serum Levels: Relation to Hemodynamics and Clinical Variables in Patients with Pulmonary Vascular Disease;** N. Selimovic<sup>1</sup>, B. Andersson<sup>1</sup>, C.H. Bergh<sup>1</sup>, E. Sakiniene<sup>2</sup>, H. Carlsten<sup>2</sup>, B. Rundqvist<sup>1</sup> <sup>1</sup>Sahlgrenska University Hospital, Gothenburg, Sweden; <sup>2</sup>Sahlgrenska University Hospital, Gothenburg, Sweden

**4:15 PM (531) Brain Natriuretic Peptide Levels: The Canary in the Right Ventricular Mine in Pulmonary Arterial Hypertension;** R.P. Frantz<sup>1</sup>, P.R. Julsrud<sup>2</sup>, C.G.A. McGregor<sup>1</sup> <sup>1</sup>College of Medicine, Mayo Clinic, Rochester, MN; <sup>2</sup>College of Medicine, Mayo Clinic, Rochester, MN; <sup>3</sup>College of Medicine, Mayo Clinic, Rochester, MN

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 35: Pediatric Thoracic Transplantation: Late Outcomes (242 AB)**

Chairs: Francisco Parisi, MD and Richard Kirk, MD

**3:00 PM (532) Genetic Polymorphisms Impact the Risk of Infection in Pediatric Heart Transplantation – A Multi-Center Study;** D.M. Giritia<sup>1</sup>, M.M. Brooks<sup>1</sup>, S.A. Webber<sup>1</sup>, G.J. Burckart<sup>2</sup>, R. Ferrell<sup>1</sup>, A.L. Giritia<sup>1</sup>, R. Chinnock<sup>3</sup>, C. Canter<sup>4</sup>, L. Addonizio<sup>5</sup>, D. Bernstein<sup>6</sup>, J.K. Kirklin<sup>7</sup>, D. Naftel<sup>7</sup>, A. Zeevi<sup>1</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>US Food and Drug Administration, Silver Spring, MD; <sup>3</sup>Loma Linda University, Loma Linda, CA; <sup>4</sup>Washington University, St. Louis, MO; <sup>5</sup>Columbia University, New York, NY; <sup>6</sup>Stanford University, Palo Alto, CA; <sup>7</sup>University of Alabama at Birmingham, Birmingham, AL

**3:15 PM (533) The Influence of CMV Status on Outcomes Following Heart Transplantation in Children – Whose Status Matters?;** R.R. Davies<sup>1</sup>, M.J. Russo<sup>1</sup>, S.R. Mital<sup>3</sup>, J.M. Chen<sup>2</sup> <sup>1</sup>Children's Hospital of New York-Presbyterian, New York, NY; <sup>2</sup>Weill Medical College of Cornell University, New York, NY; <sup>3</sup>Hospital for Sick Children, Toronto, ON, Canada

**3:30 PM (534) Mechanisms of Tumor Evasion from NK Cell-Mediated Immunity in Pediatric HTx Patients with PTLT;** S. Wiesmayr<sup>1</sup>, S.A. Webber<sup>2</sup>, L.G. Smith<sup>2</sup>, I. Popescu<sup>1</sup>, C. Macedo<sup>1</sup>, D. Metes<sup>1</sup> <sup>1</sup>Thomas E. Starzl Transplantation Institute, Pittsburgh, PA; <sup>2</sup>Children's Hospital of Pittsburgh, Pittsburgh, PA

**3:45 PM (535) Post-Transplant Lymphoproliferative Disease: 20 Year Experience in Infant Heart Transplant Recipients;** R.E. Chinnock, T. Shankel, D. Cutler, J. Johnston, J. Fitts Loma Linda University Children's Hospital, Loma Linda, CA

**4:00 PM (536) Well-Being and Functional Status of Pediatric Heart Transplant Recipients;** S.J. Anthony<sup>1</sup>, S.M. Pollock-BarZiv<sup>1</sup>, B.W. McCrindle<sup>2</sup>, L.J. West<sup>3</sup>, C. Manlhiot<sup>2</sup>, A.I. Dipchand<sup>1,2</sup> <sup>1</sup>The Hospital for Sick Children, Toronto, Canada; <sup>2</sup>The Hospital for Sick Children, Toronto, Canada; <sup>3</sup>University of Alberta, Edmonton, Canada

**4:15 PM (537) Safety and Immunogenicity of Vaccinations Against Diphtheria and Tetanus in Children after Heart Transplantation;** S. Urschel<sup>1</sup>, B. Rieck<sup>2</sup>, J. Birnbaum<sup>1</sup>, R. Dalla Pozza<sup>1</sup>, A. Fuchs<sup>1</sup>, C. Schmitz<sup>3</sup>, L.J. West<sup>4</sup>, B.H. Belohradsky<sup>2</sup>, H. Netz<sup>1</sup> <sup>1</sup>L-M- University, Munich, Germany; <sup>2</sup>L-M- University, Munich, Germany; <sup>3</sup>L-M- University, Munich, Germany; <sup>4</sup>University of Alberta, Edmonton, AB, Canada

**3:00 PM – 4:30 PM**

**CONCURRENT SESSION 36: Fitting It Together - CMV in the Underworld: Cellular & Molecular Mischief (241)**

Chairs: Eliane Billaud, MD and Martha L. Mooney, MD

**3:00 PM (538) MICA Gene Polymorphisms and Primary CMV Infection in the CMV D+/R- Thoracic Organ Transplants;** M. Askar<sup>1</sup>, S. Hemachandra<sup>2</sup>, A. Zhang<sup>1</sup>, D. Pidwell<sup>1</sup>, N. Shrestha<sup>2</sup>, D. Van Duin<sup>2</sup>, R. Avery<sup>2</sup> <sup>1</sup>Cleveland Clinic, Cleveland, OH; <sup>2</sup>Cleveland Clinic, Cleveland, OH

**3:15 PM (539) Striking Expansion and Persistence of T-bet<sup>+</sup>CD8<sup>+</sup> CMV-Specific T Cells with Primary Infection in Lung Transplant Recipients;** M.R. Pipeling<sup>1</sup>, A.B. Whitlock<sup>1</sup>, S.A. Migueles<sup>2</sup>, M. Connors<sup>2</sup>, J.F. McDyer<sup>1</sup> <sup>1</sup>Johns Hopkins University, Baltimore, MD; <sup>2</sup>National Institutes of Health, Bethesda, MD

**3:30 PM (540) Murine Cytomegalovirus Infection Leads to Elevated Levels of Transplant Arteriosclerosis in a Murine Aortic Allograft Model;** C. Heim<sup>1</sup>, S. Abele<sup>1</sup>, S. Eckl<sup>1</sup>, S. Mahmoudian<sup>2</sup>, T. Stamminger<sup>2</sup>, M. Weyand<sup>1</sup>, S.M. Ensminger<sup>1</sup> <sup>1</sup>University of Erlangen-Nuremberg, Erlangen, Germany; <sup>2</sup>University of Erlangen-Nuremberg, Erlangen, Germany

**3:45 PM (541) Increased CMV-Specific CD8<sup>+</sup> Effectors and Viral Loads in the Lung Allograft Predict Viral Pneumonitis during Primary Infection;** M.R. Pipeling<sup>1</sup>, E.E. West<sup>1</sup>, A.B. Whitlock<sup>1</sup>, M. Forman<sup>2</sup>, A. Valsamakis<sup>2</sup>, N. Lechtzin<sup>1</sup>, J.B. Orens<sup>1</sup>, J.F. McDyer<sup>1</sup> <sup>1</sup>Johns Hopkins University, Baltimore, MD; <sup>2</sup>Johns Hopkins University, Baltimore, MD

**4:00 PM (542)** *The Systemic Vascular Impairment Seen in CMV-Positive Transplant Recipients Is a Purely Post-Transplant Phenomenon*; J. Simmonds, M. Fenton, C. Scott, H. Latch, M. Charakida, M. Burch Great Ormond Street Hospital, London, United Kingdom

**4:15 PM (543)** *CMV-DNA Load Patterns Developing within the First Year after Lung Transplantation Predict Patient Mortality*; H. Kerschner<sup>1</sup>, P. Jaksch<sup>2</sup>, G. Karigl<sup>3</sup>, T. Popow-Kraupp<sup>1</sup>, W. Klepetko<sup>2</sup>, E. Puchhammer-Stockl<sup>1</sup> <sup>1</sup>Medical University of Vienna, Vienna, Austria; <sup>2</sup>Medical University of Vienna, Vienna, Austria; <sup>3</sup>Technical University of Vienna, Vienna, Austria

**4:30 PM – 5:00 PM**

Coffee Break/View Posters/Visit Exhibits (Exhibit Hall)

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 37: Emergent Analyses of Novel Devices** (Main Theatre)

Chairs: Yoshifumi Naka, MD, PhD and Takeshi Nakatani, MD, PhD

**5:00 PM (544)** *Clinical Results of the International HeartWare® LVAS Bridge to Transplant Trial*; M. Strueber<sup>1</sup>, E. Birks<sup>2</sup>, P. Jansz<sup>3</sup>, G. O'Driscoll<sup>4</sup>, G. Wieselthaler<sup>5</sup> <sup>1</sup>Hannover Medical School, Hannover, Germany; <sup>2</sup>Harefield Hospital, Harefield, United Kingdom; <sup>3</sup>St. Vincent's Hospital, Sidney, Australia; <sup>4</sup>Royal Perth Hospital, Perth, Australia; <sup>5</sup>University of Vienna, Vienna, Austria

**5:15 PM (545)** *Initial Clinical Experience with the CircuLite Synergy Partial Circulatory Support Device*; B. Meyns<sup>1</sup>, F. Rega<sup>1</sup>, W. Droogne<sup>1</sup>, A. Simon<sup>2</sup>, S. Klotz<sup>3</sup>, D. Burkhoff<sup>4</sup> <sup>1</sup>Gasthuisberg University Hospital, Leuven, Belgium; <sup>2</sup>Hannover Medical School, Hannover, Germany; <sup>3</sup>University Hospital, Muenster, Germany; <sup>4</sup>Columbia University, New York, NY

**5:30 PM (546)** *Acute In-Vivo Trial of a Novel Rotary BiVAD/TAH*; D. Timms<sup>1,2</sup>, J. Fraser<sup>1</sup>, B. Thompson<sup>1</sup>, K. McNeil<sup>1</sup> <sup>1</sup>The Prince Charles Hospital, Brisbane, Australia; <sup>2</sup>Helmholtz Institute, Aachen, Germany

**5:45 PM (547) WITHDRAWN**

**6:00 PM (548)** *Experience with the TandemHeart Percutaneous Ventricular Assist Device in Heart Failure Patients Undergoing Cardiac Surgical Procedures*; I. Gregoric<sup>1</sup>, B.A. Bruckner<sup>2</sup>, B. Kar<sup>1</sup>, P. Loyalka<sup>1</sup>, L. Jacob<sup>1</sup>, R. Delgado<sup>1</sup>, M. Loebe<sup>2</sup>, O.H. Frazier<sup>1</sup> <sup>1</sup>Texas Heart Institute, Houston, TX; <sup>2</sup>Methodist DeBakey Heart Center, Houston, TX

**6:15 PM (549)** *Incidence and Outcome of Levitronix Support for Early Cardiac Allograft Failure: A UK National Study*; H.L. Thomas<sup>1</sup>, R.S. Bonser<sup>2</sup>, N.R. Banner<sup>3</sup> <sup>1</sup>NHS Blood and Transplant, Bristol, United Kingdom; <sup>2</sup>Queen Elizabeth Hospital, Birmingham, United Kingdom; <sup>3</sup>Royal Brompton Harefield NHS Trust, Harefield, United Kingdom; <sup>4</sup>On Behalf of the UK Cardiothoracic Transplant Audit Steering Group, London, United Kingdom

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 38: Donor Contributions to Lung Allograft Function** (Blue Theatre)

Chairs: Florian Wagner, MD and Christophe Pison, MD

**5:00 PM (550)** *Lung Donor Scoring Can Optimize Donor Management, Refine Organ Utilization, and Predict Recipient Outcomes*; S. McClelland, S.-W. Pak, S. Kawut, J. Parks, D. Spiliotopoulos, T. Scripps, J. Gerson, F. D'Ovidio, M. Bacchetta, S. Arcasoy, J. Sonett Columbia University, New York, NY

**5:15 PM (551)** *Beta-Adrenergic Receptor SNPs Are Associated with Lung Graft Utilization*; A. Sapru<sup>1</sup>, L. Pawlikowska<sup>1</sup>, K. Liu<sup>1</sup>, K.K. Khush<sup>3</sup>, L.A. Baxter-Lowe<sup>1</sup>, W. Babcock<sup>4</sup>, V. Hayden<sup>4</sup>, R.L. Menza<sup>4</sup>, M. Landeck<sup>4</sup>, J.G. Zaroff<sup>2</sup>, M.A. Matthay<sup>1</sup> <sup>1</sup>University of California, San Francisco, CA; <sup>2</sup>Kaiser Permanente, San Francisco, CA; <sup>3</sup>Stanford University School of Medicine, Palo Alto, CA; <sup>4</sup>California Transplant Donor Network, Oakland, CA

**5:30 PM (552)** *The Impact of Donor-Recipient Race Matching on Survival after Lung Transplantation – An Analysis of over 11,000 Patients*; J.G. Allen<sup>1</sup>, E.S. Weiss<sup>1</sup>, C.A. Merlo<sup>2</sup>, W.A. Baumgartner<sup>1</sup>, J.V. Conte<sup>1</sup>, A.S. Shah<sup>1</sup> <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD

**5:45 PM (553)** *Size-Reduced Lung Transplantation: Is It a Solution for Small Recipients?*; G. Marulli<sup>1</sup>, M. Loy<sup>1</sup>, A. Zuin<sup>1</sup>, C. Breda<sup>1</sup>, P. Feltracco<sup>2</sup>, L. Battistella<sup>1</sup>, K.L. Oliani<sup>1</sup>, F. Rea<sup>1</sup> <sup>1</sup>Thoracic Surgery, Padova, Italy; <sup>2</sup>Anaesthesiology, Padova, Italy

**6:00 PM (554) Outcomes of 212 Lung Transplantations Using Extended Donor Criteria;** C.K.N. Wan, K. Jackson, A. Oreopoulos, P.Z.T. Wang, K.C. Stewart, J. Weinkauff, J. Mullen, D. Modry, D. Lien University of Alberta, Edmonton, AB, Canada

**6:15 PM (555) Older Donor for Older Recipient in Lung Transplantation;** Y. Toyoda, C. Bermudez, G. Speziali, S. Gilbert, J. Bhama, E. Gongora, L. Garcia, M. Zenati, R. Zomak, D. Zaltonis, B. Johnson, M. Crespo, J. Pilewski University of Pittsburgh Medical Center, Pittsburgh

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 39: Induction Therapy, Clinical Outcomes** (Salle Maillot)

Chairs: Hans B. Lehmkuhl, MD and David A. Baran, MD

**5:00 PM (556) Antithymocyte Globulin Induction Therapy for Adult Heart Transplantation;** J. Thekkudan, C.A. Rogers, R.S. Bonser, N.R. Banner The Royal College of Surgeons of England, London, United Kingdom

**5:15 PM (557) Immunosuppressive Intensity Should Be Reduced in Heart Transplant Recipients Greater Than 70 Years of Age;** J.D. Pal<sup>1</sup>, J.G. Rogers<sup>2</sup>, C.A. Milano<sup>1</sup> <sup>1</sup>Duke University, Durham, NC; <sup>2</sup>Duke University, Durham, NC

**5:30 PM (558) Pharmacogenetic Interaction of the NFAT C/G Polymorphism and the Impact of Induction Therapy on Freedom from Significant Rejection after Cardiac Transplantation;** J. Teuteberg<sup>1</sup>, K. Hanley-Yanez<sup>1</sup>, E. Pippi<sup>1</sup>, M. Shullo<sup>2</sup>, C. Bermudez<sup>3</sup>, B. London<sup>1</sup>, R. Kormos<sup>3</sup>, Y. Toyoda<sup>3</sup>, D. McNamara<sup>1</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>University of Pittsburgh, Pittsburgh, PA; <sup>3</sup>University of Pittsburgh, Pittsburgh, PA

**5:45 PM (559) No Significant Impact of HLA Specific Antibodies (Ab) and Donor Specific Antibodies (DSA) on Heart Transplant Outcome Subsequent to Thymoglobulin Induction;** K. Cao<sup>1</sup>, B. Coleman<sup>2</sup>, L.S. Czer<sup>2,3</sup>, S. Simsir<sup>3</sup>, E. Schwarz<sup>4</sup>, C.-H. Lai<sup>1</sup>, G. Ong<sup>1</sup>, Q. Wang<sup>1</sup>, M. Naim<sup>1</sup>, N.L. Reinsmoen<sup>1</sup> <sup>1</sup>Cedars-Sinai Health System, Los Angeles, CA; <sup>2</sup>Cedars-Sinai Health System, Los Angeles, CA; <sup>3</sup>Cedars-Sinai Health System, Los Angeles, CA; <sup>4</sup>Cedars-Sinai Health System, Los Angeles, CA

**6:00 PM (560) Insight into Causes for the Time-Dependent Improvement in Heart Transplantation Survival: 20-Year Analysis of United Network for Organ Sharing (UNOS) Data;** A.G. Kfoury, K.D. Brunisholz, B.D. Horne, J.R. Kotter, P.W. Fisher, B.B. Reid, J.R. Doty, S.E. Clayson, B.C. Miller, M.M. Endo, D.G. Renlund Intermountain Medical Center, Salt Lake City

**6:15 PM (561) Relationship of Race and Socioeconomic Position with Rejection Incidence in Heart Transplant Recipients;** T.P. Singh<sup>1</sup>, M. Semigran<sup>2</sup>, K. Gauvreau<sup>1</sup>, F. Costantino<sup>4</sup>, D. DeNofrio<sup>5</sup>, S. Evans<sup>1</sup>, M. Givertz<sup>3</sup> <sup>1</sup>Children's Hospital Boston, Boston, MA; <sup>2</sup>Massachusetts General Hospital, Boston, MA; <sup>3</sup>Brigham and Women's Hospital, Boston, MA; <sup>4</sup>New England Organ Bank, Watertown, MA; <sup>5</sup>Tufts Medical Center, Boston, MA

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 40: Experimental Immunosuppression: Is Regulation the Key?** (252 AB)

Chairs: Stephan M. Ensminger, MD, PhD and Patricia A. Uber, PharmD

**5:00 PM Invited Lecture: The Role of Chemokines in Transplantation,** Richard N. Pierson, III, MD, University of Maryland, Baltimore, MD

**5:15 PM (562) The Maintenance of Peripheral Tolerance Following Porcine Lung Transplantation Is Alloantigen Specific;** G. Warnecke<sup>1</sup>, B. Kruse<sup>1</sup>, S. Thissen<sup>1</sup>, M. Avsar<sup>1</sup>, C. Matiaske<sup>1</sup>, J.H. Karstens<sup>2</sup>, A.R. Simon<sup>1</sup>, A. Haverich<sup>1</sup>, M. Struber<sup>1</sup> <sup>1</sup>Hannover Medical School, Hannover, Germany; <sup>2</sup>Hannover Medical School, Hannover, Germany

**5:30 PM (563) Development of Transplant Arteriosclerosis in Porcinized Mice Is Regulated by Allogeneic Porcine CD4<sup>+</sup>CD25<sup>+</sup> T Cells;** N. Madrahimov, A.-K. Knofel, G. Warnecke, S. Thissen, B. Kruse, M. Avsar, C. Matiaske, S. Fischer, A. Haverich, M. Struber Hannover Medical School, Hannover, Germany

**5:45 PM (564) Lack of CD154 Costimulation Induces Airway Allograft Tolerance Via Uncoupling of Allospecific CD8<sup>+</sup> T Cell Proliferation from Effector Function in an IL-12 Independent Manner;** P.D. Shah, A.B. Whitlock, E.E. West, J.B. Orens, J.F. McDyer Johns Hopkins University School of Medicine, Baltimore, MD

**6:00 PM (565) Increased TGF- $\beta$  and FoxP3 Expression in Long Term Surviving Pigs after Pulmonary Transplantation;** B. Kruse<sup>1</sup>, S. Thissen<sup>1</sup>, G. Warnecke<sup>1</sup>, M. Avsar<sup>1</sup>, F. Langer<sup>2</sup>, C. Matiaske<sup>1</sup>, V. Kaefer<sup>3</sup>, J.H. Karstens<sup>4</sup>, A.R. Simon<sup>1</sup>, A. Haverich<sup>1</sup>, M. Struber<sup>1</sup> <sup>1</sup>Hannover Medical School, Hannover, Germany; <sup>2</sup>Institute for Pathology, Hannover Medical

School, Hannover, Germany; <sup>3</sup>Institute for Pharmacology, Hannover Medical School, Hannover, Germany; <sup>4</sup>Hannover Medical School, Hannover, Germany

**6:15 PM (566) Local, Graft Specific Immunosuppression: Experimental Data on Aerosolized Tacrolimus for Airway Transplantation;** T. Deuse<sup>1</sup>, D. Weill<sup>2</sup>, R.C. Robbins<sup>1</sup>, B. Reitz<sup>1</sup>, S. Schrepfer<sup>1</sup> <sup>1</sup>Stanford University School of Medicine, Stanford, CA; <sup>2</sup>Stanford University School of Medicine, Stanford, CA

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 41: Good Heart + Bad Body = Good Outcomes? (242 AB)**

Chairs: Stuart D. Russell, MD and Luciano Potena, MD

**5:00 PM (567) Risk Factors Associated with Moderate to Severe Renal Failure in Heart Transplant Patients. CAPRI Study;** J.F. Delgado<sup>1</sup>, M. Crespo-Leiro<sup>2</sup>, M.J. Paniagua<sup>2</sup>, L. Almenar<sup>3</sup>, L. Martinez-Dolz<sup>3</sup>, F. Gonzalez-Vilchez<sup>4</sup>, M.A. Gomez-Sanchez<sup>1</sup>, J. Fernandez-Yanez<sup>5</sup>, B. Diaz-Molina<sup>6</sup>, E. Roig<sup>7</sup>, J.M. Arizon<sup>8</sup>, L. Alonso-Pulpon<sup>9</sup>, I. Garrido<sup>10</sup>, L. de la Fuente<sup>11</sup>, V. Brossa<sup>12</sup>, T. Blasco<sup>13</sup>, N. Manito<sup>14</sup>, J. Muniz<sup>2</sup> <sup>1</sup>12 de Octubre, Madrid, Spain; <sup>2</sup>Juan Canalejo, A Coruña, Spain; <sup>3</sup>Hospital La Fe, Valencia, Spain; <sup>4</sup>Marqués de Valdecilla, Santander, Spain; <sup>5</sup>Gregorio Marañón, Madrid, Spain; <sup>6</sup>Central de Asturias, Oviedo, Spain; <sup>7</sup>Hospital Clinic, Barcelona, Spain; <sup>8</sup>Reina Sofia, Córdoba, Spain; <sup>9</sup>Puerta de Hierro, Madrid, Spain; <sup>10</sup>Virgen de la Arrixaca, Murcia, Spain; <sup>11</sup>Clinico de Valladolid, Valladolid, Spain; <sup>12</sup>Sant Pau, Barcelona, Spain; <sup>13</sup>Miguel Servet, Zaragoza, Spain; <sup>14</sup>Bellvitge, Barcelona, Spain

**5:15 PM (568) Cumulative Pregnancies Increase Risk of Cardiac Transplant Rejection Requiring Treatment: An Analysis of the United Network for Organ Sharing Database;** C.A. Silverstein, A.J. Naftilan, T.G. DiSalvo, M.A. Wigger, D.B. Sawyer, H. Ooi Vanderbilt Medical Center, Nashville, TN

**5:30 PM (569) Incidence and Outcome of Long-Term Renal Replacement Therapy after Adult Heart Transplantation: A UK National Study;** H.L. Thomas<sup>1</sup>, R. Birch<sup>1</sup>, R.S. Bonser<sup>2</sup>, N.R. Banner<sup>3</sup> <sup>1</sup>NHS Blood and Transplant, Bristol, United Kingdom; <sup>2</sup>Queen Elizabeth Hospital, Birmingham, United Kingdom; <sup>3</sup>Royal Brompton Harefield NHS Trust, Harefield, United Kingdom; <sup>4</sup>On Behalf of the UK Cardiothoracic Transplant Audit Steering Group, London, United Kingdom

**5:45 PM (570) Pre-Transplant FEV1/FVC but Not FEV1 Alone by Pulmonary Function Testing Predicts Poor Outcome after Heart Transplantation: The Bane of COPD;** J. Patel<sup>1</sup>, E. Shao<sup>1</sup>, J. Patel<sup>1</sup>, M. Kawano<sup>1</sup>, K. Kiyosaki<sup>1</sup>, A. Ankrom<sup>1</sup>, M. Kittleson<sup>1</sup>, J. Moriguchi<sup>1</sup>, A. Ardehali<sup>1</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**6:00 PM (571) Prevalence and Severity of Renal Dysfunction among 1059 Heart Transplant Patients According to Criteria Based on Serum Creatinine and Estimated Glomerular Filtration Rate: A Cross-Sectional Study;** M.G. Crespo-Leiro<sup>1</sup>, J.F. Delgado<sup>2</sup>, M.J. Paniagua<sup>1</sup>, L. Almenar<sup>3</sup>, L. Martinez-Dolz<sup>3</sup>, F. Gonzalez-Vilchez<sup>4</sup>, M.A. Gomez-Sanchez<sup>2</sup>, J. Fernandez-Yanez<sup>5</sup>, B. Diaz-Molina<sup>6</sup>, E. Roig<sup>7</sup>, J.M. Arizon<sup>8</sup>, L. Pulpon<sup>9</sup>, I. Garrido<sup>10</sup>, L. de la Fuente<sup>11</sup>, V. Brossa<sup>12</sup>, T. Blasco<sup>13</sup>, N. Manito<sup>14</sup>, J. Muniz<sup>1</sup> <sup>1</sup>Complejo Hospitalario Universitario Juan Canalejo, La Coruña, Spain; <sup>2</sup>Hospital 12 de Octubre, Madrid, Spain; <sup>3</sup>Hospital La Fe, Valencia, Spain; <sup>4</sup>Hospital Marques de Valdecilla, Santander, Spain; <sup>5</sup>Hospital Gregorio Marañón, Madrid, Spain; <sup>6</sup>Hospital Central de Asturias, Oviedo, Spain; <sup>7</sup>Hospital Clinic I Provincial, Barcelona, Spain; <sup>8</sup>Hospital Reina Sofia, Cordoba, Spain; <sup>9</sup>Clinica Puerta de Hierro, Madrid, Spain; <sup>10</sup>Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; <sup>11</sup>Hospital Clínico de Valladolid, Valladolid, Spain; <sup>12</sup>Hospital Santa Creu I Sant Pau, Barcelona, Spain; <sup>13</sup>Hospital Miguel Servet, Zaragoza, Spain; <sup>14</sup>Hospital de Bellvitge, Barcelona, Spain

**6:15 PM (572) Post-Transplant Outcome of Elective vs. LVAD vs. Urgent Patients Undergoing Cardiac Transplantation;** D. Zimpfer, S. Mahr, A. Aliabadi, M. Groemmer, D. Dunkler, S. Sandner, G. Wieselthaler, E. Wolner, M. Grimm, A. Zuckermann Medical University Vienna, Vienna, Austria

**5:00 PM – 6:30 PM**

**CONCURRENT SESSION 42: Optimizing the High Risk Heart Transplant Candidate (241)**

Chairs: Eulalia Roig Minguell, MD and Allen S. Anderson, MD

**5:00 PM (573) Normalization of Fixed Pulmonary Hypertension in Severe Heart Failure Patients with Placement of Left Ventricular Assist Device;** R. Zolty<sup>1</sup>, T. Vittorio<sup>1</sup>, B. Lowes<sup>2</sup>, S. Shakar<sup>2</sup>, A. Brieke<sup>2</sup>, A. Cannon<sup>2</sup>, J. Cleveland<sup>2</sup>, D. D'Alessandro<sup>3</sup>, D. Goldstein<sup>3</sup>, S. Maybaum<sup>3</sup> <sup>1</sup>Albert Einstein College of Medicine, Bronx, NY; <sup>2</sup>University of Colorado Health Sciences Center, Aurora, CO; <sup>3</sup>Montefiore Medical Center, Bronx, NY

**5:15 PM (574) Sildenafil or Bosentan in Patients Considered Ineligible for Heart Transplantation Because of Severe Pulmonary Hypertension;** M. Farrero, F. Perez-Villa, A. Arias, A. Sionis, A. Castel, E. Roig Thorax Institute, Hospital Clinic, Barcelona, Spain

**5:30 PM (575) Prognostic Value of Right Ventricular Dysfunction and Pulmonary Artery Hypertension Parameters for Risk Stratification of Patients with Heart Failure;** J.M. Barcelo, J. Segovia, M. Gomez-Bueno, P. Garcia-Pavia, M. Cobo, E. Sufrate, J. Mirelis, L. Alonso-Pulpon Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain

**5:45 PM (576) Does Treatment of Sensitized VAD Patients Improved Post Heart Transplant Outcomes?;** E.A. Hong<sup>1</sup>, R. Shemin<sup>2</sup>, A. Ardehali<sup>2</sup>, F. Esmailian<sup>2</sup>, M. Kittleson<sup>1</sup>, J. Patel<sup>1</sup>, H. Laks<sup>2</sup>, R. Jocson<sup>2</sup>, J. Kobashigawa<sup>1</sup>, J. Moriguchi<sup>1</sup><sup>1</sup>David Geffen School of Medicine, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine, Los Angeles, CA

**6:00 PM (577) Effect of Bosentan® in Candidate to Heart Transplantation with Pulmonary Hypertension Secondary to Congestive Heart Failure;** M. Maccherini, C. Tsioulpas, S. Bernazzali, F. Diciolla, E. Borrelli University of Siena, Santa Maria alle Scotte Hospital, Siena, Italy

**6:15 PM (578) The Development of Secondary Pulmonary Hypertension in Heart Failure Patients Is a Predictor of Poor Response to Cardiac Resynchronization Therapy;** B.A. Boilson, J.M. Miller, C.G. Scott, B.D. Johnson, M. M. Redfield, L.J. Olson Mayo Clinic, Rochester, MN

**6:00 PM – 7:30 PM**

**2010 Program Committee Meeting (Room 243)**

**6:30 PM – 7:30 PM**

**PAH Guidelines Workforce Meeting (Room 273)**

**6:30 PM – 7:30 PM**

**GENERAL POSTERS/WINE AND CHEESE RECEPTION (Hall Maillot)**

**(579) Featured Poster: Pain Factors and Functional Status in pts with Advanced Symptomatic Heart Failure;** N.M. Albert<sup>1</sup>, K. Trochelman<sup>1</sup>, Z. Sun<sup>1</sup>, E. Slifcak<sup>1</sup>, S.J. Goodlin<sup>2</sup>, S. Wingate<sup>3</sup>, S. Pressler<sup>4</sup>, J.R. Teerlink<sup>5</sup>, C.P. Storey<sup>6</sup>  
<sup>1</sup>Cleveland Clinic, Cleveland, OH; <sup>2</sup>Intermountain Health, Salt Lake City, UT; <sup>3</sup>Kaiser Permanente, Silver Spring, MD; <sup>4</sup>University of Michigan, Ann Arbor, MI; <sup>5</sup>UCSF/VAMC, San Francisco, San Francisco, CA; <sup>6</sup>Kaiser Permanente, Denver, CO

**(580) Drive Line Site Infections in Patients Selected for Bridged To Transplant (BTT) and Destination Therapy (DT). The UCLA Experience from 2004 – September 2008;** C.M. Eisenring, R.M. Jocson, A. Martinez, B. Kubak David Geffen School of Medicine at UCLA, Los Angeles, CA

**(581) Gynecological Complications in Adolescent Cardiothoracic Transplant Recipients;** D. Guadiz<sup>1</sup>, D. Tanaka<sup>2</sup>, M. Carson<sup>1</sup>, M.V. Horn<sup>1</sup>, M.S. Woo<sup>1</sup>  
<sup>1</sup>Childrens Hospital Los Angeles, Los Angeles, CA; <sup>2</sup>Childrens Hospital Los Angeles, Los Angeles, CA

**(582) Evaluation of after Hours Ventricular Assist Device “Hotline” Calls;** A. Kaan, J. Kealy, H. Andrews, N. Gauthier St Paul’s Hospital, Vancouver, BC, Canada

**(583) Featured Poster: Physical or Verbal Barriers Are Not Contraindication for Mechanical Assistance;** M.A. Murray<sup>1</sup>, M.A. Murray<sup>1</sup>, N. Edwards<sup>2</sup>, M.R. Johnson<sup>3</sup>, S. Osaki<sup>2</sup>, L. Lozonchi<sup>2</sup>, T. Kohmoto<sup>2</sup>  
<sup>1</sup>University of Wisconsin Hospital, Madison, WI; <sup>2</sup>University of Wisconsin Hospital, Madison, WI; <sup>3</sup>University of Wisconsin Hospital, Madison, WI

**(584) Palliative Care Referrals after Lung Transplantation in Major Transplant Centers in the U.S.;** M.K. Song<sup>1</sup>, A. De Vito Dabbs<sup>2</sup>, S. Studer<sup>3</sup>, R. Arnold<sup>4</sup>  
<sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC; <sup>2</sup>University of Pittsburgh, Pittsburgh, PA; <sup>3</sup>Newark Beth Israel Medical Center, Newark, NJ; <sup>4</sup>University of Pittsburgh, Pittsburgh, PA

**(585) The Topical Management of Drive-Line Infection: The Need for Standardization and Classification;** C.A. Wood, H.M. Hayes Royal Perth Hospital, Perth, Western Australia, Australia

**(586) Featured Poster: The “Lived Experience” of Pediatric Heart Transplant Recipients;** S.J. Anthony<sup>1</sup>, D.B. Nicholas<sup>1,2</sup>, A.I. Dipchand<sup>1</sup>, R. MacCulloch<sup>1</sup>, L.J. West<sup>3</sup>  
<sup>1</sup>The Hospital for Sick Children, Toronto, Canada; <sup>2</sup>University of Calgary, Edmonton, Canada; <sup>3</sup>University of Alberta, Edmonton, Canada

**(587) Evaluating Quality of Life Prior to MCS/Implant Is a Challenge: Results from INTERMACS;** K.L. Ullisney<sup>1</sup>, K.L. Grady<sup>2</sup>, J.K. Kirklin<sup>3</sup>, D.C. Naftel<sup>3</sup>, A.C. Gelijns<sup>4</sup>, A.J. Moskowitz<sup>4</sup>, J.B. Young<sup>5</sup>, S.L. Myers<sup>3</sup>, S.A. Wissman<sup>6</sup>  
<sup>1</sup>National Heart Lung and Blood Institute, Bethesda, MD; <sup>2</sup>Bluhm Cardiovascular Institute, Northwestern University Medical Center, Chicago, IL; <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>4</sup>Columbia University Medical Center, New York, NY; <sup>5</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>6</sup>Ohio State University Medical Center, Columbus, OH



**(588)** *Missing Data Imputation Strategies on Long-Term Quality of Life Outcome after Heart Transplant*; E.C. Wang<sup>1</sup>, K.L. Grady<sup>1</sup>, B. Rybarczyk<sup>2</sup>, D.C. Naftel<sup>3</sup>, S. Myers<sup>3</sup>, J.K. Kirklin<sup>3</sup>, J.B. Young<sup>4</sup>, D. Pelegrin<sup>4</sup>, J. Czerr<sup>4</sup>, J. Kobashigawa<sup>5</sup>, J. Chait<sup>5</sup>, A. Heroux<sup>6</sup>, R. Higgins<sup>7</sup>, C. White-Williams<sup>8</sup> <sup>1</sup>Northwestern Memorial Hospital, Chicago, IL; <sup>2</sup>Virginia Commonwealth University, Richmond, VA; <sup>3</sup>University of Alabama, Birmingham, AL; <sup>4</sup>The Cleveland Clinic, Cleveland, OH; <sup>5</sup>UCLA Medical Center, Los Angeles, LA; <sup>6</sup>Loyola University Medical Center, Chicago, IL; <sup>7</sup>Rush University Medical Center, Chicago, IL; <sup>8</sup>University of Alabama, Birmingham, AL

**(589) Featured Poster:** *New York Heart Association Functional Class Correlates Poorly with Peak Oxygen Consumption during Cardiopulmonary Exercise Tolerance Testing: Implications for Orthotopic Heart Transplantation*; P.L. Eugenio, E.C. Palma, T.J. Vittorio, R. Zolty Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

**(590)** *The Effect of the Patient's Medical Insurance on Post Cardiac Transplant Outcomes; a Single Center Experience*; I. Alesh, A. Srivastava, D. Lanfear, C. Williams, H. Neme, F. Matta, C. Tita, R. Brewer, C. Smith, B. Czerska Heart Vascular Institute, Henry Ford Hospital, Detroit, MI

**(591)** *Pretransplant Medication Nonadherence: An Underestimated Predictor of Poor Outcome after Lung Transplantation*; F. Dobbels<sup>1</sup>, L. Dupont<sup>2</sup>, G.M. Verleden<sup>2</sup>, S. De Geest<sup>1</sup> <sup>1</sup>Katholieke Universiteit Leuven, Leuven, Belgium; <sup>2</sup>University Hospitals of Leuven, Leuven, Belgium

**(592)** *Coping, Psychological Functioning, and Quality of Life among Patients Being Evaluated for Lung Transplantation*; M.R. Green, C.F. Emery, P. Ross, S.D. Moffatt-Bruce, A.L. Pope-Harman, D. Nunley, R. Long, A. Heilman The Ohio State University, Columbus, OH

**(593) Featured Poster:** *Gender Differences in One-Year Waiting List Outcomes in Heart Transplant Candidates: Results from the Waiting for a New Heart Study*; H. Spaderna<sup>1</sup>, D. Zahn<sup>1</sup>, J.M.A. Smits<sup>2</sup>, G. Weidner<sup>1</sup> <sup>1</sup>Johannes Gutenberg University, Mainz, Germany; <sup>2</sup>Eurotransplant International Foundation, Leiden, Netherlands

**(594)** *Is a Short-Term Microaxial VAD More Cost-Effective Than ECMO for Severe Cardiogenic Shock?*; A. Kaan<sup>1</sup>, J. Kealy<sup>1</sup>, B. Chow<sup>2</sup>, Y. Lemarche<sup>2</sup>, A. Cheung<sup>1</sup> <sup>1</sup>St Paul's Hospital, Vancouver, BC, Canada; <sup>2</sup>University of British Columbia, Vancouver, BC, Canada

**(595)** *Incidence, Patterns, and Cost of Permanent Pacing Following Bicaval and Biatial Orthotopic Heart Transplantation*; H.A. Tetteh<sup>1</sup>, F. Kamdar<sup>2</sup>, S. Shumway<sup>2</sup>, R. John<sup>2</sup>, L. Joyce<sup>2</sup>, E. Molina<sup>2</sup>, K. Liao<sup>2</sup> <sup>1</sup>Brigham Women's Hospital, Boston, MA; <sup>2</sup>University of Minnesota, Minneapolis, MN

#### **(596) WITHDRAWN**

**(597)** *Use of Extracorporeal Membrane Oxygenation in Advanced Cardiogenic Shock Complicating an Acute Myocardial Infarction*; C. Bermudez, L. Wei, F. Avila, Y. Toyoda, M. Siegenthaler, C. Spadaccio, S. Mulukutla, J. Schindler, M. Refaat, R. Kormos University of Pittsburgh Medical Center, Pittsburgh, PA

**(598)** *Physiological Changes Following Placement of Continuous Flow and Pulsatile Flow Left Ventricular Assist Devices*; B.A. Boilson<sup>1</sup>, J.A. Schirger<sup>1</sup>, B. Sareyyupoglu<sup>2</sup>, I. Penev<sup>2</sup>, C.G.A. McGregor<sup>2</sup>, L.C. Durham<sup>2</sup>, R.C. Daly<sup>2</sup>, B.S. Edwards<sup>1</sup>, M. M. Redfield<sup>1</sup>, S.J. Park<sup>2</sup> <sup>1</sup>Mayo Clinic, Rochester, MN; <sup>2</sup>Mayo Clinic, Rochester, MN

**(599)** *Management of Patients with Left Ventricular Assist Devices during Natural Disasters*; W. Jones<sup>1</sup>, B.A. Bruckner<sup>1</sup>, L. Garcia<sup>1</sup>, D. Labib<sup>2</sup>, N. Wexali<sup>1</sup>, B. Elias<sup>1</sup>, E. Beyer<sup>1</sup>, T.-A. Guillermo<sup>1</sup>, L. Matthias<sup>1</sup> <sup>1</sup>DeBakey Heart Center, The Methodist Hospital, Houston, TX; <sup>2</sup>Baylor College of Medicine, Houston, TX

**(600)** *Improved Survival in High-Risk Patients with Smaller Implantable LVAD's: Single-Center Experience over 3 Years*; M. Camacho, D.A. Baran, A. Martin, M.J. Zucker Newark Beth Israel Medical Center, Newark, NJ

**(601)** *End-Stage Heart Failure Medical Therapy in Patients Discharge Home with Mechanical Ventricular Assist Devices*; S.V. Chaparro<sup>1</sup>, R. Wong<sup>2</sup>, W.H.W. Tang<sup>2</sup>, R. Starling<sup>2</sup> <sup>1</sup>University of Miami, Miami, FL; <sup>2</sup>Cleveland Clinic, Cleveland, OH

**(602)** *Extracorporeal Life Support: Time Related Performance of a Fully Heparinized Circuit and Polymethylpentene Oxygenator*; G. D'Ancona<sup>1</sup>, G. Santise<sup>1</sup>, S. Sciacca<sup>1</sup>, A. Bertani<sup>1</sup>, F. Pirone<sup>1</sup>, M. Turrisi<sup>1</sup>, M. Parrinello<sup>2</sup>, G. Panarello<sup>2</sup>, M. Pilato<sup>1</sup> <sup>1</sup>ISMETT@UPMC, Palermo, Italy; <sup>2</sup>ISMETT@UPMC, Palermo, Italy

- (603)** *Late Bleeding and Thrombotic Complications with Continuous Flow Ventricular Assist Devices*; M.S. Firstenberg<sup>1</sup>, D. Blais<sup>1</sup>, C. Sai-Sudhakar<sup>1</sup>, A. Hasan<sup>2</sup>, L.B. Louis<sup>1</sup>, D. Talbott<sup>1</sup>, B. Sun<sup>1</sup>, J. Crestanello<sup>1</sup>, P.A. Vesco<sup>1</sup> <sup>1</sup>The Ohio State Medical Center, Columbus, OH; <sup>2</sup>The Ohio State Medical Center, Columbus, OH
- (604)** *Heart Transplantation as an End-Stage Treatment for Ventricular Assist Device (VAD) Infections Due to Multi-Drug Resistant Nosocomial Pathogens*; A. Gkouziouta, P. Sfirakis, E. Manoli, G. Saroglou, P.A. Alivizatos Onassis Cardiac Surgery Centre, Athens, Greece
- (605)** *Assessment of Recovery on Ventricular Assist Device Support*; C. Irving, J. Cassidy, R. Kirk, M. Griselli, A. Hasan, D. Crossland Freeman Hospital, Newcastle upon Tyne, United Kingdom
- (606)** *Mechanical Circulatory Support in Patients with Heart Failure Secondary to Transposition of the Great Arteries*; R. John<sup>3</sup>, D.L. Joyce<sup>1</sup>, S.S. Crow<sup>2</sup>, J.D. St.Louis<sup>3</sup>, E.A. Braunlin<sup>4</sup>, L.A. Pyles<sup>4</sup>, P. Kofflin<sup>4</sup>, L.D. Joyce<sup>3</sup> <sup>1</sup>Stanford University, Palo Alto, CA; <sup>2</sup>Mayo Clinic, Rochester, MN; <sup>3</sup>University of Minnesota, Minneapolis, MN; <sup>4</sup>University of Minnesota, Minneapolis, MN
- (607)** *Use of a CardioWest TAH-t for High Risk Patients Reduces Complications and Improves Survival*; M. Flattery, L. Ohler, K. Doolin, M. Hess, R. Cooke, S. Harton, V. Kasirajan Virginia Commonwealth University Health System, Richmond, VA
- (608)** *Effects of the HeartMate II Continuous-Flow Left Ventricular Assist Device on RV Function*; S. Lee<sup>1</sup>, F. Kamdar<sup>1</sup>, R. Madlon-Kay<sup>1</sup>, R. John<sup>2</sup> <sup>1</sup>University of Minnesota, Minneapolis, MN; <sup>2</sup>University of Minnesota, Minneapolis, MN
- (609)** *Improved Outcomes and Decreased Length of Stay in LVAD Patients: Increased Utilization of Cardiac Rehabilitation Centers*; T. Martin, M.J. Zucker, D. Baran, M. Camacho Newark Beth Israel Medical Center, Newark, NJ
- (610)** *Impact of Illness Acuity on Blood Products Usage in Patients Implanted with Left Ventricular Assist Devices (LVAD)*; N.O. Mason, A.G. Kfoury, L. Janicki, S. Stoker, S.P. Clayson, G.E. Thomsen, B.D. Berquist, S.N. Hurst, P.W. Fisher, B.B. Reid Intermountain Medical Center, Murray, UT
- (611)** *Neurological Complications with Pulsatile and Rotary Blood Pumps*; T. Mussivand, K.S. Holmes University of Ottawa Heart Institute, Ottawa, ON, Canada
- (612)** *Paradigm Shift in the Management of Acute Cardiogenic Shock: Use of Permanent, Dischargeable Left Ventricular Assist Device as a Bridge to Transplantation*; J. Patel, S.H. Bailey, S. Murali, G.J. Magovern, D.A. Dean Allegheny General Hospital, Pittsburgh, PA
- (613)** *Mechanical Circulatory Support in Cardiogenic Shock and Multiorgan Failure: Can We Predict Survival?*; E.V. Potapov, A. Stepanenko, F.H. Ba Fadhil, T. Krabatsch, F. Hennig, Y. Weng, M. Pasic, H.B. Lehmkuhl, R. Hetzer Deutsches Herzzentrum Berlin, Berlin, Germany
- (614)** *Risk Factor Analysis of Long-Term Support with Left Ventricular Assist System: Insights for Destination Therapy*; S. Saito, G. Matsumiya, T. Sakaguchi, T. Fujita, T. Yamauchi, T. Kuratani, H. Ichikawa, S. Yoshiki Osaka University Graduate School of Medicine, Suita, Osaka, Japan
- (615)** *Good Outcome for LVAD Patients Supported by the HeartMate II for a Mean Time of Almost One Year*; K. Sander<sup>1</sup>, C. Bogelund Andersen<sup>4</sup>, S. Boesgaard<sup>2</sup>, F. Gustafsson<sup>2</sup>, P.B. Hansen<sup>3</sup>, S.A. Mortensen<sup>2</sup>, P.S. Olsen<sup>1</sup> <sup>1</sup>Rigshospitalet, Copenhagen, Denmark; <sup>2</sup>Rigshospitalet, Copenhagen, Denmark; <sup>3</sup>Rigshospitalet, Copenhagen, Denmark; <sup>4</sup>Rigshospitalet, Copenhagen, Denmark
- (616)** *Appropriate Treatment of Complications Could Extend Supporting Duration of Extracorporeal Left Ventricular Assist System in Patients with End-Stage Heart Failure*; T. Sasaoka<sup>1</sup>, T.S. Kato<sup>1</sup>, N. Oda<sup>1</sup>, M. Yanase<sup>1</sup>, K. Hashimura<sup>1</sup>, T. Funatsu<sup>1</sup>, J. Kobayashi<sup>1</sup>, T. Shishido<sup>2</sup>, K. Komamura<sup>3</sup>, M. Isobe<sup>4</sup>, T. Nakatani<sup>1</sup> <sup>1</sup>National Cardiovascular Center, Osaka, Japan; <sup>2</sup>National Cardiovascular Center Research Institute, Osaka, Japan; <sup>3</sup>Hyogo University of Health Sciences, Hyogo, Japan; <sup>4</sup>Tokyo Medical and Dental University, Tokyo, Japan
- (617)** *Leukocyte Gene Expression Profiles of Hyperbilirubinemia Following Mechanical Circulatory Support Device Implantation*; K. Shahzad<sup>1</sup>, A. Sinha<sup>2</sup>, F. Latif<sup>1</sup>, M. Cadeiras<sup>1</sup>, S. Oz<sup>1</sup>, Y. Naka<sup>1</sup>, M.C. Deng<sup>1</sup> <sup>1</sup>Columbia University Medical Center, New York, NY; <sup>2</sup>Columbia University, New York, NY
- (618)** *Clinical Results with the Axial Flow Pump INCOR: A Single-Centre Experience*; R. Tandler, M. Kondruweit, A. Reimann, M. Weyand University of Erlangen, Erlangen, Bavaria, Germany

**(619) Featured Poster:** *Mobilization and Physiotherapy of Patients with a Levitronix CentriMag® Short-Term Mechanical Circulatory Support Device*; C. Bindoff<sup>2</sup>, R. Dean<sup>1</sup>, A. Bashford<sup>3</sup>, R. Hards<sup>1</sup>, G. Dreyfus<sup>1</sup>, A. Khaghani<sup>1</sup>, E. Birks<sup>1</sup> <sup>1</sup>Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; <sup>2</sup>Royal Brompton and Harefield NHS Trust, London, Middlesex, United Kingdom; <sup>3</sup>Royal Brompton and Harefield NHS Trust, London, Middlesex, United Kingdom

**(620)** *Percutaneous Left Ventricular Remodeling in Chronic Heart Failure Secondary to Left Ventricular Aneurysm*; K. Vershave, B. Kar, P. Loyalka, R. Delgado, I. Gregoric Texas Heart Institute, Houston, TX

**(621)** *Selecting the Patient Too Debilitated for Good Long-Term Functional Outcome after Lung Transplantation*; S. Bansal<sup>1</sup>, P.H. Tsau<sup>1</sup>, S.R. Knoper<sup>2</sup>, J. Wild<sup>1</sup>, R. Coelho-Anderson<sup>1</sup>, O. L. Amabile<sup>1</sup>, M.J. Moulton<sup>1</sup> <sup>1</sup>University of Arizona, Tucson, AZ; <sup>2</sup>University of Arizona, Tucson, AZ

**(622)** *Doxycycline Improves Decline in Pulmonary Function in OB/BOS*; T. Maughan<sup>1</sup>, K. Peterson-Short<sup>1</sup>, C. Truax<sup>1</sup>, S. Lee<sup>1</sup>, N. Kenyon<sup>1</sup>, T.G. Liou<sup>2</sup>, B.C. Cahill<sup>1,2</sup> <sup>1</sup>University of Utah, Salt Lake City, UT; <sup>2</sup>University of Utah, Salt Lake City, UT

**(623)** *Survival of Patients with Alpha 1 Antitrypsin Deficiency Receiving Lung Transplantation for Emphysema – A Review of 20 Years' Experience at a Major UK Transplant Centre*; S. Chatterji, J. Parmar Papworth Hospital, Cambridge, United Kingdom

**(624)** *Lung Function after Fundoplication in Transplanted Patients with Gastroesophageal Reflux Disease (GERD)*; G. Dauriat<sup>1</sup>, G. Thabut<sup>1</sup>, O. Brugiere<sup>1</sup>, J.P. Marmuse<sup>2</sup>, C. Clerici<sup>3</sup>, Y. Castier<sup>4</sup>, A.C. Metivier<sup>1</sup>, G. Biondi<sup>1</sup>, M. Fournier<sup>1</sup>, H. Mal<sup>1</sup> <sup>1</sup>Hôpital Bichat, Paris, France, Metropolitan; <sup>2</sup>Hôpital Bichat, Paris, France, Metropolitan; <sup>3</sup>Hôpital Bichat, Paris, France, Metropolitan; <sup>4</sup>Hôpital Bichat, Paris, France, Metropolitan

**(625)** *Impact of Coronary Artery Disease in Lung Transplant Patients. A Single Center Experience*; L. Garcia-Covarrubias, Y. Toyoda, M. Crespo, J. Pilewski, B. Johnson, J.K. Bhama, C.A. Bermudez University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA

**(626)** *Increased Incidence of Acute Rejection in Patients with Increased GER, 1 Year after LTx*; V. Mertens<sup>1</sup>, K. Blondeau<sup>1</sup>, D. Van Raemdonck<sup>2</sup>, G. Blondeau<sup>2</sup>, D. Sifrim<sup>1</sup>, L.J. Dupont<sup>2</sup> <sup>1</sup>University Hospital Gasthuisberg, Leuven, Belgium; <sup>2</sup>University Hospital Gasthuisberg, Leuven, Belgium

**(627)** *Oxidative Stress in Lung Allograft Recipients with and without Graft Dysfunction*; P.M. Naik<sup>1</sup>, L.A.S. Brown<sup>3</sup>, E.C. Lawrence<sup>1</sup>, S.D. Force<sup>2</sup>, A. Ramirez<sup>1</sup>, D.C. Neujahr<sup>1</sup>, M. Foster<sup>1</sup>, P.O. Mitchell<sup>4</sup>, A. Pelaez<sup>1</sup> <sup>1</sup>Emory University School of Medicine, Atlanta, GA; <sup>2</sup>Emory University School of Medicine, Atlanta, GA; <sup>3</sup>Emory University School of Medicine, Atlanta, GA; <sup>4</sup>Emory University School of Medicine, Atlanta, GA

**(628)** *Systemic Sclerosis and Lung Transplantation: A Single Center Experience*; R. Saggarr<sup>1</sup>, R. Saggarr<sup>1</sup>, D. Khanna<sup>3</sup>, D.E. Furst<sup>3</sup>, G.S. Park<sup>3</sup>, J.A. Belperio<sup>1</sup>, S. Weigt<sup>1</sup>, D.A. Zisman<sup>1</sup>, S. Shapiro<sup>1</sup>, C. Hunter<sup>2</sup>, P.J. Clements<sup>3</sup>, J.P. Lynch<sup>1</sup>, A. Ardehali<sup>2</sup>, D.J. Ross<sup>1</sup> <sup>1</sup>David Geffen School of Medicine, UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine, UCLA, Los Angeles, CA; <sup>3</sup>David Geffen School of Medicine, UCLA, Los Angeles, CA

**(629)** *Lung Transplantation for Patients on Mechanical Ventilation: Proceed with Caution*; J.W. Su, D.P. Mason, G.B. Pettersson, S.C. Murthy, A.A. Mehta, K.G. Reyes, J.J. Yun, M.M. Budev Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH

**(630)** *Carbapenem Resistance Klebsiella Pneumoniae among Lung Transplant Recipients*; Y. Raviv, A. Amital, D. Shitrit, B.D. Fox, M.R. Kramer Pulmonary Institute, Petach Tikva, Tel Aviv, Israel

**(631)** *Tackling Pseudomonas Infection in Our HeartMate II Patients*; J.N. Baker<sup>1</sup>, S.C. Ennis<sup>1</sup>, J.M. Camuso<sup>1</sup>, C.A. Ennis<sup>1</sup>, K.M. Lam<sup>2</sup>, S.A. Moore<sup>2</sup>, T.E. MacGillivray<sup>1</sup> <sup>1</sup>Massachusetts General Hospital, Boston, MA; <sup>2</sup>Massachusetts General Hospital, Boston, MA

**(632) Featured Poster:** *Infections in Patients on Continuous Flow LVAD: Epidemiology and Role in Causation of Cerebrovascular Accidents*; S.S. Basra<sup>1</sup>, A.A. Attallah<sup>2</sup>, R. Wagle<sup>2</sup>, P. Loyalka<sup>2</sup>, B. Kar<sup>1</sup> <sup>1</sup>University of Texas Health Science Center, Houston, TX; <sup>2</sup>Baylor College of Medicine, Houston, TX

- (633)** *Lack of Relationship between Immunosuppression and Epstein-Barr Viral Load/Lymphoproliferative Disease in Pediatric Heart Transplant Recipients*; F.I. Calo Carducci<sup>1</sup>, G. Grutter<sup>2</sup>, P. Rossi<sup>1</sup>, P. D'Argenio<sup>1</sup>, F. Parisi<sup>2</sup> <sup>1</sup>Pediatric Hospital "Bambino Gesù", Rome, Italy; <sup>2</sup>Pediatric Hospital "Bambino Gesù", Rome, Italy
- (634)** *Clinical Outcome of Brazilian Lung Transplant Recipients after Respiratory Virus Infections*; S.V. Campos<sup>1</sup>, M.L. Caramori<sup>1</sup>, R.O. Teixeira<sup>1</sup>, J.E. Afonso, Jr.<sup>1</sup>, R.M. Carraro<sup>1</sup>, T.V. Strabelli<sup>2</sup>, P.M. Pego-Fernandes<sup>1</sup>, F.B. Jatene<sup>1</sup>, L.S. Vilas-Boas<sup>3</sup>, C.M. Machado<sup>3</sup> <sup>1</sup>Heart Institute do Hospital das Clinicas FMUSP, Sao Paulo, Brazil; <sup>2</sup>Heart Institute do Hospital das Clinicas FMUSP, Sao Paulo, Brazil; <sup>3</sup>Institute of Tropical Medicine - FMUSP, Sao Paulo, Brazil
- (635)** *Clinical Impact of a New Real-Time PCR Assay (SeptiFast®) for Rapid Detection of Pathogens in Patients Bridged to Transplantation*; A. Chaidaroglou<sup>1</sup>, E. Manoli<sup>2</sup>, A. Gkouziouta<sup>1</sup>, P. Gourzi<sup>1</sup>, M.P. Pantou<sup>1</sup>, D. Hilidou<sup>3</sup>, D. Degiannis<sup>1</sup>, G. Saroglou<sup>3</sup>, P. Alivizatos<sup>3</sup> <sup>1</sup>Onassis Cardiac Surgery Center, Athens, Greece; <sup>2</sup>Onassis Cardiac Surgery Center, Athens, Greece; <sup>3</sup>Onassis Cardiac Surgery Center, Athens, Greece
- (636)** *Adenovirus Is Not Associated with Graft Dysfunction Post Lung Transplantation and Does Not Warrant Anti-Viral Therapy*; T.W.V. Daniels, D.C. Chambers, B.K.-T. Tsang, H.E. Seale, T.M. Leishfield, F.D. Kermeen, P.M.A. Hopkins Prince Charles Hospital, Brisbane, Queensland, Australia
- (637)** *Parainfluenza Infection after Lung Transplantation Is a Strong Predictor for Obliterative Bronchiolitis*; T.W.V. Daniels, B.K.-T. Tsang, D.C. Chambers, F.D. Kermeen, J.R. Walsh, C. Beck, P.M. Hopkins Prince Charles Hospital, Brisbane, Queensland, Australia
- (638)** *Effect of Preoperative Dental and Otorhinolaryngeal Foci on Posttransplantation Outcome*; S. Meyer<sup>1</sup>, C. Ivanov<sup>1</sup>, L. Baholli<sup>1</sup>, D. Knappe<sup>1</sup>, C. Thomsen<sup>1</sup>, A. von Stritzky<sup>1</sup>, F.M. Wagner<sup>2</sup>, H. Reichenspurner<sup>2</sup>, A. Costard-Jackle<sup>1</sup> <sup>1</sup>University Heart Center Hamburg, Hamburg, Germany; <sup>2</sup>University Heart Center Hamburg, Hamburg, Germany
- (639)** *Surreptitious Aspergillus Colonization Is Not Associated with Poor Outcome While on Suppressive Azole Therapy*; J. Patel<sup>1</sup>, K. Kiyosaki<sup>1</sup>, B. Kubak<sup>1</sup>, M. Kawano<sup>1</sup>, J. Patel<sup>1</sup>, A. Ankrom<sup>1</sup>, M. Kittleson<sup>1</sup>, E. Shao<sup>1</sup>, J. Moriguchi<sup>1</sup>, A. Ardehali<sup>2</sup>, J. Kobashigawa<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA
- (640)** *Infections (INF) after Heart Transplantation (HT) with Basiliximab Induction: A Single Center Experience*; V. Stosor<sup>1,2</sup>, T. Zembower<sup>1</sup>, M. Angarone<sup>1</sup>, E. McGee<sup>4</sup>, K. Scarsi<sup>1</sup>, K. Grady<sup>4</sup>, W. Cotts<sup>3</sup>, M. Ison<sup>1,2</sup> <sup>1</sup>Northwestern University Feinberg School of Medicine, Chicago, IL; <sup>2</sup>Northwestern University Feinberg School of Medicine, Chicago, IL; <sup>3</sup>Northwestern University Feinberg School of Medicine, Chicago, IL; <sup>4</sup>Northwestern University Feinberg School of Medicine, Chicago, IL
- (641)** *Infectious Complications among Elderly Lung Transplant Recipients Receiving Alemtuzumab*; A.A. Vadnerkar<sup>1</sup>, M.H. Nguyen<sup>1</sup>, Y. Toyoda<sup>2</sup>, K. McCurry<sup>2</sup>, C. Bermudez<sup>2</sup>, J. Pilewski<sup>3</sup>, M. Crespo<sup>3</sup>, E.J. Kwak<sup>1</sup>, C.J. Clancy<sup>1</sup> <sup>1</sup>University Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>University Pittsburgh Medical Center, Pittsburgh, PA; <sup>3</sup>University Pittsburgh Medical Center, Pittsburgh, PA
- (642)** *Effectiveness of Targeted Pro-Active Management of Aspergillus fumigatus Infections before and after Lung Transplantation*; D.A. Wearmouth<sup>1</sup>, C. Rennison<sup>1</sup>, A. Fisher<sup>2</sup>, J. Lordan<sup>2</sup>, P.A. Corris<sup>2</sup>, F.K. Gould<sup>1</sup> <sup>1</sup>Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; <sup>2</sup>Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom
- (643)** *Benefit of Fluconazole Prophylaxis for Candidemia in Patients with Ventricular Assist Devices (VAD)*; C. Williams<sup>1</sup>, E.N. Sorensen<sup>1</sup>, M. Lindsay<sup>1</sup>, B. Griffith<sup>2</sup>, S. Moainie<sup>2</sup>, E. Feller<sup>2</sup>, S. Murthi<sup>2</sup>, G. Forrest<sup>2</sup> <sup>1</sup>Univ. of Maryland Medical Center, Baltimore, MD; <sup>2</sup>Univ. of Maryland, Baltimore, MD
- (644)** *Different Intra-Operative Extracorporeal Circulatory Support Techniques in Lung Transplantation Surgery Lead to Significant Differences in Blood Product Management*; H.B. Bittner, K. Binner, S. Lehmann, F.W. Mohr Heart Center of the University of Leipzig, Leipzig, Germany
- (645)** *Invasive Biopsy Is Effective and Useful after Lung Transplant*; C.L. Burdett, R. Critchley, F. Black, S. Barnard, S.C. Clark, P.A. Corris, K.F. Gould, T. Butt, J.H. Dark Freeman Hospital, Newcastle upon Tyne, United Kingdom
- (646)** *Incidence of Cancer after Lung Transplantation in France*; C. Cantrelle, Transplant Teams, F. Pessione, J.M. Rebibou, B. Loty Agence de la Biomédecine, Saint Denis La Plaine, France

- (647)** *Calcineurin Inhibition Can Be Safely Maintained in Lung Transplantation Complicated by Reversible Posterior Leukoencephalopathy Syndrome*; B.K.T. Tsang, F. Kermeen, P.M.A. Hopkins, D.C. Chambers The Prince Charles Hospital, Brisbane, Queensland, Australia
- (648)** *A Review of Malignancies Developing Post Lung Transplantation and the Effect on Survival*; S. Chatterji, J. Parmar Papworth Hospital, Cambridge, United Kingdom
- (649)** *Survival of Lung Transplant Recipients with Incidental Finding of Cancer in the Explanted Lung(s)*; M.M. Crespo<sup>1</sup>, K.R. McCurry<sup>2</sup>, S. Dacic<sup>3</sup>, D. Zaltonis<sup>2</sup>, B.A. Johnson<sup>1</sup>, Y. Toyoda<sup>2</sup>, P. George<sup>1</sup>, C. Bermudez<sup>2</sup>, J.M. Pilewski<sup>1</sup> <sup>1</sup>University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>3</sup>University of Pittsburgh Medical Center, Pittsburgh, PA
- (650)** *Increased Risk of Colon Carcinoma in Lung Transplant Recipients with Cystic Fibrosis*; M. Francois<sup>1</sup>, H. Thomas<sup>1</sup>, K. Radford<sup>1</sup>, D. Hawes<sup>1</sup>, T. Mack<sup>2</sup>, R. Cornwell<sup>2</sup>, K. Meyer<sup>2</sup> <sup>1</sup>University of Wisconsin Hospital and Clinics, Madison, WI; <sup>2</sup>University of Wisconsin School of Medicine and Public Health, Madison, WI
- (651)** *Increased Mortality in Ganciclovir Resistant CMV Infection in Lung Transplantation*; J. Gagermeier<sup>1</sup>, C. Alex<sup>1</sup>, D. Dilling<sup>1</sup>, R. Love<sup>2</sup>, C. Wigfield<sup>2</sup>, J. Rusinak<sup>1</sup>, P. O'Keefe<sup>1</sup>, C. Schriever<sup>1</sup>, N. Lurain<sup>3</sup> <sup>1</sup>Loyola University Medical Center, Maywood, IL; <sup>2</sup>Loyola University Medical Center, Maywood, IL; <sup>3</sup>Rush University, Chicago, IL
- (652)** *Symptomatic Pulmonary Emboli in Lung Transplant Recipients*; S.A. Hennessy, E.L. Grogan, N.L. Harthun, D.R. Jones, B.D. Kozower, C.L. Lau University of Virginia, Charlottesville, VA
- (653)** *Death with a Functioning Graft after Lung Transplantation: Lessons from the Kidney*; C.-L. Liew<sup>1</sup>, M. Benzimra<sup>1</sup>, K. Hanning<sup>1</sup>, A. Havryk<sup>1</sup>, M. Plit<sup>1</sup>, S. Rainer<sup>2</sup>, M.A. Malouf<sup>1</sup>, A.R. Glanville<sup>1</sup> <sup>1</sup>St Vincent's Hospital, Sydney, NSW, Australia; <sup>2</sup>St Vincent's Hospital, Sydney, NSW, Australia
- (654)** *No Age Difference in Development of Obliterative Airway Disease in Tracheal Allografts*; Y. Niu, Z. Liu, H. Fan, H. Cao, G. Liu, Q. Shi Shanghai East Hospital Affiliated to Tongji University, Shanghai, China
- (655)** *Incidence of De Novo Malignancies in Lung Transplant Recipients in Italy: A Single-Institution Experience, 1991-2008*; M. Agozzino<sup>1</sup>, P. Piselli<sup>2</sup>, M. Vigano<sup>3</sup>, A. D'Armini<sup>3</sup>, A. Cascina<sup>4</sup>, T. Oggionni<sup>4</sup>, F. Meloni<sup>4</sup>, C. Cimaglia<sup>2</sup>, A. Agresta<sup>2</sup>, D. Serraino<sup>5</sup>, E. Arbustini<sup>1</sup> <sup>1</sup>IRCCS Foundation Policlinico "San Matteo", Pavia, Italy; <sup>2</sup>National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy; <sup>3</sup>IRCCS Foundation Policlinico "San Matteo", Pavia, Italy; <sup>4</sup>IRCCS Foundation Policlinico "San Matteo", Pavia, Italy; <sup>5</sup>IRCCS Centro di Riferimento Oncologico, Aviano (PN), Italy
- (656)** *Survival Following Single Lung Transplant for Pulmonary Fibrosis: Satisfactory Results in Our 16-Years Single Centre Experience*; P. Totaro<sup>1</sup>, C. Tramontin<sup>1</sup>, S. Nicolardi<sup>1</sup>, C. Pellegrini<sup>1</sup>, G. Orlandoni<sup>2</sup>, T. Oggionni<sup>3</sup>, A.M. D'Armini<sup>1</sup>, M. Vigano<sup>1</sup> <sup>1</sup>IRCCS Foundation S Matteo, Pavia, Italy; <sup>2</sup>IRCCS Foundation S Matteo, Pavia, Italy; <sup>3</sup>IRCCS Foundation S Matteo, Pavia, Italy
- (657)** *Open Lung Ventilation Mitigates Lung Ischemia Reperfusion Injury*; N.P. van der Kaaij<sup>1</sup>, J. Kluin<sup>2</sup>, R.A. Lachmann<sup>3</sup>, M.A. den Bakker<sup>4</sup>, J.J. Haitsma<sup>3</sup>, R.W.F. de Bruin<sup>5</sup>, B. Lachmann<sup>3</sup>, A.J.J.C. Bogers<sup>1</sup> <sup>1</sup>Erasmus MC, Rotterdam, Netherlands; <sup>2</sup>UMC Utrecht, Utrecht, Netherlands; <sup>3</sup>Erasmus MC, Rotterdam, Netherlands; <sup>4</sup>Erasmus MC, Rotterdam, Netherlands; <sup>5</sup>Erasmus MC, Rotterdam, Netherlands
- (658) Featured Poster:** *The Impact of Aspergillus Colonization on Acute Rejection and Lymphocytic Bronchiolitis in Lung Transplant Patients*; S.S. Weigt<sup>1</sup>, C.-H. Tseng<sup>2</sup>, C. Huang<sup>1</sup>, D.J. Ross<sup>1</sup>, R. Sagar<sup>1</sup>, R. Sagar<sup>1</sup>, J.P. Lynch<sup>1</sup>, A. Gregson<sup>3</sup>, B.M. Kubak<sup>3</sup>, A. Ardehali<sup>4</sup>, R.M. Elashoff<sup>2</sup>, J.A. Belperio<sup>1</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>3</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>4</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA
- (659)** *Strain and Strain Rate in Pediatric Cardiac Transplant Recipients: Comparison to Normal Children*; J. Bodtke, T.H. Best, R. Sachdeva, E.A. Frazier, W.R. Morrow Arkansas Children's Hospital, Little Rock, AR
- (660)** *Outcomes with Asymptomatic Antibody-Mediated Rejection in Pediatric Heart Transplant Patients*; E.L.P. Chan, D.S. Levi, J.C. Alejos, G.S. Perens Mattel Children's Hospital at UCLA, Los Angeles, CA
- (661)** *Heart Transplantation Against a Positive Crossmatch in Highly Sensitized Children*; S.F. Chandler<sup>1</sup>, C. Almond<sup>1</sup>, T.P. Singh<sup>1</sup>, H. Mah<sup>2</sup>, E. Milford<sup>2</sup>, G.S. Matte<sup>3</sup>, H. Bastardi<sup>1</sup>, J. Mayer<sup>3</sup>, F. Fynn-Thompson<sup>3</sup>, E.D. Blume<sup>1</sup> <sup>1</sup>Children's Hospital Boston, Boston, MA; <sup>2</sup>Brigham Women's Hospital, Boston, MA; <sup>3</sup>Children's Hospital Boston, Boston, MA

**(662) Volume-Outcome Relationships in Pediatric Heart Transplantation;** R.R. Davies<sup>1</sup>, M.J. Russo<sup>1</sup>, J.M. Quaegebeur<sup>1</sup>, S.R. Mital<sup>3</sup>, K.N. Hong<sup>1</sup>, R.S. Mosca<sup>1</sup>, J.M. Chen<sup>2</sup> <sup>1</sup>Children's Hospital of New York-Presbyterian, New York, NY; <sup>2</sup>Weill Medical College of Cornell University, New York, NY

**(663) Effect of ABO-Incompatible Listing on Infant Heart Transplant Waitlist Outcomes: Analysis of the United Network for Organ Sharing (UNOS) Database;** M.D. Everitt<sup>1</sup>, A.E. Donaldson<sup>1</sup>, D.G. Renlund<sup>2</sup>, E.A. Bullock<sup>1</sup>, M. Cardon<sup>1</sup>, P. Fisher<sup>2</sup>, P.C. Burch<sup>1</sup>, P.C. Kouretas<sup>1</sup>, A.K. Kaza<sup>1</sup>, J.A. Hawkins<sup>1</sup>, L.Y. Tani<sup>1</sup>, C. Norlin<sup>1</sup>, A.G. Kfoury<sup>2</sup> <sup>1</sup>University of Utah, Salt Lake City, UT; <sup>2</sup>Intermountain Medical Center, Salt Lake City, UT

**(664) Liver Cirrhosis in Patients after Fontan Operation;** R. Gupta<sup>1</sup>, S.M. Pham<sup>3</sup>, M. Rodriguez<sup>2</sup>, T.G. Bueno<sup>1</sup>, P. Rusconi<sup>1</sup> <sup>1</sup>University of Miami, Miami, FL; <sup>2</sup>University of Miami, Miami, FL; <sup>3</sup>University of Miami, Miami, FL

**(665) Post-Transplant Diabetes in Pediatric Heart Transplant Recipients Treated with Sirolimus;** E. Hathout, J. Fitts, J. Johnston, R. Chinnock Loma Linda University, Loma Linda, CA

**(666) Featured Poster: Predictors of Obesity in Children after Heart Transplant: An Analysis of the ISHLT Pediatric Heart Transplant Registry;** B.D. Kaufman<sup>1</sup>, S. Chuai<sup>2</sup>, F. Dobbels<sup>3</sup>, R.E. Shaddy<sup>1</sup> <sup>1</sup>University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, PA; <sup>2</sup>University of Pennsylvania, School of Medicine, Philadelphia, PA; <sup>3</sup>University of Leuven, Leuven, Belgium

**(667) Featured Poster: The Use of Intravascular Ultrasound in the Diagnosis of Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients: A Ten Year Experience;** M.A. Kuhn<sup>1</sup>, R.E. Chinnock<sup>2</sup>, D.D. Deming<sup>2</sup>, R.L. Larsen<sup>1</sup>, A.J. Razzouk<sup>3</sup>, L.L. Bailey<sup>3</sup> <sup>1</sup>Loma Linda University Medical Center and Children's Hospital, Loma Linda, CA; <sup>2</sup>Loma Linda University Medical Center and Children's Hospital, Loma Linda, CA; <sup>3</sup>Loma Linda University Medical and Children's Hospital, Loma Linda, CA

**(668) Does Cytomegalovirus Serology Impact Outcome Following Pediatric Heart Transplantation?;** W.T. Mahle<sup>1</sup>, J.C. Alejos<sup>2</sup>, M. Foushee<sup>3</sup>, D.C. Naftel<sup>3</sup>, J. Rao<sup>4</sup>, R. Caldwell<sup>5</sup>, K. Uzark<sup>6</sup>, A.M. Berg<sup>1</sup>, K.R. Kanter<sup>1</sup> <sup>1</sup>Emory University, Atlanta; <sup>2</sup>UCLA, Los Angeles; <sup>3</sup>University of Alabama Birmingham, Birmingham; <sup>4</sup>Riley Children's Hospital, Indianapolis; <sup>5</sup>Cincinnati Children's Medical Center, Cincinnati

**(669) Featured Poster: Intermediate Results of Sirolimus (SRL) with Reduced Calcineurin Inhibitors (CNI) in Pediatric Heart Transplant (Htx) Recipients – A Controlled Study;** K.L. Matthews, J. Gossett, P. Vande Kappelle, G. Jellen, E. Pahl Children's Memorial Hospital, Chicago, IL

**(670) Featured Poster: Lung Re-Transplantation in Children: Successful When Selectively Applied;** D.L.S. Morales<sup>1</sup>, F. Zafar<sup>1</sup>, M.G. Schechter<sup>2</sup>, J.W. Rossano<sup>3</sup>, O. Elidemir<sup>2</sup>, G.B. Mallory<sup>2</sup>, J.S. Heinle<sup>1</sup> <sup>1</sup>Texas Children's Hospital, Houston, TX; <sup>2</sup>Texas Children's Hospital, Houston, TX; <sup>3</sup>Texas Children's Hospital, Houston, TX

**(671) Two Decades of Pediatric Lung Transplantation in the United States;** D.L.S. Morales<sup>1</sup>, F. Zafar<sup>1</sup>, J.W. Rossano<sup>3</sup>, M.G. Schechter<sup>2</sup>, G.B. Mallory<sup>2</sup>, O. Elidemir<sup>2</sup>, J.S. Heinle<sup>1</sup> <sup>1</sup>Texas Children's Hospital, Houston, TX; <sup>2</sup>Texas Children's Hospital, Houston, TX; <sup>3</sup>Texas Children's Hospital, Houston, TX

**(672) Prevalence and Significance of Circulating Antibodies Prior to Lung and Heart/Lung Transplantation in Pediatric Patients: Analysis of 704 Transplants from the UNOS Database;** D.L.S. Morales<sup>1</sup>, F. Zafar<sup>1</sup>, J.W. Rossano<sup>2</sup>, G.B. Mallory<sup>3</sup>, O. Elidemir<sup>3</sup>, M.G. Schechter<sup>3</sup>, J.S. Heinle<sup>1</sup> <sup>1</sup>Texas Children's Hospital, Houston, TX; <sup>2</sup>Texas Children's Hospital, Houston, TX; <sup>3</sup>Texas Children's Hospital, Houston, TX

**(673) Presensitization Is Not a Risk Factor for Pediatric Heart Transplantation;** C. Ravishankar<sup>1</sup>, T.E. Dominguez<sup>2</sup>, B. Hanna<sup>1</sup>, S. Paridon<sup>1</sup>, B. Kaufman<sup>1</sup> <sup>1</sup>The Children's Hospital of Philadelphia, Philadelphia, PA; <sup>2</sup>The Children's Hospital of Philadelphia, Philadelphia, PA

**(674) Real-Time 3D Echo Guidance during 339 Biopsies in Children: Improved Safety and Minimized Tricuspid Valve Injury;** J.M. Ringewald, G.H. Baker, A.A. Atz, M.A. Scheurer, G.S. Shirali, V.M. Bandisode Medical University of South Carolina, Charleston, SC

**(675) Etiology-Specific Prognostic Value of Serial Measurements of NT-proBNP in Heart Failure;** P. Rusconi, D.D. Kinnamon, C. Ratnasamy, S.E. Lipshultz Miller School of Medicine University of Miami, Miami, FL

**(676) Change in Bridge Philosophy in Infants and Children from Transplantation to Recovery, a 10 Year Experience;** J.G. Copeland, H. Zimmerman, R.G. Smith, D. Covington, R.K. Bose University of Arizona, Tucson, AZ

**(677) Do Short Waitlist Times Negatively Impact Outcomes after Lung Transplantation?**; D.F. Dilling<sup>1</sup>, C.H. Wigfield<sup>2</sup>, J.P. Gagermeier<sup>1</sup>, C.G. Alex<sup>1</sup>, R.B. Love<sup>2</sup> <sup>1</sup>Loyola University Chicago, Maywood, IL; <sup>2</sup>Loyola University Chicago, Maywood, IL

**(678) A Comparison of Established Screening Scales To Predict Survival in Patients Requiring Mechanical Circulatory Support**; A. Mushtaq, J. Xu, B. Elias, C. Orrego, G. Torre-Amione, B. Bruckner, M. Loebe, J. Estep The Methodist DeBakey Heart Vascular Center, Houston, TX

**(679) Outcomes of 21 Years of Pediatric Cardiac Transplantation: The Freeman Experience**; C. Irving, G. Parry, A. Hasan, R. Kirk Freeman Hospital, Newcastle upon Tyne, United Kingdom

**(680) WITHDRAWN**

**(681) Chimerism in Pediatric Heart Transplants**; E. Minami<sup>1</sup>, G. Perens<sup>2</sup>, C. Castellani<sup>3</sup>, V. Allada<sup>4</sup>, C.E. Murry<sup>5</sup> <sup>1</sup>University of Washington, Seattle, WA; <sup>2</sup>University of California, Los Angeles, Los Angeles, CA; <sup>3</sup>University of Padua, Padua, Italy; <sup>4</sup>University of Pittsburgh, Pittsburgh, PA; <sup>5</sup>University of Washington, Seattle, WA

**SATURDAY, APRIL 25, 2009**

**8:15 AM – 10:15 AM**

**PLENARY SESSION (Main Theatre)**

*Chairs: James K. Kirklin, MD and Hermann Reichenspurner, MD, PhD*

**8:15 AM Awards Presentations**, Duane Davis, MD, Duke University Medical Center, Durham, NC

**8:30 AM (682) WITHDRAWN**

**8:30 AM Special Invited Lecture:** "Waiting for a Donor Organ: An International Patient Perspective on an Endless Journey: A Call for Action" delivered by Stephen Bacon, with an introduction by Bruce R. Rosengard, MD, FRCS

**8:50 AM (683) Featured Abstract:** *Core Lab Analysis of Intravascular Ultrasound Studies from the TICTAC Trial (Tacrolimus in Combination, Tacrolimus Alone Compared): Is There a Price To Pay for Monotherapy?*; D.A. Baran<sup>1</sup>, A. Pillai<sup>1</sup>, A. Patil<sup>1</sup>, C. Carr<sup>1</sup>, J. Prevost-Fernandez<sup>1</sup>, S. Nicholls<sup>3</sup>, K. Wolski<sup>3</sup>, S. Pardi<sup>1</sup>, V. Hou<sup>1</sup>, M. Binetti<sup>1</sup>, M.G. SanAugustin<sup>1</sup>, J. Ebuenga<sup>1</sup>, M. Camacho<sup>1</sup>, L. McBride<sup>1</sup>, A.L. Gass<sup>2</sup>, M. Cohen<sup>1</sup>, M.J. Zucker<sup>1</sup> <sup>1</sup>Transplant Center, Newark, NJ; <sup>2</sup>Westchester County Medical Center, Westchester, NY; <sup>3</sup>Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH

**Invited Discussant:** Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA

**9:10 AM (684) Featured Abstract:** *Intraoperative Versus Postoperative Rabbit Anti-Thymoglobulin Globulin Induction for Bilateral Lung Transplantation: A Single Center Randomized Double Blind Placebo Controlled Trial*; R. Saggari<sup>1</sup>, J.A. Belperio<sup>1</sup>, R. Saggari<sup>1</sup>, C. Hunter<sup>2</sup>, S.S. Weigt<sup>1</sup>, J.P. Lynch<sup>1</sup>, D.A. Zisman<sup>1</sup>, A. Gregson<sup>3</sup>, B. Kubak<sup>3</sup>, S. Lackey<sup>2</sup>, D.J. Ross<sup>1</sup>, A. Ardehali<sup>2</sup> <sup>1</sup>David Geffen School of Medicine UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine UCLA, Los Angeles, CA; <sup>3</sup>David Geffen School of Medicine, Los Angeles, CA

**Invited Discussant:** Andreas O. Zuckermann, MD, University of Vienna, Austria

**9:30 AM (685) Featured Abstract:** *Ambrisentan Therapy for Idiopathic Pulmonary Arterial Hypertension: 2 Year Follow-Up*; A. Keogh St. Vincent's Hospital, Sydney, Australia

**Invited Discussant:** Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA

**9:50 AM (686) Featured Abstract:** *Validation of Destination Therapy Risk Score in Recipients of Left-Ventricular Assist Devices (LVAD) at a Single Center*; K. Ferguson, Y. Naka, D. Mancini, K. Lietz Columbia-University Medical Center, New York, NY

**Invited Discussant:** Leslie W. Miller, MD, Washington Hospital Center, Washington, DC

**10:10 AM Invited Lecture:** *ISHLT Standards for Cardiac Allograft Vasculopathy Scoring*, Mandeep R. Mehra, MD, University of Maryland School of Medicine, Baltimore, MD

**10:15 AM – 10:30 AM**

Coffee Break (Hall Maillot)

**10:30 AM – NOON**

**CONCURRENT SESSION 43: Mechanical Support and Myocardial Recovery (Main Theatre)**

Chairs: Cumara C. Sivathasan, MBBS, FRCS and Katherine Lietz, MD, PhD

**10:30 AM (687) Myocardial Recovery from Advanced Heart Failure Using the Heartmate II LVAD Combined with Drug Therapy: Early Results from a Prospective Study;** E.J. Birks<sup>1,2</sup>, R.S. George<sup>1,2</sup>, M. Hedger<sup>1</sup>, T. Bahrami<sup>1</sup>, M. Amrani<sup>1</sup>, M.H. Yacoub<sup>2</sup>, G. Dreyfus<sup>1</sup>, A. Khaghani<sup>1</sup> <sup>1</sup>Harefield Hospital, Harefield, Middlesex, United Kingdom; <sup>2</sup>Imperial College, Harefield, Middlesex, United Kingdom

**10:45 AM (688) Usefulness of Echocardiographic Tissue Doppler and 2D-Strain Imaging for the Assessment of Unloading-Induced Cardiac Recovery in Patients with Ventricular Assist Devices;** M. Dandel, H.B. Lehmkuhl, Y. Weng, M. Pasic, C. Knosalla, T. Krabatsch, R. Hetzer Deutsches Herzzentrum Berlin, Berlin, Germany

**11:00 AM (689) Long-Term Survival after Left Ventricular Assist Device Explantation;** O.H. Frazier, S. La Francesca, Z.T. Demirozu, W.E. Cohn, R.C. Bogaev, R.M. Delgado, P. Loyalka, B. Kar, I.D. Gregoric Texas Heart Institute, Houston, TX

**11:15 AM (690) Left Ventricular Unloading Is Comparable between Axial and Centrifugal Continuous-Flow LVADs;** F. Kamdar, A. Boyle, M. Colvin-Adams, K. Liao, L. Joyce, R. John University of Minnesota, Minneapolis

**11:30 AM (184) Echocardiographic, Clinical, and Histologic Characteristics of Patients with Improved Cardiac Function Allowing Removal of Left Ventricular Assist Device (LVAD);** O.H. Frazier, A.M. Segura, I.D. Gregoric, W.E. Cohn, Z.T. Demirozu, S. LaFrancesca, L.M. Buja Texas Heart Institute, Houston

**11:45 PM (692) Aortic Insufficiency – Trends over Time in LVAD Supported Patients;** J.C. Matthews<sup>1</sup>, K.D. Aaronson<sup>2</sup>, R. Jain<sup>5</sup>, F.D. Pagani<sup>3</sup>, T.J. Koliakos<sup>4</sup> <sup>1</sup>University of Michigan Health System, Ann Arbor, MI; <sup>2</sup>University of Michigan Health System, Ann Arbor, MI

**10:30 AM – NOON**

**CONCURRENT SESSION 44: Immunosuppression for Heart Transplantation: New Strategies** (Blue Theatre)

Chairs: Stephanie A. Moore, MD and Lee R. Goldberg, MD

**10:30 AM (693) Everolimus in Longterm Heart Transplanted Patients: Effects on Renal Function. One Year Results of a Prospective Randomized Trial;** R. Fiocchi, R. Sebastiani, A. Iacovoni, A. Fontana, A. Gamba Heart Transplant Center, Bergamo, Italy

**10:45 AM (694) Balancing Rejection and Infection with Respect to Age, Race, and Gender: Clues Acquired from 17 Years of Cardiac Transplantation Data;** J.F. George, S.L. Meyers, M.T. Foushee, R.N. Brown, D.C. Naftel, O.E. Pajaro, J.K. Kirklin University of Alabama at Birmingham, Birmingham, AL

**11:00 AM (695) Rapid Achievement of Therapeutic Levels and Exposure-Efficacy Analysis in De Novo Cardiac Transplant Recipients on Everolimus-Based Immunosuppression;** U. Livi<sup>1</sup>, J. Arizon<sup>2</sup>, M.F. Mattei<sup>3</sup>, F. Musumeci<sup>4</sup>, M. Maccherini<sup>5</sup>, L. Almenar<sup>6</sup>, J. Delgado<sup>7</sup>, R. Kleinloog<sup>8</sup>, Y. Li<sup>9</sup>, H. Lehmkuhl<sup>10</sup>, R. Fiocchi<sup>11</sup> <sup>1</sup>Az. Ospedaliero-Universitaria S. Maria della Misericordia di Udine, Udine, Italy; <sup>2</sup>Hospital Universitario Reina Sofia, Cordoba, Spain; <sup>3</sup>Hopital Brabois, Nantes, France; <sup>4</sup>Ospedale S. Camillo-Forlanini - Azienda Ospedaliere, Rome, Italy; <sup>5</sup>AUO Siena, Siena, Italy; <sup>6</sup>Hospital Universitario La Fe, Valencia, Spain; <sup>7</sup>Hospital Universitario 12 de Octubre, Madrid, Spain; <sup>8</sup>University of Kwa-Zulu Natal, Durban, South Africa; <sup>9</sup>Novartis Pharmaceuticals Corporation, East Hanover; <sup>10</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>11</sup>Az. Osp. - Ospedali Riuniti di Bergamo, Bergamo, Italy

**11:15 AM (696) Comparison of Early and Late Calcineurin Inhibitor Initiation after Basiliximab Induction in Heart Transplantation;** T.B. Dick<sup>1</sup>, M.H. Watson<sup>1</sup>, C.A. Milano<sup>3</sup>, G.M. Felker<sup>2</sup>, A.F. Hernandez<sup>2</sup>, S. Dev<sup>2</sup>, P. Rosenberg<sup>2</sup>, J.G. Rogers<sup>2</sup> <sup>1</sup>Duke University Medical Center, Durham, NC; <sup>2</sup>Duke University Medical Center, Durham, NC; <sup>3</sup>Duke University Medical Center, Durham, NC

**11:30 AM (697) Aggressive Medical Therapy Can Control the Hyperlipidemia Associated with Sirolimus Utilization after Cardiac Transplantation;** M. Shullo<sup>1</sup>, R. Zomak<sup>2</sup>, C. Yost<sup>2</sup>, M. Rebel<sup>2</sup>, C. Newman<sup>2</sup>, C. Bermudez<sup>3</sup>, D. McNamara<sup>3</sup>, R.L. Kormos<sup>2</sup>, J.J. Teuteberg<sup>3</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>University of Pittsburgh, Pittsburgh, PA; <sup>3</sup>University of Pittsburgh, Pittsburgh, PA

**11:45 PM (698) Everolimus Increases the Incidence of ACE Inhibitor-Induced Angioedema in Heart Transplanted Patients;** R. Fiocchi, R. Sebastiani, A. Iacovoni, E. Radavelli, A. Gamba Heart Transplant Center, Bergamo, Italy

**10:30 AM – NOON**

**CONCURRENT SESSION 45: Primary Graft Dysfunction: Evaluating Mechanisms in the Lung** (Salle Maillot)

Chairs: Jason D. Christie, MD and Selim M. Arcasoy, MD



**10:30 AM (699) Concomitant Endothelin-1 mRNA Overexpression in Donor and Recipient Predicts Primary Graft Dysfunction after Lung Transplantation;** S. Aharinejad<sup>1,2</sup>, M. Salama<sup>1</sup>, O. Andrukhova<sup>2</sup>, S. Taghavi<sup>1</sup>, M.A.R. Hoda<sup>1</sup>, M. Gmeiner<sup>1,2</sup>, P. Jaksch<sup>1</sup>, W. Klepetko<sup>1</sup> <sup>1</sup>Medical University of Vienna, Vienna, Austria; <sup>2</sup>Medical University of Vienna, Vienna, Austria

**10:45 AM (700) Plasma Levels of Receptor for Advanced Glycation End-Products (RAGE) Are Associated with Primary Graft Dysfunction;** J.D. Christie<sup>1</sup>, C.V. Shah<sup>1</sup>, S. Kawut<sup>1</sup>, J. Sonnett<sup>2</sup>, V.N. Ahya<sup>1</sup>, K. Wille<sup>3</sup>, V. Lama<sup>4</sup>, J. Orens<sup>5</sup>, A. Shah<sup>5</sup>, A. Weinacker<sup>6</sup>, E. Demissie<sup>1</sup>, S. Bellamy<sup>1</sup>, L.B. Ware<sup>7</sup> <sup>1</sup>University of Pennsylvania, Philadelphia; <sup>2</sup>Columbia University, New York; <sup>3</sup>University of Alabama, Birmingham, Birmingham; <sup>4</sup>University of Michigan, Ann Arbor; <sup>5</sup>Johns Hopkins, Baltimore; <sup>6</sup>Stanford University, Palo Alto; <sup>7</sup>Vanderbilt University, Nashville

**11:00 AM (701) Soluble P-Selectin and the Risk of Primary Graft Dysfunction after Lung Transplantation;** S.M. Kawut<sup>1</sup>, J. Okun<sup>1</sup>, D.J. Lederer<sup>1</sup>, L.B. Ware<sup>2</sup>, V. Lama<sup>3</sup>, A. Weinacker<sup>5</sup>, E. Demissie<sup>4</sup>, J.D. Christie<sup>4</sup> <sup>1</sup>Columbia University, New York, NY; <sup>2</sup>Vanderbilt University, Nashville, TN; <sup>3</sup>University of Michigan, Ann Arbor, MI; <sup>4</sup>University of Pennsylvania, Philadelphia, PA; <sup>5</sup>Stanford University, Stanford, CA

**11:15 AM (702) Receptor for Advanced Glycation End Products Expression in Lung Allograft Recipients with Primary Graft Dysfunction (PGD);** A. Pelaez<sup>1,2</sup>, S.D. Force<sup>3</sup>, P.M. Naik<sup>1</sup>, E.C. Lawrence<sup>1,2</sup>, A.M. Ramirez<sup>1,2</sup>, D.C. Neujahr<sup>1,2</sup>, A.A. Gal<sup>4</sup>, P.O. Mitchell<sup>1</sup> <sup>1</sup>Emory University School of Medicine, Atlanta, GA; <sup>2</sup>Emory University School of Medicine, Atlanta, GA; <sup>3</sup>Emory University School of Medicine, Atlanta, GA; <sup>4</sup>Emory University School of Medicine, Atlanta, GA

### **11:30 AM (703) WITHDRAWN**

**11:45 AM (704) Donor Glutathione-S-Transferase (GST)-mu Null Genotype Is a Risk Factor for Development of Bronchiolitis Obliterans Syndrome (BOS) and Poor Survival after Lung Transplantation Even after Accounting for Primary Graft Dysfunction (PGD);** D. Hadjiliadis, R. Lingaraju, V.N. Ahya, J. Lee, A. Pochettino, R.M. Kotloff, J.D. Christie <sup>1</sup>University of Pennsylvania, Philadelphia, PA

### **10:30 AM – NOON**

**CONCURRENT SESSION 46: Pulmonary Arterial Hypertension: Lessons from Registries and the Bench (252 AB)**  
Chairs: Omar A. Minai, MD and Hans B. Lehmkuhl, MD

**10:30 AM (705) Comparison of Double-Lung and Heart-Lung Transplantation for Pulmonary Hypertension: Analysis of the UNOS Database;** K. Afshar<sup>1</sup>, D. Weill<sup>2</sup>, V.G. Valentine<sup>3</sup>, G.S. Dhillon<sup>2</sup> <sup>1</sup>University of Southern California, Los Angeles, CA; <sup>2</sup>Stanford University, Stanford, CA; <sup>3</sup>University of Texas Medical Branch, Galveston, TX

**10:45 AM (706) Dichloroacetate (DCA) Causes Beneficial Metabolic and Electrical Remodeling in Right Ventricular Hypertrophy (RVH);** L. Piao<sup>1</sup>, V.J. Cadete<sup>2</sup>, Y.H. Fang<sup>1</sup>, H. Zhang<sup>1</sup>, G.D. Lopaschuk<sup>2</sup>, D. Urboniene<sup>1</sup>, S.L. Archer<sup>1</sup> <sup>1</sup>University of Chicago, Chicago, IL; <sup>2</sup>University of Alberta, Edmonton, AB, Canada

**11:00 AM (707) REVEAL Registry: Comparison of Functional Status in Adult PAH Patients with and without Comorbid Medical Conditions;** A. Krichman<sup>1</sup>, M. Turner<sup>2</sup>, P. Wason<sup>3</sup>, A.M. Graves Jones<sup>2</sup>, M.D. McGoon<sup>4</sup>, H.W. Farber<sup>5</sup> <sup>1</sup>Duke University Medical Center, Durham, NC; <sup>2</sup>ICON Clinical Research, San Francisco, CA; <sup>3</sup>Actelion Pharmaceuticals US, Inc., South San Francisco, CA; <sup>4</sup>Mayo Clinic, Rochester, MN; <sup>5</sup>Boston University School of Medicine, Boston, MA

**11:15 AM (708) REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Pulmonary Vascular Disease Associated with Congenital Heart Disease;** R.J. Barst<sup>1</sup>, D. Ivy<sup>2</sup>, D.B. Badesch<sup>3</sup>, R.L. Benza<sup>4</sup>, C.G. Elliott<sup>5</sup>, H.W. Farber<sup>6</sup>, A.E. Frost<sup>7</sup>, A. Krichman<sup>8</sup>, T.G. Liou<sup>9</sup>, G.E. Raskob<sup>10</sup>, P. Wason<sup>11</sup>, K. Feldkircher<sup>11</sup>, A.J. Foreman<sup>12</sup>, M.D. McGoon<sup>13</sup> <sup>1</sup>Columbia University College of Physicians Surgeons, New York, NY; <sup>2</sup>University of Colorado Denver School of Medicine, The Children's Hospital, Aurora, CO; <sup>3</sup>University of Colorado Health Sciences Center, Aurora, CO; <sup>4</sup>Allegheny General Hospital, Pittsburgh, PA; <sup>5</sup>Intermountain Medical Center, Murray, UT; <sup>6</sup>Boston University School of Medicine, Boston, MA; <sup>7</sup>Baylor College of Medicine, Houston, TX; <sup>8</sup>Duke University Medical Center, Durham, NC; <sup>9</sup>University of Utah, Salt Lake City, UT; <sup>10</sup>University of Oklahoma Health Sciences Center, Oklahoma City, OK; <sup>11</sup>Actelion Pharmaceuticals US, Inc., South San Francisco, CA; <sup>12</sup>ICON Clinical Research, San Francisco, CA; <sup>13</sup>Mayo Clinic, Rochester, MN

**11:30 AM (709) Influence of Intravenous Epoprostenol on the Transpulmonary Gradient of Vascular Endothelial Growth Factor (VEGF) in Patients with Pulmonary Arterial Hypertension;** N. Selimovic, C.H. Bergh, B. Andersson, E. Sakiniene, H. Carlsten, B. Rundqvist <sup>1</sup>Sahlgrenska University Hospital, Gothenburg, Sweden; <sup>2</sup>Sahlgrenska University Hospital, Gothenburg, Sweden

**11:45 PM (710)** *HIF-1 $\alpha$  Activation by Cobalt Hyperpolarizes and Fragments Mitochondria in Pulmonary Artery Smooth Muscle Cells Creating a “Pulmonary Arterial Hypertension” Phenotype as Seen in Fawn-Hooded Rats*; P.T. Toth, H.J. Zhang, J. Rehman, Y. Zhang, S.L. Archer The University of Chicago, Chicago, IL

**10:30 AM – NOON**

**CONCURRENT SESSION 47: Novel Technologies and Therapies in Heart Failure (242 AB)**

Chairs: Jeffery J. Teuteberg, MD and Kenneth K. C. Ng, MBBS

**10:30 AM INVITED LECTURE:** *Gene Transfer of SERCA2 in Patients with Heart Failure*, Mariell Jessup, MD, University of Pennsylvania, Philadelphia, PA

**10:45 AM (711)** *Mitral Valve Repair (MVR) in Heart Failure: 5 Year Follow-Up from the MVR Stratum of the Acorn Trial*; R.C. Starling<sup>1</sup>, M. Jessup<sup>2</sup>, M.A. Acker<sup>2</sup>, S. Bolling<sup>3</sup>, J.K. Oh<sup>4</sup>, D.L. Mann<sup>5</sup>, H.N. Sabbah<sup>6</sup>, S.H. Kubo<sup>7</sup> <sup>1</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>2</sup>University of Pennsylvania, Philadelphia, PA; <sup>3</sup>University of Michigan, Ann Arbor, MI; <sup>4</sup>Mayo Clinic, Rochester, MN; <sup>5</sup>Baylor College of Medicine, Houston, TX; <sup>6</sup>Henry Ford Foundation, Detroit, MI; <sup>7</sup>Acorn Cardiovascular, St. Paul, MN

**11:00 AM (712)** *Transplant in the Elderly vs. Destination Therapy: Beginning of a Paradigm Shift?*; R.J. Morris<sup>1</sup>, Y.J. Woo<sup>1</sup>, M. O'Hara<sup>1</sup>, S. Chambers<sup>2</sup>, M. Jessup<sup>2</sup>, M.A. Acker<sup>1</sup> <sup>1</sup>University of Pennsylvania, Philadelphia, PA; <sup>2</sup>University of Pennsylvania, Philadelphia, PA

**11:15 AM (713)** *An Innovative, Sensorless, Pulsatile, Continuous Flow Total Artificial Heart*; K. Fukamachi, D.J. Horvath, A.L. Massiello, H. Fumoto, T. Horai, S. Rao, L.A.R. Golding Cleveland Clinic, Cleveland, OH

**11:30 AM (714)** *Biometal Artificial Muscle Restores Atrial Kick in a Permanent Atrial Fibrillation Animal Model and Could Represent a New Tool in the Treatment of End Stage Heart Failure*; P. Tozzi<sup>1</sup>, D. Hayoz<sup>2</sup>, F. Salchli<sup>3</sup>, L.K. von Segesser<sup>1</sup> <sup>1</sup>CHUV, Lausanne, Switzerland; <sup>2</sup>Hopital Cantonal de Fribourg, Fribourg, Switzerland; <sup>3</sup>CETT, Yverdon-les-Bains, Switzerland

**11:45 PM (715)** *Initial In Vivo Testing of a Self-Balancing Pulsatile Continuous Flow Total Artificial Heart*; L.A.R. Golding, K. Fukamachi, D.J. Horvath, A.L. Massiello, H. Fumoto, Y. Arakawa, J. Catanese, J.-F. Chen, N. Mielke, T. Horai Lerner Research Institute, Cleveland Clinic, Cleveland, OH

**10:30 AM – NOON**

**CONCURRENT SESSION 48: Organ Allocation (241)**

Chairs: Walter Weder, MD and Pascal Leprince, MD

**10:30 AM (716)** *The Impact of 2006 United Network for Organ Sharing Thoracic Organ Allocation Policy Change: Mission Accomplished?*; J.N. Nativi<sup>1</sup>, A.G. Kfoury<sup>1</sup>, C. Myrick<sup>2</sup>, M. Peters<sup>2</sup>, D. Renlund<sup>1</sup>, P. Fisher<sup>1</sup>, E. Gilbert<sup>1</sup>, F. Bader<sup>1</sup>, A. Singhal<sup>1</sup>, D. Bull<sup>1</sup>, M. Everitt<sup>1</sup>, J. Stehlik<sup>1</sup> <sup>1</sup>UTAH Cardiac Transplant Program, Salt Lake City, UT; <sup>2</sup>Intermountain Donor Services, Salt Lake City, UT

**10:45 AM (717)** *Predictors of Time on the Lung Transplant Waiting List after Implementation of the Lung Allocation Score (LAS)*; D. Hadjiiladis<sup>1</sup>, J. Munson<sup>1</sup>, V.N. Ahya<sup>1</sup>, J. Lee<sup>1</sup>, R.M. Kotloff<sup>1</sup>, A. Pochettino<sup>2</sup>, J.D. Christie<sup>1</sup> <sup>1</sup>University of Pennsylvania, Philadelphia, PA; <sup>2</sup>University of Pennsylvania, Philadelphia, PA

**11:00 AM (718)** *The Lung Allocation Score Predicts Lung Transplant Short-Term Waiting List and Late (3yr) Post-Transplant Mortality in a Non-US Center*; B.J. Levvey<sup>1</sup>, D. Keating<sup>1</sup>, A. Griffiths<sup>1</sup>, T. Oto<sup>2</sup>, G.I. Snell<sup>1</sup> <sup>1</sup>Alfred Hospital and Monash University, Melbourne, Victoria, Australia; <sup>2</sup>Okayama University, Okayama, Japan

**11:15 AM (719)** *Donor Predictors of Graft Non-Utilization Are Not Associated with Reduced Survival in Heart Transplant Recipients*; K.K. Khush<sup>1</sup>, R.L. Menza<sup>2</sup>, V. Hayden<sup>3</sup>, W. Babcock<sup>3</sup>, M. Landeck<sup>3</sup>, A. Sapru<sup>4</sup>, M.A. Matthay<sup>4</sup>, C.W. Hoopes<sup>4</sup>, J.G. Zaroff<sup>5</sup> <sup>1</sup>Stanford University, Palo Alto; <sup>2</sup>Victoria University, Wellington, New Zealand; <sup>3</sup>California Transplant Donor Network, Oakland; <sup>4</sup>University of California, San Francisco; <sup>5</sup>Kaiser Permanente, San Francisco

**11:30 AM (720)** *Oversizing Donor Cardiac Allografts for Patients with Pulmonary Hypertension May Not Be Necessary*; M. Kwon<sup>1</sup>, A. Ankrom<sup>2</sup>, A. Ardehali<sup>1</sup>, M. Kawano<sup>2</sup>, M. Kittleson<sup>2</sup>, K. Kiyosaki<sup>2</sup>, J. Kobashigawa<sup>2</sup> <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA

**11:45 PM (721)** *Effect of Donor Cause of Death on Transplant Outcomes – A Review of UNOS Experience 1988-2007*; X. Sheng, J. Stehlik, A.K. Singhal University of Utah, Salt Lake City, UT

**NOON – 1:00 PM**

Council Reports to the Membership and Board (Room 242 AB)

**1:30 PM – 5:00 PM**

ISHLT Board of Directors Meeting (Sisley Room, Hotel Concorde LaFayette)

## ALPHA LIST OF EXHIBIT COMPANIES

COMPANY NAMES	BOOTH NUMBERS
Argon Medical Devices, Inc. (USA)	012
Medica Europe BV (Europe)	
Astellas Pharma, Inc.	107
Avalon Laboratories	001
Berlin Heart	101
Cardinal Health Research Services	210
CircuLite, Inc.	203
CorMatrix Cardiovascular, Inc.	003
CSL Behring	007
Cylex Incorporated	212
Elsevier	005
F. Hoffman La Roche	106
ISHLT Tours	012
Heartware, Inc.	104
Genzyme B.V.	006
Int'l Institute for the Advancement of Medicine	103
ISHLT Thoracic Transplant Registry	003
Levitronix	202
MicroMed Cardiovascular, Inc.	206
Novartis Pharma AG	108
One Lambda, Inc.	011
Scanlan International, Inc.	109
Scholten Surgical Instruments, Inc.	010
SynCardia Systems, Inc.	204
Terumo Heart Inc.	110
Thoratec Corporation	205
TransMedics	208
Ventracor	111
Vitrolife	207
World Heart, Inc.	009
XDx	105

## EXHIBITORS AND PRODUCT DESCRIPTIONS

### **Argon Medical Devices, Inc. (USA)**

#### **Medica Europe BV (Europe)**

**1445 Flat Creek Road**

**Athens, TX 75751 (USA)**

**Website: [www.argonmedical.com](http://www.argonmedical.com) (USA)**

#### **Galliersweg 20 – 5349 AT Oss (Europe)**

**Website: [www.medica-europe.nl](http://www.medica-europe.nl) (Europe)**

**Booth Number: 012**

Argon Medical Devices, Inc. manufacturer of Jawz™ Endomyocardial Biopsy Forceps and a full line of vascular access products including introducers, guide wires, thermodilution catheters, and many customizable kits specific to needs of cardiac transplantation centers. Ask about Argon's line of Micro-Introducer kits for Biopsy IJ/Femoral access.

### **Astellas Pharma Inc**

**2-3-11, Nihonbashi-Honcho,**

**Chuo-Ku, Tokyo 103-8411, Japan**

**Website: [www.astellas.com](http://www.astellas.com)**

**Booth Number: 107**

Astellas Pharma Inc is one of the top 20 pharmaceutical companies in the world and remains committed to urology, dermatology, transplantation and anti-infectives. As a research and development organization it is passionate about bringing new interventions to the market. The Astellas Group's raison d'être is to contribute toward improving the health of

people around the world through the provision of innovative and reliable pharmaceutical products. In Transplantation, Astellas has an immuno-suppressant to prevent organ rejection in kidney and liver transplants, and its development pipeline includes further products for the prevention of organ rejection post-transplant.

**Avalon Laboratories**  
**2610 E. Homestead Place**  
**Rancho Dominguez, California 90220, USA**  
**Website: [www.avalonlags.com](http://www.avalonlags.com)**  
**Booth Number: 001**

Product Description (Not to exceed 100 words in length)

Avalon Laboratories is a leading manufacturer of wire-reinforced cardiopulmonary vascular cannula. Avalon Elite™ is the company's premium line of proprietary catheters providing new and unique solutions for patients receiving extracorporeal support. The Avalon Elite Bi-Caval Dual Lumen Catheter (DLC) is indicated for use as a single catheter for simultaneous venous drainage and reinfusion of blood via the internal jugular vein. With a wide range of sizes, the DLC is the world's first wire-reinforced, veno-venous catheter available for both pediatrics and adults. The Avalon Elite line also features the high performing Multi-Port Venous Femoral Catheter and a Vascular Access Kit.

**Berlin Heart**  
**Wiesenweg 10,**  
**12247 Berlin, Germany.**  
**Website: [www.berlinheart.com](http://www.berlinheart.com)**  
**Booth Number: 101**

Berlin Heart is the only company worldwide that develops, manufactures, and distributes implantable and paracorporeal ventricular assist devices for patients of every age and body size.

EXCOR® is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns, children, adolescents, and adults. EXCOR® Pediatric is leading the worldwide market of pediatric VADs.

INCOR® is an implantable axial-flow LVAD for adults. INCOR® is the only 3rd generation axial flow pump with CE-mark approval.

INCOR® is not FDA approved. EXCOR® is approved for clinical investigation in pediatric patients in USA.

**Cardinal Health Research Services**  
**22745 Savi Ranch Parkway**  
**Yorba Linda, California, 92887, USA**  
**Leibnizstraße 7, D-97204 Hoechberg, Bavaria, Germany**  
**Website: [www.cardinalhealth.com/researchservices](http://www.cardinalhealth.com/researchservices)**  
**Booth Number: 210**

Based in Hoechberg, Germany and Yorba Linda, CA Cardinal Health Research Services is a global market leader in providing innovative technology and service solutions to the pharmaceutical, biotechnology and telehealthcare industries. We provide centralized devices and solutions for electronic data capture of Respiratory, ECG, Cardiac Safety, Tremor, ePRO data, including Ambulatory monitoring (PEF/FEV1, ABPM, Holter, eDiary) in all phases of clinical development. With solutions designed to be as unique as your fingerprint, we approach every project with a willingness to adapt to our clients' needs and have one major goal in mind: Creating exceptional value for the customers we serve.

**CircuLite, Inc.**  
**250 Pehle Avenue, Plaza 1, 4<sup>th</sup> Floor**  
**Saddle Brook, New Jersey 07663**  
**Website: [www.circulite.net](http://www.circulite.net)**  
**Booth Number: 203**

CircuLite is transforming heart failure treatment with the development of minimally-invasive micro-pumps for long term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient's native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients and their families. CircuLite's pipeline of PCS devices is lead by the *Synergy*™ Pocket Micro-Pump System, a surgically implanted micro-pump currently in a CE Mark clinical trial. Next-generation *Synergy* micro-pumps include an endovascular system, a fully-implantable system and a pediatric system.

**CorMatrix Cardiovascular, Inc.**

**200 N. Cobb Parkway, Suite 140**  
**Marietta, GA 30062**  
**Web address: [www.cormatrix.com](http://www.cormatrix.com)**  
**Booth Number: 003**

CorMatrix Cardiovascular is a privately held company based in Atlanta, GA, that is dedicated to developing and delivering innovative cardiovascular devices that harness the body's innate ability to remodel damaged tissue. CorMatrix holds an exclusive license to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications and currently has U.S. FDA clearance and European approval with a CE Mark to market its ECM Technology as an implant for pericardial closure. Additionally, CorMatrix has received FDA clearance for cardiac tissue repair and is conducting pre-clinical studies on a number of additional cardiovascular applications. For more information, visit [www.cormatrix.com](http://www.cormatrix.com).

**CSL Behring**  
**1020 First Ave**  
**King of Prussia, Pennsylvania 19406**  
**Website: [www.cslbehring.com](http://www.cslbehring.com)**  
**Booth Number: 007**

CSL Behring is a global leader in the plasma protein biotherapeutics industry. CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services.

The company's therapies are used in organ transplantation, the treatment of hemophilia, von Willebrand disease, other bleeding disorders, immune deficiency disorders, and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, and in the treatment of burns and shock.

CSL Behring is a subsidiary of CSL Limited, biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit [www.cslbehring-us.com](http://www.cslbehring-us.com).  
Website: [www.cslbehring-us.com](http://www.cslbehring-us.com)

**Cylex Incorporated®**  
**8980-I Old Annapolis Road**  
**Columbia, MD 21045**  
**Website: [www.cylex.net](http://www.cylex.net)**  
**Booth Number: 212**

Cylex™ Inc., makers of the ImmuKnow® Assay, is a global life science company that develops and manufactures research and *in vitro* diagnostic products intended to illuminate immunity. ImmuKnow – commercialized in 2002 – is the *in vitro* diagnostic utilized to detect cell-mediated immunity in an immunosuppressed population. In 2008, Cylex received certification to ISO 13485:2003 and ISO 9001:2000. The growing company portfolio has patents in the U.S. and Australia and pending patents in Europe, Canada and Japan. The Cylex management team has extensive experience in developing, manufacturing, marketing and distributing medical diagnostic products

**Elsevier, Inc.**  
**1600 JFK Blvd**  
**Suite 1800**  
**Philadelphia, Pennsylvania 19103**  
**Web Address: [www.elsevierhealth.com](http://www.elsevierhealth.com)**  
**Booth # 005**

Elsevier ([www.elsevier.com](http://www.elsevier.com)) is proud to publish *The Journal of Heart and Lung Transplantation* ([www.jhltonline.org](http://www.jhltonline.org)), the official journal of the International Society for Heart and Lung Transplantation (ISHLT). Be sure to stop by our booth to view the latest issue of the Journal and browse our other books, journals and electronic offerings.

**F. Hoffmann-La Roche Ltd**  
**Grenzacher Str 177**  
**Basel, Switzerland CH-4070**  
**Website: <http://www.roche.com>**  
**Booth Number: 106**

#### About CellCept®

CellCept® (mycophenolate mofetil) is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving cardiac, renal or hepatic transplants.<sup>1</sup> CellCept® is available as tablets, capsules, solution or i.v.<sup>1</sup>

#### About Valcyte®\*

Valcyte® (Valganciclovir) is indicated for the prevention of CMV-disease in CMV-negative patients who have received solid organ transplants from CMV-positive donors. 900 mg Valcyte® is the correct dose for patients with normal renal function.<sup>2</sup>

Valcyte® is available as tablets or a powder for oral solution.\*\*

\*Trademark in France: RoValcyte;

\*\* not available in France

1. CellCept® SmPC
2. Valcyte® SmPC

#### **HeartWare, Inc.**

**205 Newbury Street, Suite 101**

**Framingham, Massachusetts 01701**

**Web address: [www.heartware.com](http://www.heartware.com)**

**Booth Number: 104**

HeartWare, Inc. is developing a family of implantable mechanical circulatory support systems for the treatment of advanced heart failure. Through a cadence of progressively smaller devices implanted using less invasive techniques, HeartWare expects to treat an increasing proportion of heart failure patients and to access them at an earlier stage of their disease progression. HeartWare's lead device, the HeartWare® Ventricular Assist System, incorporates state-of-the-art peripherals and features the only full-output pump designed to be implanted less invasively in the pericardial space. The HeartWare® System has CE-Mark approval and is currently the subject of a 150-patient US IDE clinical trial.

#### **Genzyme Europe**

**Gooimeer 10**

**Naarden, The Netherlands 1411 DD**

**Web address: [www.genzyme.com](http://www.genzyme.com)**

**Booth Number: 006**

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need

#### **International Institute for the Advancement of Medicine**

**125 May Street**

**Edison, New Jersey 08837**

**Website: [www.iiam.com](http://www.iiam.com)**

**Booth Number: 103**

With over 20 years experience, the International Institute for the Advancement of Medicine (IIAM) operates one of the world's largest recovery networks for donated, normal and diseased, human organs and tissue that are consented for medical research and education. IIAM works with over 50 organ recovery programs, receiving over 5,000 referrals annually of non-transplantable human organs and tissue, and distributing over 2,600 specimens that are consented for research each year. Through the continued support of donors, organ procurement organizations and tissue banks, IIAM helps advance medical research in finding cures for disease and development new drugs, therapies and surgical procedures.

#### **ISHLT Thoracic Transplant Registry**

**700 North 4<sup>th</sup> Street**

**Richmond, Virginia 23219**

**Contact: Kathryn Philibin**

**Website: [www.help@ishlt.org](mailto:www.help@ishlt.org)**

**Booth Number: 003**

The ISHLT International Registry for Heart and Lung Transplantation was created to collect on-going, current information on the worldwide thoracic organ transplantation experience. Our registry is the only one of its kind. The data we maintain

is utilized for scientific study and contributes to the body of knowledge regarding thoracic transplantation. Our goal is to identify overall and best practices for improving cardiothoracic patient care.

This year the exhibit will make center-specific information available for review by ISHLT clients. In addition, clients can view data screens and receive guidance on participation in our registry, submission of data and special data request services.

**Levitronix GmbH**  
**Technoparkstrasse 1**  
**Zürich, Switzerland CH-8005**  
**Website: [www.levitronix.com](http://www.levitronix.com)**  
**Booth Number: 202**

The Levitronix<sup>®</sup> CentriMag<sup>®</sup> and PediVAS<sup>®</sup> devices are designed to provide temporary mechanical circulatory support. In the US, the CentriMag is approved for use as an RVAS. CentriMag is also undergoing clinical trials for adult and pediatric “failure-to-wean” patients for LVAD or BVAD support. The PediVAS is optimized to provide circulatory support for neonatal patients. Both systems are CE Marked for use for up to 30 days for VAD and ECMO applications.

Caution: CentriMag is an Investigational Device. Limited by Federal (USA) law to investigational use.  
The PediVAS has not been approved by the U.S. Food and Drug Administration.

**MicroMed Cardiovascular**  
**8965 Interchange Dr.**  
**Houston, Texas 77054**  
**Website: [www.micromedcv.com](http://www.micromedcv.com)**  
**Booth Number: 206**

The Heart Assist 5™ VAD system is a result of MicroMed Cardiovascular's commitment and years of research to create an axial flow ventricular assist device which provides full support and improved quality of life to patients of all sizes suffering with heart failure. The Heart Assist 5™ is the only VAD that offers both direct real time flow data and implants above the diaphragm. It is CE-mark approved in Europe, undergoing an IDE BTT clinical study in the U.S. (as the DeBaKey VAD<sup>®</sup>) and is the only FDA approved pediatric ventricular assist device.

**Novartis Pharma AG**  
**Postfach**  
**Basel, Switzerland 4002**  
**Web address: [www.novartis.com](http://www.novartis.com)**  
**Booth Number: 108**

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world

**One Lambda, Inc.**  
**21001 Kittridge St**  
**Canoga Park, California, 91303, USA**  
**Website: [www.onelambda.com](http://www.onelambda.com)**  
**Booth Number: 011**

**Scanlan International, Inc.**  
**One Scanlan Plaza**  
**Saint Paul, Minnesota 55107**  
**Website: [www.scanlaninternational.com](http://www.scanlaninternational.com)**  
**Booth Number: 109**



Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. New instruments include the SCANLAN® LEGACY Dual Guide™ titanium forceps and a full line of MICS/VATS Thoracoscopic instruments. Single-use products include: VASCU-STATT® bulldog clamps, SCANLAN® Aorta/Vein Punch, A/C Locator® graft markers, SURG-I-PAW® jaw covers and SOFT-GRIP™ fabric clamp covers. Surgical Acuity magnifying loupes featuring titanium frames, large field size and great field depth for superior visualization. Also offering custom instrument modifications to meet your individual needs.

**Scholten Surgical Instruments, Inc.**

**170 Commerce St. # 101  
Lodi, California 95240 – USA  
Website: [www.bioptome.com](http://www.bioptome.com)  
Booth Number: 010**

Scholten Surgical Instruments is excited to be exhibiting at this year's ISHLT annual meeting in Paris where we will debut our new Novatome™ Single-Use Endomyocardial Biopsy Forceps. This new EMB device, born from the pedigree of the Scholten Bioptome, a device with 30 years of proven clinical experience, is now available in a single-use version. The Novatome offers the same precise feel, ease of placement, and large sample size expected from Scholten products. Scholten Surgical has recently received certification to the ISO 13485 quality system standard and CE mark for our products allowing world wide distribution.

**SynCardia Systems, Inc.**

**1992 E. Silverlake Rd.  
Tucson, Arizona 85713  
Website: [www.syncardia.com](http://www.syncardia.com)  
Booth Number: 204**

The CardioWest™ temporary Total Artificial Heart (TAH-t) is the only FDA, Health Canada and CE approved device that provides circulatory restoration in morbidly ill patients with irreversible bi-ventricular failure, providing a life-saving bridge until a donor human heart becomes available. In 2006, the EXCOR® TAH-t mobile driver was granted a CE mark, enabling European hospitals to discharge stable patients on the TAH-t to return home while they are awaiting a transplant. Visit our booth for updates on upcoming clinical studies for the Companion Driver, the Freedom discharge driver, the 50cc TAH-t, and the pediatric VAD.

**Terumo Heart Inc.**

**6180 Jackson Road  
Ann Arbor, Michigan 48103  
Website: [www.terumoheart.com/](http://www.terumoheart.com/)  
Booth Number: 110**

Terumo Heart, Inc. is dedicated to the innovation, introduction and advancement of products to improve the quality of healthcare for heart failure patients. Our principal focus is the development of the DuraHeart™ Left Ventricular Assist System (LVAS), designed to provide long-term circulatory support and address the shortage of donor hearts for cardiac transplantation. Combining patented magnetic-levitation and centrifugal pump technologies, the DuraHeart LVAS is expected to decrease complications and improve the lives of patients with severe heart failure. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe.

**Thoratec Corporation**

**6101 Stoneridge Drive  
Pleasanton, California 94588  
Website: [www.thoratec.com](http://www.thoratec.com)  
Booth Number: 205**

Thoratec® Corporation innovates and delivers technologies that enable a full range of therapies to save, support and restore failing hearts, allowing patients to reclaim their lives. With over 12,000 patient implants and three decades of experience, Thoratec offers the broadest portfolio of ventricular assist devices. Thoratec's product line includes the HeartMate® LVAS, Thoratec PVAD™ and IVAD™, and the HeartMate II® LVAD.

**TransMedics**

**200 Minuteman Road  
Andover MA 01810  
Website: [www.transmedics.com](http://www.transmedics.com)  
Booth Number: 208**

TransMedics is a medical technology company whose mission is to extend and expand the life saving benefits of organ transplantation. The Organ Care System™ (OCS) resuscitates and maintains human organs in a functioning state ex-vivo using warm, oxygenated, nutrient-enriched donor blood perfusion. This allows for continuous functional and metabolic assessment and results in a significant reduction of ischemia. The OCS is designed to deliver improved patient outcomes, increased utilization of donor organs, and more cost-effective transplants. OCS HEART is CE marked and available for sale in Europe. OCS LUNG is in advanced stages of development.

**Ventracor Ltd**  
**58 US Highway, 46 West**  
**Budd Lake, New Jersey 07828**  
**Website: [www.ventracor.com](http://www.ventracor.com)**  
**Booth Number: 111**

Ventracor is a global medical device company which has developed a new 3<sup>rd</sup> generation implantable blood pump, the VentrAssist® LVAD, for left ventricular support.

The VentrAssist LVAD has a hydrodynamically suspended impeller free of mechanical bearings, and a diamond-like carbon coating of the blood pathway.

The VentrAssist wearables are compact and lightweight, fitting into patients' lifestyles. The thin, flexible percutaneous lead is paired with an extracorporeal lead that can be replaced without pump exchange if damaged.

The VentrAssist LVAD has been designed to deliver safe, reliable, long-term circulatory support for patients with end-stage heart failure, and to improve their quality of life.

**Vitrolife**  
**113 Buttercup Road**  
**Lake Ozark, Missouri 65049**  
**Website: [www.vitrolife.com](http://www.vitrolife.com)**  
**Booth Number: 207**

Vitrolife manufactures and markets solutions and equipment for transplantation and thoracic surgery, designed to preserve organs and tissues prior to transplantation. These two solutions are Perfadex for flushing of the lungs and Steen Solution for ex vivo evaluation (approved in US for research purposes only.)

Vitrolife aims to:

- minimize ischemic reperfusion injuries by improving the solutions used for extra corporeal preservation of organs and tissues.
- extend the safe extra corporeal preservation time for organs and tissues prior to transplantation.
- increase the organ availability and transplantation success rates by introduction of new transplantation concepts and techniques

**World Heart, Inc.**  
**4750 Wiley Post Way, Suite 120**  
**Salt Lake City, Utah 84116, USA**  
**[www.worldheart.com](http://www.worldheart.com)**  
**Booth Number: 009**

WorldHeart's focus is to develop the innovative rotary Levacor™ VAD based on our proprietary maglev technology. The IDE application for the Levacor VAD to start a pivotal BTT trial in the USA was submitted to the FDA in January 2009. A CE Mark Study in the EU is also anticipated.

This builds on a quarter-century of support provided by the long-term implantable pulsatile Novacor® LVAS to more than 1,800 patients worldwide with life-threatening heart failure: allowing some recipients' return to families, homes, occupations, and hobbies, with the longest duration of support on an original device being more than 6 years.

**XDx Expression Diagnostics**  
**3260 Bayshore Blvd**  
**Brisbane, CA 94005**  
**Website: [www.xdx.com](http://www.xdx.com)**  
**Booth Number: 105**

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to manage the care of heart transplant patients.

AlloMap® testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment.

## **Future Annual Meetings**

**2010**

**30<sup>th</sup> ISHLT Annual Meeting and Scientific Sessions**

**Hilton Chicago**

**Chicago, IL, USA**

**April 21-24**

**2011**

**31<sup>st</sup> ISHLT Annual Meeting and Scientific Sessions**

**Hilton San Diego Bayfront**

**San Diego, CA, USA**

**April 13-16**